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Abstract
Using nationwide ‘big data’ from linked electronic health
records to help improve outcomes in cardiovascular
diseases: 33 studies using methods from epidemiology,
informatics, economics and social science in the ClinicAl
disease research using LInked Bespoke studies and Electronic
health Records (CALIBER) programme
Harry Hemingway,1,2* Gene S Feder,3 Natalie K Fitzpatrick,1,2
Spiros Denaxas,1,2 Anoop D Shah1,2 and Adam D Timmis2,4,5
1Institute of Health Informatics, University College London, London, UK
2Farr Institute of Health Informatics Research, University College London, London, UK
3Centre for Academic Primary Care, School of Social and Community Medicine, University of
Bristol, Bristol, UK
4Barts Health NHS Trust, London, UK
5Farr Institute of Health Informatics Research, Queen Mary University of London, London, UK
*Corresponding author h.hemingway@ucl.ac.uk
Background: Electronic health records (EHRs), when linked across primary and secondary care and curated
for research use, have the potential to improve our understanding of care quality and outcomes.
Objective: To evaluate new opportunities arising from linked EHRs for improving quality of care and
outcomes for patients at risk of or with coronary disease across the patient journey.
Design: Epidemiological cohort, health informatics, health economics and ethnographic approaches
were used.
Setting: 230 NHS hospitals and 226 general practices in England and Wales.
Participants: Up to 2 million initially healthy adults, 100,000 people with stable coronary artery disease
(SCAD) and up to 300,000 patients with acute coronary syndrome.
Main outcome measures: Quality of care, fatal and non-fatal cardiovascular disease (CVD) events.
Data platform and methods: We created a novel research platform [ClinicAl disease research using
LInked Bespoke studies and Electronic health Records (CALIBER)] based on linkage of four major sources of
EHR data in primary care and national registries. We carried out 33 complementary studies within the
CALIBER framework. We developed a web-based clinical decision support system (CDSS) in hospital chest
pain clinics. We established a novel consented prognostic clinical cohort of SCAD patients.
Results: CALIBER was successfully established as a valid research platform based on linked EHR data in nearly
2 million adults with > 600 EHR phenotypes implemented on the web portal (see https://caliberresearch.org/
portal). Despite national guidance, key opportunities for investigation and treatment were missed across the
patient journey, resulting in a worse prognosis for patients in the UK compared with patients in health
systems in other countries. Our novel, contemporary, high-resolution studies showed heterogeneous
associations for CVD risk factors across CVDs. The CDSS did not alter the decision-making behaviour of
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clinicians in chest pain clinics. Prognostic models using real-world data validly discriminated risk of death and
events, and were used in cost-effectiveness decision models.
Conclusions: Emerging ‘big data’ opportunities arising from the linkage of records at different stages of a
patient’s journey are vital to the generation of actionable insights into the diagnosis, risk stratification and
cost-effective treatment of people at risk of, or with, CVD.
Future work: The vast majority of NHS data remain inaccessible to research and this hampers efforts to
improve efficiency and quality of care and to drive innovation. We propose three priority directions for
further research. First, there is an urgent need to ‘unlock’ more detailed data within hospitals for the scale
of the UK’s 65 million population. Second, there is a need for scaled approaches to using EHRs to design
and carry out trials, and interpret the implementation of trial results. Third, large-scale, disease agnostic
genetic and biological collections linked to such EHRs are required in order to deliver precision medicine
and to innovate discovery.
Study registration: CALIBER studies are registered as follows: study 2 – NCT01569139, study 4 –
NCT02176174 and NCT01164371, study 5 – NCT01163513, studies 6 and 7 – NCT01804439, study 8 –
NCT02285322, and studies 26–29 – NCT01162187. Optimising the Management of Angina is registered
as Current Controlled Trials ISRCTN54381840.
Funding: The National Institute for Health Research (NIHR) Programme Grants for Applied Research
programme (RP-PG-0407-10314) (all 33 studies) and additional funding from the Wellcome Trust (study 1),
Medical Research Council Partnership grant (study 3), Servier (study 16), NIHR Research Methods Fellowship
funding (study 19) and NIHR Research for Patient Benefit (study 33).
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Plain English summary
How can we reduce death and suffering from heart disease by learning from the lifelong experience ofUK citizens? Heart disease is the most common cause of early death in the UK, but we do not know
how we can deliver benefits to patients by bringing together general practitioner and hospital records.
We established a secure, anonymous research platform [ClinicAl disease research using LInked Bespoke
studies and Electronic health Records (CALIBER)] and we used this to identify ways to improve quality of
care and prospects for patients with heart disease. We studied millions of people initially free from heart
disease and followed them up. We also studied people presenting with chest pain in the community
or suffering from a heart attack. We compared treatment in the UK and Sweden, as both countries
have similar health systems, although Sweden achieves better results for patients. We also tested a
computerised tool that helps guide doctors to make decisions in chest pain clinics. We carried out a
detailed study of hospital working practices to identify the types of care that give better results. Finally,
we recruited > 3000 patients being investigated for chest pain to help find out why diseases progress.
Our findings could help doctors and policy-makers to make better decisions on care so that patients have
better quality of life and longer life. In addition, the results will lead to better public health policy. Our
findings clearly show that research using one of the NHS’ greatest assets – its data – is vital to innovate
improvements in disease prevention, to make earlier diagnoses and to give the best treatments.
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Scientific summary
A digital trace in diverse electronic health records (EHRs) is left by everyone. The UK is arguably theonly country in the world with both nationwide EHRs in primary care and ongoing national quality
registries in cardiovascular disease (CVD). When linked, such resources have the potential to provide new
population-based insights into the quality and outcomes of care.
Coronary heart disease (CHD) is the main cause of preventable, premature mortality in the world; however,
there are unacceptable variations in prevention, investigation and treatment within and between health-care
systems. However, large-scale outcome studies using samples of nationwide data across the ‘patient
journey’ are lacking. CHD is one disease area in which large-scale, diverse data (‘big data’) exist and may
provide new opportunities for understanding quality of care and outcomes. This programme is among
the first to realise the research potential of linking big data across primary and secondary care and disease
registries.
Aim
To use nationwide linked EHR approaches to identify opportunities to improve quality of care and
outcomes for patients at risk of or with stable coronary artery disease (SCAD) and acute coronary
syndrome (ACS) across the patient journey.
Our overall approach was to build an informatics platform and then address key questions at different
stages in a person’s lifetime to reduce the risk of a major cardiovascular event: from initially healthy
populations to initial presentation with chest pain, to the initial acute admission and subsequent phases of
management of this long-term condition. We report on 33 inter-related studies (25 of which are published
in full elsewhere) which used research designs and methods from epidemiology, health informatics, health
economics and ethnographic social science approaches. Our research settings include 230 NHS hospitals
and 226 general practices in England and Wales. Our research participants include up to 2 million initially
healthy adults, 100,000 people with SCAD and up to 300,000 patients with ACS.
Chapter 2: establishing a framework to study cardiovascular diseases
across the patient journey – underlying methodology and approaches
Background
Challenges to harnessing linked EHRs include obtaining data in a research-ready format and the
compatibility of information across different sources, and there are methodological weaknesses in
prognosis research.
Objectives
To develop a platform for studying CVDs based on linked EHRs (studies 1 and 2). To establish a conceptual
framework promoting high-quality prognosis research (study 3).
Methods
We created a novel research platform [ClinicAl disease research using LInked Bespoke studies and
Electronic health Records (CALIBER)] based on linkage of four major sources of EHR data, including primary
care and national registry data, and curated > 600 EHR disease and risk factor phenotyping algorithms
(see www.caliberresearch.org/) (studies 1 and 2). We established the PROGnosis RESearch Strategy
(PROGRESS) partnership (study 3).
DOI: 10.3310/pgfar05040 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hemingway et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxix
Results
We created a linked data set encompassing nearly 2 million adults (studies 1 and 2). The PROGRESS
partnership highlighted multiple methodological shortfalls in prognosis research and made
recommendations to raise standards (study 3).
Conclusions
The CALIBER platform enables the wealth of information in UK EHRs to be exploited for research purposes.
This resource, and recommendations for improving the quality of prognosis research, provides an
important framework for high-quality research.
Chapter 3: inequalities in the incidence of 12 cardiovascular
diseases across the patient journey
Background
Investigations of the demographic determinants of CVD have focused on acute myocardial infarction
(AMI), stroke and coronary death. Little is known about their association with other common CVDs.
Objectives
To identify how 12 distinct CVD phenotypes are affected by demographic factors (study 4). To examine the
complex relationships between incidence and prognosis of CHD among people of South Asian ethnicity
(study 5).
Methods
Analyses of CALIBER linked data and a meta-analysis.
Results
We identified inequalities in the rates of initial presentation and lifetime risks of different CVDs by age, sex,
deprivation and ethnicity (study 4). Incidence of stable CHD among South Asian patients was markedly
higher than among white patients, although their prognosis was significantly better (study 5).
Conclusions
Our findings are crucial for understanding the global burden of CVDs and argue against the use of
composite measures of cardiovascular health.
Chapter 4: risk factor modification among people without
established cardiovascular disease
Background
Reported failures to meet national guideline targets and exploit treatment opportunities to optimise risk
reduction among people without established disease may represent important missed opportunities to
protect people against CVD.
Objectives
To investigate the association between type 2 diabetes mellitus and blood pressure (BP) and 12 CVDs
(studies 6 and 7). To identify whether or not targets for risk factor control are being met among people at
risk of CVD (study 8).
Methods
Analysis of CALIBER linked data.
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Results
Associations between type 2 diabetes and 12 CVD outcomes differed in terms of direction and magnitude
of effects, and there was substantial heterogeneity in associations with BP across CVDs and ages (studies 6
and 7). We identified a continuing failure to meet guideline targets for BP control (study 8).
Conclusions
Important opportunities to reduce cardiovascular risk are being missed, including more vigorous clinical
management to meet BP targets.
Initial presentation with stable chest pain
Chapter 5: initial presentation with stable chest pain: opportunities for
earlier diagnosis
Background
Delayed diagnosis represents a missed opportunity for treatment and is common in patients presenting
with chest pain.
Objectives
To determine the extent and impact of missed opportunities in diagnosis (studies 9 and 10). To develop
automated methods for extracting diagnostic information from EHR free text (studies 11 and 12).
Methods
Analyses of CALIBER data (studies 9 and 10). Development of two free-text data-mining algorithms for
extracting clinically meaningful entities from clinical narrative (studies 11 and 12).
Results
More than 70% of people presenting with chest pain in primary care received a diagnosis of unattributed
chest pain (studies 9 and 10). More CVD events occurred in this group than in the group of patients
diagnosed with angina. Unheralded AMI was uncommon. Algorithms to extract information from free text
showed promising performance (studies 11 and 12).
Conclusions
Opportunities to identify patients with angina, and to initiate the prevention of disease, are being missed.
Free-text data-mining algorithms may be able to identify early diagnostic indicators in EHRs before a formal
diagnosis is recorded.
Chapter 6: initial presentation with stable chest pain – opportunities using a clinical
decision support system – the Optimising the Management of Angina programme
Background
The diagnosis of patients with stable chest pain is challenging. Rapid access chest pain clinics (RACPCs)
may be missing significant numbers of cases.
Objectives
To pilot a multifaceted intervention [the Optimising the Management of Angina (OMA) programme]
including a computerised clinical decision support system (CDSS) targeting initial specialist management of
patients (study 13).
Methods
Mixed quantitative (before and after) and qualitative study. The OMA CDSS was based on National
Institute for Health and Care Excellence guidance and expert panel recommendations.
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Results
The OMA programme had a negligible effect on the decision-making of clinicians in RACPCs, indicating
that a larger evaluation is not justified. Barriers to implementation included the ambivalence of clinicians
towards the guidance, insufficient integration into hospital EHRs and the inability to extract clinical
information at scale from hospital information systems.
Conclusions
Decision-making in the chest pain clinic is complex. Our approach provided an in-depth understanding of
the ways in which clinicians interacted with the CDSS and could support the development of tools more
likely to be adopted in practice.
Stable chest pain and stable coronary artery disease
Chapter 7: stable chest pain and stable coronary artery disease – a novel cohort
(the Clinical Cohort in Coronary disease Collaboration)
Background
Consented cohorts recruited in clinical settings linked to -omic and biomarker data can add value to EHR
data in the study of diseases.
Objectives
To establish a novel prognostic cohort of patients with suspected SCAD with linked genetic, biomarker and
health data (study 14).
Methods
Consecutive patients undergoing investigation for chest pain at four UK NHS hospitals provided blood
samples and completed a baseline health questionnaire. Clinical information was manually extracted from
hospital electronic databases. Participants were followed up for cardiovascular events using national
registry databases.
Results
A total of 3345 patients were recruited.
Conclusions
The wealth of data in the Clinical Cohorts in Coronary disease Collaboration is a resource that will
facilitate research into the causes and consequences of SCAD.
Chapter 8: stable coronary artery disease – use of single prognostic factors
Background
Questions remain about the quality of evidence being generated on biomarkers and their clinical usefulness.
Objectives
To evaluate currently used and potentially informative biomarkers as prognostic indicators in SCAD
(studies 15–19).
Methods
Analyses of CALIBER data and literature-based evidence syntheses.
Results
Simple blood (haemoglobin) (study 15) and physiological [heart rate (study 16), systolic blood pressure
(study 19)] markers were associated with a range of prognostic outcomes. Published evidence of associations
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between C-reactive protein levels and cardiovascular events was of variable quality, and the degree of
association may have been overstated (study 17). Chromosomal marker Ch9p21 was convincingly associated
with an increased risk of a first but not subsequent cardiovascular events (study 18).
Conclusions
Biomarkers may be useful prognostic factors in SCAD, although poor methodology impairs the
interpretation of studies.
Chapter 9: stable coronary artery disease – risk prediction and cost-effective
targeting of interventions
Background
Validated prognostic models and information on resource use drawn from clinical data may assist the
management of SCAD patients and policy-making.
Objectives
To develop prognostic models for SCAD patients (study 20). To model health-care resource utilisation and
costs in SCAD patients (study 21).
Methods
Prognostic models were developed from CALIBER data and validated with independent data (study 20).
Lifetime health-care costs were calculated by applying the risk prediction model to resource use estimates
derived from CALIBER (study 21).
Results
Prognostic models based on widely available clinical data could identify patients at risk of poor outcome
with a high degree of accuracy (study 20). Long-term costs and resource use associated with SCAD were
high (study 21).
Conclusions
Prognostic models have the potential in early stages of risk assessment to identify patients for intensive
management or further investigation. Cost-modelling can inform resource allocation decisions and the
cost-effectiveness of new treatments.
Acute myocardial infarction
Chapter 10: acute myocardial infarction – missed opportunities for treatment
during and after hospitalisation
Background
Registry-based research offers a way to evaluate care once disease has manifested.
Objectives
To evaluate missed opportunities for care in hospital and after discharge (studies 22–25). To compare
outcomes in post-AMI survivors across four countries (studies 22 and 24).
Methods
Analyses of national registry data from the UK, Sweden, France and the USA.
Results
Rates of prescribing and the use of invasive procedures were lower in the UK than in Sweden or the USA
(studies 22 and 24). Short-term mortality was greater in the UK than in Sweden. More than 50% of
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eligible ST-segment elevation myocardial infarction patients did not receive nine evidence-based care
components. Greater numbers of missed opportunities for care were associated with higher mortality
(study 23). Opportunities to encourage smoking cessation were commonly missed after discharge from
hospital (study 25).
Conclusions
Despite guideline recommendations, opportunities to improve outcomes for ACS patients are being
missed. International comparisons may identify key areas that could be targeted to improve outcomes.
Chapter 11: acute myocardial infarction – evidence of treatment benefits beyond those
provided by clinical trials (further opportunities to improve outcomes)
Background
Clinical trials cannot provide evidence of long-term effectiveness or the impact of interactions between
drugs; these are issues that can be addressed using EHR data.
Objectives
To determine the use of secondary prevention medications after AMI (studies 26–29).
Methods
Analyses of CALIBER data.
Results
Use of fewer than five classes of secondary prevention drugs was associated with increased mortality,
although effects varied according to the class of drug omitted (study 26). Beta-blocker use in patients with
chronic obstructive pulmonary disease was associated with reduced mortality (study 27). Proton pump
inhibitors are unlikely to interfere with the clinical action of clopidogrel (e.g. Plavix®, Sanofi-Aventis,
Gentilly, France) (study 28). Discontinuation of clopidogrel after AMI is common and is associated with
adverse outcomes (study 29).
Conclusions
‘Real-world’ data can provide important information beyond that generated by clinical trials to guide
prescribing decisions.
Chapter 12: acute myocardial infarction – variation between hospitals in
short-term mortality outcomes
Background
Although care and outcomes vary widely between hospitals, previous studies have not accounted for
case mix, compared national health-care systems or evaluated processes of care in depth in the UK using
qualitative methods.
Objectives
To investigate the extent of, and reasons for, interhospital variation in mortality after admission for ACS
(studies 30–33).
Methods
An analysis of UK and Swedish national registry data (studies 30–32). An ethnographic study in 10 UK
hospitals (study 33).
Results
Thirty-day mortality varied substantially between UK hospitals (study 30). About 1 in 20 hospitals had an
excess mortality of ≥ 40%, and up to four seriously underperforming hospitals could be identified with
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confidence. We found no clear relationship between the number of patients admitted to individual
hospitals or the quality of BP management in primary care and 30-day mortality rates for AMI patients
(study 31). Interhospital variation in 30-day mortality was greater in the UK than in Sweden, with the
lowest mortality in hospitals adhering to guideline-recommended procedures and treatments (study 32).
Five processes were associated with high-quality care (study 33).
Conclusions
Underperformance was not wholly explained by differences in case-mix or treatment factors. Qualitative
work may be able to identify aspects of care giving, contributing to variation in outcomes.
Overall conclusions and recommendations for research
Linking national EHRs at different stages across the patient journey offers increasing opportunities to
understand and improve diagnosis, risk stratification and cost-effective treatment of people at risk of or
with coronary disease.
Using CALIBER, we addressed questions about missed opportunities across the patient journey, identifying
areas where, despite national guidance, suboptimal clinical management results in a worse prognosis for
patients. Through international comparisons, we show that these missed opportunities contribute at least
in part to differences in mortality between countries.
Our findings suggest that a systematic drive to improve quality of care may have more impact than
measures targeting the poorest-performing institutions.
We illustrated how linked EHR data can provide real-world evidence supplementing data obtained in
clinical trials on combinations of secondary prevention medications.
Our novel consented cohort study highlighted the challenges of extracting information from hospital
informatics systems. Our biomarker studies suggest that some prognostic factors, including simple clinical
measures, have the potential to improve targeting of clinical interventions in SCAD.
Our economic modelling highlighted the financial implications of growing numbers of SCAD patients.
As well as cost projections, our models provide a way to assess the probable cost-effectiveness of
new interventions.
Although these findings are in CVD, many might easily be extended in approach to any disease, both
acute and chronic, and both common and rare.
Nonetheless, the majority of NHS data remain inaccessible to research and this hampers efforts to improve
efficiency and the quality of care, and to drive innovation.
We propose three priority directions for further research. First, there is an urgent need to ‘unlock’ more
detailed data within hospitals, to expand the coverage of the UK’s 65 million people with primary care
data available for research, and to expand and make sustainable the range of record linkages (e.g. to a
wider range of disease registries). Second, there should be major expansion in the underlying methods
and applications of scaled approaches to using EHRs to design and carry out trials, and interpret the
implementation of trial results. This is important for delivering learning health systems and patient benefit.
Third, large-scale, disease agnostic genetic and biological collections linked to such EHRs are required in
order to deliver precision medicine and to innovate the discovery of new drug targets or to repurpose
existing drugs.
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Study registration
CALIBER studies are registered as follows: study 2 – NCT01569139, study 4 –
NCT01164371, study 5 – NCT01163513, studies 6 and 7 – NCT01804439, study 8 – NCT02285322, and
studies 26–29 – NCT01162187. OMA is registered as Current Controlled Trials ISRCTN54381840.
Funding
The National Institute for Health Research (NIHR) Programme Grants for Applied Research programme
(RP-PG-0407-10314) (all 33 studies) and additional funding from the Wellcome Trust (study 1), Medical
Research Council Partnership grant (study 3), Servier (study 16), NIHR Research Methods Fellowship
funding (study 19) and NIHR Research for Patient Benefit (study 33).
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Chapter 1 Introduction
Linked electronic health records and learning health systems
The global political importance of data
People increasingly leave digital ‘traces’ relevant to health in multiple different information systems as they
interact with health and other services and go about their everyday lives. The potential for such data to inform,
and potentially transform, our understanding of health and disease has been recognised by world leaders. For
example, George Osborne, the UK Chancellor of the Exchequer from 2010 to 2016, said in a Science Speech
to the Royal Society in November 2013 that the UK has ‘some of the world’s best and most complete data-sets
in healthcare’ (© Crown copyright; contains public sector information licensed under the Open Government
Licence v3.0).1 Following the 2015 State of the Union address, the White House signalled an initiative that
would ‘catalyse a new era of data-based and more precise medical treatment’ (reproduced under a Creative
Commons Attribution 3.0 License).2
Data tapestry
The electronic record relevant to health is diverse. This ‘data tapestry’ of information (Figure 1) spans records
in primary care and in hospitals, structured data (codes, values) and unstructured data (text). It includes
information on genomics, through to social media, the sensed self and wider social determinants of disease.
Deriving information and knowledge from one or more sources of these rapidly developing sources of
health-relevant data might be of great benefit to inform improvements in care and outcomes of disease.
Translational gap
One model that links the process of science and improvements in health care and that has attracted
considerable attention in the UK is the translational model, as laid out, for example, in the Cooksey
Review.4 This identified two gaps in the translation of biomedical science to health care, construed as an
essentially linear process. The first translational gap is the generation of new therapies to improve health
care based on biomedical science. Epidemiological research using electronic health records (EHRs) can help
to close the first translational gap by enabling researchers to quantify the need for new therapies, identify
risk factors and (with genomic data) suggest potential new drug targets. Randomised clinical trials with
follow-up through EHRs can be cheaper and simpler than conventional investigator-led trials and may be
particularly helpful for increasing the evidence base for non-drug interventions.
However, it is in the second translational gap, that is, the introduction of new therapies into clinical
practice, on which EHR-based research programmes may have the greatest impact.
For example, new prognostic risk scores may help interventions to be targeted most appropriately, decision
support tools embedded in clinical systems may help to improve clinical decision-making and health
economic analyses can ensure that treatments are managed in a cost-effective way.
Learning health systems
A second, more recent, model linking data, information and knowledge to improvements in health care
comes from the concept of a learning health system5 in which science and informatics, involving the
real-time access to knowledge and digital capture of the care and outcomes, are a central component.
Electronic health records: what does the UK contribute?
Although there may be a strong scientific and health system case for making much better use of the
diversity of the ‘data tapestry’, in reality, existing research efforts have been largely focused on structured
data collected as part of an interaction with one or more components of the health system.
The UK is one of the few countries in the world in which a picture of the patient journey can be traced
through EHRs spanning primary care, hospitals and, ultimately, death registries. The UK has the potential
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to address research questions that would currently not be possible in Denmark and Sweden (Table 1),
countries that do have outstanding national registries but that have not brought national primary care
records to research in the same way as is possible in the UK.
A combination of features in the UK underpin the potential of EHRs:
Free at point of use
+
unique health identifier
+
≈ every citizen registered with a general practitioner (GP)
+
≈ every general practice uses EHRs
+
wide range of linkage possibilities, including to the national heart attack registry [Myocardial Ischaemia
National Audit Project (MINAP)].
Linkage of EHR and registry data, which are commonly held separately across multiple sources, with bespoke
phenotypic and genetic information can generate a unique platform to explore why diseases occur and
Types of data
Medication
Demographics
Encounters
Diagnoses
Procedures
Diagnostics (ordered)
Diagnostics (results)
Genetics
Social history
Family history
Symptoms
Lifestyle
Socioeconomic
Social network
Environment
Structured data Unstructured data
Pro
b
ab
ilistic lin
kag
e to
 o
b
tain
 n
ew
 typ
es o
f d
ata
Probabilistic linkage to validate existing data or fill in missing data
Examples of biomedical data Ability to link data to an individual    Data quantity
More Less
Pharmacy data
Claims data Registry or clinical trial data
Health-care center (electronic
health record) data
Easier to link to individuals
Harder to link to individuals
Only aggregate data exists
Data outside of health-care system
Electronic
pill dispensers
OTC
medication Medication filled Dose
NDC
Employee sick days
Death records
23andMe.com
Police records
Ancestry.com
Indirect from OTC purchases
Fitness club memberships,
grocery store purchases
Census records, Zillow, LinkedIn
Facebook friends, Twitter hashtags
Climate, weather, public health databases,
HealthMap.org, GIS maps, EPA, phone GPS
RxNorm
HL7
Visit type and time
SNOMED
Chief complaint
Differential
diagnosis
ICD-9
ICD-9
Pathology,
histology
Lab values,
vital signs
SNPs, arrays
Tobacco/alcohol use
Radiology
CPT
LOINC
ECG
Route Allergies
Out-of-pocket
expenses
Medication
prescribed
Medication
instructions Medication taken
Diaries
Herbal remedies
Alternative
therapies
  News feeds
Reports
Tracings,
images
Digital
clinical
notes
Paper
clinical
notes
Credit
card
purchases
Home
treatments,
monitors,
tests
Personal
health
records
Patients
likeme.com
1
1 2
2
Blogs
Tweets
Facebook
postings
1
2
1
2
Physical
examinations
FIGURE 1 The tapestry of potentially high-value information sources that may be linked to an individual for use in
health care. CPT, current procedural terminology; ECG, electrocardiogram; EPA, US Environmental Protection Agency;
GIS, geographic information system; GPS, global positioning system; ICD-9, International Classification of Diseases, Ninth
Edition; LOINC, Logical Observation Identifiers Names and Codes; NDC, National Drug Code; OTC, over the counter;
SNP, single nucleotide polymorphism. Reproduced with permission fromWeber et al. Finding the missing link for big
biomedical data. JAMA 2014;311:2479–80.3 Copyright © 2014 American Medical Association. All rights reserved.
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progress, to investigate quality of care and to identify opportunities to improve health outcomes. This new
data revolution has attracted substantial investment and promotion with initiatives to improve access to and
use of linked EHR data, which will serve to decrease the burden of obtaining data in a research-ready format
and encourage research collaboration.
In what senses are linked electronic health records ‘big data’?
One widely used definition of big data concerns the 4 Vs: volume, variety, veracity and velocity. EHR data are
potentially ‘big data’ in every sense; not only do they cover a large number of people (entire populations)
with a large amount of information [e.g. 2 million patients, 5 billion rows of data in our ClinicAl disease
research using LInked Bespoke studies and Electronic health Records (CALIBER) data platform, which forms
the foundation of this programme] per patient, but the data are highly varied and complex, with different
ways of coding information (e.g. by means of International Classification of Diseases and Read codes). The
data validity (‘veracity’) is simultaneously a concern for clinical care and for research. Clearly, having data in
real time (‘velocity’) can be crucial for clinical decision support. Harnessing EHR data for research requires a
deep understanding of the health-care system from which the data originated, as well as the statistical and
computing skills to analyse large data sets.
In 2011 the UK government published a Strategy for UK Life Sciences,16 which placed EHR research as a
central part of the strategy to accelerate health research in the UK. The UK is unique in being the only
country with national cardiovascular disease (CVD) registries and primary care data (including important
information on cardiovascular risk factors and their management in the community) available at a scale for
research. The recent report on personalised health care by the National Information Board and Genomics
England17 urged the NHS to transform its use of information in order to provide better care as well as to
enable better research. This will require a substantial increase in the maturity of EHRs in the UK as well as
a framework to make these data available for research.
TABLE 1 Availability of primary care data for research in different countries
Country
National or
regional Primary and ambulatory care data available for research linkages
UK National CPRD,6 accessed through Academic Health Sciences Networks
Sweden National Primary care is organised regionally; national initiatives in SwedeHeart7 and the National
Registry of Secondary Prevention
Denmark National Register of Medicinal Product Statistics8,9
Canada Regional Ontario, Institute for Clinical Evaluative Sciences10
Regional Ontario Health Insurance Plan Physician claims database
USA National Medicare (for people aged ≥ 65 years) (see www.medicare.gov/)
National Million Veteran Program (see www.research.va.gov/mvp/veterans.cfm)
Regional Mayo Clinic11
Regional Rochester Epidemiology Project, Olmsted County (see http://rochesterproject.org/)
Regional Kaiser Permanente California Research Program on Genes, Environment, and Health12
Regional Intermountain Healthcare13
Republic of
Korea
National National health insurance claims database from the Health Insurance Review & Assessment
Service14
CPRD, Clinical Practice Research Datalink.
Reproduced from Denaxas et al.15 Published by Oxford University Press on behalf of the International Epidemiological
Association. © The Author 2012. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Current state of electronic health records in UK hospitals relevant to quality
and outcomes research
Although UK general practices have, via the Clinical Practice Research Datalink (CPRD)6 and other
initiatives, contributed EHR data that have led to > 1000 peer-reviewed publications, the use of data
within hospitals beyond the simple Hospital Episode Statistics (HES) returns to generate useful knowledge
has led to very few publications. One of the reasons for this is that UK hospitals, like those in Europe,
have been at a low level of maturity, according, for example, to the Healthcare Information Management
Systems Society classification (Table 2). This is changing rapidly in the UK in light of the emerging strategy
from the National Information Board and NHS Transformation programmes such as the Genomics
England-led 100,000 Genomes Project.19
However, part of the government’s plan for making health-care information available for research, the
care.data programme,20 aroused national anxieties about patient confidentiality and had to be suspended
pending further public consultation. This illustrates the sensitivities that must be respected in EHR research.
Technical solutions such as data pseudonymisation and secure computer workspaces (‘safe havens’) can
enable sensitive patient data to be safely used for research, but it is vital to involve patients and the public
in balancing privacy concerns against the benefits of research.
Cardiovascular disease
People at risk of, or with, CVDs increasingly leave digital ‘traces’ relevant to health in multiple different
information systems in different parts of the health-care and health systems. The potential for such data to
inform, and potentially transform, our understanding of cardiovascular health and disease is the focus of
this programme.
Cardiovascular diseases: current public health impact
Cardiovascular diseases remain the leading cause of premature death in the UK and the developed world.21
Between 1990 and 2010 there were only minor improvements (3% decrease) in years lived with disability
from coronary heart disease (CHD),22 and CVD is estimated to cost the NHS about £15.7B a year – 21% of the
total NHS budget.23 Preventing the onset or progression of CVDs remains an important national priority.
TABLE 2 Index of EHR maturity in Europe in 2016
Stage Cumulative capabilities
Percentage
of hospitals
Stage 7 Complete electronic medical record; continuity of care documents to share data;
data warehousing feeding outcomes reports, quality assurance and business intelligence;
data continuity with emergency department, ambulatory and outpatient
0.3
Stage 6 Physician documentation interaction with full clinical decision support and closed loop
medication administration
2.5
Stage 5 Full complement of picture archiving and communication systems displaces film-based images 29.5
Stage 4 Computerised physician order entry in at least one clinical service area or for medication
(ePrescribing)
6.7
Stage 3 Nursing/clinical documentation (flow sheets) 5.3
Stage 2 Clinical data repository 34.5
Stage 1 Laboratory, radiology and pharmacy information systems 7.9
Stage 0 No laboratory, radiology or pharmacy information systems 13.3
Adapted from Healthcare Information Management Systems Society (HIMSS) Europe. Electronic Medical Records Adoption
Model (EMRAM) Score Distribution – European Countries. URL: http://himss.eu/sites/himsseu/files/analytics/HE%20EMRAM
%20Score%20Distribution%20Q3_2016.pdf (accessed 7 December 2016).18
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Interventions can be targeted at different time points along the patient journey: before disease manifests
(by risk factor modification), during initial presentation of disease (with prompt and accurate diagnosis,
delivery of effective care on referral and admission to hospital) and after discharge from hospital and beyond
(optimising secondary prevention). Temporal changes in CVD management have been driven by the availability
of new treatment targets [e.g. National Institute for Health and Care Excellence (NICE) guidance and Joint
British Societies recommendations on the prevention of CVD guidance] and availability and use of effective
treatments for CVDs.24 Increases in the number of prescriptions of lipid-lowering drugs and number of
percutaneous coronary interventions (PCIs) carried out in the UK, together with changes in CVD risk
assessment and prevalence, have contributed towards decreases in CVD mortality over the past decade,
although the extent to which improved mortality can be attributed to changes in major risk factors, such as
smoking, blood pressure (BP) and cholesterol, or specific CVD treatments, remains unclear.
Concerns of a ‘broken pipeline’ in cardiovascular research
There is widespread concern that current models of discovering new interventions, evaluation in trials and
implementation in clinical practice take too long (an average of 17 years), are too costly (US$5–11B for
each new licensed drug) and are too risky for investors. There is a major need for new research models in
general and trial models in particular in cardiovascular research, for several reasons. First, because major
unmet needs remain [e.g. acute myocardial infarction (AMI) 1-year mortality is still 20% despite five proven
secondary preventative medications]. Second, because late drug failures occurring within Phase III trials
(each costing US$50M–100M) are particularly problematic and have been recently seen for drugs that raise
high-density lipoprotein (HDL) cholesterol and for heart rate-lowering agents [ivabradine (Procoralan®,
Servier, Neuilly-sur-Seine, France)]. Third, non-drug interventions, based on clinical algorithms and decision
support, are of growing importance in CVD but are rarely trialled at all. Fourth, growing use of antiplatelet
and anticoagulant drugs is associated with major side effects (bleeding is the second most common
cause of iatrogenic hospital admission). Fifth, rare CVDs are undertrialled, partly owing to difficulties in
recruitment. Finally, the observational evidence that leads to trials often comes from primary prevention
settings; however, the populations in which drugs are first trialled are often in secondary preventative and
high-risk settings. Planning a trial can be complex because of the lack of suitable populations from which
to estimate accurate event rates and select the most appropriate end points. It is too slow and costly to
evaluate feasibility, and opportunities are frequently missed to collect valuable data that will adequately
inform late-phase trials. It is inefficient to collect clinical data separately for trials and for clinical care, and
the process of randomisation and outcome ascertainment is not integrated into the pathway of clinical
care. Trial participants are highly selected, which may limit the generalisability of the trial results, and
clinical outcomes in clinical care may not be as promising as suggested by the trials.
Electronic health records data opportunities in coronary disease
It is precisely because hospital information systems have historically been unfit for any purpose relating to
understanding the quality and outcomes of care that professional societies have organised themselves and
established post hoc collections of data that populate disease registries.
There are very few countries (possibly only the UK and Sweden) that have national mandatory ongoing
heart attack registries in which every hospital in the country returns data on care and outcome. MINAP is
one of the only national registries recording continuous data from every hospital that manages acute
coronary syndrome (ACS) patients. The information it provides about clinical phenotypes is unavailable
from any other national source and has shown that the reduced rates of heart attack in the early part of
this century have been largely confined to ST-segment elevation acute myocardial infarction (STEMI),
whereas rates of non-ST-segment elevation acute myocardial infarction (NSTEMI) have remained static.25
This detailed epidemiology is less easily available for other manifestations of CVD, such as abdominal aortic
aneurysm and ischaemic stroke, because disease-specific registries either have not been developed or have
become nationwide (all hospitals) only in the past 5 years.26 This represents an important gap in our
knowledge, and it is not clear whether or not the risk factors and changing epidemiology for CHD can be
generalised to other manifestations of CVD.
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In the UK, rates of hospitalised AMI (heart attack) and coronary death can be extracted from national data
sets such as HES and the Office for National Statistics (ONS) death registry. Richer data on CVDs and
procedures are available from national cardiovascular registries. The national registry of percutaneous
intervention was originally managed by the British Cardiovascular Interventional Society, and the British
Cardiovascular Society and the Royal College of Physicians originally managed the MINAP heart attack
registry. In 2010, the Healthcare Quality Improvement Partnership handed responsibility for the six
cardiovascular registries to the newly established National Institute for Cardiovascular Outcomes Research
(NICOR), which now not only has responsibility for the annual audit reports but also makes the registry
data available to research groups.27
The overarching aim of CALIBER is to harness diverse data sources to undertake novel research in CVDs,
including opportunities improving care. Our research programme adopted the ‘patient journey’ concept
to explore missed opportunities in primary prevention, diagnosis, acute care and secondary prevention
(Figure 2). By harnessing the potential of linked EHRs, we seek to provide valuable information to guide
clinical decision-making and health policy-making, with the potential to improve quality of care and
outcomes for patients.
Owing to the evolution of coronary atherosclerosis and symptomatic manifestations (angina, heart attack),
which can be viewed as chronic, long-term conditions, our research programme adopted the ‘patient
journey’ concept to explore missed opportunities in primary prevention, diagnosis, acute care and
secondary prevention. In particular, we have attempted to exploit the potential offered by linked EHRs
spanning the patient journey through primary care, the hospital system and ultimately to death. By
identifying the nature and scale of such missed opportunities over time, we seek to provide valuable
information to guide clinical decision-making and health policy-making, with the potential to improve
quality of care and outcomes for patients. A summary of our main findings and research recommendations
for 33 studies included in our programme can be found in Table 3.
Public and user group involvement
Electronic health records are increasingly considered to belong to individual patients. The National
Information Board recommended online access to the full primary care record by April 2015.17 In CALIBER
we have had an active public and user involvement group which has had biannual meetings since 2006.
Following the INVOLVE guidelines,66 this group represents a high level of user and lay participation in
research, which includes contributing to the design and conduct of research. The group includes people
relatively new to the ‘patient journey’ and others with many years’ experience of being cared for within
the UK NHS. Our programme has benefited greatly from the group’s engagement, which has informed the
development of studies from inception through to analysis and interpretation of findings. Central to the
vision of the Farr Institute of Health Informatics Research is the need to transform the relationship between
the patient, their health record and its uses for clinical care and translational research. The Farr Patient and
Public Working Group meets biannually and is actively involved in national health informatics research
network projects, research and events which are also open to lay members of the public.
Introduction to chapters
Chapter 2 (studies 1–3): the ClinicAl disease research using LInked Bespoke
studies and Electronic health Records platform
We have established a framework for studying CVD across the patient journey, introducing novel
approaches and scrutinising underlying methodology.
l Linked EHRs: to map the patient journey, we exploited the previously untapped resource of the EHR for
research purposes and, for the first time, linked data across primary care (CPRD), hospital admission
(HES), a disease-specific registry (MINAP) and the national death registry (ONS). The resulting CALIBER
data set comprises > 2 million patient records. The governance and analytic challenges were
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TABLE 3 Summary of main findings and research recommendations for 33 studies (25 published) included in
our programme
Main research findings Research recommendations
Chapter 2: establishing a framework to study CVDs across the patient journey – underlying methodology and
approaches
Study 1: we established the CALIBER data resource.
We successfully built tools to link coded data on diagnoses,
symptoms, drugs and procedures, and clinically recorded
biomarkers across primary care, secondary care and disease
registries for almost 2 million people and curated ≈ 600
EHR disease and risk factor phenotyping algorithms based
on linked EHR data15
1. There is an urgent need to ‘unlock’ more detailed data
within hospitals, and the scale of the UK’s 65 million
population
2. There is a need for scaled approaches to using EHR
to design and carry out trials and interpret the
implementation of trial results
3. Large-scale, disease agnostic genetic and biological
collections linked to such EHRs are required in order to
deliver precision medicine and innovate discovery
Study 2: we assessed the completeness and diagnostic
validity of recording AMI events in primary care, hospital
care, disease registry and national mortality records.
Across CALIBER’s four linked sources, we found that each
source misses a substantial proportion of events; therefore,
linking multiple sources is important. AMI recorded in these
sources, in terms of risk factor profiles and mortality at
1 year was found to be valid28
Further research is required to:
1. build national and international standards for the
definition of disease EHR phenotypes, such as AMI, for
use in observational studies, and for use in FDA and EMA
approved clinical trials
2. improve data quality (e.g. through better understanding
of how clinical diagnoses become EHR codes)
3. surface currently largely hidden hospital data, including
laboratory troponin results, and digitised ECGs
Study 3: we established the PROGRESS partnership to
promote high-quality prognostic research leading to patient
benefit. We highlighted opportunities to improve the
design, conduct, analysis and reporting of prognosis
research in 24 recommendations29–33
The PROGRESS recommendations include:
l the development of new programmes of
methodological and empirical prognosis research
exploiting EHRs to define, phenotype and follow-up
people with different health-related conditions
l improving the quality of prognosis research through
integrated standards of design, analysis and reporting
across early and late stages of translation
l establishing clinical cohorts with genetic, biomarker
and linked EHR data recruiting people with specified
health-related condition(s) as platforms for addressing a
wide range translational research questions
Chapter 3: inequalities in the incidence of 12 CVDs across the patient journey
Study 4: we investigated a central question in CVD – what
is the first CVD to present across different ages, sexes,
ethnicities and levels of deprivation? We found important
differences that conventional epidemiological approaches
based on small consented studies have eluded. These
include that heart attack and stroke account for the
minority of presentations, that women are less likely to get
some CVDs than men (e.g. subarachnoid haemorrhage),
the strength and shape of association of age with many
CVDs varies substantially, and those of South Asian
ethnicity experience substantially increased hazard of stable
and unstable coronary presentations compared with white
people34,35
Estimates of national and global burden of CVDs need to
take account of the modern epidemic in which heart failure,
PAD and other chronic diseases are becoming more
common than AMI and stroke. Male sex, older age, South
Asian ethnicity and low social deprivation, although
associated with many CVDs, are not associated with all, and
this heterogeneity has implications for research into risk
prediction, aetiology and prognosis
Study 5: there was a discordance between incidence of
SCAD, which was markedly higher among those of South
Asian ethnicity than for those of white ethnicity, and
prognosis which was significantly better in South Asians36
Large-scale EHR cohort studies with detailed measures over
time of clinical risk, and patient care identified through
linkage of primary care, ACS registry, hospitalisation and
cause-specific death data are warranted to better
understand how South Asian ethnicity influences the onset
and progression of coronary and other CVDs. Such studies
will allow longitudinal patterns of risk and missed
opportunities to lower risk before admission and after
discharge to be evaluated
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TABLE 3 Summary of main findings and research recommendations for 33 studies (25 published) included in our
programme (continued )
Main research findings Research recommendations
Chapter 4: risk factor modification among people without established CVD
Study 6: among 34,198 patients with type 2 diabetes
mellitus, we found that type 2 diabetes differs in its
associations with 12 CVDs, with its greatest impact on PAD
and heart failure, but type 2 diabetes was protective
against abdominal aortic aneurysm37
In clinical trial design, selection of primary end points is
crucial and should reflect the mechanism of action of the
intervention and, where appropriate, the public health
burden of CVDs in the 21st century. This would suggest a
growing importance of trials with end points of heart failure
and PAD
Study 7: in this contemporary study of 1.25 million adults,
we found that despite the availability of modern
preventative medication, the lifetime burden of
hypertension on incidence of subsequent CVDs remains
considerable. Notably, SBP and DBP were found to differ in
their associations with 12 CVDs and at different ages38
New approaches are required to mitigate the excess CVD
risk that remains despite modern BP-lowering therapy
combinations. New and existing clinical trials investigating
the effectiveness of BP-lowering strategies should include
other common initial CVD presentations as the primary
outcome
Study 8: in a cohort of individuals with newly diagnosed
hypertension, we identified high levels of undertreatment
among hypertensives. Consultation rates were significantly
lower among those whose BP was not reduced to target
(manuscript in preparation)39
New approaches are required to close the second
translational gap in BP lowering. This may include research
on clinical decisions support for multiple drug classes to
achieve target BP levels and other interventions, as well as
understanding how best to lower absolute cardiovascular risk
Chapter 5: initial presentation with stable chest pain – opportunities for earlier diagnosis
Study 9: we identified high levels of failure to diagnose
angina at first presentation with chest pain, which led to
poor prognosis among this group (manuscript in
preparation)40
Contemporary prognostic models should be developed and
validated based on the characteristics of patients presenting
with unspecified chest pain so those at risk of cardiovascular
events can be more accurately identified
Study 10: we found that first AMI, especially with STEMI,
was heralded by previous symptomatic atherosclerotic
disease, one or more cardiovascular risk factors,
or chest pain41
Further research is warranted to better characterise the
phenotypes, causes and prognosis of unheralded STEMI and
NSTEMIs to improve the usability of EHR for research.
Analyses comparing AMI patients with a control group
without AMI, including a comparison of missed
opportunities for care in measuring and controlling elevated
risk are warranted
Study 11: we developed an open source free-text data
mining tool (the FMA) for extracting diagnoses and causes
of death from unstructured text in EHRs, which showed
high precision and recall on a test data set from CPRD, and
can be used to extract uncoded diagnosis or symptom
information for EHR research. The tool may be useful in
aiding early identification of CVD42
Machine learning and NLP approaches to examining the
large corpus of unstructured (free-text) data that exists in
primary care and hospital records should be developed in
order to identify opportunities for earlier diagnosis, add
phenotypic information and safety signals
Study 12: we developed a data mining tool (the S3CM
algorithm) to extract diagnoses and investigation results
from unstructured text in EHRs by semisupervised machine
learning, which outperformed comparator programs on
data-mining tasks43
Further testing of our semisupervised machine learning tool
should be conducted using other EHR data sets, such as
discharge letters and electronic hospital notes
Chapter 6: initial presentation with stable chest pain – opportunities using a clinical decision support system –
the Optimising the Management of Angina programme
Study 13: the OMA CDSS was used in 84% of RACPC
consultations. OMA was found to have a negligible impact
on decision-making in the hospital chest pain clinic, with
qualitative data suggesting that clinicians found OMA
useful in confirming their decision-making44,45
Based on our understanding of the ways in which clinicians
interacted with a computerised CDSS, there is a need to
develop new tools to aid clinical decision-making with a
greater likelihood of being adopted in practice
continued
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TABLE 3 Summary of main findings and research recommendations for 33 studies (25 published) included in our
programme (continued )
Main research findings Research recommendations
Chapter 7: stable chest pain and stable coronary artery disease – a novel cohort (the Clinical Cohort in Coronary
disease Collaboration)
Study 14: we established a novel consented clinical cohort
of 3345 patients being investigated for new-onset chest
pain with linked phenotypic, genetic and biomarker data.
4C is a resource for researchers investigating onset of
SCAD and its progression to CVD events (manuscript in
preparation)46
There is a need for embedding genetic information in
hospital EHR at scale in order to carry out a wide range of
translational research, from discovery efforts, through drug
repurposing and embedded pharmacogenetics for patient
safety. Collaborative research based on individual patient
data should be encouraged to strengthen prognostic model
development and external validation of models
Chapter 8: stable coronary artery disease – use of single prognostic factors
Study 15: among two study populations (patients with
new-onset stable angina and no previous ACS and patients
with a first AMI) thresholds in both men and women were
identified below which the clinically available biomarker
haemoglobin showed a linear inverse relationship with
increased mortality47
New clinical trials are warranted to assess whether or not
haemoglobin levels are causal and whether or not clinicians
should intervene to increase haemoglobin levels
Study 16: elevated heart rate was associated with increased
risk of heart failure and cardiovascular death and all-cause
mortality in patients with SCAD (manuscript in preparation)48
In designing randomised trials, the target population, the
choice of composition of the primary end point and the
likely rate at which the end point accrues can all be
informed by the examination of linked EHRs
Study 17: published evidence of associations between
levels of the novel circulating marker of inflammation CRP
levels and risk of cardiovascular events was of variable
quality, and our data suggest that the degree of
association may have been overstated49
New clinical cohorts are needed with published pre-specified
statistical analytic protocols and prospective registration of
studies, which can be pooled to evaluate the true usefulness
of the role of CRP in prognosis in SCAD
Study 18: our systematic review and meta-analysis from
> 190,000 individuals experiencing 20,000 events showed
that Ch9p21, a novel genetic factor, was associated with
increased risk of first but not subsequent cardiovascular
events50
More work should be carried out to determine the effect of
mechanistic differences for the differential genetic effect, to
enhance understanding of the underlying reasons. Our
findings argue for a consortium of studies set in individuals
with established CHD to better understand the genomic
susceptibility to subsequent CHD events and also to perform
detailed analysis, including assessment for selection biases,
which is not possible with literature-based meta-analyses
Study 19: we found that changes in BP in people with
diabetes and SCAD predict risk. SBP in type 2 diabetes
patients with stable angina declined over time. Lower
values of SBP significantly increased risk of CVD outcomes
(manuscript in preparation)51
Methods for dynamic risk prediction in which the patterns
of change of clinically measured biomarkers can be
incorporated into clinical decision support models in clinical
practice are required
Chapter 9: stable coronary artery disease – risk prediction and cost-effective targeting of interventions
Study 20: we present validated prognostic models developed
with 5-year risk predictions for estimating risk of all-cause
mortality and coronary outcomes based on clinical parameters
that are commonly available in all people with SCAD52
Further external validation in external data sets and
recalibration for different populations and time periods is
required. Economic evaluation is needed to establish the
appropriateness of using the prognostic model in practice
Study 21: our cost-effectiveness studies using linked EHR
data showed high use of primary care and frequent
hospitalisations in patients with SCAD, who incurred
considerable ongoing costs. Five-year and lifetime costs
varied according to CVD risk, which may be predicted from
baseline patient-level data. Based on published data53,54
Extend models such as the model presented here to explicitly
capture the trajectory of prognostic risk factors over time, to
address broader questions around the cost-effectiveness of
interventions that target underlying risk factors
INTRODUCTION
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TABLE 3 Summary of main findings and research recommendations for 33 studies (25 published) included in our
programme (continued )
Main research findings Research recommendations
Chapter 10: AMI – missed opportunities for treatment during and after hospitalisation
Study 22: we compared short-term mortality outcomes
among patients with a first AMI admission using
nationwide outcome registries in Sweden and the UK. Our
findings, which took into account measures of case-mix
and in-hospital treatment measures, showed that short-
term mortality after AMI was markedly higher in the UK
than in Sweden and suggest that > 10,000 early deaths
would have been prevented or delayed had UK patients
experienced the care of their Swedish counterparts55
International harmonisation of detailed measures of quality of
care in clinical registries, such as pathways of care, is needed
to identify and evaluate additional patient-level health-care
factors that are not measured here and which might explain
differences between countries. Outcomes should be compared
with those in other countries, such as France, Hungary, Poland
and the USA, through assessment of national registries.
Linkage to national EHRs will extend comparisons to include
ambulatory care before and after admission for heart attack,
non-fatal events and longer-term outcome
Study 23: we identified that high numbers of patients
hospitalised with STEMI who were eligible for nine
evidence-based care components did not receive all
components, and that these patients went on to
experience higher rates of mortality56
Outcomes research specifically designed to follow care into
the primary care setting is warranted to quantify the full
implication of CMOCs
Study 24: we carried out analyses of data from national
registries in the UK, Sweden and the USA. International
comparisons identified significant differences in use of
surgical interventions and use of some secondary
prevention medications in the UK57
Further studies are needed to better explain patterns of
clinical practice within and outside the UK, such as rates of
coronary angiography and PCI
Study 25: in a study to determine the extent to which GPs
offer recommended smoking cessation advice and
pharmacological interventions to smokers after discharge
from hospital with ACS, we found that fewer than
one-quarter of smokers received smoking cessation
interventions in the 3 months following discharge. Those
who quit experienced fewer cardiac events than those who
continued smoking58
Future research, both in larger prospective epidemiological
studies and in RCTs, of the promotion of general practice
smoking cessation interventions, the association between
interventions and cessation and the effects on long-term
clinical outcomes is warranted
Chapter 11: AMI – evidence of treatment benefits beyond those provided by clinical trials (further opportunities
to improve outcomes)
Study 26: our study using linked CALIBER data to compare
the effectiveness of drugs used for secondary prevention of
CVD after AMI showed that use of fewer than five classes
of secondary prevention drugs was associated with
increased mortality. Omission of beta-blockers or statins
from the discharge prescription was associated with a
marked increase in the hazard of death in the first 30 days,
with only minor reductions in the effect size during the first
year and beyond (based on unpublished data)
Combinations of drugs that are recommended lifelong
but have not been evaluated in RCTs should be investigated
in observational studies for associations with fatal and
non-fatal outcomes over the remaining life expectancy
Study 27: we found that use of a beta-blocker after AMI in
adults with COPD was associated with lower subsequent
mortality. Improved survival was observed for use of
beta-blockers started either at the time of hospital
admission for AMI or before an AMI59
A RCT is justified to examine the effectiveness of
beta-blockers after AMI in patients with COPD
Study 28: we used linked CALIBER data and a
self-controlled case series design to measure the
association between use of PPIs and a range of harmful
outcomes in patients using clopidogrel and aspirin. Our
findings suggest that drug interaction between PPIs and
clopidogrel does not result in clinical harm60
Methods are required by which a learning health system can
interrogate the safety of drugs and drug–drug interactions in
a more timely and more scaled fashion
Study 29: in this first study to use linked registries to
determine persistence of clopidogrel treatment after AMI in
primary care, we found that discontinuation of clopidogrel
after AMI is common and is associated with adverse
outcomes61
Further research, incorporating methods of causal inference,
is required to fully investigate the extent to which the
association between clopidogrel discontinuation and adverse
events we identified was causal or was confounded by the
influence of unrecorded comorbidities or bleeding events
continued
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considerable, requiring a series of permissions, a contractual relationship with the Medicines and
Healthcare products Regulatory Agency, engagement of a trusted third party to perform the linkage,
safe storage of the linked data sets, development of detailed algorithms to define clinical phenotypes
of interest and, finally, application of complex analytic strategies to take account of the volume of data,
missing data and hidden confounders.
l Promoting high-quality prognostic research leading to patient benefit: in order to establish a
high-quality framework for prognosis research, we created the international PROGnosis RESearch
Strategy (PROGRESS) partnership, with representatives from academia and medical journal editors, to
evaluate the field of prognosis research and make specific recommendations on improving the quality
and impact of prognosis research.
Clinical context of diagnosis, risk prediction and treatment of coronary
diseases: synopses of studies
The studies in the chapters that follow are a combination of synopses of previously published (n = 26) and
currently unpublished (n = 15) studies and are summarised in Table 3 and Figure 2. We have included
more detail for the unpublished studies. A summary of the published papers relating to individual studies is
presented in Appendix 1.
TABLE 3 Summary of main findings and research recommendations for 33 studies (25 published) included in our
programme (continued )
Main research findings Research recommendations
Chapter 12: AMI – variation between hospitals in short-term mortality outcomes
Study 30: in this study comparing mortality among
hospitals in the UK, we observed that short-term mortality
varied substantially between hospitals. Up to four severely
underperforming hospitals were identified with high
confidence but there was considerable uncertainty in
adjusted mortality rates (based on unpublished data)
Further research is required to obtain real-time risk-adjusted,
treatment-adjusted estimates of between-hospital variation
in mortality and a wider range of non-fatal outcomes
Study 31: we carried out a preliminary volume–outcome
analysis of patients with AMI admitted to all hospitals in
England and Wales. We found no clear relationship
between the number of patients admitted to individual
hospitals or the quality of BP management in primary care
and 30-day mortality rates (based on unpublished data)
Further work is necessary to assess the distribution of AMI
patients across hospitals and other hospital characteristics
that contribute to patient outcomes
Study 32: international comparisons using AMI disease
registry data in Sweden and the UK showed that
hospital-level treatment varied between the two countries.
Short-term mortality was greater in the UK than in Sweden
(9.7% vs. 8.4%, respectively)62
Opportunities for more ambitious comparisons along the
care pathway should be exploited by linkage to national
EHRs, that would permit analysis of non-fatal events before
and after hospital admission and longer-term outcomes
Study 33: our qualitative study in 10 hospitals identified
five processes that appeared to facilitate good care for
NSTEMI patients: (1) early specialist assessment; (2) active
patient monitoring and appropriate action; (3) cross-
disciplinary communication; (4) co-ordinated discharge and
initiation of secondary prevention prior to discharge; and
(5) visible cardiology leadership63–65
Mixed-methods research is required to inform actions to
reduce hospital variations in care and outcomes
4C, Clinical Cohorts in Coronary disease Collaboration; CDSS, clinical decision support system; CMOC, cumulative missed
opportunity for care; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; DBP, diastolic blood pressure;
ECG, electrocardiogram; EMA, European Medicines Agency; FDA, Food and Drug Administration; FMA, freetext matching
algorithm; NLP, natural language processing; OMA, Optimising the Management of Angina; PAD, peripheral arterial
disease; PPI, proton pump inhibitor; PROGRESS, PROGnosis RESearch Strategy; RACPC, rapid access chest pain clinic;
RCT, randomised controlled trial; S3CM, Semi-supervised Set Covering Machine; SBP, systolic blood pressure; SCAD, stable
coronary artery disease.
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Primary prevention of disease
In principle, CHD is largely preventable with behaviour change (including smoking cessation, increasing
physical activity and lowering saturated fat intake) and, in some cases, pharmaceutical intervention to
lower BP or low-density lipoprotein cholesterol.67 In the landmark INTERHEART study conducted in
52 countries, just nine potentially modifiable risk factors were found to account for > 90% of the
population attributable risk of AMI in all regions of the world.68
Primary prevention is thus an important public health priority in the UK. National public smoke-free
legislation introduced in 2006 saw an almost immediate decline in rates of STEMI,69 and the NHS Health
Check Programme introduced 2 years later identifies individuals at risk of disease development for whom
preventative strategies are deemed appropriate.70 The contemporary focus on disease prevention is
reflected in the 2014 NICE guideline,71 which has now dramatically widened its recommendations for
statin therapy to include all people with a 10-year risk of heart attack or stroke that is ≥ 10%.71 The Joint
British Societies 2014 guideline,24 which also emphasises lifetime risk assessment, further widens access to
risk-lowering strategies to many young people at risk of disease in later life.24 In practice, there are many
missed opportunities for primary prevention; this is the focus of studies in Chapters 3 and 4 of this report.
Chapter 3 (studies 4–5): inequalities in health care by demographic determinants of
cardiovascular disease
In this chapter we present a novel analysis of inequalities and their associations with age, sex, ethnicity and
socioeconomic deprivation across these 12 CVD conditions. We also unravel the complex relationships
between incidence and prognosis of CHD among people of South Asian ethnicity living in the UK and
analyse factors driving the excess coronary mortality among South Asian groups.
Chapter 4 (studies 6–8): prevention
Reported failures to meet national guideline targets and treatment opportunities to optimise risk reduction
among people without established disease represent an important missed opportunity for protecting
patients against CVD. We have investigated risk factor modification among healthy populations and
people at risk of coronary disease, specifically evaluating if guideline targets for BP reduction are being
achieved in clinical practice, as well as opportunities for risk reduction in people with diabetes mellitus. We
also investigate the association between two major risk factors (BP and type 2 diabetes) and 12 different
presentations of CVD.
Importance of studying first presentation of cardiovascular disease
The Department of Health’s 2013 Cardiovascular Outcomes strategy72 has recommended management of
CVD as a single family of diseases. An initial CVD event affecting head (stroke), abdomen (aneurysm) or
legs [peripheral arterial disease (PAD)] shows some common risk factors and usually leads to initiation of
lifelong secondary prevention medication. The pattern of initial presentation of CVD is changing, with a
decrease in relative frequency of AMI and stroke. The study of the initial presentation of other CVDs has
been difficult because of the need for large cohorts with detailed clinical follow-up, covering hospital and
ambulatory care. However, linked EHR data provide the statistical scale and clinical resolution necessary to
carry out this research.73
Initial presentation with stable chest pain
Securing a firm diagnosis of coronary artery disease (CAD) is important to reduce the number of unnecessary
invasive tests on the one hand and inappropriate discharges on the other hand. Early diagnosis of patients is
a high priority for policy-makers, as evidenced by the widespread introduction of rapid access chest pain
clinics (RACPCs) for patients with suspected coronary disease. A central requirement for early diagnosis
is that primary care physicians are able to recognise early symptoms and signs of disease and respond
appropriately with prompt referral for specialist assessment. However, there is considerable diagnostic
uncertainty surrounding the diagnosis of chest pain and we investigate this in Chapters 5 and 6. RACPCs
are effective at identifying patients with angina74 but, in study 9, we found that during follow-up nearly
one-third of cardiac events occurred in patients who had not been given a diagnosis of angina. As well as
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becoming more common, there are substantial uncertainties in how to manage such patients, including how
to identify them and stratify them according to risk. Development of new-onset chest pain is a crucial
intervention point, and identification of those at risk is a major clinical and research challenge.
Chapter 5 (studies 9–12): diagnosis and first presentation
These studies identify important missed opportunities at the point of initial presentation of disease and
opportunities for early diagnosis.
l Incidence of chest pain and heralding of AMI. We have investigated missed opportunities for diagnosis
of chest pain in RACPCs, as well as the extent and nature of STEMI and NSTEMI heralding and its
impact on primary and secondary prevention of ACS.
l Mining free text in clinical notes to improve research on symptoms. Primary care EHRs contain
clinician-entered records of patient symptoms as well as formal diagnoses. It is important to study these
symptoms in order to be able to improve primary care decision and early diagnosis, but many of the
symptoms are entered as free text rather than using medical terminology codes. We have developed
tools that may help to extract information from unstructured free text in EHRs.
Chapter 6 (study 13): tools to improve assessment
We conducted a pilot evaluation of a clinical decision support system (CDSS) aimed at optimising use of
angiography (and thereby revascularisation), secondary preventative medication, lifestyle interventions and
referral to cardiac rehabilitation in RACPCs, to determine whether or not a large trial was justified. The study
built on our earlier simulation showing that a tool incorporating contemporary appropriateness criteria could
contribute positively to clinical judgement in guiding investigation of patients with suspected angina.
l Piloting a CDSS in a RACPC. We developed a patient-specific computerised CDSS, piloting its use in
four RACPCs, to model the effectiveness of the intervention and determine the need for a definitive
trial powered on CVD events.
l Qualitative ethnographic study. To determine the utility of the tool in day-to-day practice, we conducted
an ethnographic study based on interviews with clinicians and observation of clinical practice.
Consented cohorts recruited in clinical settings make important contributions towards addressing
translational research questions in prognosis research.
Chapter 7 (study 14): clinical cohort
We have established a new cohort of patients with suspected stable coronary artery disease (SCAD), the
Clinical Cohorts in Coronary disease Collaboration (4C), consisting of genetic, biomarker, clinical and
phenotypic data, linked to outcome data from national registries. The cohort was established as a resource
to encourage collaboration among researchers through sharing of individual patient data, to strengthen
prognostic model development and external validation of data.
Stable coronary artery disease
Better diagnosis and improved survival is leading to growing numbers of patients with SCAD, spanning
two patient populations: those who have survived an AMI and are in the early very high-risk period,
arbitrarily defined as the first 6 months after an AMI event, and patients who have never had an AMI
but who have been diagnosed with coronary disease after coronary angiography or documented with
myocardial ischaemia; the latter patients usually present initially as having ‘chronic stable angina’. SCAD is
of growing importance for several reasons. Investigation of SCAD, independently of AMI, is important
because the distinction of CAD phenotypes may yield causal mechanistic insights relevant to public
health;75,76 angina pectoris is one of the most common initial presentations of coronary disease, yet it is
commonly excluded from such aggregates, and little is known about factors determining disease
progression. Furthermore, compared with ACS, there has been much less research on outcomes and
quality of care for SCAD.
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Among patients with SCAD, RACPCs now provide prompt patient access to specialist consultation and
prescription of antiplatelet and statin therapy to stabilise atherothrombotic disease and protect against
coronary events. Meanwhile, the options for correcting symptoms have been extended by the recent
introduction of novel antianginal drugs such as ivabradine and ranolazine (Ranexa®, Menarini, Florence,
Italy) which, together with rapidly changing drug-eluting stent technology, allow many patients with
coronary disease to lead an active life free from ischaemic symptoms.77,78
Chapter 8 (studies 15–19): biomarkers and prognostic indicators
Single biomarkers have traditionally lacked incremental predictive value to be considered for clinical use.
We have evaluated the use of biomarkers as prognostic indicators to improve targeting of clinical
interventions in SCAD. Using evidence syntheses and analyses of linked CALIBER data, we have examined
the strength of the evidence base supporting the use of established and novel prognostic factors in SCAD,
and evaluated the general quality of evidence being generated in prognostic factor research.
Chapter 9 (studies 20–21): prognostic and economic modelling
Improved survival after ACS and an ageing population have resulted in a large population of SCAD
patients, with high health-care resource use. Validated prognostic tools and information on resource use
and costs based on data collected as part of usual clinical care could assist in clinical management of
SCAD patients and policy-making. We have developed and validated prognostic models, which we have
used to examine health-care resource utilisation and costs, and to evaluate the cost-effectiveness of
treatments.
l Development, validation and impact of a risk prediction model. We have used linked CALIBER data sets
to develop a prognostic model for SCAD, and validated the model using data from an independent
study.
l Health-care costs, resource use and decision models using a risk prediction model. We have combined
resource use estimates derived from CALIBER data and prognostic models to model the outcomes and
lifetime health-care costs of patients with SCAD.
Acute myocardial infarction treatments
The decline in the population burden of CHD has been driven partly by novel drug and device therapies,
for which clinical efficacy has been established in randomised trials.79 Thus, reperfusion strategies in AMI
have moved away from thrombolytic therapy towards percutaneous intervention, together with potent
dual antiplatelet regimens that now include adenosine diphosphate receptor antagonists such as
clopidogrel and ticagrelor (Brilique®, AstraZeneca plc, London, UK).80 This has seen UK hospital mortality
rates for AMI drop to 9%,47 and ongoing antiplatelet therapy, statins and inhibitors of the renin
angiotensin system provide protection against recurrent coronary events and left ventricular remodelling.
Nevertheless, AMI 1-year mortality is still 20% despite five proven secondary preventative medications
(study 26 in this report) and patients remain at high risk of further CVD events and death. In Chapter 10,
we examine the extent of missed opportunities for treatment after hospitalisation for AMI, and go on in
Chapter 11 to investigate further opportunities to improve outcomes after AMI.
Chapter 10 (studies 22–25): hospital and post-discharge care
A key aim of our research programme was to determine the cumulative impact of missed opportunities
for improving patient outcomes after hospitalisation for AMI, across a spectrum of the most common
symptomatic cardiovascular presentations. We anticipated the evolving interest in outcomes research and
recognised that the management of CVD is an ongoing commitment for clinicians that spans the patient
journey from initial presentation through hospitalisations to death.
l Missed opportunities in hospital. We used linked CALIBER data to evaluate the impact of missed
opportunities in hospital for patients with ACS. We also report, for the first time, international
treatment and outcome comparisons in collaboration with investigators in the USA and Sweden.
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l Missed opportunities after discharge from hospital. We examined opportunities for smoking cessation,
which substantially reduces the risk of recurrent AMI and coronary death, in the community after
discharge from hospital, recognising that sustained lifestyle modification and secondary prevention
treatment is a key guideline recommendation in patients who have experienced AMI.
Chapter 11 (studies 26–29): ‘real-world’ evidence
We have used EHR data to explore treatment benefits beyond clinical trials, examining the efficacy of
specific drug combinations for secondary prevention, the safety and effectiveness of beta-blockers in
patients with chronic obstructive pulmonary disease (COPD), and the clinical consequences of clopidogrel’s
interaction with proton pump inhibitors (PPIs).
Hospital and clinician performance
The importance of applying evidence-based treatments equitably has been recognised through the
development of regularly updated guidelines published in the national society journals of Europe and the
USA. In the UK these have been complemented by landmark policy initiatives such as the National Service
Framework for Coronary Heart Disease in 2000,81 which focused on disease management in the hospital
sector, and the Quality and Outcomes Framework in 2004, which introduced an incentive programme to
enhance treatment in primary care.82
Recognition that a major purpose of treatment is to improve patient outcomes has led policy-makers to
shift their attention towards the monitoring of performance not only of hospitals but also of individual
clinicians.72 Methods of evaluating hospital performance have been the subject of debate but the need was
brought into sharp focus by the Mid-Staffordshire NHS Foundation Trust scandal in 2009, when it became
clear that mortality rates in preceding years had been higher than expected yet no action had been taken by
those charged with the supervision and regulation of the hospital.83 One of the main recommendations of
the 2013 Francis Report83 was that the ‘Department of Health should set up a working group to review the
use of comparative hospital mortality statistics’ for identifying underperformance (© Crown copyright 2013;
contains public sector information licensed under the Open Government Licence v3.0). We await the
working group’s report but, meanwhile, individual clinicians are increasingly being held accountable for the
outcomes of patients under their care, particularly clinicians engaged in surgical and interventional
procedures (e.g. http://scts.org/modules/surgeons/default.aspx and www.bcis.org.uk/).
This focus on performance is central to the UK Government’s 2013 transparency in health-care agenda,
which not only includes commitments to publish more clinician-level data but also to link clinical data from
primary care to hospital data systems in order ‘to allow new insights into the quality of services and better
understanding of the way services interact’.84 These commitments relate directly to some of the
achievements of our research programme.
International comparisons can provide additional insight into performance, and have highlighted poor
performance within the UK health system.22 The extent to which this applies to CVD is not yet clear.
Variation in outcomes between hospitals for ACS patients is the subject of our studies in Chapter 12.
Chapter 12 (studies 30–33): hospital variation
Using EHR data and in-depth qualitative studies, we have examined the impact of individual hospitals on
the outcomes of AMI patients.
l Hospital-level variation in outcomes after AMI. For the first time, we have analysed interhospital
variation in 30-day mortality adjusted for case-mix and hospital treatment, and examined its potential
to identify and rank underperforming hospitals. In collaboration with Swedish investigators, we have
compared interhospital mortality variations in the UK and Sweden.
l Qualitative analysis of hospital processes of care. We carried out qualitative studies examining processes
of care potentially associated with favourable outcomes.
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Chapter 2 Establishing a framework to study
cardiovascular diseases across the patient journey:
underlying methodology and approaches
Abstract
Background
Electronic health records are generated at an unprecedented scale during patients’ interactions with the
NHS. The UK is unique in being able to trace a complete patient journey through coded EHRs spanning
primary care, hospitals, disease registries and, ultimately, death registries. Large-scale linkage of EHRs in
CVD has major challenges, and the quality of prognosis research, which provides crucial evidence for
translating research findings into clinical practice, is poor.
Objectives
(1) To establish an EHR-based research platform and data resource in CVD (CALIBER) and (2) to develop a
framework for exemplary prognosis research.
Methods
(1) We linked coded EHR data from four sources spanning primary care (CPRD), secondary care (HES) and
national registry databases (MINAP and the ONS death registry). (2) We established the international
PROGRESS partnership.
Results
(1) Through CALIBER, we linked and curated data covering almost 2 million people, and curated ≈ 600 EHR
disease and risk factor phenotyping algorithms based on linked EHR data. (2) We made 24 recommendations
to address challenges and opportunities across four prognosis research themes.
Conclusions
The CALIBER platform promotes the transparent and scalable use of EHR data, enabling the wealth
of information in UK EHRs to be exploited for research purposes. Our CALIBER data resource and
recommendations for improving the quality of prognosis research provide a framework for high-quality
CVD research.
Development, feasibility and validation of our data linkage platform:
ClinicAl disease research using LInked Bespoke studies and Electronic
health Records
Patients’ interactions with the health-care system generate unprecedented amounts of structured and
unstructured EHR data that are stored in disparate clinical information systems. There, rich national EHR
data sources are increasingly being linked for translational research in the USA and Europe with the
potential to have a positive impact on medical care and research. In the UK, a unique 10-digit identifier is
assigned to each patient on their interaction with the NHS, allowing the complete patient journey to be
traced through EHRs spanning primary care, hospitals, disease registries and, ultimately, death registries.
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These features have provided a platform for the CALIBER programme, led from the Farr Institute (London,
UK, under the directorship of Harry Hemingway), which has linked EHRs from four key sources: the CPRD,
HES, MINAP and the ONS death registry. CALIBER is a research platform that aims to meet the need for a
structured approach to EHR phenotyping algorithm development for epidemiological research using
national linked data, while also providing a central online repository for the storage and distribution of
algorithms, documentation (flow charts, free-text description, pseudocode) and metadata. The platform
contains EHR data on 2 million people and provides a unique platform for investigating a range of
important issues in CVD diagnosis, management and prevention, and health system performance.
Our findings have important implications for clinicians and clinical decision-making, for health policy
and for shaping future research.
Study 1: establishing the ClinicAl disease research using LInked
Bespoke studies and Electronic health Records data resource
This study is based on the peer-reviewed paper by Denaxas et al.15
Surprisingly little is known about the initial presentation of CVD in general practice and its long-term
management through to death. However, the UK is the only country in the world where all the
components of this patient journey are recorded electronically at national scale in primary care, hospital
and death registries. Moreover, all patients in the UK are uniquely identified by a 10-digit NHS number,
providing a reliable and robust identifier for record linkage and data sharing while preserving patient
confidentiality. This has provided the opportunity to develop a programme of CVD research using linked
bespoke studies and EHRs (CALIBER) led from the Farr Institute.15 The linkage was carried out in October
2010 by a trusted third party, using a deterministic match between NHS number, date of birth and sex.
Overall, 96% of patients with a valid NHS number were successfully matched.
Linked data sources
The four linked data sets that we used are shown in Figure 3, which illustrates the longitudinal,
population-based nature of CALIBER data sets. Each source captures a different aspect of the
patient journey:
l CPRD contains longitudinal primary care coded data on symptoms, diagnosis, prescriptions, investigations,
referrals and vaccinations.85 Data are recorded prospectively as part of clinical care and are not subject to
recall bias or differential bias related to outcome. Diagnostic data are coded using Read codes, which
map to Systematic Nomenclature of Medicine – Clinical Terms. Of the 684 primary care practices in CPRD
(13.6 million patients), 226 consented to data linkage across the CALIBER data sources. These practices
contained 3.9% of the population of England in 2006.
l HES is a national data set of all admissions to NHS hospitals in the UK (see www.hscic.gov.uk/hes).
Diagnoses are recorded using the International Statistical Classification of Diseases and Health-Related
Problems, Tenth Edition (ICD-10) and procedures using the Office of Population Censuses and Surveys’
Classification of Interventions and Procedures version 4.
l MINAP is a national registry of patients admitted to all acute hospitals in England and Wales with ACS
events (n = 230). For each admission, MINAP records patient demographic characteristics, limited
medical history, clinical features and investigations, drug treatment (pre, during and post admission)
and final diagnosis, including differentiation into STEMI, NSTEMI and unstable angina. Data undergo
annual quality assessments. A descriptive review of the MINAP registry has been published.86
l The ONS provides data on cause-specific mortality for all residents of the UK.87 Cause-specific mortality
data are extracted from death certificates and recorded using ICD-10. Small-area measures of social
deprivation are recorded using the 2007 Index of Multiple Deprivation (IMD)88 and Townsend scores.
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Converting raw data to research-ready data: curated common data model
Important challenges remain in relation to converting raw EHR data into research-ready variables. The
manner and reason for the generation, capture and recording of EHR data vary substantially between
health-care settings. In addition, different medical classification systems are often used for different data
sources and, consequently, clinical information may be recorded in multiple sources but at different levels
of clinical detail. Integrating data from these different sources is therefore complex, but doing so is
advantageous for research and consequently for clinical purposes. For example, our research illustrated
how linkage of EHR data sources substantially improves the identification of AMI cases.
The complexities of EHR data mean that a structured method for combining diverse data sources and
creating EHR ‘phenotypes’ is needed, but no internationally recognised framework currently exists. An EHR
phenotyping algorithm translates these clinical requirements into queries that leverage multiple linked
EHR sources, identify relevant patients and extract disease onset, severity and subphenotype information.
Defining phenotyping algorithms for a study (disease end points, disease start points, exclusions, covariates
and risk factors) consists of identifying relevant codes for diagnosis (e.g. diagnosis of cancer) or risk
factors (e.g. recording of smoking status) and defining how they should be combined. However, these
definitions, on which research findings are based, are poorly described in published literature, with the
exception of cases in which the curation of phenotyping algorithms occurs upstream by the data provider
[e.g. electronic medical records and genomics network (eMERGE)].
CPRD BP, smoking,
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GP registration
Stable
angina
Pneumonia
hospitalisation MI hospitalisation GP follow-up Death
Blood test, BP,
prescriptions
(ACEI, statins)
Sudden
cardiac
death
Diagnosis,
blood tests,
prescriptions
(aspirin, nitrates)
Admit/discharge
dates, primary
diagnosis:
viral pneumonia
Admit/discharge
dates, primary
diagnosis:
acute MI
procedure: PCI
Diagnosis:
STEMI ECG
cardiac markers
Date of death
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1. Rupture of
    AAA
2. Previous MI
Diagnosis: MI
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MINAP
ONS
FIGURE 3 Longitudinal nature of four linked primary care and disease registry data sources in the CALIBER data
resource. AAA, abdominal aortic aneurysm; ACEI, angiotensin-converting enzyme inhibitor; ECG, electrocardiogram;
MI, myocardial infarction. Reproduced from Denaxas et al.15 Published by Oxford University Press on behalf of the
International Epidemiological Association. © The Author 2012. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits
non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.3310/pgfar05040 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hemingway et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
We created and evaluated a framework (Figure 4) for transforming raw EHR data into research-ready
phenotypes in a collaborative and transparent manner by involving domain experts across disciplines
(epidemiology, computer science, public health, health informatics) and using a centralised repository for
their distribution and curation. Here, we illustrate the steps involved in creating a phenotype using the
example of atrial fibrillation (Figure 5). The framework consists of multiple iterative steps from initial
phenotype definition with domain experts to algorithm implementation, validation and distribution to the
scientific community. All CALIBER studies are registered in the public domain on Clinicaltrials.gov, and their
analytic protocol is made available for download.
To aid the process of creating, validating and disseminating EHR phenotyping algorithms for epidemiological
research, we created the CALIBER data portal (www.caliberresearch.org/portal), an interactive online
repository of phenotyping algorithms. All algorithms are displayed on the portal, where registered external
researchers can view and comment on them. A number of metadata fields is recorded for each algorithm and
is made available. The data portal contains phenotyping algorithms that leverage multiple EHR data sources in
order to define > 90 diseases and related risk factors. The data portal also facilitates the transportability of the
developed algorithms on national EHR data from different countries where subtle differences might exist in
the manner clinical information is recorded. Algorithms available through the data portal can be utilised for
performing international comparisons between health systems (e.g. England and the USA) or act as the base
on which phenotyping algorithms reflecting the local health system are created.
The CALIBER portal operates a collaboration-driven data-sharing model and prioritises collaborations based
on scientific-added value, capacity development and sustainable funding. Details on CALIBER and how to
access CALIBER resources are available at www.ucl.ac.uk/health-informatics/caliber.
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FIGURE 4 Development of a phenotype algorithm using the CALIBER programme. Reproduced from Morley et al.89
© 2014 Morley et al. This is an open-access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original author and source are credited.
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Strengths and limitations of the data platform
The CALIBER portal spans ambulatory and hospitalised care in large population samples, permitting a
‘higher resolution’ approach to cardiovascular epidemiology in three respects:
1. resolution of broad CVD aggregates (e.g. CVD, CHD) into distinct disease phenotypes in different
vascular beds:
i. cerebral circulation – transient ischaemic attack, ischaemic stroke, subarachnoid haemorrhage,
intracerebral haemorrhage
ii. peripheral circulation – PAD, abdominal aortic aneurysm
iii. coronary circulation – stable angina, unstable angina, AMI (STEMI and NSTEMI), unheralded CHD
death, heart failure, cardiac arrest/sudden coronary death
2. sufficient temporal resolution to distinguish whether a first event (e.g. heart attack or stroke) was the
first manifestation of CVD or if it was preceded by any of a range of non-fatal events
3. sufficient number of events and patients to generate accurate estimates of risk.
The main limitations of any EHR research platform relate to data quality:
1. Missing data. Data completeness is variable [e.g. 82.6% of people have ≥ 1 body mass index (BMI)
measurement but only 44.9% have ≥ 1 cholesterol measurement]. Developments in imputation within
longitudinal cohorts may offer a partial solution.90
2. CALIBER makes use of coded data from multiple national EHR sources. A plethora of unstructured data
exist in secondary care that are recorded within hospital information systems but remain inaccessible for
research. This is mainly due to the lack of a centralised manner in which these data can be extracted,
linked and utilised at scale. Significant national initiatives such as the National Institute for Health
Research (NIHR) Health Informatics Collaborative (HIC) aim to create informatics infrastructure that will
provide means for accessing these phenotypically rich data sources.
3. An important aspect of EHR phenotype development is validation, preferably against a ‘gold standard’
(such as a manual review of case notes). We could not validate the developed phenotypes in this
manner as, for the CALIBER programme, the initiation and funding of a separate study is required for
recontacting participants or clinicians to confirm diagnoses or review records. Previous studies, however,
have shown the high degree of reliability of the data.91
4. Currently, restrictive confidentiality legislation and information governance constraints in England prevent
the use of anonymised clinical text on a large scale. Electronic free text in secondary care does not get
captured or extracted in any form by HES and is thus not available for research. In primary care, free text
from GPs contributing to CPRD is downloaded and held on government servers at CPRD, and is not
readily available at scale to researchers based in universities (researchers can get access to very small
corpora of text which has to be manually anonymised, a process that requires substantial resources and
does not scale). Consequently, our approach to developing phenotyping algorithms has limited ability to
fully utilise data elements extracted from clinical text as others have done.
Study 2: completeness and diagnostic validity of recording acute
myocardial infarction events in primary care, hospital care,
disease registry and national mortality records
This study is based on the peer-reviewed paper by Herrett et al.28 Sections of the text have been
reproduced/adapted from the original article; Copyright © Herrett et al.28 2013. This is an Open Access
article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0:
https://creativecommons.org/licenses/by-nc/3.0/) license.
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Introduction
We assessed the concordance, completeness and diagnostic validity of AMI recording across CPRD, HES,
MINAP and ONS in order to ensure the robustness of the data linkage. Our specific aims in this study were
to compare the incidence, recording, agreement of dates and codes, risk factors and all-cause mortality
of AMI.
Methods
Study population and follow-up
We identified records of AMI in CPRD, HES and ONS. In MINAP, STEMI and NSTEMI were identified
using hospital discharge diagnosis, markers of myocardial necrosis and coded electrocardiogram (ECG)
findings, in accordance with the international definition of AMI.92 The study period was 1 January 2003
to 31 March 2009 (when all record sources were concurrent) and confined to patients who had been
registered with their general practice for at least 1 year. We selected the first record of AMI during the
patient’s study period as the index event and considered AMI records in the other data sources as
representing the same event if they were dated within 30 days of the index event. Follow-up after a record
of AMI was for death as recorded in the ONS death registry. We categorised patients as having fatal or
non-fatal AMI according to whether or not they died of any cause within 7 days of AMI.
Agreement in recording
If the time difference between the earliest date of AMI in different sources was ≤ 30 days we considered
that the records of AMI in the different sources agreed. An AMI recorded > 30 days after the earliest date
was considered a new event and was not included, ensuring that each patient appeared only once in
the analysis.
Statistical analysis
We estimated population-based incidence rates of fatal and non-fatal AMI using the denominator of all
adults in the CALIBER primary care population aged ≥ 18 years (2.2 million people), followed up for a
mean 4.1 years between 2003 and 2009. We used each of the data sources separately and together to
identify incident AMI. We compared patients with fatal and non-fatal AMI identified in the four data
sources for risk factors and coexisting conditions recorded in primary care. We produced cumulative
incidence curves for coronary and non-coronary mortality for patients recorded in each data source and
compared mortality using a Cox proportional hazards model adjusted for age and sex. We would expect
patients who survived 7 days after AMI to be recorded in CPRD, MINAP and HES, and we assessed
agreement between these three sources in a Venn diagram. For patients who died within 7 days, we
examined the proportion recorded by each source but did not compare agreement across all four sources,
as we would not expect the hospital discharge data and disease registry to record patients who died
before reaching hospital. In patients who did not have a record of AMI in one or more data sources, we
looked for other codes that may have been used to describe the event. In MINAP, we looked for admission
diagnoses of any ACS. In CPRD and HES, we sought other ACS, coronary disease, chest pain or other
cardiac diagnoses (e.g. atrial fibrillation, heart failure, cardiac arrest). In CPRD we also examined codes
indicating contact with secondary care. Where none of these codes was recorded, we tabulated all
recorded codes in the 30 days before and after the date of AMI to see if there were any relevant codes
that we had overlooked. We performed a logistic regression analysis to establish whether age, sex,
deprivation, rate of primary care consultation, year of AMI or mortality at 30 days explained suboptimal
recording of AMI in CPRD, HES or MINAP sources. We calculated the positive predictive value (PPV) of
CPRD or HES diagnoses of AMI among patients who also had a record in MINAP.
Results
Some 21,482 patients had a record of fatal or non-fatal AMI recorded in any of the four data sources.
Single-source crude estimates for incident AMI per 100,000 patient-years are shown in Figure 6. The crude
incidence of AMI was 25% lower using only CPRD and 50% lower using only MINAP compared with
using all three sources.
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Cardiovascular risk factors and comorbidity
Cohorts identified from CPRD, HES and MINAP had a similar prevalence of cardiovascular risk factors and
comorbidities. However, compared with patients recorded only in MINAP or HES, those with AMI recorded
only in CPRD were, on average, 2 years younger, more likely to be current smokers and in the most
deprived quintile for socioeconomic status (p < 0.001 for these comparisons). Patients recorded in ONS
were older than patients in the other sources and had a higher burden of risk factors reflecting their age.
However, other demographic characteristics and cardiovascular risk factors were broadly similar across
patients recorded in primary care and hospital care sources.
Death after acute myocardial infarction
Crude 30-day mortality was lower in MINAP [hazard ratio (HR) 10.8%, 95% confidence interval (CI)
10.2% to 11.4%] than in HES (HR 13.9%, 95% CI 13.3% to 14.4%) or CPRD (HR 14.9%, 95% CI
14.4% to 15.5%) (Figure 7a). At 1 year, however, mortality was similar in all three groups, at around 20%
(Figure 7b).
In the linked data, patients with AMI recorded in only one source had higher mortality than those recorded
in more than one source (age- and sex-adjusted HR 2.29, 95% CI 2.17 to 2.42; p < 0.001); those recorded
only in CPRD had the highest mortality on the first day but the lowest mortality thereafter, compared with
HES and MINAP (adjusted HR for coronary mortality 0.49, 95% CI 0.40 to 0.60; p < 0.001; and for other
causes 0.57, 95% CI 0.49 to 0.67; p < 0.001). Of the 3518 patients with AMI recorded in any of the
four sources who died of any cause within 7 days, 54.4% (n = 1914) had an AMI code recorded in CPRD
within 30 days. The underlying cause of death recorded in ONS was AMI in 2924 patients (83.0%).
Of fatal AMIs identified by ONS, only 36.7% (n = 1072) were recorded in HES and 17.1% (n = 498) in
MINAP within 30 days, but 55.9% (n = 1631) were recorded in CPRD.
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FIGURE 6 Crude incidence of fatal and non-fatal AMI estimated using different combinations of data from primary
care (CPRD), hospital admissions (HES), disease registry (MINAP) and death registry (ONS). MI, myocardial infarction.
Reproduced from Herrett et al.28 Copyright © 2013, British Medical Journal Publishing Group. This is an Open
Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
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Non-fatal acute myocardial infarction
Among the 17,964 patients with at least one record of non-fatal AMI, 13,380 (74.5%) were recorded in
CPRD, 12,189 (67.9%) in HES and 9438 (52.5%) in MINAP. Overall, 5561 (31.0%) patients had the event
recorded in all three sources and 11,482 (63.9%) patients had it recorded in at least two sources (Figure 8).
When we extended the recording window from 30 to 90 days, the proportion recorded in all three sources
increased only slightly, to 32.0% (n = 5747). Only 25.1% (3364/13,380) of the non-fatal AMIs recorded in
CPRD stated the type (STEMI or NSTEMI), compared with 100% in MINAP.
Positive predictive value
For CPRD or HES patients with an associated record in MINAP, the PPV of the AMI diagnosis (the
probability that the diagnosis in MINAP was AMI rather than unstable angina or a non-cardiac diagnosis)
was 92.2% (95% CI 91.6% to 92.8%; 6660/7224) in CPRD and 91.5% (95% CI 90.8% to 92.1%;
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FIGURE 7 Kaplan–Meier curves. (a) Kaplan–Meier curves showing 30-day all-cause mortality, stratified by record
source (CPRD, HES and MINAP) in 20,819 patients. CPRD, n= 15,819; HES, n= 13,831; and MINAP, n= 10,351. MIs
recorded by the ONS are not shown, as they are, by definition, fatal on the date of AMI; and (b) Kaplan–Meier
curves showing 12-month all-cause mortality, stratified by record source (CPRD, HES and MINAP) in 20,819 patients.
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6851/7489) in HES (Table 4). Eighty-five per cent of patients recorded in CPRD and HES (7386/8707) had
a record of raised cardiac markers and half (3766/8707) had a record of ST-segment elevation on
electrocardiography.
Discussion
In comparing records of one major disease event – AMI – across CALIBER’s four linked sources, we found
that each source misses a substantial proportion of events. However, our data confirm the validity of AMI
recorded in these sources, in terms of risk factor profiles and mortality at 1 year. Taken together, these
findings support the wider use of linkage of multiple record sources by clinicians, policy-makers and
researchers in order to maximise diagnostic capture.
Fatal acute myocardial infarction
Both CPRD and ONS can be used to capture fatal AMI occurring out of hospital among people without a
record in HES or MINAP. ONS is the most useful source for research, identifying AMI as the cause of death
in 83.0% of patients who died within 7 days with AMI recorded in any of the data sources. These figures
agree with the Oxford Record Linkage Study where, among 5686 patients admitted to hospital with AMI,
85.2% who died within 30 days had AMI recorded as the underlying cause of death.93
Non-fatal acute myocardial infarction
Only one-third of non-fatal AMIs were recorded in all three data sources (primary care, hospital admissions
and disease registry) and two-thirds in at least two sources. CPRD was the single most complete source of
non-fatal AMI records, missing one-quarter of recorded cases, with HES missing one-third and MINAP
missing nearly half of recorded cases (see Figure 8). This agrees with the results of other two-source
comparisons of AMI recording in Scotland, Australia, Denmark and the Netherlands, all of which showed
that combining sources provided the highest estimates of incidence.94–97 Despite the low sensitivity of
CALIBER’s individual data sources, the diagnostic validity of AMI records in CPRD and HES was high,
as reflected by a PPV of > 90% compared with the MINAP gold standard, based on the international
definition of AMI. Our results using cross-referencing of EHRs in 20,000 patients are consistent with
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FIGURE 8 Number and percentage of records recorded in primary care (CPRD), hospital care (HES) and disease
registry (MINAP) for non-fatal AMI across the three sources (n= 17,964 patients). Reproduced from Herrett et al.28
Copyright © 2013, British Medical Journal Publishing Group. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits
non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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previous manual approaches to validation in primary care, which cross-reference a few hundred patients
with disease diagnoses recorded using Read codes against anonymised free text, death certificates, paper
medical records or hospital discharge summaries, or questionnaires to GPs.86,98–104 Our much larger sample
size, however, allowed us to evaluate individual Read terms that are used to record AMI. This type of
validation has not been done previously for AMI and may be relevant to other common conditions that
can be recorded using a variety of codes, such as stroke.105
Hospital admission data
To our knowledge, no studies have examined the PPV of ICD-10-coded AMI diagnosis in hospital admission
data (HES) against an ongoing disease registry (MINAP). We found that 62.8% of non-fatal AMIs recorded in
CPRD and 72.6% recorded in MINAP were also in the HES record. This is consistent with a single EHR source
(HES ICD-10 I21 and I22) capturing 53% of AMIs in an investigator-led cohort with active follow-up.106
Disease registry and maximising true positives
The strengths of MINAP lie in the fact that its diagnostic records (troponin values, ECG findings, and
cardiologist diagnosis of STEMI and NSTEMI), offering validated end points electronically for all hospitals in
England and Wales, are not available in other sources. An AMI recorded in MINAP is thus an EHR gold
standard and may be important for detecting end points in cohort studies and trials, in which false
positives can dilute any observed effect and reduce the power of a study. Furthermore, in such studies it
TABLE 4 Information recorded in a disease registry (MINAP) within 30 days for non-fatal AMI recorded in primary
care (CPRD) or hospital admissions (HES)
Information in MINAP
Source of AMI record
CPRD HES CPRD and HES
Number of patients 7224 7489 6006
Electrocardiographic findings, n (%)
ST-segment elevation 3373 (46.7) 3455 (46.1) 3062 (51.0)
Other abnormality 2337 (32.4) 2485 (33.2) 1816 (30.2)
Normal 389 (5.4) 429 (5.7) 306 (5.1)
Not recorded 1125 (15.6) 1120 (15) 822 (13.7)
Cardiac markers, n (%)
Raised 6149 (85.1) 6358 (84.9) 5121 (85.3)
Normal 368 (5.1) 411 (5.5) 299 (5.0)
Missing 707 (9.8) 720 (9.6) 586 (9.8)
Peak troponin
Level recorded, n (%) 6109 (84.6) 6357 (84.9) 5029 (83.7)
Median (IQR), ng/ml 2.03 (0.47–10.0) 2.04 (0.45–10.2) 2.34 (0.53–11.6)
CALIBER diagnosis
STEMI, n (%) 3386 (46.9) 3441 (46.0) 3064 (51.0)
NSTEMI, n (%) 3274 (45.3) 3410 (45.5) 2497 (41.6)
Unstable angina, n (%) 384 (5.3) 425 (5.7) 312 (5.2)
Other, n (%) 180 (2.5) 213 (2.8) 133 (2.2)
Positive predictive value (95% CI) for AMI 92.2 (91.6 to 92.8) 91.5 (90.8 to 92.1) 92.6 (91.9 to 93.3)
IQR, interquartile range.
Reproduced from Herrett et al.28 © 2013 Herrett et al.28 This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial
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has been shown that avoiding false positives is more important than avoiding false negatives.107 Validation
of AMIs recorded by primary care and hospital admissions against those recorded by the disease registry
showed a PPV of > 90%, making them suitable for detecting end points in cohort studies and trials, where
poor end-point resolution can dilute any observed effect and reduce the power of a study. The PPV was
not 100% because some AMI records in primary care may actually have been related to unstable angina or
chest pain of unknown cause.
Limitations
Our data were from a sample of 244 English general practices contributing to CPRD. However, patients
in practices that participated in CALIBER are representative of the UK population and also of CPRD as a
whole in terms of age, social deprivation, BMI and prescription of key drugs.108 Hospital admissions with
linked primary care data were also representative of all admissions to hospital in England in terms of the
distribution of age, sex and diagnostic group.109 The UK Life Sciences Strategy16 aims to increase the
proportion of the UK population available for research through the CPRD.6
A second limitation concerns the generalisability of our findings for the quality of primary care data.
Practices contributing data to CPRD are advised of recording guidelines and their data are accepted only
when they meet standards of data completeness, so they are likely to record disease events better than
practices that do not contribute. Our estimates of agreement may therefore be higher than for practices
that do not contribute to CPRD.
Third, our validation of HES and CPRD AMIs against MINAP was limited to the subset of patients with a
MINAP record, and caution must be exercised in extending these conclusions to patients with AMIs
without a MINAP record.
Implications for research using ClinicAl disease research using LInked Bespoke
studies and Electronic health Records data
Our findings show that by linking EHRs we not only provide a longitudinal component with which to map
the CVD journey from first diagnosis to death, but also enrich the data sources and maximise capture of
AMI with a high level of diagnostic validity. Assuming this extends to other manifestations of CVD, our
findings provide reassurance that the CALIBER programme has the scale and diagnostic validity necessary
for national EHR research.
Clinical and policy implication
We propose much wider use of linked record sources in commissioning and in research to estimate disease
occurrence and outcome, because of the biases inherent in using only one source of records. Our findings
underscore the importance of international initiatives to accelerate availability of linked data in the USA,
Europe and elsewhere (see www.research.va.gov/mvp/ and https://healthy.kaiserpermanente.org).110 Going
forward, a national strategy for biomedical informatics is required based on a single record for a single
health-care event that is propagated in multiple record systems. Efforts to reform the process of death
certification are already under way,111 but this needs to be broadened to include other health records.
Primary care records could be improved by recording AMI only for its occurrence rather than repeated
entries for consultations related to a history of AMI.
Future research
Several lines of research are warranted by our findings. First, research is required to understand how
the coding of EHR data can be improved. Second, more extensive cross-referencing is required against
additional sources of information on AMI. These include self-reported AMI (which may be less dependent
on specific settings in the health system) and manual review of all the available local case records (paper
and electronic). Investigation of uncoded electronic free text in the primary care record will enhance its
data yield and is a key part of both our research and that of the UK Biobank cohort (n = 500,000).107,112
Investigators are beginning to recognise the value of linking bespoke cohorts and trials with the primary
care record and also with national disease registries, such as MINAP, for the capture and validation of
ischaemic end points.113
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Conclusions
Our findings show that by linking EHRs we not only provide a longitudinal component with which to map
the CVD journey from first diagnosis to death but also enrich the data sources and maximise capture of
AMI with a high level of diagnostic validity. Assuming this extends to other manifestations of CVD, our
findings provide reassurance that the CALIBER programme has the scale and diagnostic validity necessary
for national EHR research.
PROGnosis RESearch Strategy
In an era when more people are surviving disease than ever before, researchers are increasingly focused on
the study of prognosis, which provides crucial evidence for translating research findings into clinical practice.
However, prognosis research studies often fall far short of the high standards required in other fields such
as therapeutic trials. Serious flaws in the design, conduct and reporting of prognosis studies need to be
addressed, and the clinical value of reliable prognostic evidence needs to be more widely recognised.
Hemingway et al.114 and von Elm et al.115 have highlighted that the field of prognosis research, which
spans quality of care and outcomes research, prognostic factor research and prognostic models, faces
multiple methodological challenges. These include the proliferation of small studies, lack of biomarker
replication, lack of systematic evaluations of the quality of research on a single prognostic biomarker and a
dearth of studies that provide clinically actionable decision support.
To address this issue, we established the PROGRESS partnership, with representatives from academia
and medical journals. Our aim was to create a more coherent and rigorous framework for prognosis
research, with specific recommendations on how the field can be developed and broaden its impact. Key
principles have been summarised in a series of articles in medical journals and on the PROGRESS website
(http://progress-partnership.org/).29–33
Study 3: the PROGnosis RESearch Strategy partnership
This study is based on peer-reviewed papers by Hemingway et al.,29 Hingorani et al.,30 Riley et al.,31
Steyerberg et al.32 and Peat et al.33
In 2012 we established the PROGRESS initiative, which seeks to promote high-quality prognostic research
leading to patient benefit. The partnership was set up to analyse research into quality-of-care outcomes,
prognostic factors, risk prediction models and predictors of differential treatment response. We outlined
a framework for prognosis research, published as a series of British Medical Journal (BMJ) and PLOS Medicine
articles with recommendations across five key areas: (1) fundamental prognosis research – the course of
health-related conditions in the context of current care; (2) prognostic factor research – studies of specific
factors such as biomarkers associated with prognosis; (3) prognostic model research – development,
validation and impact of statistical models that predict individual risk of a future outcome; (4) stratified
medicine research – use of prognostic information to tailor treatment decisions to an individual or group of
individuals with similar characteristics; and (5) transparency of research – the role of reporting, data sharing,
study registration and protocols.29–33 Our recommendations were designed to improve the design, conduct,
analysis and reporting of prognosis research, which will be crucial if prognosis research is ultimately to
improve patient outcomes. We made 24 recommendations to address challenges and opportunities for
prognosis research, including the introduction of new programmes of methodological and empirical
prognosis research exploiting EHRs to define, phenotype and follow up people with different health-related
conditions (recommendation 3)29 and the establishment of a comprehensive set of clinical cohorts recruiting
people with specified health-related condition(s), including diagnosed disease and symptoms as platforms for
addressing a wide range of prognosis research questions (recommendation 14).29
In many diseases, the most intensively studied prognostic factors are biomarkers. There is potential for
identifying prognostic factors, from their use within current clinical practice to their implications for
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randomised trial design and developing new interventions. With a suitable prognostic model, decision-makers
can use multiple prognostic factors to improve the targeting of interventions on the basis of patients’
predicted individual risk of subsequent outcomes.
Many prognostic models have been described, yet few are used or implemented in clinical practice.
They are often developed from inadequate data, inappropriately analysed and poorly reported, and few
models are evaluated for their impact on health outcomes (Figure 9). We outlined several key steps to
make prognostic models more useful, including improved development of models, validation, evaluation
of impact on clinical practice and outcomes, updating and clinical use. In addition, any prognostic models
are used without clear evidence of their impact, whereas other well-developed and validated models are
not used. We encourage researchers to support collaborative efforts to share individual patient data, to
improve model development and external validation. With biomarker and -omics research generating a
wealth of possible new factors to incorporate into models, the extent to which new markers add value to
existing models needs to be assessed.
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Chapter 3 Inequalities in the incidence of
12 cardiovascular diseases across the patient journey
Abstract
Background
Understanding how CVDs first present is vital to organise primary and secondary prevention efforts, but little
is known about CVDs other than AMI, stroke and coronary death. UK South Asian populations are particularly
affected by CHD but it is unclear if this reflects a higher incidence of disease, worse prognosis or both.
Objectives
(1) To identify how the development of 12 CVDs is affected by age, sex, ethnicity and socioeconomic
deprivation; and (2) to examine the complex relationships between incidence and prognosis of CHD
among South Asian populations.
Methods
(1) An analysis of CALIBER linked data; and (2) an analysis of cohort data and a meta-analysis of
published data.
Results
(1) Acute myocardial infarction, stroke and coronary death collectively account for just 34% of initial
cardiovascular events. The strength and shape of the association of CVDs differed with age, and the risk
of different CVDs differed by sex. Initial presentation of CVDs showed considerable heterogeneity with
deprivation. Those of South Asian ethnicity were at substantially increased risk of all coronary presentations
compared with white patients. (2) CHD incidence among those of South Asian ethnicity was markedly
higher than among white patients, but their prognosis was significantly better.
Conclusions
These are the only contemporary, large-scale incidence estimates of a wide range of fatal and non-fatal
cerebrovascular, cardiac and peripheral CVDs. Our findings are crucial for understanding the global burden
of CVDs. Our findings argue against the use of composite measures of cardiovascular health, which
may mask important variability across conditions.
The studies in this chapter relate to people without established disease (healthy population) (Figure 10).
Study 4: inequalities in the presentation of cardiovascular
diseases, by age, sex, ethnicity and deprivation
This study is based on the peer-reviewed papers by Pujades-Rodriguez et al.34 and George et al.35
Introduction
An important principle in CVD management is that the first lifetime diagnosis indicates the failure of
primary prevention and the need for measures to prevent subsequent events. The decades-long emphasis
given to the prevention of AMI and stroke is reflected in the significant declines in their incidence in
developed countries.119 Incidence rates for angina, heart failure and other chronic CVD presentations do
not appear to have similarly declined.119–121 Consequently, the spectrum of initial lifetime presentations
of CVD in contemporary practice is likely to have changed, compared with the end of the last century.
Cohort studies that report only fatal end points (‘final presentations’)122 are less informative for primary
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preventative efforts than those that investigate initial lifetime presentations, and studies that include
non-fatal events have generally focused on AMI and stroke while ignoring other CVDs.123–126
Large-scale studies that evaluate the first lifetime diagnosis in different ages, sexes, socioeconomic groups
and ethnicities across a wide range of acute and chronic CVDs including both fatal and non-fatal
presentations are overdue.
Fundamental unanswered questions about initial lifetime CVD presentation arise. First, what is the relative
frequency of different CVDs as they affect different ages, sexes, ethnicities and socioeconomic groups in
contemporary practice? Second, what is the lifetime risk of the most common CVDs? Lifetime risks provide
an intuitive measure of the burden of each disease in the population, relevant to public health policy and
risk communication. Lifetime risks have recently been reported for CHD and CVD aggregates127–129 and
heart failure,130 but rarely for a wide range of initial presentations of CVDs.38 Third, is male sex an equally
strong risk factor common to all CVDs, or does the association differ across a range of diseases?
The lack of large, contemporary, population-based cohorts with detailed clinical follow-up spanning
hospital and ambulatory care has hindered the study of the initial presentation of a wide range of acute
and chronic CVDs. It has been suggested that EHR data might be ‘meaningfully reused’131 to create ‘mega
cohorts’ for such research.132 We studied a contemporary, population-based cohort based on linked EHRs
across primary, secondary, disease registry and death records to address these questions.
Methods
The CALIBER study population was 1,937,360 patients for age, sex and deprivation analyses, and
1,068,318 for ethnicity analyses. For ethnicity, patients were categorised as white, black, South Asian or
other/mixed. Deprivation was measured by the IMD (2007 revision),88 derived from postcode of residence.
Patients were categorised into quintiles, where the first quintile indicated the least deprived and the fifth
quintile indicated the most deprived group. Primary end points for the analysis were the initial presentation
of fatal and non-fatal CVDs across the CALIBER data sources. CVD presentations studied were stable
angina, unstable angina, AMI, heart failure, a composite of ventricular arrhythmia, cardioversion, cardiac
arrest or sudden cardiac death (SCD), transient ischaemic attack, subarachnoid haemorrhage, intracerebral
haemorrhage, ischaemic stroke, abdominal aortic aneurysm and PAD. Data analysis was based on Cox
proportional hazards models.
Results
Follow-up was for a median of 5.5 years, during which 114,859 subjects experienced one of the 12 CVDs
(52.3% in men). AMI, stroke and coronary death accounted for less than one-third of the total CVD
presentations recorded in CALIBER.
Age
The strength and shape of the association of CVDs with age (Figure 11) varied from predominantly linear
(in angina and non-fatal AMI) to strongly quadratic (unheralded coronary death, stroke, abdominal aortic
aneurysm), and from weak (subarachnoid haemorrhage, unstable angina and cardiac arrest-SCD) to very
strong (heart failure and abdominal aortic aneurysm).35
Sex
The most frequent initial CVD presentation was non-fatal AMI for men (17% of total CVD) and stable
angina for women (12% of total CVD) (Figure 12). The cumulative lifetime incidence of CVD was 51.3%
for men and 41.2% for women. Men were more likely than women to experience non-fatal AMI (7.1% vs.
3.9%) and abdominal aortic aneurysm (2.4% vs. 0.9%). Men experienced conditions affecting the
myocardium, PAD and abdominal aortic aneurysm around 10 years earlier than women. However, the
lifetime incidence of heart failure (8%), transient ischaemic attack (5%), ischaemic stroke (3%) and
intracerebral haemorrhage (1%) was similar in men and women.
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Apart from subarachnoid haemorrhage (HR men vs. women 0.69; 95% CI 0.59 to 0.79), all presentations
showed a positive association with male sex (Figure 13). However, the strength of this association varied
markedly: for transient ischaemic attack, intracerebral haemorrhage and unstable angina, age-adjusted HRs
for male sex were < 1.5; for stable angina, ischaemic stroke, PAD, heart failure and cardiac arrest/SCD they
were between 1.5 and 2.0; and for abdominal aortic aneurysm, AMI and unheralded coronary death they
were between 3.6 and 5.0.
Ethnicity
South Asian ethnicity was associated with a substantially increased hazard of initial presentation with
coronary presentations compared with white ethnicity (stable angina: HR 1.67, 95% CI 1.52 to 1.84;
unstable angina: HR 1.82, 95% CI 1.56 to 2.13; and AMI: HR 1.67, 95% CI 1.49 to 1.87). Conversely,
black ethnicity appeared to be protective, with HRs for initial presentation with coronary presentations
consistently < 1.0. There was a tendency towards a greater hazard of initial presentation with ischaemic
stroke and intracerebral haemorrhage in people of black ethnicity, and in both black and South Asian
populations hazards of subarachnoid haemorrhage and PAD were lower than in white populations.
Deprivation
Associations of deprivation with initial presentations of CVDs showed considerable heterogeneity in
both women and men. In women (Figure 14), socioeconomic deprivation showed no association with
abdominal aortic aneurysm. In men too there was no association with abdominal aortic aneurysm and no
association with stable angina, cardiac arrest-SCD, subarachnoid haemorrhage or transient ischaemic
attack. For other CVDs, hazard increased linearly with deprivation quintile, the increase being comparable
between the sexes for unstable angina, AMI and heart failure, but steeper in men for PAD, ischaemic
stroke and intracerebral haemorrhage.
Events
Coronary
Stable angina
Unstable angina
MI
Unheralded CHD death
Other myocardial
Heart failure
Cardiac arrest/SCD
Cerebrovascular
Transient ischaemic attack
Ischaemic stroke
Subarachnoid haemorrhage
Intracerebral haemorrhage
Abdominal and lower limb
PAD
Abdominal aortic aneurysm
Heterogeneity: I2 = 99.2%, τ2 = 0.196
 
13,221
5636
16,239
5515
 
14,359
3375
 
11,714
6053
1278
2388
 
11,519
3135
1 2 3 4
 
1.64
1.46
3.72
4.32
 
2.00
2.09
 
1.24
1.62
0.69
1.39
 
1.74
3.55
 
(1.56 to 1.73)
(1.36 to 1.57)
(3.53 to 3.91)
(3.84 to 4.86)
 
(1.83 to 2.18)
(1.90 to 2.29)
 
(1.16 to 1.32)
(1.49 to 1.78)
(0.59 to 0.79)
(1.23 to 1.58)
 
(1.65 to 1.85)
(2.85 to 4.43)
HR 95% CI
HR
FIGURE 13 Hazard ratios of men vs. women for initial lifetime presentation of 12 different CVDs among a
population of 1.93 million adults. The vertical grey dotted line corresponds to the HR of the composite CVD end
point. Reproduced from George et al.35 Copyright © 2015 The Authors. Circulation is published on behalf of the
American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/4.0), which permits use, distribution, and
reproduction in any medium, provided that the original work is properly cited.
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Differences in lifetime risk between the least and most deprived quintiles were greatest for PAD in both
women (4.3% vs. 5.8%) and men (4.6% vs. 7.8%). However, in both sexes, differences were small or
non-existent for cardiac arrest-SCD, transient ischaemic attack, abdominal aortic aneurysm, and ischaemic
and intracerebral haemorrhage.
Discussion
By linking EHRs, this study has analysed > 100,000 initial CVD presentations arising in a cohort of nearly
2 million people, providing sufficient scale to distinguish multiple types of CVD and assess inequalities in
the risk of initial presentation according to age, sex, ethnicity and levels of deprivation. Through the use of
linked EHRs, we were able to capture diseases first presenting in primary care and were not confined to
hospitalised cases. Our cohort is population based, with > 99% of the English population estimated to
be registered with a family physician,133 unlike other recent large recent cohort studies, such as the UK
Biobank,107 which had response rates of < 10%.134 The size of cohort possible with this EHR platform –
nearly 2 million people – allows us to include serious but less common events such as abdominal aortic
aneurysm and subarachnoid haemorrhage, as well as to have sufficient events in women to study sex
differences reliably. We were able to follow up actual events in a clinically meaningful 5-year time frame,
similar to the time horizon of randomised controlled trials (RCTs). More broadly, we demonstrate the
potential of linked EHR cohorts to complement bespoke, investigator-led cohorts.73 The UK Biobank,107,112
the Research Program for Genes Environment and Health in Kaiser12 and the ‘precision’ medicine
initiatives135 all place a major emphasis on specific disease types and follow-up through health records.
Furthermore, such large EHR cohorts hold out the promise of a lower cost to research funders for data
collection, the intrinsic clinical relevance of ‘real-world’ data, the opportunities to study diseases with
higher specificity given the cohort sizes possible, and the prospect for researchers and clinicians to work
across the boundaries that currently impede the translation of new discoveries into public health benefit.73
Although AMI and ischaemic stroke are the most commonly used end points in trials, they collectively
account for just 34% of initial cardiovascular events. The majority of cardiovascular presentations are heart
failure, angina, transient ischaemic attack and PAD, which are rarely evaluated individually in primary
prevention studies.
Despite recent progress in prevention, there is still a 45% lifetime risk of any CVD between the ages
of 30 and 95 years, with men at greater risk than women (51.3% vs. 41.2%). However, the effect of
male sex varies significantly between the 12 different CVD presentations. Men are actually less likely to
experience subarachnoid haemorrhage and show similar incidence levels to women for several conditions.
Male sex showed a moderate association with five presentations and a strong association with abdominal
aortic aneurysm, AMI and unheralded coronary death. However, because men typically experience some
CVDs at a younger age, the lifetime incidence of several presentations (heart failure, transient ischaemic
attack, ischaemic stroke and intracerebral haemorrhage) was similar in men and women.
Differences in the risk of CVDs associated with South Asian and black ethnicity were striking but often
affected different vascular beds. Thus, the heightened risk of presenting with coronary disease among
South Asian than white populations contrasted with the reduced risk for people of black ethnicity who
were more subject to haemorrhagic stroke. However, those of both South Asian and black ethnicity had a
reduced risk of presenting with PAD than people of white ethnicity, which was consistent with the findings
of a recent meta-analysis.136
Similarly, we found that simple associations between local socioeconomic deprivation and broad categories
of CVD do not hold true for more granular CVD classifications, particularly in men. Age was an important
influence, with associations between socioeconomic deprivation and CVDs falling with increasing age.
Hence, the cardiovascular health risk linked to local socioeconomic deprivation falls most heavily on
younger people, and on young women in particular.
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Our findings suggest that future research on the primary prevention of CVDs should take account of current
patterns of disease presentation and redress the imbalance of previous literature, which has focused
overwhelmingly on heart attack and stroke. Estimates of national and global burden of CVDs need to take
account of the modern epidemic in which heart failure, PAD and other chronic diseases are becoming more
common than AMI and stroke. Male sex, older age, South Asian ethnicity and low levels of social deprivation,
although associated with some CVDs, are not associated with all, and this heterogeneity has implications for
research into risk prediction, aetiology and prognosis.
Our findings have implications for the design and interpretation of observational studies, randomised trials
and meta-analyses investigating the primary prevention of CVDs. Because the fundamental risk factors of
age and sex have such heterogeneous associations with different CVDs, and most studies are sufficiently
powered to examine only CVD aggregates, it is important to account for the relative proportion of
each disease in the composite end point in meta-analysis. These proportions have been shown to differ
substantially between studies.137 Despite an extensive literature on the underlying biological and behavioural
pathways by which sex may influence aggregates of CVD and CHD, there is a lack of mechanism studies
that investigate why sex has such heterogeneous associations with different CVDs.
Conclusions
These inequalities in CVD development support the use of separate risk models for women and men
and for different ethnic groups. They argue against the use of composite measures of cardiovascular
health, which may mask important variability across conditions. The findings suggest that policies and
interventions targeting local socioeconomic deprivation are likely to have the greatest impact on specific
forms of CVD, such as heart failure and PAD, and on women. Whether or not the complex inequalities in
CVD development are associated with inequalities in CVD outcomes is an important question that we
begin to address in the following study, which focuses on ethnicity and its association with incidence and
prognosis of CHD.
Study 5: acute coronary disease – incidence and prognosis of acute
coronary syndromes in South Asian and white populations
This study is based on a peer-reviewed paper by Zaman et al.36
Introduction
Data presented in study 4 point strongly to greater disease incidence as a key contributor to the higher
coronary death rate in South Asian people than in white people living in the UK. Whether or not a worse
prognosis among people with established coronary disease also contributes to this higher death rate remains
unresolved. Understanding the relative importance of incidence and prognosis to health outcomes would
provide important information to guide the most appropriate public health interventions. To generate a
clearer picture, this study adopted a two-pronged strategy. A systematic review and meta-analysis was carried
out to synthesise the evidence on coronary disease incidence and prognosis in South Asian populations. In
addition, MINAP data were used to generate a contemporary cohort of South Asian patients from England
and Wales, to examine possible factors affecting prognosis in this group.
Methods
The systematic review was based on an expert search strategy of the published literature in MEDLINE
(PubMed) from inception until January 2012 to identify papers on incidence or prognosis in people of
South Asian ancestry specifically related to coronary disease. Three reviewers independently extracted
information according to a predetermined protocol. The new ACS cohort was based on consecutively
collected patients from 230 hospitals in England and Wales recorded in MINAP between 2004 and 2008.
The primary outcome measures were age-adjusted mortality at 1 year and at 30 days.
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Results
Incidence
The meta-analysis was based on data for 111,555 people of South Asian ethnicity and 4,197,923 white
people included in 11 eligible studies. It showed that South Asian participants had a higher incidence of
coronary disease than white people (HR 1.35, 95% CI 1.30 to 1.40). This was consistent for the two
cohorts examining incidence of fatal coronary disease and the studies examining incidence of non-fatal
(alone or with fatal) coronary disease (Figure 15).
Prognosis
By contrast, an analysis of 12 prognosis populations including 14,531 South Asian and 274,977 white
patients showed that South Asian individuals had a better prognosis than white people (HR 0.78, 95% CI
0.74 to 0.82). This more favourable prognosis was particularly apparent in bigger, more recent studies on
acute clinical presentations (Figure 16). In the ACS cohort, diabetes was markedly more common in South
Asian than in white populations (42.4% vs. 16.9%) and had greater impact on mortality. Even so,
prognosis was superior for South Asian people overall and in most subgroups analysed, including those
with diabetes (HR 0.78, 95% CI 0.71 to 0.86), those of older age (≥ 80 years of age; HR 0.72, 95% CI
0.63 to 0.83) and those living in areas of highest social deprivation (HR 0.73, 95% CI 0.65 to 0.82).
This superior prognosis was seen for patients of Indian, Pakistani and Bangladeshi origin. It was also seen
over the 30-day time frame (HR 0.85, 95% CI 0.77 to 0.94, after adjustments). An analysis of the MINAP
cohort showed that South Asian patients with ACS were more likely than white patients to receive
revascularisation and to be discharged on four secondary prevention medications.
Discussion
The evidence synthesis suggests that South Asian ethnicity has different effects on the incidence and
prognosis of coronary disease. Although South Asian patients show a markedly higher incidence than white
patients, after adjustment for age, risk factors and disease severity, their prognosis is significantly better.
This study confirms ethnic inequality in the risk of developing coronary disease, consistent with our
CALIBER analyses in study 4. The present meta-analysis confirmed that South Asian patients with SCAD
were at no prognostic disadvantage. Indeed, among South Asian patients with ACS, prognosis was
significantly better than for white patients. There was no evidence of undertreatment, with South Asian
patients being more likely to be prescribed secondary prevention medications at discharge and more likely
to have undergone coronary angiography. This may reflect awareness on the part of physicians of the
great coronary disease risk in South Asian groups, or a more general awareness in the health system of
factors relevant to the health of South Asian individuals.
Large cohort studies identified through linkage of primary care, ACS registry, hospitalisation and
cause-specific death data are warranted to better understand how South Asian ethnicity influences the
onset and progression of coronary disease and other CVDs. Such studies will allow longitudinal patterns of
risk, and missed opportunities to lower risk before admission and after discharge, to be evaluated.
Conclusions
Although South Asian populations experience health inequalities in coronary disease, this study suggests
that this reflects a higher incidence of disease rather than deficiencies in service provision affecting
prognosis. The findings therefore suggest that public health measures to tackle ethnic inequalities in
coronary mortality should focus on primary prevention and reducing the anomalous incidence of disease in
South Asian populations.
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Chapter 4 Risk factor modification among people
without established cardiovascular disease
Abstract
Background
Reported failures to meet national guideline targets and treatment opportunities to optimise risk reduction
among people without established disease represent an important missed opportunity for protecting
patients against CVD.
Objectives
(1) To investigate and compare associations between type 2 diabetes and the risk of 12 initial cardiovascular
presentations in men and women; (2) to investigate the association between BP and 12 presentations of
CVDs; and (3) to identify the proportion of hypertensive patients attaining BP control according to national
targets and factors associated with attainment of targets.
Methods
An analysis of CALIBER linked data.
Results
(1) Type 2 diabetes had the greatest impact on PAD and heart failure but was protective against abdominal
aortic aneurysm. (2) There was substantial heterogeneity in associations with BP across different CVDs and
ages, and the lifetime burden of hypertension was considerable. (3) Twenty per cent of newly diagnosed
hypertensive patients did not achieve guideline-recommended reductions in BP, partly reflecting underuse of
antihypertensive drugs and longer time periods between diagnosis and initiation of treatment. Consultation
rates were significantly lower among those whose BP was not reduced to target (6.9 vs. 34 consultations
per year).
Conclusions
This study confirms that there are high levels of undertreatment among hypertensive patients. The lifetime
burden of hypertension remains substantial, despite modern therapy. More vigorous clinical management
could increase the numbers achieving BP targets. In patients with type 2 diabetes, more rigorous glycaemic
control could have benefits for cardiovascular health.
The studies in this chapter relate to people without established disease (healthy population) (see Figure 10)
Introduction
The CALIBER platform has enabled us to examine the use of risk-reduction strategies in primary care that
are likely to impact on later cardiovascular outcomes. The benefits of multiple risk-reduction measures
have been unequivocally demonstrated, informing the development of national and international clinical
guidelines. Failure to meet national guideline targets, or to optimise treatments in individuals in advance of
disease, may represent important missed opportunities to protect patients against CVD.
To illustrate the role of CALIBER, we examined whether or not guideline targets for BP reduction
were being achieved in clinical practice and identified factors associated with ineffective BP control.
Hypertension is a well-established and common CVD risk factor and is straightforward to identify and
treat. Failure to achieve guideline BP targets would therefore be an important missed opportunity to
reduce the impact of CVD.
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We also focused on one important patient group, namely individuals with type 2 diabetes, to assess whether or
not effective glycaemic control was associated with improved cardiovascular outcomes. We took advantage of
the scale of the CALIBER data set to explore associations between type 2 diabetes and 12 distinct subtypes
of CVD, to provide a more nuanced view of the impact of this common disease on different CVD presentations.
Study 6: diabetes, quality of care and opportunities for risk reduction
This study is based on the peer-reviewed paper by Shah et al.37
Introduction
In the UK and globally, there is an epidemic of type 2 diabetes and growing concern over the contemporary
impact of type 2 diabetes on a wide range of macrovascular consequences. The association of type 2 diabetes
with CHD and stroke is well established156 but its wider associations across the range of CVDs affecting the
myocardium and cerebral, abdominal and peripheral vasculature are less well documented. No previous
studies have been sufficiently large to compare these associations and to estimate less common outcomes
reliably. It is not clear, therefore, to what extent patients with diabetes are at risk of different CVDs, or
whether or not risks are affected by glycaemic control as reflected by glycated haemoglobin (HbA1c) levels.
The possibility that these treatment opportunities are being missed prompted this cohort study, which used
the CALIBER database of linked EHRs to investigate and compare associations between type 2 diabetes and
future risk of 12 of the most common initial cardiovascular presentations in men and women.
Methods
The study period was January 1997 to March 2010, and patients were eligible for inclusion if they were at
least 30 years of age. We excluded patients with a prior history of CVD, and patients with type 1 diabetes
or diabetes of uncertain type. We defined patients as having type 2 diabetes based on coded diagnoses
recorded in CPRD or HES on or before study entry. We assessed glycaemic control by the mean HbA1c from
3 years before to 3 years after study entry. The primary end point was the first record of one of the
following 12 cardiovascular presentations in any of the data sources: stable angina, unstable angina, AMI,
unheralded coronary death, heart failure, transient ischaemic attack, ischaemic stroke, subarachnoid
haemorrhage, intracerebral haemorrhage, PAD, abdominal aortic aneurysm and a composite ‘arrhythmia
or sudden cardiac death’ consisting of cardioversion, ventricular arrhythmia, implantable cardioverter
defibrillator, cardiac arrest or SCD.
Results
The study cohort included 1,887,062 patients without diabetes and 34,198 patient with type 2 diabetes.
The use of statins and antihypertensive medication was higher in patients with type 2 diabetes and
increased over time. Patients with type 2 diabetes were approximately twice as likely to have black or
South Asian ethnicity as those without diabetes (Table 5).
We analysed 113,638 non-fatal and fatal cardiovascular events over 11.6 million patient-years of follow-up
(median follow-up 5.5 years). PAD and heart failure were the most common end points among patients
with type 2 diabetes (16.2% and 14.1%, respectively) (Figure 17).
In multiply adjusted Cox models (Figure 18), there were strong positive associations between type 2
diabetes and PAD (HR 2.98, 95% CI 2.76 to 3.22), ischaemic stroke (HR 1.72, 95% CI 1.52 to 1.95), stable
angina (HR 1.62, 95% CI 1.49 to 1.77), heart failure (HR 1.56, 95% CI 1.45 to 1.69) and non-fatal AMI
(HR 1.54, 95% CI 1.42 to 1.67). In contrast, type 2 diabetes was inversely associated with abdominal aortic
aneurysm (HR 0.46, 95% CI 0.35 to 0.59) and subarachnoid haemorrhage (HR 0.48, 95% CI 0.26 to 0.89).
There was no statistically significant association with arrhythmia/SCD (HR 0.95, 95% CI 0.76 to 1.19).
The risk of CVDs associated with the presence of type 2 diabetes was highest for patients with a HbA1c
of > 58 mmol/mol or those in whom the HbA1c had not been recorded (Figure 19). Patients with type 2
diabetes and a HbA1c of < 48 mmol/mol had an increased risk of PAD (HR 1.82, 95% CI 1.52 to 2.18)
and ischaemic stroke (HR 1.53, 95% CI 1.18 to 1.98), but no greater risk of any of the other CVDs.
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TABLE 5 Baseline patient characteristics among 1,921,260 people without CVD at baseline, according to type 2
diabetes status
Characteristics at baseline
Women Men
No
diabetes
Type 2
diabetes
No
diabetes
Type 2
diabetes
Number of patients 955,655 15,805 931,407 18,393
Age (years), mean (SD) 48.2 (16.2) 64.7 (14.4) 45.4 (14) 60.8 (13)
Social deprivation (% in most deprived quintile) 19.4 27.3 20.3 23.3
Ethnicity (%)
White 90.8 81.8 90.5 82.4
South Asian 2.6 7.7 3.0 8.0
Black 3.0 6.3 3.1 5.2
Other 3.5 4.2 3.4 4.5
Smoking (%)
Current 17.6 14.4 23.7 20.6
Ex 11.4 18.5 11.8 29.9
Never 67.9 64.9 58.7 45.3
SBP (mmHg), mean (SD)a 127 (19.6) 141 (19.7) 133 (17.2) 139 (17.6)
DBP (mmHg), mean (SD)a 77.1 (10.3) 79.5 (10.1) 80.3 (10.0) 80.5 (10.0)
Total cholesterol (mmol/l), mean (SD)a 5.54 (1.14) 5.08 (1.22) 5.39 (1.11) 4.77 (1.16)
HDL cholesterol (mmol/l), mean (SD)a 1.57 (0.45) 1.34 (0.39) 1.28 (0.37) 1.14 (0.33)
BMI (kg/m2), mean (SD)a 26.0 (5.59) 30.5 (6.76) 26.5 (4.43) 29.3 (5.43)
Random glucose (mmol/l), mean (SD)a 5.35 (1.16) 10.4 (4.93) 5.56 (1.29) 10.7 (4.78)
Fasting glucose (mmol/l), mean (SD)a 5.14 (0.75) 8.72 (3.53) 5.31 (0.79) 9.1 (3.51)
Glycaemic controlb
HbA1c recorded (%) 1.3 77.1 1.3 78.5
HbA1c (mmol/l), mean (SD) 44.3 (14.7) 59.3 (18) 46.9 (16.3) 60.5 (18.1)
Diabetes treatment in year before study entry (%)
Diabetes treated using diet alone 29.0 29.7
Metformin 0.1 48.8 0 47.6
Sulphonylurea 0 39.5 0 40.9
Insulin 0 12.3 0 10.2
Thiazolidinedione 0 6.1 0 6.7
DPP4 inhibitor, meglitinide derivative or GLP-1 agonist 0 1.0 0 1.0
Cardiovascular preventative treatment in year prior to study entry (%)
Statin 1.9 35.7 2.1 36.3
Any antihypertensive medication 16.3 59.5 10.6 53.8
ACEI 6.2 33.4 4.7 34.4
ARB 0.8 8.6 0.6 6.9
Beta-blocker 5.7 17.4 3.7 14.8
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; DPP4,
dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; SBP, systolic blood pressure; SD, standard deviation.
a Most recent measurement within 1 year of study entry.
b Mean HbA1c during the 3 years before or after study entry.
Adapted from Shah et al.37 Copyright © 2015 Shah et al. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited. Published by Elsevier Ltd.
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Adjusted HRs for different initial presentations of CVDs associated with type 2 diabetes, adjusted for age,
sex, BMI, level of deprivation, HDL cholesterol, total cholesterol, systolic blood pressure (SBP), smoking
status and statin and antihypertensive drug prescriptions. Two non-specific components of the primary end
point are not shown in the figure for simplicity (they are imprecisely recorded versions of one of the 12
initial presentations): coronary disease not further specified (HR 1.58, 95% CI 1.45 to 1.73; p < 0.0001);
stroke not further specified (HR 1.64, 95% CI 1.48 to 1.81; p < 0.0001).
Discussion
This population-based, contemporary study of nearly 2 million individuals with a median follow-up of
5.5 years provides strong evidence that associations between type 2 diabetes and 12 specific CVD outcomes
differ in terms of direction and magnitude of effects. The most frequent cardiovascular presentations were
PAD and heart failure. For those CVD presentations associated with type 2 diabetes, the risk is greatest
when glycaemic control is poor, as reflected by a HbA1c of > 58 mmol/mol. Our findings support the use of
clinically collected real-world data from EHRs in studying risk of different CVDs among people with type 2
diabetes, and to complement findings from smaller, less contemporary, investigator-led cohort studies,
and suggest that intensifying glycaemic control in type 2 diabetes provides an important opportunity for
reducing the risk of major cardiovascular complications.
A key finding of our study was that PAD was among the most common first presentations of CVD,
which is consistent with the increase in prevalence between 2000 and 2010 found in a recent systematic
review.157 Furthermore, of all the 12 diseases studied, PAD showed the strongest association with type 2
diabetes, with an adjusted HR of 3, which is consistent with previous studies.157 Heart failure was also
among the most common first presentations, with possible mechanisms including prolonged hypertension,
chronic hyperglycaemia, microvascular disease, glycosylation of myocardial proteins, diabetic nephropathy
and autonomic neuropathy.156
Conversely, type 2 diabetes appeared protective against abdominal aortic aneurysm and subarachnoid
haemorrhage, consistent with previous reports from cross-sectional screening studies158–160 and case–control
studies.161,162 Potential mechanisms for diabetic protection against aneurysmal disease, which might have
therapeutic implications, include diabetes-mediated changes in the vascular extracellular matrix, such as
glycation of the extracellular matrix and covalent cross-linking between elastin and collagen in the
aortic wall.163
Our finding that levels of HbA1c were associated with the risk of many CVDs strengthens the case for
the causal relevance of blood glucose. It also provides support for management strategies directed at
intensifying glycaemic control in type 2 diabetes, although targets should probably fall short of ‘normalising’
HbA1c levels in light of the negative findings with respect to cardiovascular death and non-fatal stroke and
AMI in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.164
The differences between relative risks of different CVDs in patients with type 2 diabetes have implications
for clinical risk assessment and trial design. Our findings point to the importance of considering chronic
disease end points such as heart failure, PAD and stable angina in the primary end point because they are
common, have a high morbidity burden and might have different treatment effects from AMI or stroke.
Conclusions
This study has shown heterogeneous associations between type 2 diabetes and 12 different CVDs, the
most frequent presentations with PAD, heart failure and angina, reinforcing guideline recommendations
for treating type 2 diabetes patients with statins. Guidelines also recommend angiotensin-converting
enzyme inhibitors (ACEIs) to protect against microvascular complications but our data suggest that these
drugs may also have a role in protecting against left ventricular remodelling and progressive heart failure.
Our finding that the risk of many CVDs increases substantially with increasing HbA1c concentrations
identifies enhanced glycaemic control as a potentially important opportunity for improving outcomes in
these patients.
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Study 7: blood pressure and incidence of 12 cardiovascular diseases
This study is based on the peer-reviewed paper by Rapsomaniki et al.38 Sections of the text have been
reproduced/adapted from the original article. Copyright © 2014 Rapsomaniki et al.38 This is an open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Introduction
Hypertension is a major risk factor for all forms of major CVD events and the leading risk factor for overall
recent global burden of disease.165 A meta-analysis of 61 cohorts containing individual data for 1 million
adults aged between 40 and 89 years recruited between 1950 and 1990 reported log-linear associations
between SBP and diastolic blood pressure (DBP) and ischaemic heart disease and stroke mortality.122 The
study found no apparent threshold below which any further reduction in risk is observed, down to a BP of
115/75 mmHg. However, no previous study has compared the associations of BP across a wide range of
incident CVDs, across a broad age range (among people aged < 40 years of age) and a wider range of BP
values (including < 115/75 mmHg). In this novel contemporary study using the CALIBER linked data set,
we set out to investigate the association between BP and 12 different presentations of CVD. Study
findings could help to refine strategies for primary prevention and inform the design of future clinical trials.
Methods
Using CALIBER linked EHR data, we selected 1.25 million patients from 225 general practices in England
registered between January 1997 and March 2010. Patients were eligible for inclusion if they were aged
≥ 30 years at study entry, had been registered with their practice for at least 1 year before the index date,
had not been diagnosed with CVD and had at least one baseline BP measurement. Baseline BP, recorded
during consultations in primary care, was based on mean SBP or DBP readings taken within 2 years of the
index date. Where multiple BP measurements were available, an average reading was calculated. In
sensitivity analyses, we used the BP measurement recorded closest to the index date. Hypertension was
defined as baseline BP of ≥ 140/90 mmHg, a recorded diagnosis of hypertension, or evidence of repeat
prescriptions (at least two monthly packs) for BP-lowering drugs, including thiazide diuretics, beta-blockers,
ACEIs, angiotensin receptor blockers (ARBs) or calcium channel blockers. The most recent BP measurement
recorded in the year before the index date was used for covariate adjustments. Missing covariate values
were imputed using multiple imputation using the ‘mice’ algorithm in the statistical package R version 15.2
(The R Foundation for Statistical Computing, Vienna, Austria). Patients were censored on the date of first
CVD presentation, death from other causes, deregistration from the practice or final practice data
collection, whichever occurred first. Initial presentation of CVD was defined as 12 CVDs diagnosed in
primary or secondary care, or death, and total CVD (all 12 CVDs combined). HRs were based on disease-
specific Cox models with time since study entry as the timescale, adjusted for baseline age (linear and
quadratic term) and stratified by sex and primary care practice.
Results
Among 1,258,006 patients included in the cohort, a total of 83,098 initial CVD presentations were
recorded over a median of 5.2 years’ follow-up. SBP and DBP showed a range of associations with
different CVD outcomes (Figure 20). A 20-mmHg rise in SBP showed marked associations with stable
angina (HR 1.41, 95% CI 1.36 to 1.46), subarachnoid haemorrhage (HR 1.43, 95% CI 1.25 to 1.63) and
intracerebral haemorrhage (HR 1.44, 95% CI 1.32 to 1.58). DBP showed substantially weaker associations
with stable angina, PAD, AMI and with total CVD. The strongest associations of all CVDs were observed
for abdominal aortic aneurysm: with DBP (HR 1.45, 95% CI 1.34 to 1.56) and mean arterial pressure
(HR per 10 mmHg 1.61, 95% CI 1.48 to 1.75). It also showed the weakest association with SBP (HR 1.08,
95% CI 1.00 to 1.17) per 20 mmHg, and was the only CVD presentation where the association with
higher pulse pressure was reversed (HR per 10 mmHg 0.91, 95% CI 0.86 to 0.98). AMI had a stronger
association with SBP in women than in men (p < 0.0001), but associations with other CVD presentations
were similar in both sexes.
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Associations with both SBP and DBP decreased with age for all outcomes at varying rates for different CVD
presentations (Figure 21).
The shape of associations for SBP and DBP showed substantial variation across different CVDs and ages.
Between the ages of 30 and 79 years, we observed linear associations between SBP and DBP with stable
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FIGURE 20 Forest plot of HRs and 95% CIs for 12 CVDs per 20/10-mmHg increase in SBP or DBP, adjusted for age and
sex. SBP is represented by a black box, DBP is represented by a green box. Vertical dashed lines correspond to the
associations of SBP (black) or DBP (green) with total CVD. Adjustments include age, quadratic age and stratification by
sex and primary care practice. CIs are Bonferroni corrected (13 end points × 2 variables= 26 tests). MI, myocardial
infarction. Reproduced from Rapsomaniki et al.38 Copyright © 2014 Rapsomaniki et al. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.
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angina, AMI, unstable angina, unheralded coronary death and subarachnoid haemorrhage. Risk was
lowest among those with a SBP of 90–114 mmHg and was significantly lower than among those
with a higher SBP of 115–129 mmHg. Associations with other CVDs were mostly log-linear, with little
or no reduction in risk for BP of < 130/85 mmHg. However, modest increases in either SBP or DBP of
> 130/85 mmHg were associated with large increases in risk, especially for unheralded coronary death,
heart failure, ischaemic stroke, intracerebral haemorrhage and PAD.
The observed association between SBP and subarachnoid haemorrhage or abdominal aortic aneurysm
disappeared in people aged ≥ 60 years of age. Among people aged ≥ 80 years of age (men and women),
SBP was strongly associated with stable angina, AMI, intracerebral haemorrhage and PAD.
Receipt of BP-lowering medication at baseline did not decrease the associations with SBP and DBP.
Hypertensive patients (diagnosed as having a BP of ≥ 140/90 mmHg or being in receipt of BP-lowering
drugs) developed CVD 5 years earlier than patients without hypertension (95% CI 4.8 to 5.2) and had a
lifetime risk of overall CVD at 30 years of age of 63.3% (95% CI 62.9% to 63.8%) compared with
non-hypertensive people (HR 46.1%, 95% CI 45.5% to 46.8%).
The mean number of CVD-free life-years lost associated with hypertension was 5.0 years (95% CI 4.8 to
5.4 years) from 30 years of age, 3.4 years (95% 3.3 to 3.6 years) from 60 years and 1.6 years (95% CI
1.5 to 1.7 years) from 80 years (Figure 22). The largest proportions of CVD-free years of life lost associated
with hypertension at index 30 years of age were attributable to stable angina (22%), unstable angina
(21%) and AMI (15%). However, from an index age of 80 years, stable angina and heart failure accounted
for most (19% each) of all CVD-free years of life lost, followed by unstable angina (15%), AMI (12%) and
ischaemic stroke (10%).
Discussion
In this contemporary study of 1.25 million adults, we show that, despite availability of modern preventative
medication, the lifetime burden of hypertension remains considerable. Our findings challenge previous
assumptions that BP has strong associations with incidence of all CVDs and across a wide age range,
and that diastolic and systolic associations are concordant.
Our study has important advantages over previous research. First, we report associations of BP across
12 CVDs in a validated EHR linkage setting, including younger adults and a lower range of BP values than
in other studies. Second, our findings are generalisable to the general population (99% of the UK
population are registered with a primary care practice) and focus on measurements obtained as part of
clinical practice, and, as such, are clinically relevant.
Our findings have important clinical implications. In this study, we show the high burden of CVDs such as
stable and unstable angina, and heart failure in older age (≥ 80 years). The lifetime burden of BP in
relation to different CVDs that we observed in this study can be used to inform decision-making and
extend counselling treatments of patients, as emphasised in recent published national and international
guidance.24,166 Our findings also emphasise an unmet need, in the form of improved BP management and
better management of other CVD risk factors as part of global risk estimation, to reduce risks of CVD.
Our findings can be used to help inform the design of new clinical trials and to aid interpretation of
existing trials to assess new BP-lowering strategies. Although heart failure and PAD are observed to be
common initial presentations of CVD, they are included less frequently in the primary outcome of
BP-lowering trials.167
Conclusions
Our novel, contemporary, high-resolution study showed that SBP and DBP show heterogeneous
associations across a wide range of CVDs and at different ages. Our findings have implications for the
design of new trials and preventative strategies to address the substantial contemporary unmitigated
lifetime burden of hypertension.
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Study 8: control of blood pressure
This manuscript by Pujades-Rodriguez et al. is in preparation.39
Introduction
The value of risk factor modification for protecting against CVD has long been recognised and is written
into all international guidelines. In the landmark INTERHEART study, just nine potentially modifiable risk
factors were found to account for > 90% of the population-attributable risk of AMI in all regions of the
world.68 Among these risk factors, hypertension is particularly important because it is common, easily
diagnosed and readily treatable.
In patients with diagnosed hypertension, guidelines set treatment targets to optimise risk reduction,
with the recent report from the Eighth Joint National Committee (JNC 8) recommending < 140 mmHg
for SBP (< 150 mmHg for patients aged ≥ 60 years without diabetes and chronic kidney disease) and
< 90 mmHg for DBP.168 Historically, however, there is evidence that guideline targets for BP reduction
are not consistently achieved in clinical practice,169–171 although contemporary data for primary care
populations are unavailable. A continuing failure to meet guideline targets would represent an important
missed opportunity for protecting patients against CVD. We have used the CALIBER data set to analyse the
scale of this missed opportunity in contemporary UK practice, with the primary objectives of describing
(1) the proportion of hypertensive patients attaining BP control according to JNC 8 targets168 and
(2) factors associated with attainment of BP targets.
Methods
We analysed a cohort of all individuals prospectively and newly identified with high BP among individuals
aged ≥ 18 years, registered in the general practices contributing data to the CALIBER data set between
January 1997 and March 2010 (the administrative censoring date of the CPRD database). Individuals had
a minimum of 1 year of follow-up after practice registration, no prior history of CVD and a minimum of
6 months of follow-up since their high BP diagnosis. Individuals with drug-induced hypertension and those
with pregnancy-induced hypertension were excluded (Figure 23).
High BP was defined as the record of three or more systolic or diastolic high BP readings within a
1-year period, or two or more systolic or diastolic high BP readings within a 6-month period in CPRD.
High BP measurements were defined as in the 2014 JNC 8 guidelines168 for patient management, that is,
≥ 140/90 mmHg for individuals aged ≤ 60 years and ≥ 150/90 mmHg for individuals aged ≥ 60 years.
The date of diagnosis of high BP was the earliest date of the last BP reading that identified the individual
as having high BP (e.g. the date of the third reading when defined as three or more systolic or diastolic
high BP readings within 1 year). In sensitivity analyses, high BP was defined as the record of two or more
systolic or diastolic high BP readings within a 1-year period.
CALIBER patients
(n = 2,682,517)
Patients with high BP
(n = 196,212)
Patients excluded
• Not meeting hypertensive definition, n = 1,947,521
• History of CVD, n = 116,834
• Pregnancy-related hypertension, n = 485
• Drug-related hypertension, n = 147
• History of hypertension before eligibility date,
   n = 197,785
• < 6 months of follow-up, n = 223,533
FIGURE 23 CALIBER patient inclusion flow diagram.
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Results
Of the 196,212 patients with newly diagnosed high BP, 156,587 (79.8%) attained BP control during
follow-up (Table 6). The median yearly consultation rate was higher in patients who reached BP control
than in those who did not (6.9 vs. 34 per year). BP-lowering medication was prescribed to 95,972 (48.9%)
individuals during a median of 8.0 months after diagnosis, with the proportion receiving treatment being
higher in those who did achieve BP control than in those who did not (56.3% vs. 19.9%). Lifestyle
interventions were more frequently recorded for patients who achieved BP control.
TABLE 6 Baseline characteristics of CALIBER patients with newly identified high BP by attainment of BP control
Characteristics at baseline
BP control attained
(N= 156,587)
BP control not attained
(N= 39,625)
Age (years), median (IQR) 55 (44–65) 49 (41–57)
Women, n (%) 90,342 (57.7) 16,883 (42.6)
IMD in quintiles, n (%)
1 (least deprived) 33,531 (21.5) 8527 (21.6)
5 (most deprived) 25,944 (16.6) 6941 (17.6)
Ethnicity, n (%)
White 81,171 (93.7) 15,737 (92.6)
Asian 2444 (2.8) 434 (2.5)
Afro-Caribbean 18,513 (2.1) 536 (3.2)
General practice registration
Duration of registration (years), median (IQR) 13.1 (6.4–22.5) 12.3 (5.5–20.7)
Any GP consultation rate in previous year, median (IQR) 5 (3–9) 4 (3–7)
Hypertension diagnosis
1998–2003 81,603 (52.1) 12,268 (31.0)
2004–6 47,590 (30.4) 11,739 (29.6)
2007–9 27,394 (17.5) 15,618 (39.4)
SBP (mmHg), mean (SD) 154 (17.0) 152 (15.1)
DBP (mmHg), mean (SD) 91 (9.8) 91 (9.4)
Hypertension grade
Grade 1 (≥ 140/90 mmHg) 89,453 (57.1) 25,741 (65.0)
Grade 2 (≥ 160/100 mmHg) 48,909 (31.2) 10,603 (26.8)
Grade 3 (≥ 180/110 mmHg) 18,225 (11.6) 3281 (8.3)
Cardiovascular risk factors
Smoking, n (%)
Current 19,499 (15.1) 7122 (21.0)
Former 31,614 (24.5) 7992 (23.5)
Never 77,876 (60.4) 18,877 (55.5)
BMI (kg/m2), mean (SD) 28.4 (5.6) 29.3 (6.0)
Underweight (< 18.5) 597 (0.8) 154 (0.9)
Normal weight (18.5–24.9) 16,657 (23.5) 3352 (19.0)
continued
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Factors significantly associated with BP control (Table 7) in the fully adjusted model included female sex
[odds ratio (OR) 2.34, 95% CI 2.25 to 2.43], BP-lowering treatment (OR 4.90, 95% CI 4.48 to 5.35),
statin medication (OR 1.78, 95% CI 1.58 to 2.003) and diabetes (OR 2.53, 95% CI 2.32 to 2.77).
Patients diagnosed earlier during the study period were also more likely to achieve BP control than
those diagnosed later. BP control was less likely to be achieved in patients with more severe grades of
hypertension (grade 2: OR 0.79, 95% CI 0.75 to 0.82; grade 3: OR 0.59, 95% CI 0.54 to 0.63, compared
with grade 1), those with abnormal weight (lower or higher than normal) and those who did not receive
thiazides as BP-lowering medication.
Discussion
In this population-based CALIBER cohort of patients presenting with newly diagnosed hypertension, BP
control according to JNC 8168 targets was achieved in about 20% of patients. Patients in whom BP control
was achieved were more likely to have grade 2 and 3 than grade 1 hypertension, to visit their doctor
more often and to receive BP-lowering treatment and statins. The longer the delay between diagnosis of
hypertension and the prescription of treatment, the less likely patients were to achieve control.
Importantly, despite the availability of a range of effective antihypertensive drug classes, the BP targets
set by the JNC 8168 were not achieved in one in five hypertensive patients. The failure to optimally reduce
cardiovascular risk in such a large proportion of patients must contribute significantly to the CVD burden,
given its direct association with BP across a wide spectrum of measurements.122,172 The relative underuse
of antihypertensive drugs and delays between diagnosis and initiation of treatment are making a major
contribution to this missed opportunity to reduce cardiovascular risk. Nevertheless, our data show that
other factors, beyond utilisation of antihypertensive drugs, are also important, including higher rates of
obesity and smoking, and lower rates of prescription of secondary prevention drugs, particularly statins,
among patients who did not achieve BP control.
TABLE 6 Baseline characteristics of CALIBER patients with newly identified high BP by attainment of BP control
(continued )
Characteristics at baseline
BP control attained
(N= 156,587)
BP control not attained
(N= 39,625)
Overweight (25.0–29.9) 27,386 (38.6) 6416 (36.3)
Obese I (30.0–34.9) 16,315 (23.0) 4556 (25.8)
Obese II (35.0–39.9) 6602 (9.3) 1976 (11.2)
Obese III (≥ 40) 3438 (4.8) 1211 (6.9)
Total cholesterol (mmol/l), mean (SD) 5.7 (1.1) 5.7 (1.1)
Serum creatinine (mg/l), mean (SD) 85.7 (17.8) 85.9 (17.1)
Medication prescribed, n (%)
Statins 5560 (3.6) 764 (1.9)
Antiplatelet drugs 3454 (2.2) 335 (0.9)
Comorbidities, n (%)
Diabetes 9772 (6.2) 827 (2.1)
PAD 1381 (0.9) 204 (0.5)
COPD 39,908 (25.5) 9161 (23.1)
Renal disease 199 (0.1) 78 (0.2)
IQR, interquartile range; SD, standard deviation.
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TABLE 7 Associations between baseline factors and attainment of BP control among CALIBER patients with newly
identified high BP
Characteristics at baseline OR adjusted for age and sex (95% CI) OR fully adjusted (95% CI)
Age (years)* 1.02 (1.02 to 1.03) 1.01 (1.01 to 1.01)
Women vs. men* 1.93 (1.89 to 1.98) 2.34 (2.25 to 2.43)
Most vs. least deprived quintile (IMD) 0.94 (0.89 to 0.98) 0.97 (0.90 to 1.04)
Year of diagnosis
1998–2003 3.67 (3.57 to 3.78) 2.89 (2.76 to 3.03)
2004–6 2.32 (2.25 to 2.39) 2.16 (2.06 to 2.26)
Hypertension grade (vs. grade 1)
Grade 2* 1.21 (1.17 to 1.24) 0.79 (0.75 to 0.82)
Grade 3 1.35 (1.30 to 1.41) 0.59 (0.54 to 0.63)
Smoking (vs. never)*
Ex-smoker 0.99 (0.96 to 1.03) 1.14 (1.09 to 1.19)
Current smoker 0.76 (0.74 to 0.79) 0.86 (0.81 to 0.90)
BMI (kg/m2) (vs. 18.5–24.9)*
Underweight (< 18.5) 0.60 (0.50 to 0.73) 0.70 (0.57 to 0.85)
Obese III (≥ 40.0) 0.69 (0.63 to 0.74) 0.54 (0.49 to 0.59)
BP-lowering medication prescribed* 5.25 (5.11 to 5.40) 4.90 (4.48 to 5.35)
First drug (vs. thiazides)*
ACEIs 0.74 (0.70 to 0.79) 0.87 (0.78 to 0.96)
Calcium blockers 0.70 (0.65 to 0.76) 0.83 (0.74 to 0.94)
Beta-blockers 0.73 (0.67 to 0.80) 0.78 (0.67 to 0.91)
ARBs 0.95 (0.81 to 1.11) 0.99 (0.78 to 1.27)
Centrally acting 0.77 (0.63 to 0.93) 0.94 (0.63 to 1.42)
Alpha-blockers 0.90 (0.71 to 1.15) 0.62 (0.45 to 0.84)
Time between diagnosis and first prescription (vs. no medication)*
Time to first drug prescription*
≤ 1 month 4.11 (3.93 to 4.29) 5.17 (4.80 to 5.57)
1–3 months 5.48 (5.11 to 5.87) 6.08 (5.44 to 6.80)
3–12 months 4.85 (4.57 to 5.14) 4.52 (4.13 to 4.95)
13–36 months 5.84 (5.53 to 6.17) 4.71 (4.34 to 5.11)
3–13 years 7.00 (6.61 to 7.41) 4.90 (4.48 to 5.35)
Statin medication* 1.79 (1.66 to 1.93) 1.78 (1.58 to 2.00)
Comorbidities vs. none
Diabetes* 3.43 (3.19 to 3.69) 2.53 (2.32 to 2.77)
PAD* 1.41 (1.22 to 1.64) 1.14 (0.88 to 1.47)
COPD* 1.05 (1.02 to 1.08) 1.15 (1.10 to 1.20)
*p < 0.0001.
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Conclusions
This study confirms high levels of undertreatment among hypertensive patients and shows that the missed
opportunity to reduce cardiovascular risk includes a range of lifestyle factors that are all potentially
amenable to modification. However, successful treatment of hypertension requires vigilant clinical
supervision, and it was notable that consultation rates were significantly lower among patients whose BP
was not treated to target (although we cannot be sure that frequent consultation to monitor BP and other
cardiovascular risk factors would lead to more effective risk reduction). If the 20% of hypertensive patients
who fail to achieve JNC 8168 targets were treated more vigorously in terms of BP reduction and lifestyle
modification, the dividend for cardiovascular morbidity and mortality would be substantial.
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Chapter 5 Initial presentation with stable chest
pain: opportunities for earlier diagnosis
Abstract
Background
Delayed diagnosis in patients with symptoms suggestive of ischaemic heart disease is a common missed
opportunity for treatment.
Objectives
(1) To determine the incidence of chest pain according to diagnostic type and the extent and nature of
AMI heralding; and (2) to develop automated methods for identifying relevant texts and extracting coded
information from unstructured free text in EHRs.
Methods
An analysis of CALIBER linked data. In a subset of CALIBER patients we developed and tested two free-text
data-mining tools: the freetext matching algorithm (FMA) and a novel machine-learning algorithm [the
‘Semi-supervised Set Covering Machine’ (S3CM)].
Results
(1) Among 172,181 patients with a first recorded label of chest pain, we identified high levels (72%) of
failure to attribute a cause for chest pain at first presentation, and many members of this group went on
to experience cardiovascular events. (2) Among patients experiencing a first AMI, only 14% of STEMI
events and 9% of NSTEMI events were unheralded. (3) FMA achieved high precision and recall.
(4) The S3CM algorithm outperformed comparator programs on data-mining tasks.
Conclusions
(1) Failure to attribute a cause to chest pain is leading to missed opportunities for primary or secondary
prevention of disease. Most AMIs are heralded by prior atherosclerotic disease or cardiovascular risk
factors. (2) Further development of natural language processing algorithms such as FMA and S3CM may
improve the usability of EHR for research on CVDs and symptoms.
The CALIBER programme provides a unique opportunity to explore the events leading up to an AMI,
as it contains data from primary care (risk factors and consultations prior to the event) and secondary care
(hospital admission and disease registry data). The primary care data in CALIBER includes access to limited
samples of unstructured free text entered by GPs, and we have developed tools to make the free text a
useful data source for research. However, detailed information about patients’ hospital admissions are not
currently collected at scale; future work on hospital informatics should aim to address this.
The studies in this chapter relate to patients presenting for the first time with stable chest pain (Figure 24).
Missed opportunities in primary care
Early diagnosis, particularly in patients with life-threatening disorders, is now a high priority for policy-makers,
as evidenced by the 2-week referral standard for patients with suspected cancer and the widespread
introduction of RACPCs for patients with suspected coronary disease.173,174 A central requirement for early
diagnosis is that primary care physicians, who are usually the first port of call, are able to recognise early
symptoms and signs of disease and respond appropriately with prompt referral for specialist assessment.
This requirement is not, however, always met, with patients often receiving benign reassurance at first
presentation, only to find later that their symptoms were portentous of something more serious.74
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To explore this issue, we used the CALIBER platform to explore the assessment of chest pain in RACPCs.
We also examined the later incidence of cardiovascular events in patients given a diagnosis of angina or
unattributed chest pain.
‘Early warning signs’ of impending AMI would provide opportunities for intervention with more intensive
preventative strategies. The degree to which STEMI and NSTEMI are heralded by atherosclerotic disease or
prodromal symptoms, or cardiovascular risk factors, is unclear, although it has been suggested that STEMI
in particular often occurs ‘out of the blue’. The CALIBER platform has enabled us to examine this issue by
evaluating prospectively collected information on the onset of atherosclerotic disease (in coronary, cerebral
and peripheral circulations), cardiovascular risk factors and prodromal chest pain in advance of AMI.
Study 9: trajectories of care determined by the categorisation
of chest pain at first presentation
A paper by Jordan et al. is in preparation.40
Introduction
Cardiac diagnosis that is delayed after first symptomatic presentation or not made until the advent of a
major complication represents a clear missed opportunity for treatment and occurs not uncommonly in the
patient presenting with cardiac chest pain. Thus, in a cohort analysis of patients attending a RACPC we
have previously reported that about one-third of major events (non-fatal AMI or coronary death) during
follow-up occurred in patients reassured with a non-cardiac diagnosis.74 We have now undertaken a more
detailed analysis using the CALIBER data set, with the aim of determining:
l the annual distribution of chest pain presentations in primary and secondary care according to
diagnostic type (unattributed to a cause, attributed to non-coronary cause, recorded as angina)
l the common short-term (6-month) trajectories of presented chest pain in primary and secondary care
l the annual incidence of cardiovascular events in patients with a first chest pain presentation.
Methods
We included only patients with a first recorded label of chest pain (cause unattributed or attributed to
non-coronary cause) or angina code or at least two anti-anginal drugs in primary or secondary care
between 2002 and 2009. This first recorded label was defined as the index presentation. No patient who
had a prior record of chest pain or of any prior cardiovascular event was included. Follow-up was for a
median of 3.3 years [interquartile range (IQR) 1.6–5.5 years].
Results
Clinical characteristics of the 172,181 patients meeting inclusion criteria are shown in Table 8. There was a
preponderance of women, who constituted 54% of the group, with no significant change across index
years. Only 5% of the group received a diagnosis of angina, with the majority of chest pain presentations
being ‘unattributed’. There was a significant difference in the distribution of chest pain categories across
index years, rates of unattributed and non-coronary chest pain increasing from 2002 to 2009, while rates
of diagnosed angina diminished (p < 0.001) (Figure 25). Deprivation quintile had no apparent effect on
index chest pain presentations in contrast to age, the proportion of unattributed and non-coronary
presentations tending to diminish as angina presentations increased with advancing age.
Figure 26a and b shows follow-up consultations for chest pain by month after index diagnoses of
unattributed and non-cardiac chest pain, respectively. Less than 25% of patients in either diagnostic group
attended for follow-up consultations during the first 6 months, most commonly in the first month. For the
majority of these patients, the consultation resulted in no modification of the index diagnosis, with < 1%
per month of all patients in either diagnostic group converting to a diagnosis of angina.
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TABLE 8 Baseline characteristics of CALIBER patients with a first recorded label of chest pain by diagnosis
Characteristic Chest pain unattributed, n (%) Chest pain non-coronary, n (%) Angina, n (%)
Male 59,036 (74) 16,607 (21) 4104 (5)
Female 65,652 (71) 22,625 (24) 4156 (4)
Age (years)
18–44 53,900 (72) 20,159 (27) 563 (< 1)
45–64 46,498 (75) 12,694 (20) 2869 (5)
65–74 14,032 (71) 3588 (18) 2158 (11)
≥ 75 10,258 (65) 2791 (18) 2670 (17)
Deprivation quintile
1: least deprived 25,698 (72) 8328 (23) 1568 (4)
2 25,331 (72) 7995 (23) 1643 (5)
3 24,825 (72) 7664 (22) 1765 (5)
4 24,660 (73) 7460 (22) 1714 (5)
5: most deprived 23,738 (72) 7632 (23) 1545 (5)
Year of index date
2002 14,384 (70) 4500 (22) 1594 (8)
2003 15,370 (72) 4723 (22) 1327 (6)
2004 16,493 (73) 5062 (22) 1139 (5)
2005 16,228 (73) 5007 (23) 989 (4)
2006 15,826 (73) 4862 (23) 874 (4)
2007 15,753 (73) 4889 (23) 847 (4)
2008 15,477 (73) 5064 (24) 723 (3)
2009 15,157 (72) 5125 (24) 767 (4)
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FIGURE 25 Type of chest pain diagnosis by year among CALIBER patients with a first recorded label of chest pain.
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The incidence of cardiovascular events during follow-up for patients with index diagnoses of non-coronary
chest pain and unattributed chest pain was < 10% and < 20%, respectively. Patients with an index diagnosis
of angina were considerably older and 62% experienced cardiovascular events during follow-up (Table 9).
Discussion
The annual incidence of recorded chest pain from 2002 to 2009 has shown progressive reductions in rates
of diagnosed angina as rates of unattributed and non-coronary chest pain have increased. Our data
emphasise how trajectories of care and cardiovascular outcomes are largely predetermined by the initial
diagnostic categorisation of chest pain. This initial categorisation was generally stable and in only a very
small proportion of patients was it modified during follow-up consultations in the first 6 months. Although
the data were generally reassuring with regard to the prognostic validity of the first recorded chest pain
category, substantial numbers of patients with unattributed chest pain went on to experience cardiovascular
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FIGURE 26 Number of follow-up consultations for chest pain by diagnosis and by month after index diagnosis of
(a) unattributed chest pain and (b) non-coronary chest pain. Data are proportions (%) of patients attending for
consultation stratified by diagnosis.
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events, including AMI and coronary death. In a significant proportion of these cases it must be assumed that
failure to diagnose angina at first presentation resulted in an inappropriate trajectory of care, representing
an important missed opportunity to provide treatment and lifestyle advice to protect against the progression
of CVD.
Failure to attribute a cause for chest pain at first presentation occurred in > 70% of cases and it was in this
group that prognostic consequences were particularly telling, with an 8% incidence of cardiovascular
events during follow-up, accounting for more than four times the absolute number of events compared
with the angina group. This has important clinical implications, indicating a need for contemporary
prognostic models based on the characteristics of patients presenting with unspecified chest pain so that
those at risk of cardiovascular events can be more accurately identified.
Conclusions
Only 5% of patients assessed for chest pain receive a diagnosis of angina and this proportion has been
falling over the past decade. One in 12 of the > 70% of patients diagnosed with unattributed chest pain
went to experience a cardiovascular event; indeed, more events occurred in this group than in the group
diagnosed with angina. A failure to identify patients with chest pain of cardiac origin at first presentation is
an important missed opportunity for initiating preventative treatment and reducing the incidence of CVD.
Study 10: heralding of acute myocardial infarction – opportunities for
primary and secondary prevention
This study is based on the peer-reviewed paper by Herrett et al.41 Sections of the text have been adapted
from the original article; copyright © 2013, SAGE Publications. This open access article is distributed under
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Introduction
In the weeks or months prior to AMI, heralding by major risk factors, established atherosclerotic disease or
prodromal symptoms provide an important opportunity to intervene with preventative strategies. Studies
that have retrospectively evaluated medical history suggest that risk factors and prior atherosclerotic
disease are common in people experiencing AMI, particularly NSTEMI, but they may underestimate the
burden of disease and may poorly reflect the timing of prodromal symptoms.175–179 CALIBER’s linked
registries permit, for the first time, an evaluation of the extent and nature of STEMI and NSTEMI heralding
using prospectively collected information on the onset of atherosclerotic disease (in coronary, cerebral and
peripheral circulations), cardiovascular risk factors and prodromal chest pain.
TABLE 9 Number and percentage of cardiovascular events during follow-up by chest pain diagnosis among
CALIBER patients with a first recorded label of chest pain
Patient characteristics
Chest pain unattributed
(N= 124,689)
Chest pain non-coronary
(N= 39,232)
Angina
(N= 8260)
Age (years), mean (SD) 49 (17) 46 (17) 67 (14)
Angina, n (%) 8167 (7) 681 (2)
AMI, n (%) 2148 (2) 277 (< 1) 745 (9)
Coronary heart disease not otherwise specified,
n (%)
5893 (5) 539 (1) 3059 (37)
Other cardiovascular, n (%)a 4931 (4) 1129 (3) 1292 (16)
SD, standard deviation.
a Heart failure, cardiac arrest/sudden death, ischaemic stroke, haemorrhagic stroke, stroke not specified, transient
ischaemic attack, PAD and abdominal aortic aneurysm.
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Methods
We included patients aged ≥ 18 years experiencing a first AMI between 1 January 2003 and 31 December
2008, with at least 1 year of prior observation in CPRD and at least one consultation during that period.
Atherosclerotic disease, risk factors or chest pain recorded in MINAP or CPRD at any time prior to AMI
were defined as ‘heralding’ the AMI. The earliest record of atherosclerotic disease in CPRD was taken
as the date of onset (dates were not recorded in MINAP). Risk factors investigated were smoking,
hypertension, dyslipidaemia and diabetes (diagnosed diabetes or insulin prescription) and were defined by
codes in CPRD or MINAP. We also determined whether or not patients had been prescribed BP-lowering,
lipid-lowering or antiplatelet medications in the 6 months before AMI. The frequency of primary care
consultations for chest pain was assessed in patients without diagnosed atherosclerotic disease.
Results
There were 8174 eligible patients with a first AMI. Figure 27 shows that only 14% (95% CI 13% to 16%)
of STEMIs and 9% (95% CI 9% to 10%) of NSTEMIs were unheralded by prior atherosclerotic disease,
one or more cardiovascular risk factors or chest pain, leaving 14% (95% CI 13% to 16%) unheralded by
these factors.
Some 41% of patients had previously diagnosed atherosclerotic disease (Table 10), more of whom had
NSTEMI than STEMI (50% vs. 29%). Coronary disease was the most common presentation in the year
before AMI, recorded in 21% of STEMI and 41% of NSTEMI patients, with rates rising rapidly in the
3 months before AMI (Figure 28a). A similar pattern was observed for chest pain consultations in patients
without diagnosed atherosclerotic disease (Figure 28b). Among patients with previously diagnosed
atherosclerotic disease, 87% were being prescribed one or more of aspirin, statins and BP-lowering
treatment in the 6 months before AMI, but only 34% were receiving all three forms of medication.
Some 59% of AMIs were unheralded by previously diagnosed atherosclerotic disease; 79% of these
patients had one or more risk factors (a record of diabetes, hypertension, dyslipidaemia, current smoking,
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FIGURE 27 Percentage of patients with previous atherosclerotic disease and risk factors in patients experiencing
first STEMI (n= 3780) and NSTEMI (n= 4394). Reproduced from Herrett et al.41 Copyright © The European Society
of Cardiology 2013. Published by SAGE. This article is distributed under the terms of the Creative Commons
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or a prescription for statins, BP-lowering medication or antiplatelet medication in the 6 months before
AMI). This was the same in STEMI (79%) and NSTEMI (80%) patients. AMI was unheralded by all the
factors discussed in 546 (14%) STEMI patients and 413 (9%) NSTEMI patients. These patients were more
likely to be younger [median age 67 years (IQR 58–77 years ) vs. 71 years (IQR 60–80 years)], male (72%
vs. 63%) and to have a lower rate of primary care consultation prior to AMI (median four vs. seven
consultations per year) than those with heralded infarction.
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FIGURE 28 Rates of (a) coronary diagnosis and (b) chest pain consultations in the months leading to first STEMI and
NSTEMI, with 95% CIs among CALIBER patients. Each time point covers a 1-month time band (0–1 months, 1–2 months,
etc.). Part (b) represents chest pain consultations just in patients without previously diagnosed atherosclerotic disease;
although these patients have not received a coronary disease diagnosis, they may well be heralded by possible coronary
symptoms. Reproduced from Herrett et al.41 Copyright © The European Society of Cardiology 2013. Published by SAGE.
This article is distributed under the terms of the Creative Commons Attribution License (www.creativecommons.org/
licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the
original work is attributed as specified on the SAGE and Open Access page (www.uk.sagepub.com/aboutus/
openaccess.htm).
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Discussion
This study shows how important opportunities for the primary or secondary prevention of arterial disease
are either being missed or failing to protect against AMI. In patients with previously diagnosed
atherosclerotic disease or risk factors, AMI represents the unmet potential of secondary or primary
prevention, respectively. In the majority of cases, prior atherosclerotic disease was diagnosed long in
advance of both STEMI and NSTEMI, providing an extended period during which secondary prevention
could be implemented. Our data describing the use of secondary prevention measures in the 6 months
before AMI showed that most patients with diagnosed atherosclerotic disease were receiving one of either
statins, aspirin or BP-lowering drugs, but only one-third were receiving all three, indicating that there are
likely to be missed opportunities for secondary prevention in this group.
Coronary disease was the most common pre-AMI presentation, but 10% of both STEMIs and NSTEMIs
were heralded by PAD and/or cerebrovascular disease alone. This emphasises the importance of further
efforts to improve secondary prevention following diagnoses in the cerebral and peripheral arteries in order
to prevent an important proportion of AMI. The high prevalence of risk factors in both STEMI and NSTEMI
highlights the importance of tackling the widely reported missed opportunities for the implementation of
existing interventions that are known to be effective.
In addition, the categorisation of continuous measures in this analysis may have been an oversimplification
of cardiovascular risk. Although a binary indicator is simple to interpret in studies and a useful basis on
which to prescribe treatment, it does not reflect the continuum of risk over the full range of measurements.
A more detailed investigation of these risk factors might reveal borderline raised risk in many patients,
and lowering BP and lipids in those not diagnosed as hypertensive or dyslipidaemic may also prevent AMI.
However, the implications of our analysis are limited by a lack of comparison to AMI-free controls. Such a
comparison may allow further conclusions to be drawn from these data.
Clinical experience and retrospective studies have long suggested that AMI might be preceded by
premonitory symptoms of chest pain presenting to a GP or ambulatory care.180,181 Our study extends
knowledge in several respects. First, we confirmed this association with prospective data. Second, we
found that there were increases in coronary disease diagnoses and chest pain consultations in both
STEMI and NSTEMI. This is in contrast to the widely held view that STEMI is usually of sudden onset.
Third, we showed that the increases were specific to coronary diagnoses and chest pain, rather
than to disease in cerebral or peripheral circulations, suggesting a local rather than systemic
pro-thrombotic state.
Further research is warranted to better characterise the phenotypes, causes and prognoses of unheralded
STEMI and NSTEMIs to improve the usability of EHRs for research. Analyses comparing AMI patients with a
control group without AMI, including a comparison of missed opportunities for care in measuring and
controlling elevated risk, are needed.
Conclusions
New-onset chest pain, even in the absence of major risk factors or prior atherosclerotic disease, may
identify patients at risk of imminent AMI. Interestingly, a further CALIBER analysis has shown that chest
pain and other ischaemic presentations in the 7 days preceding AMI reduces the risk of death in the first
week by more than one-third, perhaps owing to a natural preconditioning effect.182 Nevertheless, the
opportunity for careful triage of these patients, in accordance with the recommendations of recent
guidelines,183 should not be missed to ensure that high-risk individuals can be identified and treated to
prevent progression to AMI.
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Missed opportunities for earlier diagnosis: a role for free-text
data mining?
It is important to determine if opportunities for early diagnosis are being missed, and the unstructured
free-text notes of EHRs provide a good starting point from which to answer this question. A large volume
of clinical information in primary care is not coded within the EHR but stored as free text, isolating it from
researchers. It is often in uncoded free text that the apparently ‘trivial’ presenting symptoms, signs and test
results of life-threatening disease are recorded before a coded diagnosis is arrived at.43,184–186
This uncoded free text is, therefore, a potentially rich source of diagnostic information, and there is
considerable interest in methods of accessing it for research purposes. We have developed algorithms to
extract useful information from free-text fields of EHRs as a step towards identifying early symptoms of
CVD before a formal diagnosis is made.
Study 11: a freetext matching algorithm for extracting diagnoses
and causes of death from unstructured text in electronic
health records
This study is based on the peer-reviewed paper by Shah et al.42
Introduction
Electronic health records research to date has predominantly used coded data, which are readily available
for analysis, but free-text fields may contain important additional information.43,184–186 Manual review of
free-text records is time-consuming, so there has been interest in developing software algorithms to extract
diagnoses and other clinical information from free text. Development of such software algorithms is
challenging, however, as clinical text contains complex language structures and specialist terminology, as
well as context-specific abbreviations. Some algorithms have been developed to extract information about
specific subjects, such as smoking status, heart failure or family history.187–191 Other programs have wider
functionality but have tended not to be widely used outside the laboratories that developed them.190 The
linked CPRD record in CALIBER includes coded information but also free-text fields containing information
recorded by GPs or derived from hospital letters. One potentially valuable use of free-text information is in
investigations of cause of death, which are often recorded in free-text fields. This study describes the
development of a software tool for extracting information about cause of death, as well as a selection of
other clinical information, from free-text fields in CPRD.
Methods
The FMA was developed to extract diagnoses, dates, durations, laboratory results and heart rate and blood
measures from free-text fields. Using lookup tables and synonyms, the program aims to match samples
of free text to the standard Read codes used by GPs (Figure 29) (www.connectingforhealth.nhs.uk/
systemsandservices/data/uktc/readcodes). The EHRs of a random sample of 3310 patients who died in
2001 were manually analysed to identify causes of death. The initial version of the program was developed
to extract causes of death from these data, and iterations of the program were tested on random
samples of several hundred free-text entries. The prototype program was developed in Visual Basic
with a Microsoft Access® 2000 (Microsoft Corporation, Redmond, WA, USA) user interface to facilitate
reviewing. Following this development phase, FMA was tested on two samples of free text, from the
CPRD (1000 texts associated with death in 2001) and 1000 general texts from a CAD study. Results were
compared with those generated by the US Library of Medicine’s MetaMap program and manual review
(the gold standard).192
DOI: 10.3310/pgfar05040 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hemingway et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
Results
When tested on the 1000 texts associated with death, FMA successfully matched 683 out of 735 positive
diagnoses, achieving a precision (PPV) of 98.4% (95% CI 97.2% to 99.2%) and a recall (sensitivity) of
92.9% (95% CI 90.8% to 94.7%). On the general sample, FMA successfully identified 346 of the 447
positive diagnoses, achieving a precision of 91.5% (95% CI 88.3% to 94.1%) and a recall of 77.4%
(95% CI 73.2% to 81.2%). Its performance was similar to that of MetaMap (Table 11).
Discussion
Through the analysis of free text in CPRD, FMA was able to correctly assign Read terms of death in 93% of
cases, achieving a precision of > 90% on various types of free text. FMA also proved capable of extracting
information about test results such as pulse rate. FMA may provide a valuable tool for extracting information
from EHRs for research, reducing the need for manual review and overcoming confidentiality concerns over
access to free text for researchers. This could potentially generate important additional information; in the
2001 CPRD data, for example, almost 20% of causes of death are recorded in free-text rather than coded
form. FMA can also extract useful supporting information such as timing and suddenness of death.
Identify dates, numbers
and words that may
be part of clinical terms.
Attempt to correct
spelling mistakes
Search for word patterns
to assign attributes
Extend attributes (e.g. negation)
to a sequence or words, guided by
punctuation and stop words
(e.g. ‘but’)
Attempt to match
sequences of words
to Read terms
Output structured data
Input free text
(e.g. GP history
or physical examination,
scanned clinic
letters, discharge
summaries)
Example of analysis
Fracture of right femur in July 2010
fracture (WORD)
of (IGNORE)
right (WORD)
femur (WORD)
in (IGNORE)
Jul 2010 (DATE: July 2010)
Pattern matching:
‘. . . in (DATE)’ maps to ‘. . . in Jul 2010’ 
means that the date refers to the
preceding diagnosis
1. OXMIS 8210 FRACTURE FEMUR
2. Date of preceding diagnosis: July 2010
Matching to Read/OXMIS term
‘fracture of right femur’ maps to ‘fracture femur’
(OXMIS term 8210 ‘FRACTURE FEMUR’)
‘of’ is ignored
‘right’ is ignored as long as there is no ‘left’ in the
Read term
FIGURE 29 Flow chart showing the stages of matching samples of text used by GPs in primary care using the FMA
program and analysis of text. OXMIS, Oxford Medical Information System. Reproduced from Shah et al.42 © 2012
Shah et al.; licensee BioMed Central Ltd. This article is published under license to BioMed Central Ltd. This is an Open
Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.
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The code of FMA is available in an open-access repository, under the GNU General Public Licence
(see https://github.com/anoopshah/freetext-matching-algorithm) to enable use and modification of the
algorithm by other researchers and to facilitate further collaborative development.
Machine learning and natural language processing approaches to examining the large corpus of
unstructured (free-text) data that exist in primary care and hospital records should be developed in order to
identify opportunities for earlier diagnosis and to add phenotypic information and safety signals.
Finally, as well as research on EHRs, real-time natural language processing systems could support enhanced
coding in clinical practice. Such systems are recommended in the Connecting for Health NHS Common
TABLE 11 Performance of the FMA program compared with the US Library of Medicine’s MetaMap program
Performance criterion
Algorithm
FMA MetaMap
Deatha
(Read/OXMISb)
Generala
(Read/OXMISb)
Generala
(Read/OXMISb)
Generala
(full readb)
Number of text 1000 1000 1000 1000
Number of words 7534 25,981 25,981 25,981
Positive diagnoses detected in free text
True positives 683 346 286 273
False positives 11 32 126 18
False negatives 52 101 161 174
Precision, % (95% CI) 98.4 (97.2 to 99.2) 91.5 (88.3 to 94.1) 69.4 (64.7 to 73.8) 93.8 (90.4 to 96.3)
Recall, % (95% CI) 92.9 (90.8 to 94.7) 77.4 (73.2 to 81.2) 64.0 (59.3 to 68.4) 61.1 (56.4 to 65.6)
F-score 0.96 0.84 0.67 0.74
Strictly defined precision for 625 positive diagnoses (best term and correct attribute)
Number strictly correct 625 315 260 247
Precision, % (95% CI) 90.1 (87.6 to 92.2) 83.3 (79.2 to 86.9) 63.1 (58.2 to 67.8) 84.9 (80.2 to 88.8)
Precision of non-diagnosis positive concepts
True positives 84 304 295 453
False positives 2 22 55 41
Precision, % (95% CI) 97.7 (91.9 to 99.7) 93.3 (90.0 to 95.7) 84.3 (80.0 to 87.9) 91.7 (88.9 to 94.0)
Overall precision of positive concepts detected (diagnostic and non-diagnostic)
True positives 767 650 581 726
False positives 13 54 181 59
Precision, % (95% CI) 98.3 (97.2 to 99.1) 92.3 (90.1 to 94.2) 76.2 (73.1 to 79.2) 92.5 (90.4 to 94.2)
OXMIS, Oxford Medical Information System.
a Test set.
b Vocabulary.
Source: reproduced from Shah et al.42 © 2012 Shah et al.; licensee BioMed Central Ltd. This article is published under
license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Notes
Comparison of precision (PPV) and recall (sensitivity) of the FMA and MetaMap against the gold standard of manual review,
for two test sets: ‘General’, a random sample of 500 texts from cases and 500 from controls in a study on CAD; and
‘Death’, a random sample of 1000 texts associated with Read terms for death or suicide in 2001.
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User Interface guidance,193 to enable clinicians to enter information in a natural form that is automatically
converted into the appropriate codes.
Conclusions
The FMA is an open source, free-text data-mining tool, which showed high precision and recall on a test
data set from the CPRD and can be used to extract uncoded diagnosis or symptom information for
EHR research.
Study 12: extracting diagnoses and investigation results from
unstructured text in electronic health records by semisupervised
machine learning
This study is based on the peer-reviewed paper by Wang et al.43
Introduction
In developing our FMA we were able to match samples of free text to the standard Read codes used by
GPs, thereby coding the samples to make them available for research. The analysis of clinical text is
challenging, however, because of its specialist terminology, potentially complex language structures and
use of context-specific abbreviations. In this study we adopted a different approach termed ‘machine
learning’, in which we do encode detailed language rules by hand, but allow a learning computer
algorithm to derive its own rules based on some training data.187,194,195 In some studies, tools that
incorporate machine learning components have been shown to perform better than purely rule-based or
pattern-matching approaches.196–198
Here, we describe the development of a machine learning algorithm (S3CM) related to previous models
developed by Rosales et al.199 to determine whether or not clinical free text contains specific information of
interest. Its ability to detect coronary angiogram test results and a diagnosis of ovarian cancer was compared
with a fully supervised predecessor system,200 the transductive support vector machine (TSVM),201 and FMA.42
A potential advantage of S3CM was that it did not require a perfectly labelled training set, which means
that the existing Read codes associated with each free text could be used as the label, rather than requiring
time-consuming manual labelling of the training data set.
Methods
We tested S3CM on free-text records in CPRD that might contain coronary angiogram results. Just 4.2% of
CPRD records have angiogram results coded, but a much larger number have codes indicating that an
angiogram was performed. The results of these ‘missing’ angiograms may be available in free-text fields.
A second task was to detect a suspected or definite diagnosis of ovarian cancer. This cancer is difficult to
diagnose, and clinicians may note down suspicions before a formal diagnosis is recorded. An analysis of
these earlier thoughts would provide useful insight into clinical decision-making processes.
The algorithms were trained using texts with Read codes relevant to the two tasks. The performance of
S3CM and the other tools was compared with the gold standard of manual review by a specialist clinician.
Results
In the training set for the coronary angiogram task, only 60% of records with an angiogram result Read
code actually had angiogram results in the free-text field. Nevertheless, presented with unlabelled texts,
S3CM achieved 87% recall with 64% precision. It outperformed both the fully supervised SCM (60%
precision, 78% recall) and the TSVM (3% precision, 2% recall). Similarly, in the ovarian cancer diagnosis
task, S3CM outperformed both SCM and TSVM, detecting 303 out of 353 diagnoses (86% recall, 74%
precision). FMA achieved greater precision (85%) but lower recall (62%). In a test set, S3CM identified
99% of patients with ovarian cancer, even though only 82% had a formally coded diagnosis.
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Discussion
The S3CM algorithm was developed as a semisupervised learning algorithm for the classification of clinical
test records. It has shown promising performance in two unrelated pilot tasks, even though the training
data set for the first of these tests was far from perfect. One advantage of S3CM is that training examples
can be obtained simply through the use of diagnostic codes rather than by manual review. Moreover,
because it does not depend on a subject-specific knowledge base or set of linguistic rules, it is, in theory,
applicable to other subject areas (and languages). Its main disadvantage is that it will not detect
particularly complex or rare forms of language. Misspellings and abbreviations may also present issues.
Further testing of our semisupervised machine-learning tool should be conducted using other EHR data
sets, such as discharge letters and electronic hospital notes.
Conclusions
The tool is likely to be of most value in applications in which diagnostic or other information is typically
recorded in free-text form. It is semi-automatic and easy to run, and may have most use as a way of
winnowing large data sets for more detailed review. It would also be suitable for use on other sources of
data, such as electronic hospital notes, and is sufficiently flexible to be used across multiple disease areas,
requiring only a small number of labelled data for training.
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Chapter 6 Initial presentation with stable chest
pain: opportunities using a clinical decision support
system – the Optimising the Management of
Angina programme
Abstract
Background
Evidence from EHR- and investigator-led studies suggests that angina is not being adequately diagnosed in
RACPCs and potential cardiac-related chest pain may be being inappropriately investigated. CDSSs provide
an approach for guiding appropriate investigation and initial treatment decisions, but their integration into
hospital information systems and usual practice remains challenging.
Objectives
To assess the feasibility, use and outcomes of a web-based CDSS [Optimising the Management of Angina
(OMA)] in RACPCs.
Methods
Patients from three UK NHS RACPCs were recruited before and after the introduction of OMA. We carried
out an ethnographic study of OMA use.
Results
Integration of the CDSS with hospital information systems and the clinical workflow was hindered by
multiple technical and procedural problems. OMA was used in 84% of consultations. There were no
differences in medication prescribing or investigation within 6 months between groups using OMA and
delivering usual care. Qualitative data suggested that clinicians found OMA useful in confirming rather than
guiding their decision-making, but it had no impact on the assessment of the most difficult-to-interpret
cases. Difficulties implementing the CDSS and a strong belief in the primacy of clinicians’ judgements were
associated with OMA’s lack of influence.
Conclusions
The OMA programme had a negligible effect on the decision-making behaviour of clinicians in RACPCs,
and a trial powered on cardiac events was deemed unwarranted. Insight into the ways in which clinicians
interacted with OMA could inform development of new tools to aid clinical decision-making with a greater
likelihood of being adopted in practice.
The studies in this chapter relate to patients presenting for the first time with stable chest pain (see Figure 24).
Introduction
The reliable diagnosis of angina is essential for ensuring that patients receive the most appropriate
treatments for symptoms and the prevention of cardiovascular events. There is growing evidence, including
from our CALIBER-based study reported above (study 6), that angina is currently being underdiagnosed,
even in specialist centres such as RACPCs. Assessment of chest pain is difficult, and the diagnosis of
angina could potentially be enhanced by a suitable CDSS. Drawing on recommendations in clinical
guidelines and a behaviour-change framework, we have developed a CDSS to support chest pain
assessment and angina diagnosis, with associated training and support, namely the OMA programme.
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After encountering technical difficulties integrating with the hospital information system in each hospital,
we designed the CDSS as a web-based tool that could integrate with the clinical care workflow with
minimal data duplication and additional resource requirements.
To assess its impact on clinical decision-making behaviour and its acceptability to clinicians, we carried out
a pilot study of OMA in RACPCs. We adopted a mixed-methods approach, combining a quantitative study
of OMA use and its impact on clinical decision-making, alongside a qualitative study exploring clinicians’
attitudes to and interactions with the tool. The study was planned as a pilot to inform the feasibility and
design of a RCT of the OMA CDSS, powered to detect differences in cardiovascular event.
Study 13: Optimising the Management of Angina pilot study
This study is based on the peer-reviewed papers by Cramer et al.44 and Johnson et al.45
Introduction
Rapid access chest pain clinics may incorrectly diagnose some patients, and not all of those patients
diagnosed with angina receive appropriate secondary prevention measures. For example, in a cohort of
8762 patients followed for 3 years after attending a chest pain clinic, 33.1% of all cardiovascular events
occurred in patients with a diagnosis of non-cardiac chest pain.74 This study also reported underprescription
of evidence-based treatments for angina: of those patients receiving a diagnosis of angina, only 28% were
taking a statin. The need for better decision-making for patients presenting with new-onset stable chest
pain was highlighted in the 2010 NICE chest pain guidelines,202 which recommended investigation decisions
based on the pre-test probability of coronary disease.
The OMA CDSS is a web-based computerised version of the NICE Clinical Guideline (CG)95,202 with additional
guidance provided on investigation and prescribing decisions derived from a RAND (RAND Corporation,
Santa Monica, CA, USA) Delphi panel of 11 experts in the fields of general cardiology, imaging, radiology,
general practice, chest pain clinics, clinical pharmacology and biomarkers/inflammation. The panel was
convened in December 2009, and panel members were asked to rate the appropriateness of investigation
and risk-lowering medication in patients with suspected stable angina pectoris attending RACPCs. Members
rated the appropriateness (inappropriate, uncertain or appropriate) of 2400 hypothetical patient-specific
indications for exercise ECG, coronary computerised tomography (CT), functional imaging and invasive
coronary angiography and initiation of the risk-lowering medications aspirin, beta-blocker, ACEI and statin.
This involves eliciting decision thresholds using pre-test probability (diagnostic) and 10-year risk (prognostic)
scores and categorical clinical information.
Optimising the Management of Angina clinicians entered the following data into the CDSS: age, sex,
typicality of chest pain, resting ECG result and cardiovascular risk factors (smoking status, diabetes and
hyperlipidaemia). These data are used to calculate the individual’s pre-test probability for coronary heart
disease and to give investigation recommendations in line with the NICE guideline.
The OMA programme (Figure 30) is a complex intervention delivered at the clinic level. The program has
three stages: preparation, training and clinic tools. The aim of the preparation and training stages is to
facilitate the use of the clinic tools and, in particular, the CDSS. The components of the intervention were
developed with attention to the behavioural change domains identified by Michie et al.203
Clinical decision support systems can be effective at modifying clinician behaviour,204 with four factors
predicting improved clinical practice. We planned the design of OMA to incorporate all of these
components, that is, provision of decision support at the time and place of decision-making, provision of
recommendations rather than just assessments, computer-based decision support and real-time provision
of decision support to clinicians during the consultation. However, less is known about the effect of CDSSs
on patient outcomes, and what evidence does exist is conflicting. A systematic review205 of studies
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evaluating the effectiveness of computer-based guideline implementation systems providing real-time
interaction during consultations in ambulatory care settings identified a lack of evidence of an effect of
these systems on patient outcomes and conflicting evidence of effect on process outcomes.
A meta-regression of 162 randomised trials of CDSSs206 identified several factors that could explain why
some systems succeed in terms of clinician behaviour change and others fail. Systems were more likely to
be successful if they required practitioners to provide reasons when over-riding advice and if they provided
advice concurrently to patients and practitioners. A linked editorial207 argued for an approach including
qualitative contextual evaluation and observation to further our understanding of the factors that make
CDSSs successful.
Implementation of CDSSs is a complex intervention. The Medical Research Council (MRC) framework208 for
the development of complex interventions promotes a focus on feasibility and pilot work, using a mixture
of qualitative and quantitative methods where appropriate, so that full evaluations, preferably in RCTs,
are conducted only on interventions that are feasible and acceptable, and that have a likelihood of
improving outcomes.
Methods
In this study we used a mixed-methods approach to answer the following research questions:
1. Is delivery and use of the OMA CDSS feasible in chest pain clinics?
2. In what proportion of consultations is the OMA CDSS used?
3. Are the OMA CDSS recommendations for investigation and medication followed?
4. Does the investigation and medication treatment of participants differ before and after delivery of the
OMA programme, and is this likely to impact on outcomes?
Quantitative methods were used to answer questions 2–4. Qualitative ethnographic methods were used to
answer question 1, and to help explain the quantitative results.
Clinic scoping
An understanding of the
clinic context is reached
through meeting with
 chest pain clinicians
Preparation Training Clinic tools
Trust A: July–December 2009
Trust B: December 2009–November 2010
Trust A: March 2010
Trust B: January 2011
Trust A: July–November 2010
Trust B: January–May 2011
Education sessions
Drawing on behaviour
change theory, a session
to promote use of the
clinic tools
Patient leaflets
Including advice on
modifiable risk factors 
and medications
GP letter modified to give
prominence 10 medication
recommendations and
behavioural advice
CDSS:
web based tool offering 
guidance on prescribing 
and investigation
Clinic champion
Identification of a 
clinician to support 
and champion the 
intervention
FIGURE 30 Summary of the OMA intervention. Source: reproduced from Johnson et al.45 © Johnson et al. 2015. This is
an open-access article distributed under the terms of the Creative Commons Attribution License (http://creative
commons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
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Setting and study population
We recruited patients from one chest pain clinic in a provincial city centre (A) in two phases: (1) before and
(2) after the delivery of the OMA programme. A second chest pain clinic in a suburban hospital (B) was
chosen to provide a comparison site. We were unable to deliver the OMA programme at hospital B as
clinics did not have web access, which was required to use the CDSS. Therefore, the intervention was
delivered at a third chest pain clinic in a suburban hospital (C). Hence, clinic A recruited patients before
and after delivery of the OMA programme, clinic B recruited participants before the delivery of the OMA
programme and clinic C recruited patients after delivery of the OMA programme only. Where the OMA
programme was not delivered, patients received usual care.
Patients were eligible for the study if they had been referred to the chest pain clinic by their GP. We excluded
patients who had a previous history of CVD and patients who did not speak English. Participants were invited
to provide consent for the study team to access their hospital and primary care records through their GP.
Quantitative data
Baseline patient characteristics
Age, sex, prescribed medications [antiplatelet (aspirin or clopidogrel), statins and beta-blockers] and
cardiovascular risk factors (smoking status, hyperlipidaemia and diabetes) were determined for each
participant at baseline. Data on age and sex were taken from consent forms. Medication prescriptions
current on the day of chest pain clinic were manually extracted from the primary care EHR by two
researchers. Cardiovascular risk factor data were taken from the CDSS database where used, and from the
chest pain clinic record, GP referral letter, or primary care electronic record for all other participants.
The CDSS database stored data on chest pain that were not routinely collected as part of standard clinical
care. The CDSS stored the classification of the chest pain according to the Diamond and Forrester criteria209
(typical, atypical or non-anginal), ECG findings and cardiovascular risk factors.
For participants for whom the CDSS was not used during a consultation at the clinic, CDSS rules were
applied retrospectively on patient data during the analysis stage. Resting ECGs were reported as normal or
abnormal independently by two clinical researchers and disagreements were resolved by a consultant
cardiologist. Typicality of chest pain was determined primarily from the clinic description of the participant’s
chest pain, with the addition of general practice referral information where the clinic description was
insufficient. Clinic descriptions of chest pain were considered by two clinical cardiologists and discussed by
the research team where they were unable to reach a decision. If agreement could not be reached, patients
were excluded from analyses requiring typicality of chest pain. Data from the CDSS and the clinical record
were managed in a Microsoft Access database.
Process outcomes at 6 months
Participants were followed up for at least 6 months. Prescriptions of antiplatelet medication (aspirin or
clopidogrel), beta-blockers and statins at 6 months were extracted from the electronic primary care record.
Cardiac investigations (CT calcium scoring, CT coronary angiography, stress echocardiography, myocardial
perfusion scanning, angiography/angioplasty, cardiac magnetic resonance imaging) performed in the
6 months after consultation were manually extracted from the hospital EHR by trained researchers.
Qualitative data
To examine how the CDSS was used in practice and how it might impact on clinicians’ diagnostic
decision-making and patient management, we carried out an ethnographic study in clinic A 2 months before
and after the introduction of the CDSS (Table 12). This included observations of chest pain consultations and
testing, interviews with clinicians and patients, and a focus group with clinicians at the end of the pilot.
Quantitative analysis
We compared the management of patients seen before (clinic A, phase 1, and clinic B) and after (clinic A,
phase 2, and clinic C) receipt of the OMA programme. For the period after the receipt of the programme,
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we compared patients managed with and without the use of the CDSS, giving three groups for analysis:
(1) before OMA; (2) after OMA, CDSS used; and (3) after OMA, CDSS not used. We determined that
the CDSS had been used when data had been entered into the CDSS database. At baseline (date of
consultation), we compared age, sex, prescribed medications (antiplatelet medication, statins and
beta-blockers) and risk factors (smoking status, diabetes and hyperlipidaemia).
The proportions of patients for whom there was concordance of investigation choice and medication
prescribed with CDSS guidance at 6 months were reported, using the CDSS recommendations for patients
for whom the CDSS was used, and what the CDSS would have recommended for patients for whom the
CDSS was not used.
For each study group, we compared the prescription of statins, beta-blockers and antiplatelet medication
at 6 months after consultation. We calculated the mean number of medication classes prescribed for each
CDSS recommendation (no medications, statin and beta-blocker, and aspirin, statin and beta-blocker).
Concordance of investigation choice with the guidance of the CDSS was assessed by determining the
pattern of first investigations within 6 months for each study group.
National Institute for Health and Care Excellence CG95202 does not give investigation recommendations for
individuals with a pre-test probability of coronary disease of > 90%. A consensus panel of 12 experts in
cardiovascular care recommended angiography for patients with a pre-test probability of > 90%. The expert
panel also provided medication recommendations for the CDSS, based on each patient’s pre-test probability.
Qualitative analysis
Interview and consultation transcripts and observational notes were imported into qualitative data
analysis software [ATLAS.ti version 5.0 (Scientific Software Development, Berlin, Germany) and NVivo
(QSR International, Warrington, UK)], coded and analysed thematically using the constant comparative
method.210 Analyses of the interview and focus group data focused on identifying advantages and
limitations of using the CDSS in practice from clinicians’ points of view. Coding categories were iteratively
developed into themes that were further interpreted in the context of the literature on the role of CDSSs in
clinical decision-making and on professional behaviour change in clinical practice.
The analysis of the consultation data proceeded in two stages. First, transcripts and field notes (FNs) for the
observed post-intervention consultations were linked to clinical and diagnostic information from patients’
medical records and to the recommendations for drug treatment and investigative procedures generated
by the CDSS. Cases were indexed with the help of NVivo qualitative software to record clinicians’
classification of patients’ chest pain on the CDSS (typical, atypical or non-anginal), whether or not their
decision matched the CDSS recommendation and, in cases of mismatch, whether or not clinicians had
opted for different investigations from those recommended by the CDSS.
In a second step, the resulting typology of decision scenarios was used to guide a more detailed
qualitative examination of the consultation processes and contextual factors that had contributed to
TABLE 12 Summary of qualitative data gathered in clinics after delivery of the OMA programme
Data type Data type Number Sites
Observational Post-intervention consultations 40 Clinic A
Self-reported Field interviews immediately following observation of CDSS 25 Clinic A
Clinician interviews 5 Clinic A (4) and clinic C (1)a
Clinician focus group 1 Clinic A
a Interview carried out with lead clinician at clinic C to explore the diversity of issues across sites.
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clinical decision-making in each case based on the available ethnographic material. This included an
analysis of patients’ provision of medical history, patients’ treadmill performance, clinicians’ explanations to
patients, clinicians’ ‘think alouds’ delivered to researchers after consultations and researchers’ observations
of clinicians’ interaction with the CDSS. Insights gained from the case-by-case analysis of clinicians’ use and
non-use of the CDSS in practice were then synthesised with the themes that emerged from the analysis of
clinicians’ views based on the interview and focus group data.
Technical implementation
Originally, we had planned to deploy the OMA decision support tool by embedding it in the EHR systems
of each participating chest pain clinic. This would enable the seamless interaction with clinicians during the
routine clinical workflow and the extraction of data items directly from EHRs with minimal intervention.
We performed an initial scoping exercise that discovered and documented the different EHR systems
(and their respective components) used in the three chest pain clinics. We discovered significant variation
within and across clinics on the manner in which data were recorded and the EHR systems used to record
information. In the vast majority of cases, the EHR systems did not provide a software layer enabling
programmatic access by external software modules, thus rendering the ability to embed a decision support
tool directly in the system unfeasible. The option of contacting the system vendors and adding this was not
considered, as it was outside the scope of this project and would require significant resources. As a result,
the decision support tool was developed and deployed as an online application accessible through web
browser software.
The decision support tool was hosted on a secure university server behind a firewall and access was
protected using dedicated firewall rules and a Secure Sockets Layer certificate. Each user had two
authentication credentials (password and personal identification number) and the internet protocol
addresses of their host institutions had to be verified and added to the firewall prior to account activation.
The DST was developed on a Linux (The Linux Foundation, San Francisco, CA, USA) platform using Perl 5.8
(The Perl Foundation, Walnut, CA, USA), Apache (Apache Software Foundation, Los Angeles, CA, USA),
MySQL (Cupertino, CA, USA), Yahoo User Interface (Verizon, Basking Ridge, NJ, USA) and CGI (CGI Group,
Montreal, QC, Canada). Despite deploying the tool via the web, significant challenges were still
encountered. There was significant variation in the browsers and browser versions both within and across
hospital trusts, making the development of a uniform tool challenging. In addition, constant liaison
with NHS Information Technology was required to whitelist access to the tool despite the fact that no
patient-sensitive identifiers were ever stored or transmitted when using it.
Results
Quantitative study
We recruited 294 patients to the quantitative study between November 2009 and May 2011 (Figure 31),
291 of whom were followed up for 6 months. The web-based CDSS was used in the chest pain clinic in
two of the pilot sites, clinics A and C.
Baseline characteristics and clinical decision support system use
The baseline characteristics of recruited patients are shown in Table 13. Of the 183 consultations in a clinic
after delivery of the OMA programme, the CDSS was used in 154 (84%).
There were no clear differences in either medications at 6 months or first investigation within 6 months
between the before and after OMA groups, suggesting that the OMA CDSS did not change prescribing
practice or patterns of investigation. Furthermore, clinicians’ decisions were often in conflict with OMA
recommendations. Among patients for whom OMA recommended no investigation, 86% of patients did
not receive an investigation in clinics before the OMA intervention, and the same percentage did not
receive an investigation in clinics trained in the use of OMA. However, among patients for whom the OMA
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CDSS would recommend an investigation, 50% of patients underwent any investigation before the OMA
programme and just 59% underwent any investigation after OMA training.
Qualitative findings
In this section, we describe the range of perceptual and contextual factors that contributed to clinicians
using the CDSS in a manner different from that which was originally intended. We begin by outlining
obvious structural and practical barriers that limited clinicians’ ability to use the CDSS or to implement its
recommendations. We then consider the extent and direction of clinicians’ disagreements with CDSS
recommendation based on the full sample of observed post-intervention consultations in clinic A.
Finally, we move on to a more detailed examination of the meanings that clinicians attached to
different stages of their interaction with the CDSS in terms of its required patient-specific input, its
underlying algorithms and the interpretation and contextualisation of its outputs. Our aim here is to
provide an explanatory account of clinicians’ engagement with the CDSS that probes beyond the
appearance of intervention non-compliance to generate a better understanding of the extent to which
clinicians’ decision-making processes within the chest pain clinic are amenable to being supported by
CDSS technology in principle. Verbatim participant quotations on the role of computerised decision
support in clinical decision-making and clinicians’ perceptions about possible uses of the OMA CDSS
in clinical practice are presented in Appendices 2 and 3, respectively.
We present our findings from the analysis of clinicians’ self-reported and observational data in an
integrated manner.
Before OMAa
Assessed for eligibility
 (n = 120)
Included in the 
before-and-after study
(n = 109)
Analysed
(n = 106)
Excluded from analysis
(n = 3)
•  Unable to trace medical 
    records, n = 1
•  Unable to assign typicality, n = 2
After OMAb
Assessed for eligibility 
(n = 192)
Included in the 
before-and-after study
(n = 185)
Analysed
(n = 179)
Excluded from analysis
(n = 6)
•  Data incomplete, n = 2
•  Unable to assign typicality, n = 2
•  Withdrew content, n = 2
•  Refused consent, n = 3
•  Not GP referral, n = 1
•  Previous CVD, n = 3
Excluded 
(n = 7)
•  Refused consent, n = 2
•  Not GP referral, n = 1
•  Previous CVD, n = 8
Excluded 
(n = 11)
FIGURE 31 Flow diagram showing recruitment of patients attending RACPCs to the OMA programme. a, Trust 1,
Clinic A Before OMA and Trust 2, Clinic B; b, Trust 1, Clinic A After OMA and Trust 2, Clinic C. Reproduced from
Johnson et al.45 © Johnson et al. 2015. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.
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Structural and practical barriers to use of the clinical decision support system
as intended
Several structural barriers prevented the implementation of the CDSS recommendations, including clinicians’
lack of authority to prescribe medication and the non-availability of specific investigative procedures at the
hospital site. Two members of staff at the observed site were not able to prescribe medications. Chest pain
clinicians who were authorised prescribers rarely made use of the facility for the direct issuing of medication
from the hospital pharmacy instituted to facilitate prescribing. Reasons cited for this were lack of habit, GPs
having a better grasp of how medication fitted with patients’ existing drug regimen and additional cost to
the hospital trust. At the time of the pilot, calcium scoring was not available, and CT angiogram became
available only half-way through the pilot.
Practical barriers to the integration of the CDSS into the workflow of the clinic included computer glitches,
such as the program suddenly freezing up and the loss of data already entered. Although rare, these
occurrences caused frustration among clinicians. Clinicians also had to complete separate electronic
records with similar information to that requested by the CDSS, which may have felt like an avoidable
duplication of effort.
TABLE 13 Baseline characteristics of patients before and after implementation of the OMA program at time of
chest pain clinic attendance
Characteristics at
baseline
Before OMA (n= 106) (seen in clinic which
had not received OMA programme)a
After OMA (n= 179) (seen in clinic
which had received OMA programme)b
Age (years), mean (SD) 59.4 (11.0) 59.0 (11.6)
Sex, n (%)
Male 52 (49) 97 (54)
Female 54 (51) 82 (45)
Risk factors, n/N (%)c
Smoking 43/106 (41) 59/179 (33)
Diabetes 9/106 (8) 20/179 (11)
Hyperlipidaemia 34/106 (32) 62/179 (35)
Medications current at chest pain clinic, n/N (%)
Antiplateletd 23/106 (22) 34/179 (19)
Beta-blocker 5/106 (5) 17/179 (9)
Statin 26/106 (25) 37/179 (21)
Typicality of chest pain, n/N (%)
Typical 20/106 (19) 46/179 (26)
Atypical 17/106 (16) 28/179 (16)
Non-cardiac 69/106 (65) 105/179 (59)
SD, standard deviation.
a Clinic A phase 1, and clinic B; see Methods, Setting and study population for further details.
b Clinic A, phase 2, and clinic C; see Methods, Setting and study population for further details.
c Risk factors data taken from either GP referral or chest pain clinic data.
d Aspirin or clopidogrel.
Adapted from Johnson et al.45 © Johnson et al. 2015. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.
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The extent and direction of clinicians’ disagreement with clinical decision
support system recommendations
Observational data on clinicians’ decision-making and use of the CDSS were available for 37 patients
(Table 14). Clinicians disagreed with CDSS recommendations about investigative procedures in almost half
of all observed cases. Clinician disagreement encompassed both more and fewer investigations than
recommended by the CDSS. Researcher observations confirmed that in all these cases, clinicians stuck
to their original decision instead of considering changes in light of the CDSS output. Indeed, there
was a broad consensus among clinicians, articulated in interviews and the focus group, that clinical
decision-making should not be driven by technology and that clinicians should remain the final arbiters
of any decisions to be implemented.
Clinicians described the possible benefits to themselves of using the OMA CDSS mainly in terms of
providing reassurance and supporting a systematic approach to conducting consultations. This orientation
towards the CDSS as ‘decision feedback’ rather than ‘decision support’ was also reflected in the timing of
clinicians’ engagement with the CDSS. In two-thirds of the observed cases, clinicians used the CDSS after
they had communicated an independently made decision to the patient and the patient had left the room.
Looking at individual cases of clinicians’ agreement and disagreement with the CDSS recommendations,
clinicians were most likely to agree with the CDSS recommendation of ‘no further investigation’ when pain
was categorised as ‘non-anginal’ (15/19 cases). For typical angina symptoms, clinicians also expressed
agreement with CDSS recommendations in theory, although, in practice, they occasionally ‘downgraded’
the recommended methods of investigation when they felt that a more aggressive approach was not in
the patient’s best interest or was clinically unwarranted.
Clinicians were most likely to disagree with the CDSS when pain had been categorised as ‘atypical’
(12/18 cases). When the CDSS was being developed, patients presenting with atypical pain had been seen
as the category for which computerised decision support had most to offer in terms of supplementing
clinician expertise. It is therefore of particular interest that, in practice, clinicians regarded CDSS
recommendations as most reliable and trustworthy – but probably also least needed – when case histories
were typical for angina or clearly non-anginal.
Problems with the entry of patient information into the clinical decision
support system
Clinicians felt that there were a number of problems relating to how patient information had to be
entered into the CDSS. These included (1) classifying patient-reported symptoms according to Diamond
TABLE 14 Clinician agreement with CDSS recommendations for investigation of chest pain
CDSS recommendation
Investigation done
n Done Percentage done (95% CI)
Before OMA CDSS recommendation (investigation or no investigation) followed in 78 out of 106 cases
(74%, 95% CI 65% to 82%)
Investigation 36 18 50 (34 to 66)
No investigation 70 10 14 (6 to 22)
After OMA CDSS recommendation (investigation or no investigation) followed in 134 out of 179 cases
(75%, 95 CI 69% to 81%)
Investigation 74 44 59 (48 to 70)
No investigation 105 15 14 (7 to 21)
Reproduced from Johnson et al.45 © Johnson et al. 2015. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.
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and Forrester criteria,209 (2) an inability to update previously entered information and (3) concern over
entering information about risk information in a binary format as ‘present’ or ‘absent’ rather than in a
more graded manner.
Concerns over available clinical information not used by the clinical decision
support system
The results of patients’ exercise treadmill test (ETT) performance were not taken into account in the CDSS.
However, from observations and interviews there was evidence of the continued impact of the ETT on
clinicians’ decision-making in terms of upgrading or downgrading the investigative procedures indicated
by NICE guidelines on the basis of patient history (pain classification and risk factors). Clinicians freely
admitted their unwillingness to do away with the additional information that they felt that they could gain
from ETT results; one clinician explained that she would use the CDSS only after she had interpreted the
ETT results so as not to ‘cloud her judgement’. At the same time, clinicians acknowledged the limitations
of the ETT’s diagnostic value. We have explored the use of the ETT in the chest pain clinic in a previously
published paper.44
Discussion
Clinical decision support systems are often considered one of the most important rationales for developing
flexible and extendable hospital EHR systems. The long-term viability and sustainability of the CDSS
requires modular access to the underlying EHR system and ongoing, bidirectional data flows between
research and care components. In this study, we attempted to develop, implement and evaluate a CDSS in
a clinical setting lacking a modular EHR system that can foster CDSS integration – a situation that is still
widespread within both primary care and secondary physician information systems in the NHS. Our initial
technical scoping exercise revealed significant variation both within and across hospitals, which rendered
the option of creating an integrated CDSS unfeasible. As a result, we built and deployed a system
that was accessible through the internet and required minimal interaction with the underlying hospital
information systems.
Through our mixed-methods study, we have developed an in-depth understanding of the feasibility and
plausibility of the proposed OMA CDSS, and compared process outcomes in patients managed in clinics
before and after delivery of the OMA programme. The OMA CDSS, delivered within the OMA programme,
has been shown not to be feasible in its present form and, in line with MRC guidance, these findings do
not support a trial of the OMA programme.
Although the CDSS was used in 84% of consultations for which it was available, it had little impact on
medication prescribing at 6 months and first investigation within 6 months, and we have, therefore, not
carried out an expected value of information analysis. Of those patients recommended an investigation by
the CDSS, 50% of patients before OMA and 59% of patients after OMA did not receive any investigation,
and it is possible that this potential underinvestigation could lead to incorrect diagnoses of non-cardiac
chest pain. The range of investigations requested by clinicians was more limited than recommended by the
CDSS, with invasive angiography being the most commonly undertaken investigation.
The qualitative analysis describes how the CDSS was used in practice, highlighting structural and practical
difficulties, issues with data input and how the data are processed by the CDSS problems with matching of
all clinically available information to the CDSS algorithm, and difficulties with implementation of the
CDSS recommendations.
The strengths of this study lie in its mixed-methods approach. The quantitative study used both hospital
and primary care records to allow follow-up of patients at 6 months, and high rates of follow-up were
achieved (99% at 6 months). The qualitative study was extensive and was conducted by experienced
ethnographers who were familiar with the chest pain clinic setting. Although the quantitative data
suggested that the CDSS was used, the qualitative data were essential in developing a more complete
understanding of how it was used and provided multiple examples of difficulties in practice. Linking
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qualitative data to clinical and diagnostic information helped to make sense of the ways in which the
CDSS was used and recommendations followed. The ethnographic method uses several sources of data
(interviews, observations, focus groups), allowing comparisons to be made between what clinicians say
they do and what they actually do.
The qualitative data collection was limited by the inclusion of observations after the delivery of the OMA
programme in only one site, although we were able to interview one clinician from the second site at
which the OMA programme was delivered. Each of the researchers involved in collection of qualitative
data was involved in the development of the OMA programme.
For patients for whom the CDSS was not available or, when available, was not used during the clinical
consultation, the assessment of cardiovascular risk factors was retrospectively made using routinely
collected data for which there was more than one source (GP referral and hospital record). Data were
collected from the GP referral only when it was not available in the hospital clinic record. We found
disagreement between the sources for the presence of hyperlipidaemia and for smoking status, which may
affect the comparison of the groups at baseline.
For the purposes of populating the CDSS for this group of patients, the clinic data were used to determine
the typicality of chest pain. The complexity of categorising chest pain based on a patient’s description has
been described before.211 We found labelling chest pain typicality to be difficult, which resonated with the
difficulties the chest pain clinicians described. Given that typicality is central to the pre-test probability of
coronary disease and, hence, to CDSS recommendations, the difficulties experienced by both the research
team and chest pain clinicians are important.
The OMA CDSS is a component of the OMA programme, which includes preparation and education
stages. This study focuses on the CDSS, but clearly the other components of the OMA programme may
have an important impact on the way in which the CDSS is received and used.
We have measured medication prescription in general practice 6 months after consultation, as a proxy for
the use of secondary prevention medication. Clearly, there are many factors affecting whether or not
medication is continued at 6 months. For example, medications may be prescribed for new indications or
may be stopped following investigations that rule out coronary disease.
Tools to aid decision-making are introduced into the clinical workplace, a dynamic and complex system
in which technologies, people and organisational routines dynamically interact. The OMA CDSS was
introduced at a time of transition, NICE CG95202 having been published 4 months earlier. At this time,
the ETT had a central role in chest pain clinic routines, and our main qualitative study site did not routinely
use CT or CT coronary angiography for the diagnosis of angina. Although our original plan had been to
develop a CDSS with both medication and investigation guidance taken from our expert panel, and
allowing the incorporation of exercise test findings, given the primacy of NICE as a source of national
guidance, it seemed prudent to incorporate NICE guidance. However, the absence of a test that was an
entrenched part of chest pain clinic practice added to the difficulties of the clinicians in using the CDSS.
Chest pain clinics are unlikely to be able to incorporate guidance immediately, and it is possible that the
CDSS would have had more impact on clinic processes when clinics were more able to follow guidance.
Although largely based on national guidance, the CDSS did not ‘fit’ with established clinical practice in
several ways. Gaining entry to the guideline requires clear categorisation of a patient, in this case through
entering clinical data, which results in an estimate of a patient’s pre-test probability of significant CAD.
This categorisation is dependent on multiple inputs, including typicality of chest pain and risk factors.
The CDSS requires data entry in a dichotomised way, in contrast to the contextualised and nuanced
information available to the clinician. Use of the CDSS could be viewed as a series of interactions during
which the clinician first decides how to fit clinical inputs to the CDSS and subsequently considers how to
act on the CDSS outputs, given the clinical context and structural factors, such as the availability of
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particular investigations. Each of these interactions requires the clinician to balance the requirements
of the tool and the breadth of information available within the clinical context. Actions contrary to CDSS
recommendations could be seen not as ‘non-compliance’ but as rational decision-making under conditions
of uncertainty.
The privileging of clinical expertise in decision-making
Superficially, our findings suggest a failure to integrate the CDSS into the chest pain clinic workflow
and reluctance among clinicians to engage with computerised decision support. Indeed, resistance to
professional behaviour change and distrust of new technologies are previously cited factors for past
failures in CDSS implementation.212 The finding that the CDSS did not alter clinicians’ decision-making
about investigative and prescription medication means that it is unlikely that the OMA intervention would
result in more appropriate treatment and improved patient outcomes.
Rather than read clinicians’ behaviour as intervention non-compliance, however, we should aim to
understand it as reasoned action within complex real-life settings. Clinical decision-making does not occur
in a vacuum of probabilistic reasoning, but is steered to at least some extent by concerns over professional
accountability, the threat of litigation if mistakes are made, concerns over scarce resources and so on.
Our qualitative analysis of rich ethnographic data collected in one of the intervention pilot sites has
enabled a more in-depth understanding of how clinicians engaged with the CDSS in specific decision
scenarios, why they felt confident to over-rule its recommendations, and importantly, what might need to
change to make the CDSS relevant and helpful to their decision-making process. These investigations have
highlighted important factors such as clinicians’ fears about missing things and erring on the side of
caution when deciding on further investigative procedures, and entrenched ways of practising, with a
reluctance to abandon established diagnostic approaches.
Conclusions
Our pilot study suggests that the OMA intervention has no significant impact on the decision-making
behaviour of clinicians in chest pain clinics, and significant challenges were encountered when attempting
to integrate it with standard clinical workflows and hospital EHR systems. It is not feasible in its current
form and should not be evaluated further. The mixed-methods approach that we adopted, including
qualitative ethnographic methods, has provided an in-depth understanding of the ways in which clinicians
interacted with a CDSS. This understanding could support the development of new tools to aid clinical
decision-making with a greater likelihood of being adopted in practice and with higher integration with
hospital EHR systems.
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Chapter 7 Stable chest pain and stable coronary
artery disease: a novel cohort – the Clinical Cohorts
in Coronary disease Collaboration
Abstract
Background
Cohorts recruited in clinical settings make important contributions to addressing translational research questions
in prognosis research. Few large, well-characterised cohorts are available to support research into CVD.
Objectives
To establish a contemporary, prospective clinical cohort of patients with linked phenotypic, genetic and
biomarker data as a resource.
Methods
Consecutive patients undergoing investigation for new-onset, non-acute chest pain were recruited
between 2009 and 2014 from four UK NHS hospitals. Participants provided blood samples for biomarker
and genetic analysis, and completed a health questionnaire at baseline. Detailed clinical information was
manually extracted from hospital electronic databases. Participants are being followed up for CVD events,
and health-related quality of life was assessed using a postal questionnaire (mean follow-up of 469 days).
Results
We enrolled 3345 consecutive patients {63.1% men; mean age 58.0 years [standard deviation (SD) ± 12.5
years]}. Blood samples were collected for 84% of patients, baseline questionnaire data for 89% of patients
and clinical data for 99% of patients.
Conclusions
The Clinical Cohorts in Coronary disease Collaboration is a contemporary consented genetic bioresource
linked to hospital EHRs, questionnaire data and health outcomes. Significant challenges remain for
automatically extracting the entire patient EHR from health information systems and, as a result, a wealth of
data remain inaccessible for research. The design, development and provision of common infrastructure, data
standards and services that will allow researchers to access and exploit such data are crucial for expanding 4C
in the future. Related initiatives such as the NIHR HIC will provide best practices and guidelines for doing so.
The studies in this chapter relate to patients presenting for the first time with stable chest pain (see Figure 24).
Introduction
Despite their value in translational research, few large, prospective clinical cohorts have been established in
SCAD. To provide a new resource for prognosis research, we have established a novel, contemporary clinical
cohort, the 4C, which includes a genetic and biomarker resource linked to hospital EHRs, questionnaire data
and health outcomes. Using a combination of -omic, clinical and phenotypic data, 4C will support research
on the causes of SCAD and its main complication, ACS, and the complex interactions between genetic
and environmental determinants of post-AMI outcomes. 4C forms part of GENIUS-CHD,213 an international
consortium of 63 clinical cohorts containing CHD patients and deoxyribonucleic acid (DNA) to associate
genetic variants with subsequent events. The consortium was established in 2014 and contains data
from cohorts from 17 countries, including > 270,000 patients – the largest effort of its kind studying
determinants of risk for subsequent CHD events. This study describes the rationale and design of the 4C
cohort, and baseline characteristics of patients.
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Study 14: establishment of a novel consented clinical cohort
and blood resource (the Clinical Cohorts in Coronary disease
Collaboration) – study design and baseline characteristics
This manuscript by Fitzpatrick et al.46 is in preparation.
Introduction
Consented cohorts recruited in clinical settings make important contributions to addressing translational
research questions in prognosis research.29–32 However, despite their potential advantages, large
prospective clinical cohorts are lacking across all disease areas, and only a handful exist for CAD.214–217
There is a stark contrast between the significant scientific interest in and the lack of clinically useful novel
biomarkers. New technologies such as mass spectrometry and nuclear magnetic resonance spectroscopy
for measuring metabolites (metabolomics) or proteins (proteomics) have the potential to provide early
insight into the aetiology of CAD and, thus, better predictive performance. However, the value of existing
circulating biomarkers, or panels of biomarkers, for predicting or mediating disease prognosis has yet to
be proven.
Although in its early stages, the adoption of information technology in health care and biosciences –
‘clinical informatics’ – is gaining rapid momentum and is predicted to revolutionise the way -omics data
linked to phenotypes recorded within EHRs will drive translation of scientific discovery into clinical practice
and patient benefit. In the USA, consented biorepositories linked to EHRs are increasingly successfully
being used for translational research at scale.218 For example, BioVU (Vanderbilt University Medical Centre,
Nashville, TN, USA)219 is a biorepository containing over 200,000 DNA samples extracted from discarded
blood linked to the full hospital EHR of consented patients attending the Vanderbilt University
Medical Centre.
To advance research through collaboration, 4C was established in the UK in 2009 as a resource in which
DNA and biomarker samples were obtained at the time of presentation with chest pain and linked to
detailed phenotypic data obtained from EHRs and participant self-completed questionnaires. We sought
to explore and assess the current potential of setting up a comparable consented research platform by
collecting DNA samples and to quantify the extent to which diverse NHS hospital information systems are
accessible for extracting secondary care data (structured and unstructured) for research purposes at scale.
Methods
Design and setting
Prospective, observational cohort study in which participants were recruited from RACPCs, cardiac catheter
laboratories and coronary angiogram pre-assessment clinics in four ethnically diverse NHS hospitals: the
Heart Hospital, University College London Hospitals NHS Foundation Trust; the London Chest Hospital and
Newham University Hospital, Barts Health NHS Trust; and the Bristol Heart Institute, University Hospitals
Bristol NHS Foundation Trust.
Study cohort
Eligibility
Consecutive patients undergoing evaluation for chest pain at RACPCs or elective invasive coronary
angiography at participating hospitals were approached for inclusion (Figure 32). Patients were not eligible
for inclusion if they were diagnosed with structural heart disease, cardiomyopathy or arrhythmia, or were
referred for ablation or placement of devices (e.g. pacemakers). No patients were excluded on the basis of
age or coexisting conditions. Trained researchers identified eligible patients by checking clinic appointment
databases and angiogram procedure lists on a daily basis.
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Participant consent
Patients were approached directly by a researcher at the hospital at the time of their clinic appointment.
Informed consent was sought for (1) completion of a baseline health questionnaire; (2) provision of a
blood sample for long-term storage and analysis of DNA and biomarkers; (3) extraction of patient hospital
data; and (4) linkage of patient data with national EHR data sources (e.g. coded hospitalisations and
procedures, emergency admissions and cause-specific mortality) (see Appendix 4).
Baseline data collection and measures
Measures were piloted and refined prior to commencement of the study. Three unique sources of data
contributed to the participant baseline assessment, which took place during patients’ scheduled
hospital appointments.
Collection of research measures
Blood resource A non-fasting blood sample was obtained from consenting participants, including those
in whom a diagnosis of angina was subsequently ruled out, by staff trained in venepuncture. A total of
20.0 ml of blood was drawn to enable a wide range of research measures to be obtained. Samples were
processed in accordance with protocol and aliquoted into 0.5-ml 2-D barcoded cryovial tubes suitable
for long-term cryopreservation. Each cryovial was individually logged in two unlinked databases using a
single-tube quick response code reader, placed in a 96-position rack and stored locally at –20 °C. PAXgene
[PAXgene Blood RNA System (PreAnalytiX, Switzerland)] ribonucleic acid tubes were stored as whole blood
at –20 °C. DNA was collected using a buccal swab from consenting participants who did not provide a
venous blood sample. All samples were transported in temperature-controlled shipping boxes for
long-term storage at a biobank at –80 °C (see Appendix 5).
Extraction of deoxyribonucleic acid and single-nucleotide polymorphism genotyping DNA was
extracted from 2556 individual participant samples, and genotyping of 51 CHD-specific single-nucleotide
polymorphisms identified in Coronary ARtery DIsease Genome wide Replication and Meta-analysis
(CARDIoGRAM PlusC4D)220 was carried out at a company with specialised services for extraction of DNA
and genotyping, in accordance with specification.
Metabolomic profiling Hydrogen-1 nuclear magnetic resonance spectroscopy was used to quantify 216
metabolites in serum from 2323 participants.
Phenotyping questionnaire Patients completed a health questionnaire (average completion time of
5–10 minutes), which included questions on education, ethnicity, general health functioning [EuroQol-5
Dimensions (EQ-5D)],221 functional chest pain (Rose angina questionnaire),222 angina severity [Canadian
Cardiovascular Society (CCS) classification],223 and symptoms of anxiety [Generalized Anxiety Disorder
7-item scale (GAD-7)]224 and depression [Patient Health Questionnaire-9 (PHQ-9)]225 at baseline
(see Appendix 6).
Extended physical examination and measures obtained in substudy Additional measures obtained
from a subset of patients for research use included a 60-minute physical examination [anthropometric
measures, lung function, aortic BP, pulse wave (augmentation) index, pulse wave velocity and ankle
brachial index] and 31-hour ambulatory ECG, and tri-axial accelerometry and sleep measures. Substudy
participants also completed an extended health questionnaire which included questions on diet and sleep.
Collection of information collected as part of standard clinical care
Trained extractors reviewed hospital databases and recorded detailed clinical information on standardised
case report forms (see Appendix 7). Depending on the clinic or hospital, different clinical systems were
searched to manually extract data that could not be downloaded or exported as a data file (Table 15).
Information included reason(s) for referral, history of chest pain, physician-recorded risk factors for CAD,
previously diagnosed medical history and test results. The resting ECG and ETT had to be removed from
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the notes or ordered from medical records and photocopied. The manual extraction of clinical biochemistry
results from the hospital systems proved burdensome and was abandoned.
Data were then manually entered onto a research database at the study co-ordinating centre, cleaned and
coded ready for analysis.
Electronic health records linkages for participant follow-up
We linked consented individuals with secondary care data from HES, a national data warehouse of
administrative data containing ICD-10-coded hospital diagnoses and OPCS4-coded procedures. We additionally
linked participants with mortality data from the ONS, which provided ICD-10-coded cause-specific mortality
data. The linkages were conducted via the NHS Health and Social Care Information Centre (formerly known as
the NHS Information Centre) and patients were identified using their NHS number (a unique 10-digit numeric
identifier for the health-care system), sex, date of birth and postcode.
Postal questionnaire participant follow-up
A postal follow-up questionnaire was sent to study participants (mean follow-up of 469 days) after
recruitment to assess general health status (EQ-5D), functional status (Rose Angina Questionnaire,222
Seattle Angina Questionnaire),226 symptoms of depression (Patient Health Questionnaire-2) and anxiety
(GAD-7),224 and use of nitrate medication.
Clinical outcomes
The primary end point is a pre-specified composite of cardiovascular mortality, non-fatal AMI, non-fatal
stroke and PAD. The secondary outcomes are angina status (CCS classification, Seattle Angina
Questionnaire, nitrate use) and general health functioning (EQ-5D) from the follow-up questionnaire.
Study approvals
The study protocol was approved by the London City Road and Hampstead National Research Ethics
Committee (reference 11/LO/1621) and local NHS Research and Development committees.
Results
Challenges obtaining data from hospital databases
We identified many challenges to the collection of data from hospital electronic databases in a
research-ready format. We accessed multiple clinical systems containing different sources of information
but we were unable to download or export data as electronic files at any of the hospitals.
Baseline data
Between 9 July 2009 and 9 January 2014, 3345 participants [63.1% men; mean age (± SD) 58.8 years
(± 12.5 years)] were enrolled in the study. Detailed clinical information was manually extracted from
hospital EHRs 6 months after the baseline assessment, to allow time for procedure and test results to be
uploaded. Approximately half (52%) of the participants were recruited from RACPCs and 48% were
recruited from angiography pre-assessment clinics and cardiac catheter laboratories. Ethnicity was available
for 98.5% of participants, with 54.8% describing themselves as white, 23.1% describing themselves as
South Asian (Indian, Pakistani and Bangladeshi) and 11% describing themselves as black (Table 16).
Of the 3345 participants recruited into the study, 3315 (99.1%) granted full access to their medical
records. Chest pain was the presenting symptom in 94.5% of the participants, of whom 33.4%
complained of associated shortness of breath (31.2% for men and 37.2% for women; p = 0.001).
Risk factors
Smoking status was recorded for 74% of participants, of whom 19.1% were current smokers. Men were
more likely than women to smoke or be ex-smokers (21.8% and 30.6%, respectively, vs. 14.6% and
18.3%, respectively). Participants were defined as being hypertensive if they fulfilled any of the following
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TABLE 16 Baseline clinical characteristics of the 4C study cohort
Baseline characteristics Alla (N= 3315) Men (n= 2089) Women (n= 1226) p< 0.05b
Symptoms on presentation (%)
Chest pain 95.5 95.5 95.5 NS
Shortness of breath 33.4 31.2 37.2 0.001
Characterisation of chest pain (%) < 0.001
Typical 34.8 38.8 38.6
Atypical 45.5 42.4 50.4
Non-cardiac 19.7 18.8 21.2
Cardiac history (%)
Ischaemic/coronary heart disease 29.0 34.0 20.6 < 0.001
AMI 11.3 14.1 6.4 < 0.001
Unstable angina 0.9 1.1 0.5 NS
Heart failure 2.4 2.7 1.8 NS
Risk factors for CAD
Smoking status (current/ex/non) (%) 19.1/26.0/28.9 21.8/30.6/23.8 14.6/18.3/37.4 < 0.001
Family history of coronary disease (%) 31.3 30.0 33.5 NS
Hypercholesterolaemia (%) 52.5 53.2 51.7 NS
Hypertension (%) 66.2 66.5 69.2 NS
Type 1 diabetes (%) 0.7 0.7 0.7 NS
Type 2 diabetes (%) 22.4 24.3 19.3 0.001
BMI (kg/m2), mean (SD) 29.5 (± 5.5) 29.1 (± 4.9) 30.5 (± 6.5) < 0.001
Pre-test probability of CAD reported for stable angina patient (%) NS
Low 3.4 3.4 3.5
Medium 18.5 16.6 22.4
High 78.1 80.0 74.1
Investigations performed (index procedure) (%)
Invasive coronary angiogram 54.9 60.0 47.1 < 0.001
Coronary CT angiogram 6.3 5.5 7.7 0.013
Angiogram assessment (%) < 0.001
Normal angiogram 28.0 11.0 15.2
Non-obstructive CAD 12.3 22.0 40.4
One diseased vessel 21.2 22.0 20.3
Two diseased vessels 23.5 26.9 16.4
Three diseased vessels 14.9 18.5 7.8
Medication on referral (%)
Aspirin/antiplatelet medication 19.8 21.5 16.9 0.001
Beta-blocker 14.5 16.4 11.3 < 0.001
ACEI 12.6 13.9 10.4 0.004
Statin 23.2 25.1 20.1 0.001
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criteria: (1) previous diagnosis of hypertension was recorded on referral or during appointment at the time
of recruitment; (2) another diagnosis from which hypertension can be inferred was recorded (e.g. chronic
kidney disease due to hypertension); (3) SBP measurement recorded up to 3 months prior to recruitment
was ≥ 140 mmHg and/or DBP was ≥ 0 mmHg; or (4) participants were taking BP-lowering medication on
referral. Following these criteria, 68.1% of the cohort was defined as hypertensive at baseline. Using
criteria 1, 2 and 4, 27.6% of the cohort was classified as being diabetic, with a higher percentage of men
diagnosed with diabetes than women (29.2% vs. 25.0%; p = 0.008). Of these, 22.4% were recorded as
having type 2 diabetes, whereas 0.7% of the cohort presented with type 1 diabetes. A previous diagnosis
of hypercholesterolaemia was recorded for 52.5% of the cohort, with no significant difference between
men and women (53.2% vs. 51.7%, respectively). A BMI of ≥ 30 kg/m2 was recorded for only 37.4% of
the cohort, with a significantly higher percentage of women than men recorded as being obese (43.5% vs.
34.1%; p < 0.001). A positive family history of coronary disease was present in 31.3% of participants, with
women presenting a higher percentage of first-degree relatives with history of CAD than men (33.5% vs.
30.0%, p = 0.035).
Cardiac history
A positive history of ischaemic heart disease (IHD) was recorded for 29% of patients, with a significantly
higher percentage of men than women (34.0% vs. 20.6%; p < 0.001) with a previous diagnosis;
unsurprisingly, more men had previous coronary angiograms than women (21.0% vs. 13.2%; p < 0.001).
Similarly, history of previous AMI was higher among men than women (14.1% vs. 6.4%; p < 0.001), with
17.5% of men having had a previous PCI (vs. 7.9% of women; p < 0.001) and 7.4% having had previous
coronary artery bypass surgery (vs. 3.0% of women; p < 0.001).
Physical measurements
Baseline heart rate was obtained from resting ECGs performed on the day of the participants’ appointment
and is available for 67.5% of the participants. Women had a significantly higher heart than men
[74.5 ± 13.6 beats per minute (b.p.m.) vs. 71.6 ± 14.6 b.p.m.; p < 0.001]. SBP and DBP were obtained
from referral letters and GP correspondence up to 3 months before recruitment or discharge letters from
RACPC on the date of recruitment. Both SBP and DBP were significantly lower in men than in women
(130.0 ± 19.8 mmHg and 77.9 ± 11.7 mmHg, respectively for men vs. 133.8 ± 21.0 mmHg and
79.0 ± 11.6 mmHg, respectively for women; p < 0.001).
TABLE 16 Baseline clinical characteristics of the 4C study cohort (continued )
Baseline characteristics Alla (N= 3315) Men (n= 2089) Women (n= 1226) p< 0.05b
Glyceryl trinitrate 8.1 7.4 9.3 0.049
Long-acting nitrate 6.2 6.9 4.9 0.018
Calcium channel blocker 10.2 9.7 11.1 NS
ARB 4.3 4.3 4.5 NS
Outcome (%) 0.229
No treatment 54.4 52.6 57.5
Medical management 19.6 20.2 18.5
PCI 19.2 20.2 17.5
Coronary artery bypass surgery 3.9 3.9 3.9
Further investigation 1.4 3.1 1.6
NS, not significant.
a 3315 participants who consented to their medical records being accessed.
b Men vs. women.
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Investigation
The initial diagnosis provided by the clinician or nurse assigned to the patient was stable angina in 51.5%
of the cohort for whom this information was recorded. Surprisingly, 41.4% of the participants were
initially diagnosed as having non-CAD chest pain, of whom a higher percentage were women (51.7% vs.
36.0% for men). However, only 56.1% of our cohort had information available on initial diagnosis.
The overall assessment of diseased vessels, obtained for 61.1% of the cohort, was based on the angiogram
assessment of severity or percentage of luminal diameter stenosis, with number of diseased vessels classified
according to vascular territory of the three major coronaries. The following criteria were then applied: (1) no
evidence of disease in any of the territories was classified as normal; (2) non-obstructive disease (e.g. mild
disease or irregularities, ‘no significant disease’, ‘no flow limiting disease’) classified as less than moderate
(obstruction ≤ 50%) in severity, was considered non-obstructive CAD; (3) evidence of moderate (50–69%)
or worse (severe: ≥ 70%) disease in any one of the three territories was classified as one diseased vessels;
(4) evidence of moderate or worse disease in any two territories or the left main stem was classified as two
diseased vessels; and (5) evidence of moderate or worse in all three territories was classified as three
diseased vessels. Applying these criteria, 28.0% of our cohort was classified as having a normal angiogram,
12.3% as having non-obstructive CAD, 21.2% as having one diseased vessel, 23.5% as having two
diseased vessels and 14.9% as having three diseased vessels. Women had a higher percentage of normal
coronaries than men (40.4% vs. 22.0%; p < 0.05), whereas men had more coronary angiograms classified
as three diseased vessels than women (18.4% vs. 7.7%; p < 0.05). These findings are consistent with the
higher percentage of men presenting risk factors and a previous history of CAD (IHD, AMI).
Management
Medical management was the opted treatment for 16.4% of participants, whereas a subsequent PCI was
required for 19.2%. A smaller percentage of cases were recommended for coronary artery bypass graft
(CABG) (4.6%).
Sex differences
In our cohort, men were more likely than women to smoke, be hypertensive and diabetic, have previous
diagnoses of IHD and/or AMI, and have had a previous interventional procedure (PCI or CABG surgery).
The index investigation also showed that men were more likely to have a higher number of vessels
obstructed and were more likely to require CAD-specific treatment than women.
Baseline health questionnaire
A total of 2981 participants (89%) completed a baseline health questionnaire (Table 17). Three-quarters
(76.4%) of participants reported pain/discomfort problems (73.6% of men vs. 81.3% of women;
p < 0.001), and nearly half (45.6%) reported problems with anxiety/depression (42.3% of men vs. 51.6%
of women; p < 0.001). However, only 14.4% of participants reported problems with self-care (14.5% of
men vs. 16% of women; p < 0.001). More than three-quarters of participants (78.4%) were classified as
experiencing exertional chest pain based on the Rose Angina Questionnaire, with no significant difference
between men and women (77.2% vs. 80.4%, respectively). Many participants (60.7%) reported moderate
limitations in daily living activities or an inability to perform any activity without angina or angina at rest
(CCS classification III or IV). Women were more likely than men to report depression and anxiety based on
the PHQ-9 and GAD-7 assessment questionnaires.
Single-nucleotide polymorphism genotyping
Minor allele frequencies were replicated from published data (Figure 33).
Metabolic profiling
1H-NMR spectroscopy was used to resource 225 cardiovascular-related metabolites in human serum. These
included (1) lipoprotein lipids consisting of lipids, serum albumin and albumin-bound fatty acid resonances;
(2) low-molecular-weight molecules, pyruvic acid, amino acids, ketone bodies and creatinine; and (3) serum
constituents with detailed molecular information on serum lipid extracts including free and esterified
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TABLE 17 Baseline health questionnaire responses of the 4C study cohort
Baseline health questionnaire
Alla (n= 2981)
(%)
Men (n= 1897)
(%)
Women (n= 1084)
(%) p< 0.05b
Functional health status (EQ-5D)221
Mobility < 0.001
Respondents reporting no problems 60.4 64.3 53.6
Respondents reporting any problem 39.6 35.7 46.4
Self-care NS
Respondents reporting no problems 85.6 86.5 84.0
Respondents reporting any problem 14.4 14.5 16.0
Usual activities < 0.001
Respondents reporting no problems 64.2 68.2 57.1
Respondents reporting any problem 35.8 31.8 42.9
Pain/discomfort < 0.001
Respondents reporting no problems 23.6 26.4 18.7
Respondents reporting any problem 76.4 73.6 81.3
Anxiety/depression < 0.001
Respondents reporting no problems 54.4 57.7 48.4
Respondents reporting any problem 45.6 42.3 51.6
Rose Angina Questionnaire222 NS
Exertional chest pain 78.4 77.2 80.4
Non-cardiac chest pain 21.6 22.8 19.6
CCS classification223 < 0.001
I 16.8 19.1 12.7
II 22.6 21.5 24.6
III 10.5 11.2 9.2
IV 50.2 48.3 53.6
Mental health
Depression (PHQ-9)225 < 0.001
None 46.7 49.9 40.9
Mild 28.2 26.6 31.2
Moderate 14.9 14.0 16.6
Moderate/severe 6.2 5.5 7.3
Severe 4.0 4.0 4.0
Anxiety (GAD-7)224 0.002
None 53.6 51.0 46.1
Mild 23.2 24.0 25.5
Moderate 15.1 16.7 19.6
Severe 8.1 8.3 8.7
NS, not significant.
a 2981 participants who completed baseline health questionnaire.
b Men vs. women.
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cholesterol, sphingomyelin and omega-3 fatty acids. A total of 2323 samples were successfully analysed,
and 2025 patients underwent angiography (1816 invasive coronary angiograms and 209 coronary
CT angiograms).
Interim follow-up data for hospital admissions and procedures and mortality
A high proportion of consented participants were successfully linked to hospital admission and procedure
data in HES (96.7% of patients sent for matching to date). In addition, 99% of participants were linked
successfully with the ONS national death registry and 84 incident deaths were recorded [with 25 recorded
as CHD-related deaths (ICD-10 codes I20–25) as the underlying cause of death] (Table 18).
Discussion
Although researchers carrying out large-scale studies were previously limited to utilising EHR data from
single sources, the potential to access data spanning the entire translational cycle now exists, with new
opportunities to link clinical health-care data with other sources of electronic information and bespoke
data on a large scale. To exploit these new opportunities, we established the 4C cohort, a contemporary,
prospective cohort of 3345 patients undergoing investigation for SCAD, with blood and questionnaire
data linked to the hospital EHRs, who are being followed up for a range of disease end points recorded
in national registry databases. The cohort was established as a resource to encourage collaborative
research based on individual patient data, in order to strengthen prognostic model development and
external validation.
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We faced two significant challenges during the conduct of our study. First, despite attempts to co-ordinate
permissions from NHS organisations to undertake clinical research with the introduction of the NIHR
Co-ordinated System for Permissions in 2008, we experienced significant delays in obtaining the required
approvals [mean NHS Trust site-specific approval time was 85 days (range 50–115 days) across four sites],
delaying recruitment of sites and influencing participant accrual targets. Health Research Authority plans to
unify the approvals process for research in the UK came into effect at the end of 2015 (see www.hra.nhs.uk/),
and it remains to be seen whether or not efforts to reduce the time it takes to approve research are
successful, in the same way that regulatory approval of clinical trials was expedited following a highly
critical Academy of Medical Sciences report on the effect of delays on approvals on scientific discovery.227
Contractual negotiations, human resources checks and governance relating to cross-site working within NHS
hospital trusts further impacted on recruitment and must also be reviewed.228
A second challenge was an inability to download data electronically from the hospital EHR, resulting in
time-consuming manual collection and recording of clinical data. The lack of efficient means to access or
transfer EHR data, including discharge summaries and biochemistry results stored on separate clinical
systems, greatly increased the time and resulting financial cost required to collect complete data.
The design, development and provision of common infrastructure, data standards and services are required
to allow researchers to seamlessly interact and extract clinical data for research purposes across hospitals.
An example of such an initiative is the NIHR-funded HIC health informatics programme. Across five
participating Biomedical Research Centres (University College London Hospitals, Imperial College
Healthcare, Guy’s and St Thomas’ NHS Foundation Trust, Oxford University Hospitals and Cambridge
University Hospitals), the HIC aims to enable the collaborative sharing of NHS data collected and captured
as part of usual clinical care to facilitate more effective clinical research. HIC investigators have developed a
common data model that is used to extract clinical data (retrospectively and prospectively) from hospital
TABLE 18 Follow-up for hospitalisations and mortality in the 4C cohort
Follow-up ONS (mortality)
HES (non-fatal diagnoses
and procedures)a
Patients who consented to follow-up (of 3345 recruited to 4C), N (%) 3315 (99.1) 3315 (99.1)
Patients sent for matching, n (%) 3315 (100) 867 (26.2)a
Patients matched to record, n (%) 3311 (99.9) 839 (96.7)a
Follow-up (months), median (IQR) 20 (14–26) 326 (155–563)
Observed participants with end point from ONS, n (%)
All-cause deaths 84 (2.5) –
Cause of death registered 54 (64.3) –
CHD-related deaths (ICD-10 codes I20–25)b 25 (46.3) –
Non-CHD CVD-related deaths (ICD-10 codes: I010–I99, excluding
I200–I259)c
9 (16.7) –
Non-CVD deaths 20 (37.3) –
Awaiting cause of death registration 30 (35.7) –
Observed participants with end point from HES, n (%)
Non-fatal AMI + non-fatal stroke + PAD – 27 (3.2)
Approximate annual risk (%) 1.3 3.6
a Updated HES data are awaiting release by the NHS Information Centre.
b ICD-10 codes: I20, angina pectoris; I21, STEMI and NSTEMI; I22, subsequent STEMI and NSTEMI; I23, certain current
complications following STEMI and NSTEMI (within 28-day period); I24, other acute ischaemic heart diseases; I25,
chronic ischaemic heart disease.
c I010–I99, excluding I200 unstable angina to I259 chronic ischaemic heart disease, unspecified.
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information systems across five scientific themes (viral hepatology, ACS, ovarian cancer, renal
transplantation and clinical care). The extracted data are catalogued through a common metadata
catalogue and shared via the use of secure safe havens that are accredited to international information
security standards such as International Organization for Standardization (ISO) 27001:2013. The HIC
approach has demonstrated how robust e-infrastructure and health information modelling approaches are
required in order to enable the extraction of clinical data for research from hospitals and to tackle the
challenges associated with diverse vendors and information systems being used within and across trusts.
A streamlined technical approach also enables researchers to effectively address generic challenges related
to data sharing, information governance and patient confidentiality more effectively through the use
of standards.
In his State of the Union address in 2015, US President Barack Obama emphasised the power of big data
in his personalised medicine initiative.2 The new era of ‘big data’ brings unprecedented opportunities for
prognosis research. Proposals to link clinical data systems locally and embed patient consent for research
into clinical care would mitigate the complexities of obtaining complete data and recruiting patients in
busy clinical settings, and thereby increase the utility of such cohorts. High-throughput, high-quality
research will also be expedited by ambitious discovery projects that are linking EHR data to genomic data,
such as the 100,000 Genomes Project,19 and large international EHR research platforms such as the
eMERGE network,229 the Danish National Biobank Registry230 and the UK Biobank.107 However, complex
issues, such as how to repurpose EHR data for research (acquisition of ‘research-ready’ data) and extract
accurate phenotypes from EHRs, will require careful consideration.
Strengths and limitations
The 4C study adopted rigorous standards for data collection. A wealth of bespoke phenotypic information,
including self-reported health functioning, and quality-of-life and clinical data from the EHR, has been
collected and is linked to biomarker and genetic data. More than 99% of participants have been linked to
comprehensive, nationally collected data on hospitalisations, procedures and mortality.
This study has limitations. Half of the patients approached for inclusion in the study were either ineligible or
declined to participate, and low response rates were more marked in hospitals serving an ethnically diverse
population, so selection bias must be considered. Sex differences should take into account the fact that a
higher percentage of men were recruited into the study, raising questions about whether or not there are
sex differences in health-seeking behaviour that could partially account for more severe obstructive CAD
cases among men or if there are, in fact, underlying differences in the aetiology, diagnosis, management
and treatment of CAD between men and women that are not yet fully understood. EHR data quality varied
significantly between hospital information systems and data were often missing or incomplete, which
required manual adjudication and validation by trained staff. In particular, we found a high proportion of
missing data in the EHR, so under-reporting of medical history, risk factors for coronary disease and clinical
symptoms is likely. Finally, in the UK, there is currently no centralised conduit, with national coverage, for
linking and extracting primary care data at scale for research. We attempted to link consented participants
with primary care resources but that involved going to individual GP practices and performing manual
queries and data extraction operations – a route that is both unscalable and cost inefficient. As a result, we
were unable to obtain the primary care EHR for our participants but it is foreseen that substantial investment
in this area (e.g. CPRD) will make this process feasible in the future.
Conclusions
The 4C cohort is a novel contemporary DNA and plasma resource linked to detailed information collected
from the hospital EHR and questionnaire data and health outcomes. Significant challenges remain for
automatically extracting the entire patient EHR from health information systems and, as a result, a wealth of
data remains inaccessible for research. The design, development and provision of common infrastructure,
data standards and services that will allow researchers to access and exploit such data are crucial for
expanding 4C in the future, driven by best-practice initiatives such as the NIHR HIC.
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Chapter 8 Stable coronary artery disease: use of
single prognostic factors
Abstract
Background
The scope and impact of prognosis research and EHR research (in primary and secondary care, and in
disease and procedure registries) are intimately related. Guidelines recommend measuring a wide range of
clinical factors, but there are uncertainties in the reliability of individual biomarkers and their clinical
usefulness in predicting clinical outcomes.
Objectives
To examine evidence supporting the use of five established and novel prognostic factors for predicting the
progression of disease and outcomes among SCAD patients.
Methods
An analysis of CALIBER data and literature-based systematic reviews and meta-analyses.
Results
(1) Haemoglobin below 13.5 g/dl for men and 12.8 g/dl for women was associated with increased
mortality. (2) Heart rate of > 87 b.p.m. was associated with increased hazard of heart failure and mortality.
(3) Published evidence of associations between C-reactive protein (CRP) levels and risk of cardiovascular
events was of variable quality, and the degree of association may have been overstated. (4) Pooled data
showed that Ch9p21 was convincingly associated with increased risk of first but not subsequent
cardiovascular events. (5) SBP in type 2 diabetes patients diagnosed with stable angina declined over time.
Lower values of SBP significantly increased the risk of all-cause mortality, non-fatal AMI or non-fatal stroke,
as did a greater decline in the rate of change of SBP.
Conclusions
Some biomarkers appear to be useful prognostic factors in SCAD, although poor methodology impairs the
interpretation of many study findings.
The studies in this chapter relate to patients presenting for the first time with SCAD (Figure 34).
Introduction
The era of ‘big data’ heralds opportunities to conduct large-scale studies in prognosis research arising from
linking EHRs. Prognostic factors for SCAD are measurements associated with the risk of subsequent clinical
outcomes, such as (further) heart attack or other CVD, or death. As such, prognostic factors are a specific
subset of biomarkers that are related over time to such end points. Although the term ‘risk factors’ is
commonly used in the setting of disease onset, prognostic factors are related to disease progression.
There are several reasons why the reliable identification of a prognostic factor may be important:
l It may improve the accuracy of prognostic models, enabling clinicians to assess patient risk more
effectively and providing policy-makers with more effective planning tools.
l It may provide insight into causal processes or mechanisms in disease progression, including some that
may suggest new interventions (or new uses for existing interventions).
l Even if not causally implicated, a prognostic factor may be useful in multivariate risk prediction models,
if it is associated with outcomes independently of other prognostic factors.
l It might be useful on its own as a way to monitor disease progression. For this use, prognostic factors
need to be assessed at multiple time points.
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The risk factors for the incidence of stable angina and AMI have not been previously compared in
large-scale studies. We have demonstrated that associations between the initial presentation of
12 different CVDs and BP,231 smoking,232 diabetes,37 resting heart rate and BMI vary in terms of presence,
strength and shape of association. Our findings signify that these are not the same diseases and challenge
the widely held assumptions that risk factors have strong associations with the occurrence of all CVDs.
In the studies that follow, we have evaluated a range of potential prognostic factors. These included
measurements made in clinical practice that are not currently used prognostically, namely a molecular
measure (the blood test haemoglobin) and a physiological measure (heart rate), two of the most widely
performed and cheapest clinical measures available. We also evaluated two ‘novel’ markers that are under
evaluation and not used in normal clinical practice (the genetic marker Ch9p21) or that are used to a
varying degree in clinical practice (CRP). The European Society of Cardiology (ESC) recommends measuring
a wide range of clinical factors, including haemoglobin and heart rate, both of which have been
incorporated in prognostic models.233 However, current models are not in routine clinical use, and
additional informative biomarkers would be valuable.
Study 15: clinically available biomarkers – threshold haemoglobin
levels and prognosis of stable coronary artery disease
This study is based on the peer-reviewed paper by Shah et al.47 Sections of the text have been reproduced/
adapted from the original article; © 2011 Shah et al.47 This is an open-access article distributed under the
terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
Introduction
Given the known links between myocardial hypoxia and later acute coronary events, low haemoglobin
levels may be a useful prognostic biomarker in SCAD. Furthermore, haemoglobin levels are routinely
monitored, and well-established interventions exist to boost haemoglobin levels.
Previous studies have identified an association between low haemoglobin levels and mortality in patients
with CAD.234,235 However, these studies have not been able to characterise the shape of the relationship
between haemoglobin levels and mortality, or to determine whether or not threshold levels exist. In addition,
they did not examine sex differences and did not distinguish patients with a history of either angina or AMI.
Methods
A retrospective cohort study using CPRD data was carried out. Among CPRD patients aged 35–90 years,
we defined two study populations on the basis of coded diagnoses between 2001 and 2006: first 20,131
patients with new-onset stable angina and no prior ACS and second, 14,171 patients with an AMI with
survival beyond 7 days. The date of the earliest stable angina or AMI diagnosis for each patient was
designated the ‘index date’. For the stable angina population, we included patients with a code for
angioplasty or coronary artery bypass but not angina only if they had evidence of previous angina symptoms
(e.g. a code for chest pain or a nitrate prescription; the date of the earliest such entry was taken as the index
date). We excluded patients with ACS within 7 days of the index date because their initial presentation may
have been unstable rather than stable angina. From both populations we excluded patients who died within
7 days of the index date, patients with other cardiac conditions prior to the index date (myocarditis,
endocarditis, pericarditis, valve disease or congenital cardiac abnormalities) and patients who were pregnant
less than 3 months before the index date. We estimated the glomerular filtration rate from serum creatinine
using the four-variable Modification of Diet in Renal Disease formula. Follow-up data were available for a
mean of 3.2 years. We analysed data using semiparametric Cox regression with multiple adjustment.
We carried out a systematic review, which involved searching MEDLINE and EMBASE databases between 1966
and November 2008 for prospective studies in which blood biomarkers were measured in patients with stable
angina or at least 2 weeks after ACS, and a relative risk for mortality or coronary events by haemoglobin
DOI: 10.3310/pgfar05040 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hemingway et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
concentration was reported with a p-value or CI. Two reviewers reviewed article titles and abstracts for
eligibility and independently abstracted data from eligible articles using a pre-defined coding protocol. Studies
with less than 1-year follow-up were excluded. Two reviewers independently abstracted data from eligible
articles, with disagreements resolved by consensus, or adjudication by a third reviewer if required.
Results
Patients with lower haemoglobin tended to be older and were more likely to have diabetes, renal
impairment, cancer, lower mean corpuscular volume and to be taking iron supplements and nitrates
(p < 0.001 for all) (Figures 35 and 36).
In both men and women, thresholds were identified below which mortality showed a linear inverse
relationship with haemoglobin levels (Figures 36 and 37).
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FIGURE 35 Adjusted HRs for death for patients with stable angina or AMI by haemoglobin concentration.
(a) Schematic diagram of haemoglobin threshold model for adjusted HRs for mortality; (b) women with stable
angina; (c) men with stable angina; (d) women with AMI; and (e) men with AMI. Reproduced from Shah et al.47
© 2011 Shah et al.47 This is an open-access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original author and source are credited.
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FIGURE 36 Multiply adjusted Kaplan–Meier curves showing the probability in (a) women and (b) men with
new-onset stable angina according to haemoglobin level. Adjustment was done by stratification on linear
predictors from a Cox model, which included age, eGFR, SBP, total cholesterol, family history of diabetes,
stroke and comorbidity (Charlson Index), but not sex or haemoglobin. Reproduced from Shah et al.47 © 2011
Shah et al.47 This is an open-access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
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For stable angina patients, the lower threshold was 11.9 g/dl (95% CI 11.5 to 13.5 g/dl) for women and
13.1 g/dl (95% CI 13.0 to 13.4 g/dl) for men. For men with AMI, this threshold was 13.5 g/dl (95% CI
13.2 to 13.9 g/dl). For the AMI population, the threshold for women with AMI was slightly lower, at
12.8 g/dl (95% CI 12.1 to 13.5 g/dl) compared with 13.5 g/dl (95% CI 13.2 to 13.9 g/dl) for men. The
shape and strength of the association was similar in both sexes, and in both AMI and angina patients.
A total of 29.5% of male AMI patients with subthreshold haemoglobin levels were at statistically
significantly greater risk of death (HR 2.00, 95% CI 1.76 to 2.29).
The systematic review and meta-analysis identified 10 published studies reporting just 1127 end points in
total, not one of which examined risk thresholds.
Discussion
This study has reported more data than all previous studies combined (3174 deaths vs. 1127 events),
providing the first estimates of haemoglobin level thresholds associated with a markedly enhanced risk of
death. As well as identifying risk thresholds, the study indicates that, contrary to previous assumptions,
the relationship between risk and haemoglobin levels is not linear.
Thresholds are higher than might have been anticipated, placing large numbers of patients (15–30%)
in a high-risk category. Elevated risk associated with subthreshold haemoglobin levels was seen in both
women and men, and in both AMI and angina patients, with risk being more pronounced in AMI patients.
Attributable risk calculations suggest that the link between haemoglobin levels and mortality could be
responsible for up to one-quarter of deaths after AMI. This level of risk is similar to that identified for LDL
cholesterol and fibrinogen. There was some evidence of an association between high haemoglobin levels
and poor outcomes, but the number of patients affected was small.
New clinical trials to assess whether or not haemoglobin levels are causal and whether or not clinicians
should intervene to increase haemoglobin levels are warranted.
Conclusions
Our findings provide support for clinical trials to evaluate strategies to increase haemoglobin levels in
patients with SCAD, through either iron supplementation or more aggressive treatments, such as
intravenous iron infusions or erythropoiesis-stimulating agents. Further studies are needed to assess the
potential prognostic value of haemoglobin in stratifying SCAD patients.
Study 16: clinically available biomarkers – heart rate as a physiological
prognostic biomarker for stable coronary artery disease
This manuscript by Archangelidi et al.48 is in preparation.
Introduction
The relationship between resting heart rate and CVD and mortality has been extensively investigated
and acknowledged in patients with SCAD236 and in the general population. However, findings remain
controversial. In 2008, two large trials of ivabradine, a pure heart rate-lowering agent without other
known cardiovascular effects, showed controversial effects related to risk reduction for both stable and
unstable coronary disease in patients with CAD and chronic heart failure,237 and in patients without
reduced left ventricular function with SCAD;237 these results indicated conflicting scenarios for the
mechanisms through which an increased heart rate could be involved in an increased risk of CVD.238
Contemporary data regarding elevated heart rate and prognosis of CAD patients are derived from clinical
trials or angiographic registries that are collected solely for research purposes and are confined to high-risk
patients238–240 or those admitted for ACS,240,241 and not among the general population.236,238 These data are
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biased by the selective nature of the populations studied and might compromise external validity.233 In
addition, much of the evidence draws on the effect of heart rate-lowering medication and not the actual
heart rate marker on cardiovascular end points.237,242,243 The majority of studies have also failed to examine
potential differences in heart rate effects on cardiovascular events between men and women, probably
owing to limited sample sizes and subsequent restricted statistical power.240,244–246 The preponderance of
composite cardiovascular end points in the published literature indicates the need for a study that will
investigate the association of heart rate and specific cardiovascular events in a SCAD population.
Using linked EHRs we investigated the prognosis of SCAD in patients with low or elevated heart rate, using
real-world data in a general population. The aim of this study was to examine the relationship between
resting heart rate and a range of previously unexplored future cardiovascular phenotypes and non-cardiac
complications, as well as cerebrovascular events, in a large population of patients with suspected or proven
SCAD. We also aimed to determine the shape of any associations and to explore potential differences in
the associations between men and women.
Methods
Data sources
Linked CALIBER data. CPRD data were used to obtain heart rate measurements, demographic variables
and other risk factors.
Study design
Observational prospective cohort study.
Study population
A cohort of 2.23 million people covering approximately 5% of the UK population was drawn from patients
registered with their general practice between January 1997 and March 2010. Participants were eligible for
inclusion if they were aged ≥ 30 years at study entry (‘index date’), had been registered with the practice
≥ 1 year prior to the index date, had at least one prior diagnosis of CVD (any time prior to the index
date, or in case of its absence, any time after the index date) and had at least one recorded heart rate
measurement after the index date. Where patients had a non-fatal or fatal CVD event prior to and after
the index date, we used the date of the event after the index date. Participants were censored on the date
of leaving the practice, last submission of data, death or end-point occurrence.
Heart rate
Heart rate (in b.p.m.) was prospectively collected by general practice staff. The method of heart rate
measurement was not recorded in the database, although values are likely to have been obtained through
palpation at the wrist, auscultation of the heart and readings from an automated BP device or ECG.
Cardiovascular risk factors
Information on CVD risk factors was obtained from CPRD, as recorded during consultations in primary
care. The most recent measurement (or prescription) recorded in CPRD up to 1 year before or on the date
of study entry (first heart rate measurement after the index date) was used to define baseline covariates.
Socioeconomic status was derived from the ONS using the IMD,88 which was divided into five categories
(quintiles), whereby the first quintile corresponds to the least deprived and the fifth quintile to the most
deprived groups. The most recent smoking record before the index date was used to classify participants
as never, ex or current smokers.
End points
The primary end points were the first presentation of non-fatal or fatal CVDs after the heart rate
measurement date across the four data sources. CVD outcomes included stable angina, AMI, heart failure,
a composite of cardiac arrest plus ventricular fibrillation plus SCD, a composite of cerebrovascular diseases
including ischaemic stroke plus subarachnoid haemorrhage plus intracerebral haemorrhage, PAD and CVD
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mortality and all-cause mortality. Diagnoses were identified using ICD-10 codes for hospital data (HES) and
mortality data (ONS), from Read Codes for primary care data (CPRD) and bespoke variables in the ACS
registry (MINAP).
Statistical analysis
Heart rate was divided into sex-specific quintiles (with quintile 1 as the reference). In sensitivity analyses we
used heart rate as a continuous variable of a 10-b.p.m. increase. Differences in risk factors according to
heart rate quintiles were tested using the F-statistic from analysis of variance or its non-parametric version
(Kruskal–Wallis test) and the chi-squared statistic, as appropriate. The association between heart rate and
each end point was assessed using Cox proportional hazard models with time since study entry as the
timescale, adjusting for baseline age and sex and stratified by primary care practice. Covariates were added
in the models in two steps (sex- and age-adjusted) and were adjusted for common CVD factors (SBP,
smoking, BMI, diabetes, HDLs, total serum cholesterol and IMD classification).
Change in heart rate was classified as either downwards (a fall of one, two or three quintiles), upwards
(one, two or three quintiles higher) or stable. This risk represented the hazard of experiencing a
cardiovascular event when the proportion of quintile changes increased (i.e. whether or not downwards
or upwards jumps in heart rate quintiles affect risk). Statistical analyses were performed using Stata®
version 13 (StataCorp LP, College Station, TX, USA) and R version 3.0.3.
Results
Baseline characteristics
The cohort consisted of 51,703 patients (44% women) with heart rate measurements available at baseline
(Table 19). Participants experienced 21,918 cardiovascular events (including 9960 atrial fibrillation and
4216 bleeding events) during 132,359.7 person-years of follow-up (mean follow-up of 2.56 years per
patient). Women were less likely than men to have experienced an AMI event prior to their inclusion in the
study (p < 0.05). Compared with quintile group 1 (heart rate < 65 b.p.m.), patients in quintile group 5
(heart rate > 83 b.p.m.) were more commonly female, current smokers, hypertensive and diabetic, and had
larger proportions of people in the top deprivation quintile (p < 0.05). Fewer patients in quintile group 5
were receiving cardiovascular medications, including beta-blockers, than in quintile 1. Participants who had
a past unstable angina episode and were stabilised were more likely to be white, hypertensive and diabetic
than participants with past stable angina or AMI, who received more beta-blocker medication and had
higher BP or antiarrhythmic medication (p < 0.05).
Heart rate and presentation of cardiovascular diseases
Age- and sex-adjusted analyses showed a significantly increased hazard of heart failure, cardiovascular and
all-cause death and atrial fibrillation in quintile 5 compared with quintile 1 (Figure 37). An increased risk of
stroke and bleeding events was also identified. These associations remained after adjusting for sex, age,
smoking, SBP, diabetes, cholesterol, HDL, BMI and IMD. Strong associations were found between high
heart rate and hazard of heart failure independently of the type of previous coronary event (for overall
coronary event types HR 2.42, 95% CI 2.19 to 2.68). Association with the risk of stroke was also found for
participants in quintile 5 (HR 1.25, 95% CI 1.10 to 1.43) and for people who experienced a previous stable
angina event (HR 1.28, 95% CI 1.11 to 1.48), but not in people who experienced an AMI or unstable
angina, probably owing to the smaller number of cases and the subsequent loss of statistical power.
Similarly, bleeding and atrial fibrillation events were higher in people in quintile 5 (HR 1.21, 95% CI 1.10 to
1.33) than in people in quintile 1 (HR 1.58, 95% CI 1.49 to 1.68). The association with atrial fibrillation was
present when taking into account the different subtypes of prior stable coronary events. No association was
found between heart rate and AMI, PAD, stable angina or SCD, the last of which perhaps as a result of the
limited number of events.
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Increased risk of heart failure, AMI and stable angina were found among participants with increased heart
rate quintile changes, irrespective of their direction (upwards or downwards). However, the small sample
size resulted in low power and such effects were significant only at the 10% level (results not shown).
Effects of age and sex
We found a slightly higher increase in the risk of stroke among women (HR 1.36, 95% CI 1.13 to 1.64) as
opposed to among men (HR 1.12, 95% CI 0.92 to 1.37) in quintile 5. However, at lower heart rate values
these associations were reversed, with men in quintile 4 having a greater risk of stroke (HR 1.35, 95% CI
1.13 to 1.62); for women this association was not statistically significant. A higher risk of atrial fibrillation
was found in men in quintiles 4 and 5 (HR 1.28, 95% CI 1.18 to 1.39 and HR 1.73, 95% CI 1.59 to 1.88,
respectively) than in women, with risk restricted to heart rate values > 87 b.p.m. (HR 1.39, 95% CI 1.27 to
1.53). Higher risk of heart failure was similar between men and women in quintiles 4 and 5, as was the
risk for a 10-b.p.m. increase in heart rate. For every 10-b.p.m. heart rate increase, the risk for CVD and
all-cause mortality was attenuated in people aged > 80 years. A mild but consistent decrease of heart
failure, atrial fibrillation and bleeding risk was also found in people aged > 80 years, with the risk of heart
failure falling for those aged > 60 years.
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FIGURE 37 Multivariable-adjusted HRs for the association between heart rate (top vs. bottom quintile) and the risk
of eight CVDs, atrial fibrillation and bleeding events in CALIBER patients. MI, myocardial infarction.
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Discussion
In this prospective study, we report an association between elevated heart rate and risk of cardiovascular
end points in patients with SCAD. Our study confirms previous reports that elevated heart rate is a
predictor of mortality and heart failure in patients with SCAD.236,238,239
However, our results also extend these observations to cerebrovascular events, atrial fibrillation and
complications such as bleeding events. We found no association between increased heart rate and AMI,
stable angina, SCD or PAD, whereas a strong association was identified with heart failure, cardiovascular
death and all-cause mortality. An increased risk of stroke, atrial fibrillation and bleeding events was also
found in both univariate and multivariate analyses in people with heart rates of > 87 b.p.m. in quintile 5
compared with people in quintile 1 (< 65 b.p.m.).
The effects of heart rate-lowering medication on mortality in patients with CAD have been extensively
demonstrated.247–249 However, the association between resting heart rate values (without the mediation of
heart rate medication in analyses) and specific cardiovascular end points and atrial fibrillation has been
underinvestigated. The lack of association between heart rate and CHD found in this study contrasts
with results from previous post hoc analyses of trials with heart rate-lowering agents (e.g. ivabradine),
suggesting that it would improve outcomes in patients with SCAD.250
In patients with heart failure, the reduction in heart rate with ivabradine has been shown to improve
clinical outcomes, beyond the improvements observed with beta-blockers.251 The benefits of lowering
heart rate in patients with heart failure but not in those with SCAD may reflect the fact that an elevated
heart rate is attributable to different pathophysiological mechanisms in these two conditions,252 such as
neurohormonal activation in patients with heart failure and further ventricular remodelling. Sympathetic
activation and progressive disruption of autonomic balance may also be important in the pathogenesis of
atrial fibrillation after coronary artery bypass grafting.253,254 White et al.255 found a significant increase in the
incidence of atrial fibrillation among patients in whom the administration of beta-adrenoceptor antagonists
was ceased compared with those whose drug treatment was continued after surgery. Further evidence of
a mechanistic link of heart rate with atrial fibrillation comes from genome-wide association studies that
have identified heart rate-increasing alleles at five loci associated with both increased and decreased risk of
atrial fibrillation.256
Published studies have suggested a threshold effect of heart rate on mortality outcomes, above which risk
increases steeply. Data from the Coronary Artery Surgery Study (CASS) registry suggested an increased risk
of all-cause mortality for a heart rate of > 77 b.p.m. and of CVD death at a heart rate of > 83 b.p.m.,236
whereas other studies have supported a slightly lower threshold of > 70 b.p.m.246 Data from the ivabradine
for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) study
have suggested that the increase in death and heart failure outcomes rose continuously at ≥ 70 b.p.m.,
whereas the relationship was less pronounced for AMI and revascularisation.238 Our study provides
evidence for a similar shape in risk as the BEAUTIFUL study, with a steep increase in risk for heart failure
and cardiovascular mortality at > 70 b.p.m., a threshold significantly lower than the majority of the
available studies. A similar steep increase was also found for atrial fibrillation events above a heart rate of
70 b.p.m., whereas the risk of SCD shows an increase at higher heart rate values (> 90 b.p.m.).
Heart rate is one of the most easily accessible biomarkers; however, rates of adequate heart rate control
appear to be low in current clinical practice, potentially representing a missed therapeutic opportunity.
In designing randomised trials, the target population, the choice of composition of the primary end point
and the likely rate at which the end point accrues can all be informed by the examination of linked EHRs.
Future clinical trials on heart rate-specific medications, such as ivabradine, should refine our understanding
of the potential role for specific heart rate lowering in the treatment and prevention of people at early
stages of heart failure and resting tachycardia.
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Conclusions
Resting heart rate is an easily accessible biomarker in primary and secondary care patients with
heterogeneous associations with CVDs. Higher resting heart rates increase the hazard of heart failure
events, stroke in women, atrial fibrillation and bleeding events, without substantially affecting the hazard
of vascular events in the coronary arterial beds. Our findings show how disaggregation of CVD into
specific phenotypes can help to disentangle the underlying disease mechanisms, with implications for
clinical practice and the design and interpretation of clinical trials.
Study 17: novel biomarkers – circulating marker of inflammation
(evaluation of the quality of research using C-reactive protein in
stable coronary artery disease)
This study is based on the peer-reviewed paper by Hemingway et al.49
Introduction
Prognostic biomarkers have great potential in translational medicine research and could support clinical
decision-making. However, based mainly on experience in cancer, concerns have been raised about the
quality of prognostic biomarker research.31 In particular, evidence syntheses have highlighted issues with
publication bias and the selective reporting of results.257,258 In addition, few evaluations have assessed the
quality of research evidence related to individual biomarkers.
It is unclear whether or not similar biases affect the evidence base for biomarkers in CVD. To address this
question, we systematically analysed the evidence related to use of CRP as a prognostic biomarker in
SCAD. CRP has been widely studied in this context, and its measurement is recommended in US259 and
European260 clinical guidelines (although actual clinical practice varies widely).
We undertook a systematic review, meta-analysis and metaregression of published evidence on CRP. Our
key aims were to assess the quality of published evidence, the extent to which reported associations are
independent of other prognostic factors, the scale of any bias attributable to small study size, any possible
sources of heterogeneity and whether or not papers report clinically useful figures on the ability of CRP
measurements to distinguish patients who experience a coronary event from those who do not.
Methods
As no agreed criteria exist for assessing reporting quality, we developed a 17-item list based on previous
work in CVD and cancer (including the REMARK reporting guidelines). Notably, this list also included
whether or not studies reported a reference to a study protocol or statistical protocol specified in advance
of data collection.
MEDLINE (1966–2009) and EMBASE (1980–2009) were searched and selected prospective studies of
patients with stable coronary disease, reporting a relative risk for the association of CRP with death and
non-fatal cardiovascular events. We identified relevant papers and assessed individual papers according to
the 17-item checklist. Two reviewers independently abstracted data from eligible articles (n = 116) using a
predefined coding protocol. Individual item disagreement between the two reviewers was resolved by
consensus or, rarely, adjudication by a third reviewer. Reported relative risk, ORs or HRs were extracted
from each eligible paper.
Statistical analysis
Relative risk estimates were converted to a standard scale of effect, in which the highest third in the
CRP distribution was compared with the lowest third. The I2-statistic was used to assess statistical
heterogeneity among studies. Funnel plots and quantitative methods (including Egger’s test) were used to
assess small-study publication bias.
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Results
Of 1566 articles, 83 studies met inclusion criteria, covering 61,684 patients and 6485 events.
The median number of study-quality items reported was seven out of a possible 17, with no increase
between 1997 and 2009. Just two studies reported a study protocol; none reported a statistical analysis
protocol (Figure 38). The meta-analysis generated a relative risk for the top versus bottom third of the CRP
distribution of 1.97 (95% CI 1.78 to 2.17), although the size of effect varied widely (I2 = 79.5) (Figure 39).
Just 13 studies adjusted for standard risk factors; adjustment lowered relative risk to 1.65 (95% CI 1.39 to
1.96). Ten different methods were used to compare CRP levels, with use of continuous measures giving
lower relative risks.
Funnel plots and quantitative analyses provided strong evidence for publication bias (Figure 40). Further
adjustment for publication bias reduced the relative risk to 1.19 (95% CI 1.13 to 1.25). Just two studies
reported a measure of discrimination (c-statistic). When data from 20 suitable studies were pooled,
the detection rate was calculated as 31% for a 10% false-positive rate, giving a c-statistic value of 0.61
(95% CI 0.57 to 0.66).
Discussion
This large-scale systematic review and meta-analysis identified significant shortcomings in the evidence
base on CRP as a prognostic biomarker, particularly the absence of a pre-specified statistical analysis
protocol and strong evidence of publication bias having a sizeable impact on association.
There are no agreed comprehensive criteria for measuring the quality of study reports. The REMARK
reporting guidelines for tumour prognostic markers provide a useful start, but are not currently in a form
that lend themselves to measurement and omit reference to statistical analytic protocols.
Our review suggests that there is a need for new clinical cohorts with published pre-specified statistical
analytic protocols and prospective registration of studies, which can be pooled to evaluate the true
usefulness of the role of CRP in prognosis in SCAD. Better reporting is required and existing guidelines
require development across disease areas and formalisation into data extraction tools.
Along with a widespread failure to adjust for potential confounders, the findings call into question the
reported association between CRP and prognosis of patents with SCAD. Furthermore, the discriminatory
potential of CRP was so low as to offer little clinically useful information.
Conclusions
The findings of this evaluation suggest that current CG recommendations on the measurement of CRP
need to be revised. More generally, they highlight major flaws in the design of studies on prognostic
biomarkers. There is a need for enhanced reporting and, in particular, for the registration of studies and
statistical analysis protocols.
Study 18: novel genetic factors – the 9p21 chromosomal locus
and risk of coronary disease events
This study is based on the peer-reviewed paper by Patel et al.50
Introduction
Chromosomal locus 9p21 (Ch9p21) is a well-established genetic risk factor for CHD. Several lines of
evidence have implicated Ch9p21 in risk of first coronary events,314 but it is less clear whether or not it also
influences susceptibility to further coronary events, with conflicting results from mostly small-scale studies.
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FIGURE 39 Forest plot of the effect of CRP on prognosis among patients with SCAD based on 83 studies included in
our systematic review and meta-analysis. For example, Jánoskuti et al.264 adjusted for age, sex, smoking and obesity
and three other non-conventional risk factors, but not for diabetes. a, Four studies did not report the number of
events; b, five studies made no adjustments at all; one (Minoretti 2006313) adjusted for age and sex. A, age;
D, diabetes; G, sex; L, lipids; O, obesity; S, smoking; Wt, study weight percentage from random-effects meta-analysis.
Reproduced from Hemingway et al.49 © 2010 Hemingway et al.49 This is an open-access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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The distinction is important, as the predictive value of genetic variants at Ch9p21 may differ for first and
subsequent coronary events. In addition, differences would also imply that the mechanisms of disease may
not be the same in first and subsequent coronary events, which would have important implications for
secondary prevention and drug development.
To address this question, we carried out a systematic review and meta-analysis to synthesise the evidence
relating to Ch9p21 and the risk of first and subsequent coronary events, and to identify any sources of
bias that could influence associations.
Methods
We searched PubMed and EMBASE from inception to 30 June 2013 for studies reporting associations
between genetic variants at Ch9p21 and CHD up to 30 June 2013. Two reviewers extracted information,
and discrepancies were resolved by consensus. We also searched studies reporting associations of genetic
risk scores with CHD, as they may have incorporated data on the Ch9p21 locus [thus, our search strategy
encompassed terms capturing the genetic locus (9p21 or 9p21.3), genetic risk score and CHD].
Prospective cohorts and nested case–control or cohort studies were included in the review. We excluded
case–control or cross-sectional studies of Ch9p21 and CHD, editorials and reviews.
Two authors independently extracted data and any discrepancies were resolved by consensus.
Statistical analysis
The size of effect was quantified as HRs per Ch9p21 risk allele. Funnel plots and quantitative analyses
(Egger’s test) were used to examine small-study bias. The possibility of survival bias was examined by
comparison of risk allele frequencies in CHD-free population cohorts and in clinical cohorts.
Results
Of 327 papers identified, 25 satisfied inclusion criteria. As well as these data, from 33 cohorts, we added
data from two unpublished studies. After the elimination of data from four cohorts reporting genetic
results in a recessive format, we analysed 31 cohorts in total, covering 193,372 individuals and 20,100
coronary events.
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FIGURE 40 Funnel plot showing extent of publication bias for studies included in our systematic review and
meta-analysis of CRP as a prognostic biomarker in SCAD, with contours showing different levels of study significance.
MA, meta-analysis. Reproduced from Hemingway et al.49 © 2010 Hemingway et al.49 This is an open-access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.
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In the 16 cohorts reporting first events, 15,664 events occurred among a population of 168,209.
The pooled HR for Ch9p21 was 1.19 (95% CI 1.17 to 1.22) per risk allele. In cohorts of individuals who
had already experienced CHD, 4436 events occurred among a population of 25,163. The pooled HR for
Ch9p21 for subsequent events was 1.01 (95% CI 0.97 to 1.06) per risk allele. Funnel plots revealed no
evidence of small-study bias (Figure 41). Risk allele frequencies were similar in population and clinical
cohorts, arguing against any survival bias.
Discussion
This systematic review and meta-analysis of data from more than 190,000 individuals, experiencing
20,000 events, has confirmed that genetic variants at Ch9p21 are associated with initial CHD events.
However, it found no evidence to suggest that Ch9p21 contributes to the risk of further events in patients
with established CHD. There was no evidence to suggest that this differential association reflected a lack
of power or publication or survival bias.
Our study has important research and clinical implications. First, our findings suggest that future genetic
association studies should be cautious in assuming that genetic variants have similar effects for both first
and subsequent CHD events. Second, further research into mechanistic differences that may account for
the differential genetic effect is warranted to enhance understanding of the underlying reasons for this.
Our findings point to the need for a consortium of studies among individuals with established CHD to
better understand the genomic susceptibility for subsequent CHD events and to carry out analysis,
including assessment for selection biases, which is not possible with literature-based meta-analyses. More
research is warranted to determine the effect of mechanistic differences for the differential genetic effect,
to enhance understanding of the underlying reasons.
Conclusions
Our findings suggest that disease processes may differ between first and subsequent coronary events, with
Ch9p21 playing a part only in the former. The precise role of Ch9p21 in disease is difficult to assess, as the
molecular mechanisms affected by Ch9p21 genetic variants are unclear. A better understanding of Ch9p2’s
role could help to clarify how pathogenic processes differ between first and subsequent experiences of CHD.
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FIGURE 41 Small-study bias illustrated by funnel plots of the association of Ch9p21 (per risk allele) with (a) first
and (b) subsequent coronary heart disease events in 31 studies included in our systematic review and meta-analysis.
Reproduced from Patel et al.50 Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier
Inc. This article is available under the terms of the Creative Commons Attribution License (CC BY). You may copy
and distribute the article, create extracts, abstracts and new works from the article, alter and revise the article, text
or data mine the article and otherwise reuse the article commercially (including reuse and/or resale of the article)
without permission from Elsevier.
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The findings call for caution in extrapolating the results of genetic association studies from first
presentation of CHD to subsequent events. In addition, they raise questions about the use of genetic
testing to assess risk – direct-to-consumer and physician-ordered testing options exist, but are unlikely to
provide useful information in patients with existing disease.
Study 19: patient journey approaches to prognostic factors – clinically
available biomarkers (changes in blood pressure in people with diabetes
and stable coronary artery disease and dynamic risk prediction)
This manuscript by Crowther et al. is in preparation.51
Introduction
Biomarker levels, such as BP, are recorded in clinical practice at more than one time point, often as a
monitoring tool to indicate patient status, as well as clinical event data such as time to AMI, stroke or death.
Extensive studies in CVD have been conducted to assess the role of one or more biomarkers measured at a
single time point in predicting clinical events, such as death from cardiovascular causes.49,315–317 Repeated
measurements have only recently received attention, demonstrating that variation in BP during follow-up is
independently (of baseline BP) associated with risk of adverse events, such as stroke and AMI.318 Many
biomarkers, such as SBP and DBP, are now collected as part of usual care over time, and this vast resource
of information, existing in registry sources such as CPRD, is yet to be fully explored.319 Furthermore, as data
linkage becomes more common,320 there are great opportunities for the development of real-time dynamic
risk prediction models.321
Through a joint modelling approach, we can both directly model a biomarker profile over time, accounting
for measurement error and capturing between-patient variability, and directly link aspects of the biomarker
profile to the time to event. This methodological approach is now well established, minimising bias and
improving efficiency in estimates of association between longitudinal and clinical event data.322–324
Alternatively, a joint model can be thought of modelling a biomarker profile over time, adjusting for
informative drop-out, often owing to death.
In this study, our aim was to determine the extent to which current values of BP, trend over time or
within-person variability adds information beyond a single baseline value in the prediction of death among
people with stable angina and type 2 diabetes, AMI and stroke. We studied people with angina and type 2
diabetes as a high-risk population in whom clinical guidelines recommend close BP monitoring. Despite
this, little is known about patterns of BP change (e.g. whether or not it increases with age as in the
general population).
Methods
Patient population
The study cohort was derived from the CALIBER linked data set.15 The study period was January 1998 to
March 2010, and individuals were eligible if they had a pre-existing diagnosis of type 2 diabetes and
subsequently entered the study cohort at diagnosis of stable angina. Study participants also had a BP
recording in the year prior to diagnosis of stable angina (baseline measure of BP).
Covariates
Covariates available for analysis include age at baseline (in years) and sex. In all analyses, age was centred
at 68 years.
End points
The combined primary end points were SBP, measured repeatedly, and the time to composite end point of
all-cause mortality, non-fatal AMI or non-fatal stroke. Baseline SBP was defined as the measurement at,
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or within 1 year prior to, a diagnosis of stable angina. All subsequent SBP measurements were included
prior to an event or censoring; however, for any patients with > 20 SBP measures, we sampled
20 observations at random.
Statistical analysis
Exploratory plots were used to summarise the trend in SBP over time, using a non-parametric smoother.
Joint longitudinal survival plots were also used to investigate differences in the average SBP trend prior to
being censored or experiencing the event, reversing the timescale by taking away each patient’s censoring
or event time.325
To inform the joint model, we fitted linear mixed-effects models to the repeated measures of SBP,
investigating the trajectory using polynomials of time. We adjusted for age and sex at baseline, and
investigated any interactions between age, sex and time. We also fitted Weibull survival models for the
time to composite end point, including the observed repeated SBP measures as a time-varying covariate.
We adjusted for age and sex at baseline and any interactions. Non-linear associations in continuous
covariates (SBP and age) were investigated using polynomials. We used predicted plots of the estimated
HR to summarise the association between SBP and the risk of death, AMI or stroke.
We then fitted a full joint model, combining a linear mixed-effects model and a Weibull time-to-event
model, investigating the association between the time to death, AMI or stroke, and the current value and
rate of change in SBP. We plotted conditional survival predictions to indicate how a patient-specific SBP
profile can be used to predict survival probabilities, based on the fitted joint model.326
In all analyses, the timescale is derived by taking away each patient’s date of study entry from the date of
SBP measurement.
All analyses were conducted using Stata version 13.1.
Results
Baseline characteristics of study participants
The study cohort included 5246 patients with type 2 diabetes diagnosed with stable angina at study entry,
and consisted of 2920 men and 2326 women. The mean age at baseline was 69.8 years (SD 11.4 years) in
women and 67.6 years (SD 10.5 years) in men. Mean SBP at baseline was 143.8 mmHg (SD 21.0 mmHg)
in women and 141.3 mmHg (SD 18.9 mmHg) in men. A total of 85,428 SBP measurements were available
for analysis, with a median number of SBP measures of 12 (range 1–336) in women and 11 (range 1–131)
in men; however, for any patients with > 20 measures, we sampled 20 at random from those available.
This led to a total of 61,507 repeated SBP measurements being available for analysis.
Exploratory analysis
Figure 42 shows the observed SBP values for a patient with 336 repeated measures, illustrating the
trajectory of SBP over time. Figure 43 shows the overall trend in observed SBP profiles for all patients.
Figure 43a shows a non-parametric smoother of SBP from time since diagnosis of stable angina, separately
for patients who were censored at the end of follow-up, and those who experienced the composite end
point. In Figure 43b we use the same non-parametric smoother of SBP, but adjust the timescale by taking
away each patient’s observed censoring or event time. This gives an indication of any differences in the
trend of SBP over time in the period leading up to an event, compared with patients who are censored.
Figure 43b indicates that patients who experience the composite end point have a pronounced decline in
SBP in the 2–3 years prior to an event, which could imply that the rate of change of SBP over time could
play an important part in the risk of composite end point.
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Profile of systolic blood pressure over time
We observed an estimated population-level mean SBP at baseline of 141.089 mmHg for a male aged
68 years. There is an estimated average decrease in SBP of –0.831 mmHg per year, again for a male aged
68 years. For patients aged 68 years, a female has an estimated 2.664 mmHg higher SBP than a male at
baseline (Table 20).
Modelling the time to death, acute myocardial infarction or stroke
For a female as opposed to a male of the same age at baseline and at the same value of SBP, the risk of
an event is reduced by 17.2% (95% CI 8.9% to 24.8%) (Table 21).
Interpretation of covariate effects is complicated with the introduction of polynomial terms of SBP and age.
Figure 44 shows the non-linear relationship between SBP and the risk of composite end point.
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FIGURE 42 Observed SBP for a CALIBER patient with type 2 diabetes and stable angina with 336 repeated
measurements of BP.
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FIGURE 43 Non-parametric smoothed estimates of observed SBP among CALIBER patients with type 2 diabetes and
stable angina. (a) Time from diagnosis as the timescale; and (b) adjusted timescale, with each patient’s censoring/
event time taken away from the measurement times.
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Joint modelling of the profile of systolic blood pressure and time to death,
acute myocardial infarction or stroke
The results from the full joint model, linking repeatedly measured SBP and the time to composite end point
are presented in Table 22.
We found highly statistically significant associations (p < 0.001) between the risk of composite end point
and both the current value of SBP and the rate of change. Both association coefficients are negative,
indicating that lower values of SBP increase the risk of an event, and a greater decline in the rate of
change of SBP increases a patient’s risk.
This is illustrated in Figure 45, which shows predicted event probabilities for two patients of the same sex
and similar age at baseline, conditional on patient-specific SBP profiles. Patient A shows a slightly increasing
trend in SBP over time compared with patient B, who has a decreasing trend in SBP. Subsequently, patient A
has an improved event probability prediction compared with patient B.
TABLE 21 Results from fitting a Weibull survival model to CALIBER patients with type 2 diabetes and stable angina,
with SBP as a time-varying covariate
Parameter Log-HR p-value 95% CI
SBP –0.0704 < 0.001 –0.1020 to –0.0389
SBP2 0.0345 < 0.001 0.0287 to 0.0403
SBP3 –0.0021 0.001 –0.0034 to –0.0009
Age 0.0554 < 0.001 0.0503 to 0.0605
Age2 0.0004 0.032 0.0000 to 0.0605
Female –0.1888 < 0.001 –0.2848 to –0.0928
Intercept –2.5811 < 0.001 –2.6798 to –2.4824
log-(gamma) –0.0780 < 0.001 –0.1179 to –0.0380
SBP= (SBP – 140)/10.
Age= Age – 68.
TABLE 20 Linear mixed-effect model results with outcome repeatedly measured SBP among 5246 CALIBER patients
with type 2 diabetes and stable angina
Covariate Estimate p-value 95% CI
Time –0.0831 < 0.001 –0.0930 to –0.0732
Age (centred) 0.0051 0.036 0.0003 to 0.0103
Female 0.2664 < 0.001 0.1882 to 0.3446
Age female 0.0145 < 0.001 0.0073 to 0.0217
Intercept 14.1089 < 0.001 14.0518 to 14.1659
Random effects
sd(time) 0.2022 0.1916 to 0.2133
sd(Intercept) 1.4728 1.4372 to 1.5092
corr(time,intercept) –0.5659 –0.6021 to –0.5273
sd(Residual) 1.5428 1.5336 to 1.5521
Outcome is SBP/10.
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TABLE 22 Joint model of repeatedly measured SBP and time to composite end point of death, AMI and stroke
among CALIBER patients with type 2 diabetes and stable angina
Parameter Coefficient p-value 95% CI
Longitudinal
Time –0.0951 < 0.001 –0.1061 to –0.0842
Age 0.0046 0.070 –0.0004 to 0.0097
Female 0.2710 < 0.001 0.1927 to 0.3494
Age × female 0.0138 < 0.001 0.0066 to 0.0211
Intercept 14.1143 < 0.001 14.0570 to 14.1717
Survival
Association (current value) –0.1382 < 0.001 –0.1869 to –0.0894
Association (slope) –1.0552 < 0.001 –1.4820 to –0.6285
Age 0.0560 < 0.001 0.0509 to 0.0612
Age2 0.0005 0.005 0.0001 to 0.0008
Female –0.1574 0.002 –0.2549 to –0.0600
Intercept –0.6142 0.070 –1.2786 to 0.0501
log-(gamma) –0.0971 < 0.001 –0.1386 to –0.0556
Random effects
sd(time) 0.2048 0.1942 to 0.2161
sd(intercept) 1.4805 1.4448 to 1.5173
corr(time,intercept) –0.5717 –0.6075 to –0.5336
sd(residual) 1.5423 1.5331 to 1.5516
Longitudinal outcome is SBP/10.
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FIGURE 44 Estimated HR for the effect of SBP on the risk of composite end point, relative to a reference value of
SBP of 140mmHg in CALIBER patients with type 2 diabetes and stable angina.
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Discussion
This linked EHR-based study of type 2 diabetes patients diagnosed with stable angina provides strong
evidence of a declining trend in SBP following diagnosis. This is in contrast to a generally increasing trend
among a healthy population. The current value and rate of change of SBP over time are strongly
associated with the risk of death, AMI or stroke, indicating that lower values of SBP and a declining trend
in SBP may have an important role in identifying patients at increased risk.
This is the first study to use repeated measures of SBP, both to model its trend over time adjusting for
dropout and to investigate how time-dependent aspects such as the current value and rate of change are
associated with risk of death, AMI or stroke. The joint model results provide a platform for dynamic risk
prediction, whereby individual patients’ risk profiles can be updated when new measurements become
available. To date, all current prediction models for cardiovascular risk use single baseline measurements
for all modelled covariates (i.e. measurements taken at the start of follow-up). Methods for dynamic risk
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FIGURE 45 Predicted event probabilities conditional on patient-specific SBP profiles among CALIBER patients with
type 2 diabetes and stable angina for (a) patient A and (b) patient B.
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prediction in which the patterns of change of clinically measured biomarkers can be incorporated into
clinical decision support models in clinical practice are required.
Conclusions
Patients with type 2 diabetes and diagnoses of stable angina have an overall decreasing trend in SBP over
time. The current value and rate of change of SBP over time are both strongly associated with the risk of
death, AMI or stroke, indicating that lower values of SBP and a declining trend in SBP may have an
important role in identifying patients at increased risk.
Joint modelling provides the ability to investigate trends in a biomarker over time, accounting for
measurement error and dropout (often as a result of death) or, alternatively, to assess the association
between a biomarker profile (or aspects of the trajectory such as rate of change) and the time to event
of interest.
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Chapter 9 Stable coronary artery disease: risk
prediction and cost-effective targeting of interventions
Abstract
Background
Real-world data based on linked EHRs can contribute important prognostic information in unselected
patients. Improved survival after ACS and in an ageing population have resulted in a large population of
patients with SCAD who require high health-care resource use. Validated prognostic models could assist in
clinical management of SCAD patients and, in combination with information on resource use and costs,
provide valuable tools for policy-makers.
Objectives
To develop prognostic models, examine health-care use and costs, and to provide a framework to evaluate
the cost-effectiveness of treatments in SCAD patients.
Methods
Prognostic models and 5-year risk predictions were developed, and lifetime health-care costs were
calculated using CALIBER data.
Results
Prognostic models achieved a C-index of 0.811 for all-cause mortality and 0.778 for non-fatal AMI or
coronary death. The strongest predictors were initial diagnosis, CVD comorbidities and biomarker levels.
Five-year and lifetime costs were £9181 (57% CVD related) and £107,052 (60% CVD related), respectively,
for lowest-risk patients, versus £21,872 (72% CVD related) and £38,606 (72% CVD related) for highest-risk
patients. A new treatment with 20% hazard reduction for AMI, ischaemic stroke or CVD death would
be cost-effective if priced at < £61 per year for the lowest-risk group and < £657 per year for the
highest-risk group.
Conclusions
Validated prognostic models could be used to support the clinical management of SCAD patients.
Cost modelling can inform resource allocation decisions and be used to assess the cost-effectiveness of
new treatments.
The studies in this chapter relate to patients presenting for the first time with SCAD (see Figure 34).
Introduction
Electronic health records research provides new opportunities to use clinically recorded information to identify
candidate prognostic factors, which can then be incorporated into multivariate prognostic models. Our
PROGRESS initiative recommended new programmes of methodological and empirical prognosis research
exploiting EHRs to define, phenotype and follow up people with different health-related conditions.29 We
have developed prognostic models using a large contemporary and representative population of UK patients
with SCAD within the linked CALIBER data resource, validated the models using data from an independent
study, and assessed their clinical usefulness in terms of life-years saved had they been implemented.
An important use of validated prognostic factors is the development of models that predict the risk of
future coronary or other health-related events. The prognosis for SCAD patients is topical, with new
treatments327 and new applications of existing treatments328 currently undergoing Phase III trials in this
patient population. With policy-makers and the clinical community233,329–331 increasingly turning their
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attention to SCAD, risk equations have recently been published for this population.52 These emerging
prognostic models are of potential value in clinical practice, helping to stratify patients and guide choice of
treatment, and more widely in public health, providing insight into the probable future burdens of disease.
As the number of people with SCAD continues to increase, it is important that policy-makers are able to
estimate the probable future health-care research usage of this group of patients. We have used our
prognostic model to address the limitations of previous attempts to model costs, providing estimates of
medium-term and lifetime health-care costs and health outcomes of patients with SCAD, stratified
according to their initial levels of risk. This modelling also provides a valuable tool for assessing the
cost-effectiveness of new interventions.
Study 20: risk prediction – development and validation of a
prognostic model
This study is based on the peer-reviewed paper by Rapsomaniki et al.52
Introduction
Stable coronary artery disease is becoming increasingly common, as a result of an ageing population and
enhanced survival after ACS. In the USA alone, it affects approximately 7% of the population.332 Guidelines
produced by the American College of Cardiology Foundation (ACCF)329 and American Heart Association
(AHA)329 recommend that patients should be stratified into high-, intermediate- and low-risk groups on the
basis of their annual mortality risk, a classification that should then guide further investigation and choice of
treatment. However, prognostic tools developed to date have typically been based on data collected in
clinical trials rather than ‘real-world’ data gathered as part of clinical practice.260,329,333 Furthermore, despite
recommendations in guidelines, models have not assessed both all-cause mortality and coronary events,
and no model has been validated using an independent data set. None has yet been recommended for
clinical use.
To address these gaps, we used the CALIBER platform to develop prognostic models consistent with the
recommendations made in clinical guidelines. Using CALIBER linked data, we sought to identify associations
between outcomes and a wide range of clinical and other measures. Prognostically useful factors were
incorporated into prognostic models for all-cause mortality and non-fatal AMI or coronary death, and
models were assessed to quantify the accuracy of their predictions and their clinical usefulness – in terms of
life-years saved had they been implemented. The performance of prognostic models was validated using an
independent data set.
Methods
Candidate prognostic factors were identified from recent guidelines on the management of SCAD
and included demographic factors, disease subtype, nitrate use, previous experience of heart surgery,
history of other conditions, various physiological measures, psychosocial factors and standard clinically
assessed biomarkers.
Prognostic models were developed according to the checklist in the Transparent Reporting of a Model for
Individual Prognosis or Diagnosis (TRIPOD) guidelines. Five-year risk predictions were developed, extending
annual mortality risks to < 5% (low), 5–14% (intermediate) and > 15% (high), and a net reclassification
improvement was calculated for each factor added to the model. The potential clinical impact of each
model was estimated by calculating the number of additional years of life saved had the model been
implemented. Models were validated using data from 4020 patients in the Appropriateness of Coronary
REvascularisation (ACRE) study, which followed patients from 1996/97 to 2004.334
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Results
Of 102,023 patients identified, 44.7% had stable angina, 21.5% had another CHD, 13.1% had unstable
angina, 4.7% had STEMI, 6.7% had NSTEMI and 9.4% had unclassified AMI. The 5-year mortality for the
group as a whole was 20.6% (95% CI 20.3% to 20.9%) but varied markedly among disease subtypes. The
5-year risk for non-fatal AMI or coronary death was 9.7% (95% CI 9.4% to 9.9%). Factors with prognostic
value included age, sex, diagnosis, socioeconomic deprivation, smoking, hypertension, diabetes, lipid levels,
heart failure, PAD, atrial fibrillation, stroke, chronic kidney disease, chronic pulmonary disease, liver disease,
cancer, depression, anxiety, heart rate, creatinine levels, white cell count and haemoglobin levels (Table 23).
TABLE 23 Prognostic factors and their association with all-cause mortality and non-fatal AMI or coronary death in
patients with SCAD in CALIBER
Prognostic factors All-cause mortality, HRa (95% CI)
Non-fatal AMI or coronary
death, HRb (95% CI)
Sociodemographic characteristics
Age in men, per year 1.065 (1.063 to 1.067) 1.046 (1.043 to 1.048)
Age in women, per year 1.081 (1.078 to 1.083) 1.065 (1.061 to 1.069)
Women vs. men 0.204 (0.162 to 0.257) 0.158 (0.112 to 0.221)
Most deprived quintile, yes vs. no 1.151 (1.111 to 1.192) 1.117 (1.060 to 1.178)
SCAD diagnosis and severity
Other CHD vs. stable angina 1.024 (0.982 to 1.067) 1.180 (1.107 to 1.257)
Unstable angina vs. stable angina 1.021 (0.970 to 1.075) 1.323 (1.232 to 1.421)
NSTEMI vs. stable angina 1.298 (1.238 to 1.360) 2.373 (2.217 to 2.539)
STEMI vs. stable angina 1.083 (1.006 to 1.166) 1.940 (1.750 to 2.149)
PCI in last 6 months, yes vs. no 0.651 (0.605 to 0.699) 0.702 (0.642 to 0.768)
CABG in last 6 months, yes vs. no 0.516 (0.469 to 0.566) 0.424 (0.370 to 0.486)
Previous/current AMI, yes vs. no 1.136 (1.095 to 1.179) 1.399 (1.330 to 1.472)
Use of nitrates, yes vs. no 1.152 (1.118 to 1.188) 1.405 (1.342 to 1.470)
CVD risk factors
Ex-smoker vs. never 1.110 (1.065 to 1.157) 1.094 (1.008 to 1.188)
Current smoker vs. never 1.315 (1.245 to 1.389) 1.215 (1.126 to 1.311)
Hypertension, present vs. absent 0.965 (0.929 to 1.001) 1.064 (1.000 to 1.131)
Diabetes, present vs. absent 1.203 (1.160 to 1.248) 1.387 (1.315 to 1.463)
Total cholesterol per 1-mmol/l increase 1.012 (0.983 to 1.042) 1.061 (1.029 to 1.094)
HDL per 0.5-mmol/l increase 1.006 (0.987 to 1.025) 0.910 (0.879 to 0.942)
CVD comorbidities
Heart failure, present vs. absent 1.543 (1.495 to 1.593) 1.181 (1.089 to 1.281)
PAD, present vs. absent 1.286 (1.234 to 1.340) 1.085 (1.031 to 1.142)
Atrial fibrillation, present vs. absent 1.280 (1.236 to 1.326) 0.952 (0.887 to 1.021)
Stroke, present vs. absent 1.329 (1.277 to 1.382) 1.138 (0.925 to 1.401)
continued
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Models incorporating these factors achieved a C-index of 0.811 for all-cause mortality (95% CI 0.806 to
0.816) and 0.778 for non-fatal AMI or coronary death (95% CI 0.770 to 0.785) (i.e. when comparing two
patients, the model correctly predicted who would have an earlier event 81.1% of the time). The strongest
predictors were initial diagnosis, CVD comorbidities and biomarker levels (Figure 46).
If the models had been used to identify patients at high risk (3% annual mortality), and a management
programme with a HR of 0.8 had been implemented, an additional 13–16 life-years or 15–18 coronary-
free years could have been achieved per 1000 patients screened, in comparison with models based only on
sex, age and deprivation (Figure 47).
In the ACRE validation, 872 deaths and 1238 non-fatal AMI or coronary deaths were seen during 7.5 years
of follow-up. In this data set, the model’s C-index for discrimination was 0.735 for all-cause mortality
(95% CI 0.715 to 0.755) and 0.718 for non-fatal AMI or coronary death (95% CI 0.700 to 0.736).
Discussion
In this population-based study of > 100,000 SCAD patients, prognostic models based on widely available
clinical data could identify patients at high risk of long-term mortality and coronary events with a high
degree of accuracy.
TABLE 23 Prognostic factors and their association with all-cause mortality and non-fatal AMI or coronary death in
patients with SCAD in CALIBER (continued )
Prognostic factors All-cause mortality, HRa (95% CI)
Non-fatal AMI or coronary
death, HRb (95% CI)
Non-CVD comorbidities
Chronic kidney disease, present vs. absent 1.116 (1.058 to 1.178) 1.085 (1.031 to 1.142)
COPD, present vs. absent 1.150 (1.114 to 1.187) 1.081 (1.089 to 1.281)
Cancer, present vs. absent 1.377 (1.324 to 1.432) 0.952 (0.887 to 1.021)
Chronic liver disease, present vs. absent 1.631 (1.443 to 1.842) 1.138 (0.925 to 1.401)
Psychosocial characteristics
Depression at diagnosis, present vs. absent 1.179 (1.135 to 1.225) 1.059 (0.998 to 1.124)
Anxiety at diagnosis, present vs. absent 1.172 (1.116 to 2.231) 1.015 (0.937 to 1.100)
Biomarkers
Heart rate per 10-b.p.m. increase 1.098 (1.04 to 1.112) 1.069 (1.030 to 1.110)
Creatinine per 30-µmol/l increase 1.065 (1.051 to 1.080) 1.087 (1.064 to 1.110)
White cell count per 15 × 109/l increase 1.120 (1.106 to 1.135) 1.111 (1.088 to 1.135)
Haemoglobin per 1.5-g/dl increase 0.758 (0.724 to 0.794) 0.822 (0.800 to 0.845)
C-index
Internal cross-validation 0.811 (0.806 to 0.816) 0.778 (0.770 to 0.785)
External validation (ACRE study) 0.735 (0.715 to 0.755) 0.718 (0.700 to 0.736)
a Exponential hazards regression with scale 92 (95% CI 89 to 94).
b Exponential hazards regression with scale 88 (95% CI 84 to 92).
Reproduced from Rapsomaniki et al.52 Copyright © 2014, © The author 2013. Published by Oxford University Press on behalf
of the European Society of Cardiology. This is an open-access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial reuse, distribution,
and reproduction in any medium, provided the original work is properly cited.
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The models showed good calibration and discrimination, when applied to both original source data and
an independent data set. Their relevance to clinical decision-making was confirmed through calculations
demonstrating significant benefits had they been applied in practice to stratify patients. As there is no cost
involved in acquiring new data, use of the models is likely to be highly cost-effective.
The models have been developed to be consistent with ACCF/AHA definitions and guidelines.329 The findings
support use of the models in early stages of stepwise risk assessment, to identify patients for intensive
management or further investigation. Further external validation in external data sets and recalibration for
different populations and time periods is required. An economic evaluation is needed to establish the
appropriateness of using the prognostic model in practice.
Conclusions
We present validated prognostic models for estimating the risk of all-cause mortality and coronary
outcomes based on clinical parameters that are commonly available in all people with SCAD. These models
can be implemented alongside further medical investigations to support medical decision-making. Further
independent evaluation is required in different settings, including different EHR systems, health-care
organisations and geographic locations to guide use in clinical practice. A risk calculator is available online
(www.caliberresearch.org/model).
Study 21: resource use, costs and health outcomes in patients with stable
coronary artery disease using linked electronic health record data
This study is based on the peer-reviewed papers by Asaria et al.,53 and Walker et al.54
Introduction
Stable coronary arterial disease patients vary widely in their risk of subsequent AMI or coronary death
(about 10-fold, between top and bottom deciles of risk).52 Understanding how drug use, procedures,
primary care consultations and hospital admissions vary according to baseline risk may contribute to clinical
decision-making for SCAD patients and policy-making.
However, existing studies on resource use and costs in SCAD have important limitations. Studies have been
based on populations with disease and do not reflect contemporary and standard clinical practice; for
example, they use selected small samples from trials undergoing non-standard care.335 Despite the need to
understand the long-term course of SCAD, previous studies have taken AMI as a starting point336 and use
overly simplistic models. We are not aware of any published study using data collected as part of usual care
that has evaluated resource utilisation and costs according to baseline cardiovascular risk, and longer-term
and lifetime implications of SCAD have not been reported accurately elsewhere.
The majority of models estimating the costs and health effects of CVD have focused on primary prevention,337,338
and have made predictions over relatively short time horizons.339 Hence, they are unable to capture lifetime
costs and health effects, are based on selected samples (potentially biasing baseline risk and cost estimates,
and limiting their generalisability) and fail to model all relevant end points and their interdependence.335
Population-based contemporary linked EHRs could be used to provide reliable estimates of the lifetime cost
and quality-adjusted life expectancy of patients with this important chronic condition. Using CALIBER
linked data, we set out to (1) determine health-care utilisation and the associated costs in the first year
with SCAD and in the year following a first non-fatal event (AMI, ischaemic or haemorrhagic stroke),
(2) identify predictors of costs in the first year of SCAD and (3) model patients with SCAD, estimating their
baseline risk of experiencing further CVD events and then predicting both costs and key health outcomes
over the lifetime of these patients stratified by their baseline CVD risk. This model will allow us both to
understand the cost implications of managing this growing population under current standards of care and
to evaluate the cost-effectiveness of new treatment strategies, potentially differentiated by risk group.
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Methods
Study population
The analysis was based on 94,966 SCAD patients in CALIBER identified between January 2001 and March
2010. Eligible patients were those with a diagnosis of stable angina, history of AMI, CABG or PCI prior to
the start of the study period, or a diagnosis of ACS within the study period (unstable angina or AMI).
Patients with prior ACS were defined as stable if they had survived > 6 months following the acute event.
Health-care utilisation
Health-care use extracted from the data set included primary care consultations, pharmaceutical prescriptions,
inpatient stays (which included procedure costs) and diagnostic tests. Primary care consultations included all
contact between the patient and health-care professionals captured in the CPRD. Prescription data were
available from the CPRD. Inpatient stays extracted from HES were based on Healthcare Resource Group codes
and defined as CVD or non-CVD related. Diagnostic tests, but not outpatient consultations, were also
extracted from HES; the latter were not extracted owing to the absence of outpatient HES data linkage.
Resource use
Costs were calculated from the perspective of the UK NHS in UK pounds sterling based on 2011/12 prices.
Costs were calculated by combining health-care use with associated unit costs that were taken from
published UK sources.340–342 For hospitalisations, costs were calculated based on finished consultant
episodes in HES.
Health-care resource use was estimated from the CALIBER data set. A panel was constructed using a 90-day
cycle length for SCAD patients capturing resource use in terms of hospital episodes, use of drugs, diagnostic
tests and primary care costs. Costs were attached to this resource use using the NHS Reference Costs,341
NHS Prescription Cost Analysis342 and Personal Social Services Research Unit costs for primary care340
data sets.
Model
A state transition model was developed to capture the natural history of SCAD patients based on previous
models in CVD335 and clinical advice. The model (Figure 48) focuses on predicting the first non-fatal CVD
event that SCAD patients are likely to experience as well as CVD and non-CVD mortality. The model has a
lifetime time horizon and uses a 90-day cycle length to capture the time-varying and age-dependent
nature of risks, costs and health-related quality of life. Costs and health-related quality of life were
attached to model states and were adjusted for patient covariates at baseline as well as age and time post
event in the model.
End points
The median follow-up of SCAD patients in CALIBER was 4.2 years (IQR 1.9–6.9 years), during which
16,783 deaths and 8203 coronary outcomes were observed. The primary clinical end points in the model
were first occurrences of non-fatal AMI, ischaemic stroke and haemorrhagic stroke, as well as CVD and
non-CVD mortality. Other clinical end points were CVD and non-CVD mortality following a non-fatal
event. These were combined to produce the primary economic outputs from the model, which were
expected survival duration, quality-adjusted life-years (QALYs) total and CVD-specific costs, each predicted
over the remaining lifetime of the patient. The model was also used to produce estimates of event rates
and disease progression over time stratified by baseline CVD risk.
Statistical modelling of risk equations
A range of parametric survival models (generalised gamma, log-normal, Weibull, exponential) was
estimated for each of the end points, and the best fitting parametric model for each end point was
selected. Key prognostic factors included in the models were based on those used by Rapsomaniki et al.52
and included demographic measures (age, sex, ethnicity, social deprivation), SCAD subtype (stable angina,
other CHD, unstable angina, AMI, STEMI, NSTEMI), use of long-acting nitrates, whether CABG or PCI was
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performed in the 6 months following CAD diagnosis, previous AMI, smoking, BP, diagnosis of
hypertension, diabetes, lipids, CVD comorbidities (heart failure, PAD, atrial fibrillation, stroke), non-CVD
comorbidities [chronic renal disease, COPD, cancer, chronic liver disease, psychosocial factors (depression,
anxiety)] and clinically assessed biomarkers (heart rate, white cell count, haemoglobin, creatinine).
Risk equations for the six subsequent events (CVD and non-CVD mortality following non-fatal AMI,
ischaemic stroke and haemorrhagic stroke) were estimated in a similar way. Owing to the greatly reduced
numbers of events observed, these were based only on sex and age at the time of the non-fatal event.
Non-CVD mortality beyond the maximum follow-up in the CALIBER data set (10 years) was based on
age- and sex-specific non-CVD mortality from national life tables.
Risk equations were combined using a competing risks framework to account for the interdependence of
the risks.343 Models were estimated using R (version 3.1.0) and the R package flexsurv (version 0.3).
Health-related quality of life
EuroQol-5 Dimensions scores for the UK344 were used to calculate age-, condition- and event-specific
health-related quality of life and included in the model to calculate QALYs.
Statistical analysis
Estimates of health-care utilisation and costs are presented for the first year with SCAD and the first year
following a non-fatal event (either AMI, ischaemic or haemorrhagic stroke), with results reported in terms
of mean (SD) or median (IQR). Patients who were censored (i.e. those for whom the data are incomplete
for the year but who did not die) were excluded from the analysis.
We used ordinary least squares regression analysis to estimate the impact of baseline covariates on costs in
the first year. Covariates were based on those used in the prognostic model for SCAD patients described
above, on the assumption that predictors of costs were likely linked to prognostic indicators. Models were
fitted on five multiply imputed data sets and estimates combined using Rubin’s rules.345
Panel data methods with time-invariant covariates were used to estimate patient costs over each 90-day period,
as well as the impact of events (non-fatal AMI, ischaemic and haemorrhagic stroke, CVD- and non-CVD-related
death) on the costs in the period of the event and subsequent periods if the event was non-fatal. These costs
were then combined with the state transition Markov model to estimate costs over a longer period.
Given that the model was designed to be used with a heterogeneous population, results were produced by
risk groups. The 5-year baseline CVD risk for each SCAD patient was calculated based on the estimated risk
equations, and patients were ranked and grouped into 10 equally sized risk groups based on this calculation.
Model results were calculated at the mean covariate values across patients within each risk group.
The model was used to calculate life expectancy, QALYs, 5-year and lifetime total health-care costs, and
CVD-specific health-care costs for standard care, as well as for indicative new treatments that are assumed
to reduce CVD hazards by 10%, 20%, 30% and 40% (including hazards of AMI, ischaemic stroke or CVD
death). The results were used to estimate the maximum price that could be charged for the new treatments
in each of the risk groups assuming a cost-effectiveness threshold of £20,000 per QALY as used by NICE.346
The model was evaluated probabilistically by means of a Monte Carlo simulation run for 1000 iterations in
order to incorporate and characterise the uncertainty in the model inputs. The model was run for each of the
10 profiles evaluated against each of the five treatment scenarios using R (version 3.1.0) on the N8 HPC
supercomputer [N8 HPC Centre of Excellence, funded by the N8 consortium and the Engineering and
Physical Sciences Research Council (EPSRC) (Grant No. EP/K000225/1), Universities of Leeds and Manchester].
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Results
Health-care utilisation
Table 24 reports health-care utilisation in the first year with SCAD and in the first year following a
non-fatal event (AMI, ischaemic or haemorrhagic stroke). In the first year with SCAD, 26.9% of patients
(n = 23,801) were hospitalised for CVD, and those who were hospitalised had an average 1.9 stays (spells)
in hospital. In the year following a non-fatal event, 76% of patients (n = 5613) were hospitalised for CVD
and spent an average of 2.4 stays in hospital. In the first year with SCAD, patients had an average of 10.8
TABLE 24 Health-care utilisation in first year with SCAD and first year following a non-fatal event (AMI, ischaemic
or haemorrhagic stroke) in CALIBER patients
Health-care utilisation Mean (SD) Median (IQR)
Health-care utilisation in first year (n = 85,605)
Hospitalisations
Percentage hospitalised 0.38 (0.48) 0 (0–1)
Percentage hospitalised for CVD 0.27 (0.44) 0 (0–1)
Inpatient stays 0.87 (4.42) 0 (0–1)
Inpatient stays for CVD 0.5 (2.55) 0 (0–1)
With any hospitalisation (n= 32,160)
Inpatient stays 2.33 (6.98) 1 (1–2)
With any hospitalisation for CVD (n= 23,081)
Inpatient stays for CVD 1.86 (4.64) 1 (1–2)
Primary care consultations 10.77 (10.86) 8 (0–30)
Number of diagnostic tests 31.25 (38.73) 22 (2–44)
Drugs
Percentage of patients on any drugs 0.91 (0.28) 1 (1–1)
Percentage of patients on CVD drugs 0.88 (0.32) 1 (1–1)
Health-care utilisation in year following non-fatal event (n = 7762)
Hospitalisations
Percentage hospitalised 0.76 (0.42) 1 (1–1)
Percentage hospitalised for CVD 0.72 (0.45) 1 (0–1)
Inpatient stays 2.16 (5.97) 1 (1–3)
Inpatient stays for CVD 1.71 (4.72) 1 (0–2)
With any hospitalisation (n= 5936)
Inpatient stays 2.83 (6.69) 2 (1–3)
With any hospitalisation for CVD (n= 5613)
Inpatient stays for CVD 2.37 (5.41) 2 (1–3)
Primary care consultations 13.57 (14.84) 10 (0–38)
Number of diagnostic tests 40.42 (45.87) 31 (4–58)
Drugs
Percentage of patients on any drugs 0.91 (0.28) 1 (1–1)
Percentage of patients on CVD drugs 0.9 (0.3) 1 (1–1)
Adapted from Walker et al.54 © 2016 Walker et al.54 Published by Oxford University Press on behalf of the European Society
of Cardiology. This is an open-access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any
medium, provided the original work is properly cited.
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primary care appointments, which increased to 13.6 in the first year following a non-fatal event. In the
first year with SCAD, 88% of patients were taking cardiovascular medication, which increased to 90% in
the year following a non-fatal event.
Costs
Table 25 reports costs for hospitalisations, primary care consultations, diagnostic tests and drugs in
patients in the first year with SCAD and in the first year following a non-fatal event (AMI, ischaemic or
haemorrhagic stroke). Average total health-care costs in the first year with SCAD were £3127 per patient,
of which 70.2% (£2194) was related to CVD, increasing to £9239 per patient in the year following a
non-fatal event, of which 84.5% (£7809) was CVD related. The majority of health-care costs were driven
by hospitalisations (64% in first year with SCAD and 83% in the year following a non-fatal event). Costs in
all categories were highly skewed, with mean costs considerably higher than the median.
TABLE 25 Costs in first year with SCAD and in the first year following an event (AMI, ischaemic or haemorrhagic
stroke) in CALIBER patients
Cost Mean (SD) (£) Median (IQR) (£)
Costs in first year (n = 85,605)
Total costs
Total cost 3127 (6096.61) 1147 (506–3145)
Total CVD cost 2194 (4628.17) 734 (367–1818)
Hospitalisations
Inpatient costs 2012 (5629.07) 0 (0–1606)
Inpatient CVD costs 1481 (4488.98) 0 (0–695)
Primary care costs 466 (463.27) 361 (0–1291)
Diagnostic test costs 141 (231.49) 70 (0–537)
Drugs
All drug costs 508 (1546.28) 209 (0–1698)
CVD drug costs 105 (113.48) 84 (0–272)
Costs in first year following an event (n = 7762)
Total costs
Total cost 9239 (11,684.65) 5942 (2119–12,229)
Total CVD cost 7809 (10,367.94) 4817 (1367–10,372)
Hospitalisations
Inpatient costs 7643 (11,029.41) 4393 (561–10,261)
Inpatient CVD costs 6863 (10,232.13) 3926 (0–9333)
Primary care costs 585 (603.095) 447 (192–794)
Diagnostic test costs 222 (305.015) 124 (27–287)
Drugs
All drug costs 789 (2932.95) 287 (124–671)
CVD drug costs 139 (161.26) 108 (46–182)
Adapted from Walker et al.54 © 2016 Walker et al.54 Published by Oxford University Press on behalf of the European Society
of Cardiology. This is an open-access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any
medium, provided the original work is properly cited.
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Cost predictors in the first year with stable coronary artery disease
Non-CVD-related comorbidities had the largest impact on costs, with a history of renal disease having the
largest increment of £2432 per patient. Of possible SCAD diagnoses, NSTEMI had the largest impact on
cost, with an increment of £742 per patient compared with stable angina. Women incurred significantly
lower costs than men, with a decrement of £652 per patient.
Estimated 90-day period and event costs
Panel data methods were used to calculate 90-day period costs and impacts of events on costs. For
example, the background total health-care costs for a male, aged 69 years, with no comorbidities, would
be £349 in the first 90 days, increasing by £9 for each subsequent 90-day period. If the patient has a
non-fatal AMI she or he would incur an incremental cost (on top of the normal period cost of £372) of
£4817 in the 90 days following the AMI, with the incremental costs decreasing in subsequent 90-day
periods until 360 days, after which there is an incremental cost of £426 per 90 days, suggesting significant
ongoing lifetime costs of events. Also of note, the costs of death from CVD- and non-CVD-related causes
are £1402 and £1583, respectively.
Lifetime costs and outcomes
There was large variation in CVD risk between the lowest- and highest-risk groups, with an absolute
difference in risk of 40% over 5 years. The risk of clinical events was positively correlated with age and
higher levels of CVD risk factors such as hypertension and diabetes, as well as with higher prevalence of
CVD comorbidities. There were no obvious trends in the key modifiable CVD risk factors such as
cholesterol, HDL and heart rate in this population of clinically managed patients.
The modelled progression of CVD over time by risk group is shown in Figure 49. Higher-risk groups were
predicted to have much higher levels of CVD mortality than lower-risk groups, who were predicted to
remain event free for a much longer period.
Estimated costs over time for stable coronary artery disease patients
A patient with SCAD representative of the lowest-risk group (5-year cardiovascular risk of 3.43% and a
life expectancy of 26.9 years) would have expected undiscounted costs of £9181 over 5 years, of which
57% would be CVD related, and undiscounted lifetime costs of £107,052, of which 60% would be CVD
related. A representative patient of the highest-risk group (5-year cardiovascular risk of 43.7% and a life
expectancy of 5.3 years) would have expected undiscounted costs of £21,872 over 5 years, of which 72%
would be CVD related, and lifetime undiscounted costs of £38,606, of which 72% would be CVD related.
Figure 50 shows the predicted total and CVD-related costs over a 25-year period for average characteristics
of risk groups 1 (lowest risk), 4, 7 and 10 (highest risk). Higher-risk patients with SCAD have higher initial
costs, which are overtaken by the lower-risk patients as a result of greater mortality in the higher-risk
groups, resulting in less time to accrue costs.
Estimated costs and outcomes over time for stable coronary artery
disease patients
Summary model results by risk group are shown in Table 26. Lower-risk patients were estimated to have
both greater remaining QALYs and greater health-care costs. Combining these factors, we observed that,
under standard care, mean total costs per QALY over the remaining lifetime in the lowest-risk group are
projected to be £5581, compared with £11,806 in the highest-risk group.
Policy implications
Using these results, we calculated the maximum price that the NHS should be willing to pay for new
treatments targeted at each risk group that reduce CVD hazards by between 10% and 40% (Figure 51).
This maximum price increases with both increasing baseline risk and with the higher relative risk-reduction
impact of treatments.
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FIGURE 49 Progression of disease over time by baseline CVD risk group among CALIBER patients with SCAD.
(a) Lowest risk; (b) decile 2; (c) decile 3; (d) decile 4; (e) decile 5; (f) decile 6; (g) decile 7; (h) decile 8; (i) decile 9;
and (j) highest risk. MI, myocardial infarction. Reproduced from Asaria et al.53 Copyright © 2016, BMJ Publishing
Group Ltd and the British Cardiovascular Society. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited. (continued )
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Discussion
In this study we address a fundamental gap in knowledge: what is the clinical, health service and
economic burden associated with SCAD? Using data from a large, contemporary and representative
population of UK patients with SCAD, we have shown that substantial health-care costs are likely to be
incurred as a result of improved ACS survivorship and the ageing population. Moreover, 5-year and
lifetime costs vary according to CVD risk, which may be predicted from baseline patient-level data.
Stable coronary artery disease patients might be considered to have ‘fallen off the radar’ of clinical interest:
they are no longer in cardiac rehabilitation (mainly offered to those immediately after AMI or CABG),
no longer on dual antiplatelet therapy (maximum current recommendation for therapy is 12 months) and,
in most cases, discharged from specialist care, with prescribing adherence to secondary preventative
medication waning. SCAD guidelines give little guidance about how such patients should be followed up
in health care or how they should be appropriately risk stratified.233,329 Our results clearly highlight the
unmet need and the shortfalls of current approaches: they experience high use of primary care and
frequent hospitalisations, incurring considerable ongoing costs. The number of primary care consultations,
a mean of 10.76 per patient in the first year with SCAD, is higher than previous estimates for the average
population (5.5 per year).347 In the first year with SCAD, 37% of patients were hospitalised (26.9% for a
CVD). This is markedly higher than recent estimates for the general population in one area of the UK
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FIGURE 49 Progression of disease over time by baseline CVD risk group among CALIBER patients with SCAD.
(a) Lowest risk; (b) decile 2; (c) decile 3; (d) decile 4; (e) decile 5; (f) decile 6; (g) decile 7; (h) decile 8; (i) decile 9;
and (j) highest risk. MI, myocardial infarction. Reproduced from Asaria et al.53 Copyright © 2016, BMJ Publishing
Group Ltd and the British Cardiovascular Society. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
STABLE CORONARY ARTERY DISEASE: RISK PREDICTION AND COST-EFFECTIVE TARGETING OF INTERVENTIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
142
(14.9%)348 and higher than that in the general population for similar age groups (23.4% and 21.2% of
60- to 74-year-old males and females, respectively, based on HES data).
Health-care utilisation is insufficient as a metric of the impact on the health-care system. It is also
important to consider the costs associated with those resources to the NHS. Average costs of £3127 in the
first year with SCAD are markedly higher than those in patients with no chronic conditions (£293) but
comparable with other chronic conditions (e.g. diabetes £3036).348 High costs in the first year following a
non-fatal event (£9239) reflect the health-care resources required to treat that event.
We provide here, for the first time, estimates of lifetime health-care costs. In low-risk patients (5-year CVD
risk of 3%), remaining lifetime health-care costs were £117,000 and remaining lifetime QALYs were 19.11
years; in the highest-risk group (5-year CVD risk of 44%), remaining lifetime health-care costs were
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FIGURE 50 (a) Expected total health-care costs and (b) CVD-related health-care costs over time for patients in
cardiovascular risk groups 1 (lowest-risk group), 4, 7 and 10 (highest-risk group) in CALIBER patients with SCAD.
Reproduced from Walker et al.54 © 2016 Walker et al.54 Published by Oxford University Press on behalf of the
European Society of Cardiology. This is an open-access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and
reproduction in any medium, provided the original work is properly cited.
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£43,000 and remaining lifetime QALYs were 3.34 years. This is important because it illustrates and
quantifies the general phenomenon that the highest costs per patient occur in the highest-risk patients
and are concentrated towards the end of life.
Importantly, we provide new information on the price that the NHS should be willing to pay for new
treatments to reduce CVD risk in SCAD patients. A new treatment giving a 20% hazard reduction in
cardiovascular events would be cost-effective if priced < £61 per year in the lowest-risk group and £657
per year in the highest-risk group. The relatively high cost and modest efficacy of the newer treatments
currently completing Phase III trials suggests that they should be targeted at the highest-risk patient groups
in order to be cost-effective.
Our model is the first comprehensive lifetime model based on long-term EHR data modelling the full range of
CVD end points and accounting for the interdependence of CVD risks in the SCAD population. We have
demonstrated that such data can be used to model the long-term costs and health effects of chronic
conditions. Furthermore, the size of such data sets (number of patients and the number of years of follow-up)
and their scope (number of end points and risk factors captured) enable increasingly biologically plausible
models of such conditions to be built.
The model allows policy-makers to quantify and understand both the health and the cost burden of SCAD,
and serves as a basis for evaluating the cost-effectiveness of new treatments aiming to reduce CVD risk in
this population. Our results suggest that, for the vast majority of SCAD patients, it is likely that low-cost
interventions to improve adherence to existing secondary prevention drugs should be prioritised over
high-cost new treatments. It is also notable from our results that, even among the groups with the highest
CVD risk, more patients are predicted to die of non-CVD-related than CVD-related causes, highlighting the
vital role of primary care in the holistic management of both cardiovascular and non-cardiovascular risk for
these patients.
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FIGURE 51 Theoretical maximum price of new treatments by risk for cardiovascular events among CALIBER
patients with SCAD. MI, myocardial infarction. Reproduced from Asaria et al.53 Copyright © 2016, BMJ Publishing
Group Ltd and the British Cardiovascular Society. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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As the data sets underpinning this analysis are further enriched in terms of both length of follow-up and
breadth of linked data sets, it will become feasible for models such as ours to be extended to capture
the trajectory of prognostic risk factors over time. This would allow us to go beyond a focus solely on
treatments that directly impact on CVD risk to address broader questions around the cost-effectiveness of
interventions that target these underlying risk factors.
This study has limitations. First, outpatient appointment costs cannot currently be linked from HES, so we
were unable to include them. As a result, all estimates are underestimates of the total health-care costs of
this population. Second, the estimation of costs and consequences involved extrapolation over longer time
periods than is currently available. This extrapolation is reflected in the uncertainty around the model
predictions. Third, health-related quality-of-life data were not recorded in CALIBER and were drawn from
external studies. Finally, changes in prognostic risk factors over time were not explicitly modelled; instead,
the equations underpinning our model are informed by the baseline values of these risk factors.
Conclusions
Patients with SCAD account for significant use of health-care resources and incur substantial health-care
costs, which can be predicted by individual 5-year CVD risk profiles. We provide a model for estimating the
lifetime health-care costs and health outcomes of patients with SCAD. This model lends itself to informing
decisions on commissioning, regulatory approval and the ongoing evaluation of new interventions. It also
demonstrates the value of utilising linked EHRs for economic evaluation purposes. Improved ACS survivorship
and an ageing UK population will require targeted resource allocation in anticipation of burgeoning demand.
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Chapter 10 Acute myocardial infarction: missed
opportunities for treatment during and after
hospitalisation
Abstract
Background
Disease registries have been invaluable in collecting information about a specific disease and its treatment
in order to drive audit and research, thus improving the quality of care. AMI is exceptional among diseases
in being one of the most ‘registered’, and in being a disease for which health-care interventions have
significantly improved prognosis over the years.
Objectives
To evaluate missed opportunities for care in hospital and after discharge for AMI using CVD registries in
the UK and other countries.
Methods
Analyses of data from national AMI registries in the UK, Sweden and the USA.
Results
(1) International comparisons identified significant differences in use of surgical interventions and use of
some secondary prevention medications in the UK. Short-term mortality after AMI was markedly higher in
the UK than in Sweden. (2) More than half of hospitalised STEMI patients eligible for nine evidence-based
care components did not receive all components. Greater numbers of missed opportunities for care were
associated with higher mortality. (3) Only 23% of smokers received smoking cessation interventions in the
3 months following discharge. Those who ceased smoking experienced fewer cardiac events than those
who continued smoking.
Conclusions
Despite guideline recommendations, major opportunities to improve cardiovascular outcomes for ACS
patients are being missed, during hospital stays and after discharge. International comparisons may identify
key areas that could be targeted to improve outcomes in the UK.
The studies in this chapter relate to patients presenting for the first time with ACS (Figure 52).
Introduction
Abundant evidence has been gathered from RCTs on the most appropriate management of patients after
AMI. Recommended practice is incorporated into national and international guidelines, but implementation
of these guidelines is frequently imperfect; even without the introduction of new treatments, optimisation
of existing treatments could significantly reduce coronary mortality.349
We have used the UK’s national ACS registry, MINAP, to investigate the extent to which guidelines are
being followed in practice, and what impact non-adherence has on survival. We have also examined one
specific recommendation after discharge, for smokers experiencing an AMI to be offered smoking-cessation
advice and support.
We have further taken advantage of comprehensive national disease registries in the UK and Sweden,
and a selective but large US registry, to compare practices in the three countries. For Sweden and the UK,
we were also able to analyse how these differences translated into difference in outcome after AMI.
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Study 22: comparative effectiveness of systems of care for acute
myocardial infarction – a comparison of short-term survival using
nationwide outcome registries in Sweden and the UK
This study is based on the peer-reviewed paper by Chung et al.55
Introduction
Our comparative analysis of NSTEMI management in the UK, Sweden and the USA highlighted apparent
underuse of invasive procedures and beta-blockers in the UK. How these potential missed opportunities
for care influenced prognosis, however, could not be determined owing to the absence of studies that
simultaneously examine care and outcomes. Additional uncertainty was introduced by differences in the
hospitals contributing data to the national registries, with those in the USA being a self-selected subset of
hospitals contributing on a voluntary basis, in contrast to the UK and Sweden where data contribution is
mandated across all hospitals. Indeed, the UK and Sweden are the only countries in the world with
continuous national ACS registries. These are linked to mortality records and therefore offer a unique
opportunity for comparative effectiveness research between whole health systems, incorporating both
treatment and outcome data. Until now, studies have not standardised the mortality of patients in one
country by the case mix in another, resulting in international comparison studies between health systems.
Our objectives in the present study were (1) to evaluate the validity of comparing data from these two
nationwide clinical registries; (2) to compare changes over time in the proportions of patients receiving
effective interventions during hospitalisation and at discharge between 2004 and 2010; (3) to compare
crude and case-mix-standardised 30-day mortality between the two countries, and in clinically important
subgroups; (4) to estimate and compare time trends in case-mix-standardised mortality in Sweden and the
UK; and (5) to explore the contribution of clinical care to any mortality difference.
Methods
The study population was drawn from all hospitals that provide AMI care in Sweden (n = 86) and the UK
(n = 242), and contribute data on consecutive patients to Swedish Web-system for Enhancement and
Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies/
Register of Information and Knowledge about Swedish Heart Intensive care Admissions (SWEDEHEART/
RIKS-HIA) and MINAP, respectively. Patients with a first AMI admission between 1 January 2004 and
31 December 2010 were included. Fields in SWEDEHEART/RIKS-HIA and MINAP were compared, leading
to selection of 17 case-mix measures and 14 in-hospital treatment measures (Table 27). The primary clinical
outcome was all-cause mortality within 30 days after hospital admission, as recorded in Swedish and UK
national death registries (data available for 99.3% and 98.7% of patients, respectively).
TABLE 27 Case mix and treatment for patients with AMI in Sweden (n= 119,786 in the SWEDEHEART/RIKS-HIA
registry) and the UK (n= 391,077 in MINAP)
Case mix and treatment
Sweden UK
n % (95% CI) n % (95% CI)
STEMI 38,432 32.1 (31.8 to 32.3) 157,418 40.3 (40.1 to 40.4)
Age (years), mean (SD) 71.2 (12.3) 69.5 (13.6)
Female 43,512 36.3 (36.1 to 36.6) 135,664 34.8 (34.7 to 34.9)
AMI severity, median (Q1, Q2)
SBP (mmHg) 145 (125, 165) 139 (120, 158)
Heart rate (b.p.m.) 78 (65, 93) 79 (66, 94)
Troponin I (µg/l) 4.2 (0.8, 18.0) 4.4 (0.8, 21.7)
Troponin T (µg/l) 0.7 (0.2, 2.3) 0.65 (0.2, 2.3)
continued
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TABLE 27 Case mix and treatment for patients with AMI in Sweden (n= 119,786 in the SWEDEHEART/RIKS-HIA
registry) and the UK (n= 391,077 in MINAP) (continued )
Case mix and treatment
Sweden UK
n % (95% CI) n % (95% CI)
Risk factor
Current smoking 25,085 23.3 (23.0 to 23.5) 104,522 29.5 (29.3 to 29.6)
History of diabetes 26,992 22.7 (22.4 to 22.9) 65,458 17.6 (17.4 to 17.7)
History of hypertension 53,155 45.2 (44.9 to 45.5) 173,342 47.3 (47.2 to 47.5)
CVD history
Heart failure 10,859 9.7 (9.5 to 9.8) 18,944 5.3 (5.2 to 5.4)
Cardiac arrest prior to admission 1578 1.3 (1.3 to 1.4) 8478 2.3 (2.2 to 2.3)
Cerebrovascular disease 9816 10.1 (9.9 to 10.3) 30,091 8.5 (8.4 to 8.5)
Myocardial infarction 26,526 22.4 (22.1 to 22.6) 67,346 18.3 (18.1 to 18.4)
Pre-hospital treatment
Antiplatelet monotherapy 43,485 36.6 (36.3 to 36.6) 98,247 26.4 (26.3 to 26.6)
Antiplatelet dual therapy 4788 4.0 (3.9 to 4.1) 10,931 2.9 (2.9 to 3)
PCI 9475 8.0 (7.8 to 8.2) 19,473 5.4 (5.4 to 5.5)
CABG 9192 7.7 (7.6 to 7.9) 17,383 4.8 (4.8 to 4.9)
Hospital treatment
STEMI patients
Total reperfusion treatment 27,354 71.2 (70.7 to 71.6) 118,880 76.6 (76.4 to 76.8)
Pre-hospital fibrinolysis 1533 4.1 (3.9 to 4.4) 13,903 9.3 (9.2 to 9.5)
In-hospital fibrinolysisa 4539 11.8 (11.5 to 12.1) 84,112 54.2 (54.0 to 54.5)
Primary PCI 22,773 59.3 (58.8 to 59.8) 34,695 22.4 (22.2 to 22.6)
Delay: symptom to fibrinolysis (minutes),
median (Q1, Q3)
177 (108, 322) 150 (94, 285)
Delay: symptom to primary PCI (minutes),
median (Q1, Q3)
198 (129, 365) 199 (140, 328)
NSTEMI and STEMI patients
Coronary intervention other than primary
PCI
34,288 28.6 (28.4 to 28.9) 58,492 17.3 (17.2 to 17.5)
IV glycoprotein IIb/IIIa receptor inhibitors 24,993 21.0 (20.8 to 21.2) 28,389 8.6 (8.5 to 8.7)
Anticoagulants 87,271 73.2 (73.0 to 73.5) 283,344 83.0 (82.9 to 83.1)
Hospitalisation (days), medium (Q1, Q3) 5 (3, 7) 6 (3, 10)
Discharge medication
Antiplatelet monotherapy 30,409 27 (26.8 to 27.3) 103,218 34.2 (34.1 to 34.4)
Antiplatelet dual therapy 76,099 67.6 (67.3 to 67.9) 183,753 60.9 (60.8 to 61.1)
Beta-blocker 99,779 88.7 (88.5 to 88.9) 231,505 78.2 (78 to 78.3)
ACEI or ARB 63,102 56.2 (55.9 to 56.5) 242,300 82.3 (82.2 to 82.5)
Statin 89,767 79.7 (79.5 to 79.9) 276,335 92.8 (92.7 to 92.9)
a Pre-hospital fibrinolysis is not mutually exclusive.
Reproduced from Chung et al.55 Copyright © 2014 Chung et al. This is an open-access article distributed under the terms
of CC BY. Published by Elsevier Ltd. This document may be redistributed and reused, subject to certain conditions.
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Statistical analysis
We compared mortality outcomes using Kaplan–Meier survival curves. We modelled 30-day mortality for
both countries using the 17 case-mix variables, and then applied the Sweden model to the UK AMI
population to estimate the case-mix-standardised relative risk of observed versus expected UK 30-day
mortality, for each study year and all years. In propensity matching, we estimated the propensity of being a
STEMI patient and the propensity of being a NSTEMI patient in Sweden and the UK based on logistic
regression models of the 17 case-mix variables, and then matched patients based on the propensity score.
Case-mix models incorporated a random effect for each participant hospital. The extent of missing values
was examined and then managed by multiple imputation. We explored the extent to which mortality
differences between countries might be explained by differences in medical care by standardisation with
case-mix and in-hospital treatment and also by estimating the ‘what if’ scenario of UK having had the
same use of primary PCI and beta-blocker medication as Sweden from year 2004 onwards, assuming
treatment benefits reported in clinical trials.
Results
Eligible patients with AMI included 119,786 from Sweden and 391,077 from the UK (see Table 27). There
was a lower proportion of STEMI in Sweden (32% vs. 40%) but indices of infarct severity were similar in
Sweden and the UK. In patients with STEMI, primary PCI was more common in Sweden (59% vs. 22%)
compared with the UK, where fibrinolysis was used more frequently. In both countries, use of primary PCI
increased with time, whereas use of fibrinolysis decreased (Figure 53).
For patients surviving to hospital discharge, Swedish patients were more likely than UK patients to be
prescribed dual antiplatelet therapy (68% vs. 61%) and beta-blockers (89% vs. 78%), but less likely to be
prescribed ACEIs or ARBs (56% vs. 82%) and statins (80% vs. 93%). The cumulative 30-day mortality was
7.6% (95% CI 7.4% to 7.7%) in Sweden and 10.5% (95% CI 10.4% to 10.6%) in the UK (Figure 54).
In the UK, 30-day mortality was consistently higher in strata defined by measures of infarct severity
(troponins, heart rate and BP), age, sex, calendar year, smoking and diabetes status. Standardising the
30-day mortality of UK patients using the Swedish case mix reduced forecast mortality to 7.7% (95% CI
7.3% to 8.2%) with a standardised mortality ratio of 1.37 (95% CI 1.30 to 1.45), corresponding to an
estimated 11,263 (95% CI 9620 to 12,827) more deaths in the UK between 2004 and 2010. However,
standardised mortality ratios decreased progressively from 1.47 (95% CI 1.38 to 1.58) in 2004 to 1.20
(95% CI 1.12 to 1.29), p-value for trend 0.01 in 2010 (Figure 55). Propensity-matched analyses gave
similar findings.
Discussion
We found greater cumulative 30-day mortality after AMI in the UK (10.5%) than in Sweden (7.6%).
Case-mix standardisation attenuated the mortality difference. The findings suggest that > 10,000 early
deaths would have been prevented or delayed had UK patients experienced the care of their Swedish
counterparts. We believe that the comparison between Sweden and the UK was valid because, for both
countries, we captured consecutive AMI admissions across all hospitals, using common data definitions,
and we showed that the diagnosis of AMI was comparable, with similar troponin values and similar
propensity to make a diagnosis.
Variation in the way patients were managed in the UK and in Sweden may have contributed to the
30-day mortality differences. Use of primary PCI for STEMI patients in the UK lagged behind Sweden; the
rate in 2010 in the UK (53%) was similar to that of Sweden in 2005. Primary PCI is more effective than
fibrinolysis and was incorporated into US and European guidelines in 2004 and 2005, respectively;
however, the UK did not have a national policy for primary PCI until 2008. This probably explains the rapid
increase in primary PCI at that time, although only in 2011–12 did rates exceed 90%.350 The use of
evidence-based secondary prevention medication showed a mixed pattern, with statins and ACEIs/ARBs
being more commonly prescribed in the UK, whereas beta-blocker use on discharge was more common in
Sweden. The mortality gap between Sweden and the UK decreased over time, from a standardised
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mortality ratio of 1.47 in 2004 to 1.20 in 2010, consistent with a narrowing of gaps in treatment
differences. Other unmeasured aspects of health care, which probably contributed to the mortality gap,
include the dose, timing and adherence to drugs, differences in operator experience, shared and specialty
care pathways, use of decision support tools and organisational culture.351
This study comparing the delivery of health care in different health-care systems has demonstrated
differences in short-term outcomes for AMI patients; however, many patients remain at increased risk
beyond this period. We analysed linked EHR and disease registry data in four countries {England (CALIBER),
Sweden [Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of
Myocardial Infarction and Additional Risk Factors for Atherothrombosis (HELICON)], the US (Medicare) and
France [Echantillon Généraliste des Bénéficiaires (EGB)]} to investigate longer-term CVD risk among
140,880 patients surviving to the first anniversary of their heart attack. Our study found that cumulative
risk of AMI, stroke, CVD death, all-cause mortality and hospitalised bleeding remained high for 3 years
across all four countries, and predictors of risk had similar strong positive associations with the outcomes in
each country. This work further highlights the power and generalisability of prognosis research that utilises
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the EHRs across different health-care systems.352 Linkage to national EHRs will extend comparisons
to include ambulatory care before and after admission for heart attack, non-fatal events and
longer-term outcome.
Policy initiatives are required to identify, understand and reduce gaps in treatments and outcomes between
health systems. We suggest that progress towards this goal is achievable, as mortality differences are
narrowing and are, therefore, reversible. The study suggests a novel approach of between-country
comparison; to date, quality outcome initiatives have emphasised within-country, within-system metrics.
For Sweden, these results provide further evidence of the value of sustained, system-wide quality
improvement initiatives, including public reporting of mortality outcomes at hospital level. For the UK,
these results suggest the value of learning from systems that appear to be better performing.
International harmonisation of detailed measures of quality of care in clinical registries, such as pathways
of care, is needed to identify and evaluate additional patient-level health-care factors that are not
measured here that might explain differences between countries. Outcomes should be compared with
those in other countries, such as France, Hungary, Poland and the USA, through assessment of
national registries.
Limitations include the possibility of unmeasured confounders and the potential for patients not captured
in national registries – who are at higher risk – to distort the findings. However, such missed cases may be
less common in Sweden, where nationwide registries have a more established history than in the UK,
suggesting the mortality difference may actually be wider.
Conclusions
In conclusion, clinically important differences in the care and outcomes of AMI are observed between
Sweden and the UK. International comparisons of care and outcome registries may inform new research
and policy initiatives to improve the quality of health systems.
Study 23: mortality and missed opportunities along the pathway of
care for ST-segment elevation acute myocardial infarction –
a national cohort study
This study is based on the peer-reviewed paper by Simms et al.56 Sections of the text have been adapted
from the original article; Copyright © 2015, © SAGE Publications.
Introduction
There are many guideline-recommended acute interventions for patients with ACSs. Monitoring adherence
to guidelines is important in order to continually improve the quality of clinical care, and the MINAP
registry is invaluable in this respect. In this study we used MINAP to evaluate the association between
cumulative missed opportunities for care (CMOCs) and mortality in patients hospitalised with STEMI.
Methods
The MINAP study population was drawn from 121,567 consecutive patients aged ≥ 18 years presenting
for the first time with STEMI to hospitals in England and Wales from 1 January 2007 to 31 December 2010
and surviving to be discharged. Mortality data (30-day and 1-year all-cause) were obtained from the ONS.
We identified nine guideline-recommended care opportunities recorded in MINAP along the pathway of
STEMI care: (1) the recording of a pre-hospital ECG; (2) use of acute aspirin; (3) timely coronary reperfusion
(within 120 minutes or thrombolysis within 60 minutes of the call for help); (4) the individual prescriptions
of aspirin; (5) the individual prescription of thienopyridine inhibitor; (6) the individual prescription of
beta-blockers; (7) the individual prescription of an ACEI or ARB; (8) the individual prescription of statins;
and (9) enrolment into a cardiac rehabilitation programme at the time of discharge from hospital.353–355
A CMOC score was calculated for each patient, based on the number of these nine components that were
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not provided. To overcome instability due to small numbers, patients were categorised into CMOC groups
of 0, 1, 2, 3 and ≥ 4 missed care opportunities.
Statistical analysis
Fixed-effects univariable logistic regression models were built to identify possible factors associated with
ineligibility for care and model estimates expressed as ORs with 95% CIs. Similar models were fitted to
quantify the relative risk of missing ‘upstream’ interventions (pre-hospital ECG and timely reperfusion) on
the number of missed ‘downstream’ (hospital and cardiac rehabilitation) interventions. The association
between CMOC and mortality was quantified using mixed-effects models. We adjusted for case mix using
variables from the Global Registry of Acute Coronary Event (GRACE) risk score356,357 and patient
characteristics. These models were then used to estimate risk-adjusted mortality rates.
Results
A total of 112,286 patients were discharged alive from hospital following STEMI, of whom 62,267 were
eligible for all nine care interventions. Of the 31,187 (50.1%) eligible for all nine care interventions who
had complete data, 49.4%, 36.4%, 11.5%, 1.9% and 0.8% had CMOC scores of 0, 1, 2, 3 and ≥ 4,
respectively (Table 28). No patient eligible for all care opportunities missed more than eight components.
Patients with higher CMOC scores more frequently were older and female. Patients also had a greater
burden of comorbidity, higher GRACE risk scores and less frequently received coronary angiography.
Figure 56 shows that acute aspirin therapy was the least frequent contributor to CMOC, whereas
pre-hospital ECG and timely reperfusion were commonly included in CMOC. Both of these upstream
interventions independently predicted further downstream missed opportunities [pre-hospital ECG: incident
rate ratio (IRR) 1.64, 95% CI 1.58 to 1.70; and timely reperfusion: IRR 9.94, 95% CI 9.51 to 10.40].
Hospitals with ≤ 30 cardiology beds had significantly higher CMOC scores than those with > 50 beds.
Hospital volume of STEMI was negatively associated with CMOC score but there was no significant
association between CMOC score and whether or not hospitals had on-site coronary angiography/
PCI facilities.
Risk-adjusted mortality rates rose with increasing CMOC (Figure 57). Kaplan–Meier survival estimates
stratified by CMOC also showed a positive association between CMOC and mortality (Figure 58), and this
was confirmed by the risk-adjusted Cox analysis (Figure 59).
Discussion
This study shows that missed opportunities during the patient journey extend beyond primary care and are
common following hospital admission in patients with STEMI. More than half of this high-risk group failed
to receive at least one of nine components of care recommended in national guidelines. We found a
significant relationship between CMOC score and early mortality, which remained significant after 1 year.
The data suggest that CMOC represents an important target for improving quality of care and outcomes.
Patients with higher CMOC scores were at greater baseline risk and had more comorbid conditions. Failure
to provide upstream interventions – pre-hospital ECG and timely coronary reperfusion – significantly
predicted downstream missed opportunities. The association between CMOC score and mortality remained
strong, despite adjustment for case mix and invasive treatments, suggesting that it was driven more by
hospital factors than the risk characteristics of the patients. Thus, our data identified underprovision of
designated cardiology beds and larger catchment populations as hospital factors significantly associated
with CMOC. However, hospital associations with CMOC were complex, with low-volume centres reporting
more missed components of the care pathway. Overall, our findings suggest that adequately resourced,
high-throughput, high-volume hospitals (heart attack centres) with appropriate facilities may offer superior
care and may, therefore, deliver better outcomes. Outcomes research specifically designed to follow care
into the primary care setting is warranted to quantify the full implication of CMOCs.
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Conclusions
Of patients with STEMI eligible for nine evidence-based care components, over half did not receive all
components. Missed opportunities for care were significantly associated with early- and longer-term
mortality. Outcomes for STEMI would likely improve if CMOC was reduced and physicians provided all
components of the pathway of care to their patients.
Study 24: international comparisons of the management of patients
with non-ST-segment elevation acute myocardial infarction
This study is based on the peer-reviewed paper by McNamara et al.57 Sections of the text have
been reproduced/adapted from the original article. Copyright © 2014 The Authors. Published by
Elsevier Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0/).
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Introduction
Our analysis of missed opportunities for care along CALIBER’s patient journey has focused largely on
deviations from guideline recommendations in the management of patients with CVD, both in primary
care and hospital settings. However, registry-based research offers an alternative means of evaluating care
through the comparison of management strategies in different countries. To date, there have been few
international comparisons of care for patients with NSTEMI, and none that reflects the recent changes in
clinical management recommended in international guidelines.
We have established a collaboration with investigators in Sweden and the USA in order to compare
patterns of in-hospital treatment and use of interventional diagnostic and therapeutic procedures among
patients admitted with NSTEMI across three national clinical registries: MINAP in the UK, SWEDEHEART/
RIKS-HIA in Sweden and Acute Coronary Treatment and Intervention Outcomes Network Registry
(ACTION) in the USA.7,358 SWEDEHEART/RIKS-HIA and MINAP cover all hospitals providing care for ACS in
Sweden and the UK, respectively; ACTION is a voluntary registry that includes patients in a large but
self-selected group of hospitals in the USA. Data validity checks in SWEDEHEART/RIKS-HIA, MINAP and
ACTION have demonstrated agreement rates of 96.1%, 89.5% and 89.7%, respectively.7,86,359
Methods
The study population was drawn from all hospitals providing AMI care in England and Wales (236
hospitals, 137,009 patients), Sweden (74 hospitals, 45,069 patients) and a voluntary subset of hospitals,
most with the capability to perform PCI, in the USA (500 hospitals, 147,438 patients). We included
patients admitted between 1 January 2007 and 31 December 2010, and aged ≤ 30 years with first
recorded NSTEMI. The distribution of case-mix (demographics, past history and presentation characteristics)
and treatment variables was compared in the UK, Sweden and the USA. Recognising the difference
between nationwide and voluntary registries, we conducted a sensitivity analysis, comparing results of
NSTEMI patients attending PCI hospitals only. We defined PCI hospitals as those performing at least 24
procedures in a calendar year.
Results
Patients were youngest in the USA, where rates of smoking, diabetes, hypertension, prior heart failure and
prior AMI were higher than in Sweden or the UK (Table 29). Prior use of medications, PCI and CABG was
also higher in the USA. Angiography and PCI were performed more often in the USA and Sweden than in
the UK, but the rate of increase in these procedures from 2007 to 2010 was greatest in the UK (Table 30).
Similarly, PCI was performed more in the USA. Prescription of dual antiplatelet therapy was similar across
the countries. UK physicians prescribed beta-blockers at discharge least often but statins and ACEIs/ARBs
most often.
Discussion
This comparison of ongoing national registries showed important differences in the application of
guideline-recommended treatments in the UK compared with in Sweden and the USA, despite close
similarities in case mix. The data suggest missed opportunities for care on a national scale reflected in the
UK’s less aggressive use of interventional procedures for NSTEMI, although the gap with Sweden and the
USA narrowed over time. In contrast, secondary prevention medications (except beta-blockers) were more
commonly prescribed in the UK than in Sweden or the USA.
Clinical trials have previously shown wide variation in practice among countries or groups of countries in
the management of AMI patients.360–362 However, management patterns within a clinical trial do not
necessarily reflect management in usual clinical practice.363 Clinical registries address some of the selection
bias and are valuable resources for comparison and for assessing trends in treatment.363–367 The finding of
similarly high PCI rates in an unselected (SWEDEHEART/RIKS-HIA) and a selected (ACTION) registry makes
the differences seen in other aspects of NSTEMI care more informative. It suggests that US procedure rates
are not being driven by fee for service and that Sweden’s increased emphasis on system-wide quality
improvement is bearing fruit.368,369 The lower rates of interventional management in the UK provide further
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TABLE 29 Baseline characteristics of patients with first recorded NSTEMI in the UK (MINAP), Sweden
(SWEDEHEART/RIKS-HIA registry) and USA (ACTION registry)
Characteristics at baseline
Total NSTEMI
UK Sweden USA
Number of patients 137,009 45,069 147,438
Number of participating hospitals 236 74 500
Demographics
Age (years), median (IQR) 73 (62–82) 73 (64–82) 67 (56–78)
Female sex (%) 37.5 37.6 38.7
Risk factors (%)
Current smoker 23 19.6 29.6
Diabetes 21.7 25.0 35.4
Hypertension 53.1 50.6 76.3
History of CVD (%)
Heart failure 7.0 11.5 16.9
AMI 22.8 27.8 28.8
Treatment prior to hospital admission
Single antiplatelet (%) 30.4 42.2 39.4
Dual antiplatelet (%) 4.3 4.4 13.4
Beta-blocker (%) 28.8 44.4 44.2
ACEI or ARB (%) 38.3 37.3 42.5
Statin (%) 44.8 32.3 43.5
PCI (%) 7.5 12.3 25.0
CABG (%) 7.2 10.4 19.0
SBP (mmHg), median (IQR) 140 (121–160) 149 (130–168) 145 (125–166)
Heart rate (b.p.m.), median (IQR) 80 (68–96) 79 (66–94) 83 (70–99)
Haemoglobin (g/dl), median (IQR) 13.5 (12.0–14.8) 13.7 (12.5–14.8) 13.7 (12.2–14.9)
Creatinine (mmol/l), median (IQR) 95 (79–119) 86 (72–107) 97.2 (79.6–123.8)
Troponin, median (IQR)a
Troponin T (ng/ml) 0.33 (0.13–0.91) 0.39 (0.14–1.09) 0.1 (0.03–0.4)
Troponin I (ng/ml) 1.9 (0.39–7.59) 2.0 (0.48–7.2) 0.4 (0.1–1.8)
Initial ECG or ECG determining treatment (%)
Transient ST-segment elevation 2.7 4.0 2.7
ST-segment depression 30.3 34.3 23.8
Other T-wave abnormalitiesb 29.8 14.9 14.1
No ST-segment abnormalitiesc 37.2 46.8 59.4
a Troponin values in the UK and Sweden are a mix of initial and peak. Peak troponin values in the USA were 0.6 ng/ml
(IQR 0.2–1.7 ng/ml) and 4.7 ng/ml (IQR 1.5–14.3 ng/ml) for troponin T and I, respectively.
b Includes ‘T wave inversion’ in RIKS-HIA and ACTION and ‘T wave changes only’ in MINAP.
c Includes ‘normal’, ‘none’ and ‘other’ categories.
Reproduced from McNamara et al.57 Copyright © 2014 The Authors. Published by Elsevier Inc. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/),
which permits reuse, distribution, and reproduction in any medium, provided the original author and source are credited.
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evidence of slow implementation of emerging technologies, although the steeper increase in in-hospital
procedure rates between 2007 and 2010 suggests that concerted efforts to increase PCI capability have
been effective.370
The lower use of beta-blockers in the UK than in the USA and Sweden was accompanied by higher use of
statins and cannot, therefore, be driven by economic factors or by delayed implementation (the evidence
for beta-blockers in AMI pre-dates that for statins). One possibility is that UK patients had more perceived
contraindications, such as COPD, although our CALIBER study (see study 27 below) has shown that
beta-blockers are beneficial and safe in patients with COPD who present with AMI.59
Further studies are warranted to better explain patterns of clinical practice within and outside the UK,
such as rates of coronary angiography and PCI.
Conclusions
Differences exist in the acute management of NSTEMI among patients in national registries from the UK,
Sweden and the USA. Specifically, the use of invasive procedures such as angiography and PCI and of
beta-blockers on discharge was higher in the USA and Sweden than in the UK. Differences are becoming
smaller but need to be understood if areas for improvement are to be identified.
TABLE 30 Treatment over time among NSTEMI patients between 2007 and 2010 in the UK, Sweden and the USA
Treatment Data set (country)
Year of hospital admission (%)
2007 2008 2009 2010 2007–10
In-hospital angiography MINAP (UK) 22.9 27.9 35.5 38.8 31.8
RIKS-HIA (Sweden) 60.4 62.7 66.8 69.8 64.8
ACTION (USA) 72.4 75.2 76.6 78.3 76.0
In-hospital PCI MINAP (UK) 16.5 20.0 23.4 26.1 21.8
RIKS-HIA (Sweden) 39.0 40.2 42.7 45.9 41.9
ACTION (USA) 41.8 43.3 44.2 45.5 43.9
Beta-blocker at discharge MINAP (UK) 73.1 74.9 76.5 78.7 76.0
RIKS-HIA (Sweden) 88.8 88.6 88.2 89.0 88.6
ACTION (USA) 90.1 89.4 89.1 89.1 89.4
Antiplatelet at discharge (Any) MINAP (UK) 94.2 94.0 94.7 95.4 94.6
RIKS-HIA (Sweden) 93.6 94.4 95.0 94.9 94.5
ACTION (USA) 95.0 95.1 95.6 95.7 95.4
Antiplatelet at discharge (Dual) MINAP (UK) 74.9 74.6 76.4 78.6 76.2
RIKS-HIA (Sweden) 63.2 66.9 70.6 72.4 68.1
ACTION (USA) 64.7 65.1 66.9 68.0 66.4
Statin at discharge MINAP (UK) 91.2 91.0 91.5 92.1 91.5
RIKS-HIA (Sweden) 79.7 81.4 82.7 83.6 81.1
ACTION (USA) 82.0 83.7 85.4 85.9 84.5
ACEI or ARB at discharge MINAP (UK) 77.1 77.5 79 80.6 78.7
RIKS-HIA (Sweden) 65.5 68.3 69.9 72.1 68.8
ACTION (USA) 65.9 64.5 64.3 63.9 64.5
Reproduced from McNamara et al.57 Copyright © 2014 The Authors. Published by Elsevier Inc. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/),
which permits reuse, distributed, and reproduction in any medium, provided the original author and source are credited.
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Study 25: smoking cessation interventions following acute
coronary syndrome – a missed opportunity?
This study is based on the peer-reviewed paper by Boggon et al.58 Sections of the text have been adapted
from the original article; © The European Society of Cardiology.
Introduction
In mapping the CVD journey in CALIBER, we had the unique opportunity to examine patient care in the
community after discharge from hospital, recognising that sustained lifestyle modification and secondary
prevention treatment is a key guideline recommendation in patients who have experienced AMI. Perhaps
the most important lifestyle modification is smoking cessation, which substantially reduces the risk of
recurrent AMI and coronary death.371 Recommendations are for GPs to offer smoking cessation advice and
specific treatment to all smokers after ACS,330 but the extent to which this opportunity to reduce mortality
is missed has not been clarified. To answer this question, we used linked CALIBER records to analyse the
extent of smoking cessation advice and pharmaceutical interventions for smoking cessation provided by
GPs after AMI and to describe patient outcomes stratified by smoking status.
Methods
We studied 4834 patients aged ≥ 30 years discharged alive from hospital after AMI between 1 January
2002 and 30 September 2009. Patients were followed to death, transfer out of the general practice or the
last data collection date. Smoking interventions recorded in CPRD were classified as follows: (1) prescribed
pharmacological interventions for smoking cessation; (2) GP smoking cessation advice or referral to
stop-smoking clinic (without pharmaceutical interventions); and (3) no GP intervention.
Major clinical outcomes were explored in patients who smoked prior to their ACS, stratified by quitting
status. Outcomes included death, recurrent AMI, stroke, heart failure and major adverse cardiac events,
defined as death, recurrent ACS, CABG or target lesion revascularisation.
Results
Characteristics of patients are shown in Table 31. Of the 4834 patients, 33% were non-smokers, 44%
were ex-smokers and 20% were smokers.
In the 3 months following discharge, over three-quarters of smokers received no smoking intervention,
despite 99% of patients having had some contact with their GP (Table 32). The 320 (33%) smokers who
quit in the first 3 months after ACS experienced significantly lower rates of death and major adverse
cardiac events than non-quitters (Figure 60).
Discussion
This CALIBER study provides a unique longitudinal perspective on smoking cessation interventions after
hospitalisation for AMI. The results show that only a minority of patients received interventions for
smoking cessation and a large number continued to smoke. This missed opportunity for care is important
because patients who continued to smoke had a significantly worse prognosis than those who quit.
In the first 3 months after ACS, when motivation to stop smoking was likely to be high, only 23% of
smokers received smoking cessation interventions. The benefits of smoking cessation interventions are well
established372–375 and the demonstrated failure of adherence to guideline recommendations for smoking
cessation interventions no doubt contributed to the high proportion of smokers who failed to quit after
ACS and who were thereby exposed to an increased risk of adverse outcomes.
To further understand the association between interventions and cessation and the effects on long-term
clinical outcomes, future research into the promotion of GP smoking cessation interventions in both larger
prospective epidemiological studies and RCTs is warranted.
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TABLE 31 Baseline characteristics of 4834 patients in CALIBER with ACS by smoking status measured prior
to hospitalisation
Characteristics
Non-smokers
(N= 1611)
Ex-smokers
(N= 2122)
Smokers
(N= 965)
Unknown
(N= 136)
Total
(N= 4834)
Men, n (%) 743 (46.1) 1437(67.7) 690 (71.5) 81 (59.6) 2951(61.0)
Age (years) at ACS hospitalisation, n (%)
30–39 6 (0.4) 6 (0.3) 23 (2.4) 4 (2.9) 39 (0.8)
40–49 42 (2.6) 41 (1.9) 139 (14.4) 9 (6.6) 231 (4.8)
50–59 149 (9.2) 145 (6.8) 248 (25.7) 19 (14.0) 561 (11.6)
60–69 214 (13.3) 395 (18.6) 233 (24.1) 20 (14.7) 862 (17.8)
70–79 468 (29.1) 700 (33.0) 204 (21.1) 24 (17.6) 1396 (28.9)
≥ 80 732 (45.4) 835 (39.3) 118 (12.2) 60 (44.1) 1745 (36.1)
Alcohol consumption, n (%)
Non-drinker 310 (19.2) 214 (10.1) 109 (11.3) 1 (0.7) 634 (13.1)
Ex-drinker 164 (10.2) 244 (11.5) 96 (9.9) 1 (0.7) 505 (10.4)
Drinker 955 (59.3) 1527 (72.0) 657 (68.1) 6 (4.4) 3145 (65.1)
Unknown 182 (11.3) 137 (6.5) 103 (10.7) 128 (94.1) 550 (11.4)
SBP (mmHg) mean (median) 139.1 (140.0) 138.3 (139.0) 137.8 (138.0) 143.1 (140.0) 138.6 (139.0)
Total/HDL cholesterol, n (%)
≤ 7 971 (60.3) 1530(72.1) 498 (51.6) 19 (14.0) 3018 (62.4)
≥ 7 29 (1.8) 25 (1.2) 39 (4.0) 0 (0.0) 93 (1.9)
Unknown 611 (37.9) 567 (26.7) 428 (44.4) 117 (86.0) 1723 (35.6)
Deprivation (IMD) quintile, n (%)
0 (least deprived) 287 (17.8) 328 (15.5) 84 (8.7) 17 (12.5) 716 (14.8)
1 378 (23.5) 465 (21.9) 158 (16.4) 32 (23.5) 1033 (21.4)
2 351 (21.8) 444 (20.9) 203 (21.0) 31 (22.8) 1029 (21.3)
3 317 (19.7) 441 (20.8) 237 (24.6) 30 (22.1) 1025 (21.3)
4 (most deprived) 278 (17.3) 444 (20.9) 283 (29.3) 26 (19.1) 1031 (21.3)
Peak troponin (ng/ml), mean
(median)
5.3 (0.8) 6.8 (0.8) 6.6 (0.8) 5.0 (0.9) 6.2 (0.8)
Reproduced from Boggon et al.58 © 2014 SAGE publications. This article is distributed under the terms of the Creative
Commons Attribution License (www.creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as specified
on the SAGE and Open Access page (www.uk.sagepub.com/aboutus/openaccess.htm).
TABLE 32 Smoking cessation interventions in primary care during first 3 months after ACS among 965 people who
were current smokers at the time of hospital admission with AMI in CALIBER
Intervention Coded data, n (%) Free text, n (%) Combined, n (%)
Pharmacological 141 (14.6) 42 (4.4) 143 (14.8)
Advice/referral 4 (0.4) 107 (11.1) 82 (8.5)
None 820 (85.0) 816 (84.6) 740 (76.7)
Modified from Boggon et al.58 © 2014 SAGE publications. This article is distributed under the terms of the Creative
Commons Attribution License (www.creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as specified
on the SAGE and Open Access page (www.uk.sagepub.com/aboutus/openaccess.htm).
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This study has limitations. Smoking cessation advice may have been provided without being recorded in
the patient record.376 GP recording of smoking status and of advice against smoking may have changed
following the introduction in 2004 of the Quality and Outcomes Framework contract, which offers
financial incentives for the recording of smoking status and advice.377,378
Conclusions
This CALIBER study provides evidence that smoking is common among those patients hospitalised for ACS.
However, despite NICE guideline recommendations, few GPs offer smoking cessation advice, referral to
smoking clinics, or pharmacological intervention in the 3 months following ACS discharge. Given the lower
rates of major clinical outcomes, including mortality and major adverse cardiac events, among those who
quit smoking following ACS, there remains a significant opportunity for GPs to actively engage smokers in
cessation interventions.
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FIGURE 60 Relative rate of major clinical outcomes comparing smokers who quit in the first 3 months after ACS
compared with people who continued to smoke in CALIBER. MACE, major acute coronary events. Reproduced from
Boggon et al.58 © 2014 SAGE publications. This article is distributed under the terms of the Creative Commons
Attribution License (www.creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (www.uk.sagepub.com/aboutus/openaccess.htm).
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Chapter 11 Acute myocardial infarction: evidence
of treatment benefits beyond those provided by
clinical trials – further opportunities to improve
outcomes
Abstract
Background
Guidelines recommending use of secondary prevention drugs after AMI are based on results from clinical
trials. However, trials do not provide evidence of long-term effectiveness of treatments or impact of
interactions between them. Analysis of EHRs may help address these questions.
Objectives
To examine the use, timing, potential drug interactions and long-term effectiveness of secondary
prevention medications after AMI.
Methods
An analysis of CALIBER linked data.
Results
(1) Among patients who had experienced an AMI, prognosis was most favourable in patients given a
discharge prescription including all five classes of secondary prevention drugs. Use of fewer drugs was
associated with increased mortality, particularly within the first 30 days and where beta-blockers, ACEIs and
statins were omitted. (2) Use of a beta-blocker during and before AMI admission in patients with COPD was
associated with reduced mortality. (3) Among AMI patients receiving clopidogrel plus aspirin, use of a PPI
was associated with increased risk of AMI and death, as was use of drugs not predicted to interact with
clopidogrel. A case series found no evidence that PPIs increased risk of death. (4) Discontinuation of
clopidogrel after AMI is common and is associated with adverse outcomes.
Conclusions
‘Real-world’ data can provide important information beyond that generated by clinical trials to guide
prescribing decisions.
The studies in this chapter relate to patients presenting for the first time with ACS (see Figure 52).
Introduction
Electronic health record observational data are a key resource for evaluating benefits and harms. The
characteristics and richness of CPRD data (the world’s largest computerised database of anonymised
longitudinal clinical records from primary care) have been significant in informing regulatory pharmacovigilance
decision-making. Novel statistical methods such as self-controlled case series, where cases act as their own
controls and, thus, where the effect of fixed confounders is eliminated, may be useful in active surveillance of
drug safety.
Randomised clinical trials have led to recommendations for a range of secondary prevention drugs in AMI
patients. However, the relative effectiveness of these drugs is unknown and the need for extended
treatment beyond 2–3 years has never been tested. Treatment recommendations, therefore, are to some
extent pragmatic and have been made in an attempt to ensure that no patient is denied the opportunity
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of benefiting from these drugs. Pragmatism is also required in dealing with recruitment biases and
explicit exclusion criteria of clinical trials, which lead to important differences in the characteristics of
trial participants compared with real-world populations.379,380 Guideline groups will often generalise trial
results to include a broader swathe of patients, but the potential exists for important missed treatment
opportunities if specific patient groups that might otherwise have benefited are excluded from treatment.
Thus, beta-blockers are recommended for secondary prevention after AMI, but there are concerns that
they might exacerbate reversible airways obstruction, leading to treatment being withheld in many of
these patients. This might represent a missed treatment opportunity adversely affecting prognosis.381
The use of surrogate outcomes in drug studies can cause further difficulty when it comes to clinical
decision-making, an important recent example being reports of an interaction of PPIs with clopidogrel,
reducing its antiplatelet activity.382–393 This has led to suggestions that PPIs should not be used after AMI,
even though these drugs are of proven value for gastric protection.394
We have taken advantage of the MINAP data set to examine the relative effectiveness of beta-blockers
and other drugs for secondary prevention after AMI. We have also re-examined the use of beta-blockers
for COPD patients, using the CALIBER data set to examine the effects of these drugs on mortality after
AMI. We then used CALIBER to determine whether or not use of PPIs alongside clopidogrel affects
prognosis after AMI.
Study 26: comparative effectiveness of drugs used for secondary
prevention of cardiovascular disease after acute myocardial infarction
This study is based on previously unpublished data by A Timmis (Farr Institute of Health Informatics
Research and Barts Health NHS Trust), O Nicholas (Department of Epidemiology and Public Health,
University College London), S-C Chung (Farr Institute of Health Informatics Research) and H Hemingway
(Farr Institute of Health Informatics Research) 2015.
Introduction
Guideline recommendations for secondary prevention drugs after AMI include aspirin, clopidogrel,
beta-blockers, ACEIs and statins.353,395,396 For all but clopidogrel, the recommendation is for life-long
treatment, on the assumption that benefits are additive and efficacy remains undiminished in the longer
term. However, none of the trials was designed to measure the additive effects of treatment or the relative
efficacy of the various drugs. Moreover, follow-up in these trials was rarely longer than 3 years and often
shorter. It is open to question, therefore, whether indefinite treatment is necessary or whether some of the
recommended drugs might be discontinued, with potential benefits for patient safety and health-care costs.
A number of observational studies have suggested that the benefits of secondary prevention drugs after
AMI are additive, mortality declining with the number prescribed. However, these studies are likely to be
confounded by healthy user bias and are too small to answer the question of comparative effectiveness of
specific drug combinations, with most enrolling fewer than 6000 patients.397–401 The MINAP registry is
substantially larger and has provided, for the first time, the opportunity to evaluate the comparative
effectiveness of aspirin, clopidogrel, beta-blockers, ACEIs and statins individually and in all combinations.
Methods
We included patients aged ≥ 30, with a first STEMI or NSTEMI in the period 1 January 2004 to 6 August
2009 (n = 316,648). MINAP records if patients were discharged on aspirin, clopidogrel, an ACEI or ARB
(conflated as ACEI in this study), a beta-blocker and a statin. Primary outcomes were survival from
discharge to 30 days; survival from 30 days after discharge to 1 year; and survival beyond 1 year.
Statistical analysis
We analysed the effects on mortality of five classes of secondary prevention drugs prescribed individually
and in all possible combinations using survival analysis to allow patients lost to follow-up to contribute
information. For analysis, we imputed missing covariate data (comprising 21% of the overall amount of
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covariate data missing or not) independently for STEMI and NSTEMI, using Gibbs sampling to generate a
600 long chain from which we selected 10 hypothetical data sets from the last 300.402 We used model
covariates for imputation with the addition of angiography. Models were fitted to each data set using
maximum likelihood.
Results
The study group comprised 287,615 patients discharged from hospital with diagnoses of STEMI (39%) or
NSTEMI (61%). Rates of omission of secondary prevention drugs were 10% and 11% for aspirin and
statins, increasing to 21% and 26% for ACEIs and beta-blockers, respectively, and to 45% for clopidogrel
(Table 33). Patients in whom any of the secondary prevention drugs were omitted were older than the
mean age of the group, more frequently female and more likely to have a discharge diagnosis of NSTEMI.
TABLE 33 Cohort characteristics overall, and by omission of each secondary prevention medication, among patients
with a first STEMI or NSTEMI in MINAP
Characteristics
All (n= 287,615,
mean (% recorded)
Patients (%) with discharge medication omitted: observed
(imputed)
Beta-blocker ACEI Statin Aspirin Clopidogrel
Missing data for
discharge drugs
0.11 0.11 0.10 0.10 0.44
Proportion 0.26 (0.26) 0.21 (0.21) 0.11
(0.11)
0.10
(0.10)
0.25 (0.45)
Age (years) 68.9 (100) 73.1 (72.7) 72.4 (72.0) 74.1
(73.8)
72.2
(71.9)
72.2 (70.0)
Female 0.34 (100) 0.41 (0.40) 0.40 (0.40) 0.43
(0.42)
0.39
(0.39)
0.38 (0.36)
Ethnicity non-white 0.05 (86) 0.04 (0.03) 0.04 (0.04) 0.03
(0.03)
0.04
(0.03)
0.04 (0.03)
IMD 23 (90) 23 (23) 23 (22) 22 (22) 23 (23) 22 (23)
NSTEMI 0.61 (100) 0.71 (0.72) 0.76 (0.76) 0.77
(0.78)
0.74
(0.75)
0.61 (0.61)
STEMI 0.39 (100) 0.29 (0.28) 0.24 (0.24) 0.23
(0.22)
0.26
(0.25)
0.39 (0.39)
ECG abnormal 0.92 (92) 0.92 (0.92) 0.90 (0.90) 0.92
(0.91)
0.92
(0.92)
0.94 (0.93)
Current smoker 0.31 (92) 0.27 (0.26) 0.25 (0.24) 0.22
(0.22)
0.23
(0.23)
0.26 (0.29)
Diabetes 0.18 (94) 0.21 (0.20) 0.18 (0.18) 0.18
(0.18)
0.21
(0.21)
0.19 (0.18)
Hypertension 0.47 (94) 0.47 (0.47) 0.46 (0.46) 0.47
(0.47)
0.50
(0.49)
0.48 (0.46)
SBP (mmHg) 142 (85) 140 (140) 139 (139) 140
(140)
140
(140)
140 (141)
Heart rate (b.p.m.) 82 (86) 85 (85) 84 (84) 86 (86) 86 (86) 85 (83)
Left ventricular
function < 50%
0.19 (18) 0.20 (0.44) 0.19 (0.40) 0.21
(0.45)
0.21
(0.45)
0.22 (0.43)
Troponin (top
quintile)
0.13 (44) 0.10 (0.12) 0.08 (0.10) 0.08
(0.10)
0.09
(0.11)
0.11 (0.16)
Glucose (mmol/l) 8.2 (59) 8.4 (8.3) 8.1 (8.0) 8.2 (8.2) 8.3 (8.3) 8.3 (8.3)
continued
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The Kaplan–Meier landmark analysis showed that in each of the three time periods (first 30 days, 31 days
to 1 year, beyond 1 year) there was progressive worsening of crude and adjusted survival as the number
of omitted secondary prevention drugs increased (Figure 61). Only the group with all five secondary
prevention drugs omitted deviated from the dose–response relationship, exhibiting a survival trajectory
intermediate between two and three omitted drugs.
TABLE 33 Cohort characteristics overall, and by omission of each secondary prevention medication, among patients
with a first STEMI or NSTEMI in MINAP (continued )
Characteristics
All (n= 287,615,
mean (% recorded)
Patients (%) with discharge medication omitted: observed
(imputed)
Beta-blocker ACEI Statin Aspirin Clopidogrel
Haemoglobin
(mmol/l)
13.6 (32) 13.3 (13.3) 13.2 (13.2) 13.4
(13.2)
13.3
(13.2)
13.2 (13.6)
Creatinine (mmol/l) 104.7 (34) 109.7 (110.1) 116.1 (117.9) 109.2
(111.1)
109.7
(109.5)
112.3
(106.8)
Cholesterol (mmol/l) 5.2 (72) 4.9 (4.9) 5.0 (4.9) 4.9 (4.9) 4.9 (4.8) 5.0 (5.1)
AMI 0.19 (95) 0.22 (0.22) 0.21 (0.21) 0.21
(0.21)
0.23
(0.23)
0.19 (0.20)
Other 0.34 (85) 0.42 (0.42) 0.40 (0.41) 0.41
(0.42)
0.43
(0.44)
0.38 (0.37)
Aspirin 0.60 (93) 0.56 (0.56) 0.56 (0.56) 0.53
(0.53)
0.43
(0.44)
0.58 (0.59)
Beta-blocker 0.28 (60) 0.13 (0.14) 0.28 (0.29) 0.26
(0.27)
0.28
(0.29)
0.28 (0.29)
ACEI or ARB 0.33 (60) 0.36 (0.36) 0.21 (0.21) 0.34
(0.35)
0.37
(0.37)
0.35 (0.34)
Statin 0.40 (61) 0.41 (0.41) 0.40 (0.40) 0.25
(0.25)
0.43
(0.43)
0.39 (0.39)
Previous PCI 0.05 (91) 0.05 (0.05) 0.05 (0.05) 0.04
(0.05)
0.05
(0.05)
0.04 (0.04)
Previous CABG 0.05 (92) 0.05 (0.05) 0.05 (0.05) 0.05
(0.05)
0.06
(0.06)
0.05 (0.05)
Arrival time (hours) 2.8 (82) 2.8 (2.8) 2.8 (2.9) 2.8 (2.8) 2.8 (2.8) 2.7 (2.8)
CCU 0.56 (99) 0.47 (0.47) 0.44 (0.45) 0.42
(0.42)
0.47
(0.47)
0.54 (0.56)
Reperfusion therapy 0.84 (62) 0.84 (0.58) 0.79 (0.61) 0.82
(0.65)
0.85
(0.62)
0.81 (0.51)
IIb/IIIa inhibition 0.08 (82) 0.05 (0.06) 0.05 (0.06) 0.05
(0.06)
0.05
(0.05)
0.03 (0.06)
In-hospital CABG 0.02 (85) 0.02 (0.02) 0.03 (0.03) 0.03
(0.03)
0.03
(0.04)
0.04 (0.03)
Heparin 0.95 (75) 0.94 (0.94) 0.94 (0.94) 0.92
(0.93)
0.89
(0.90)
0.91 (0.96)
Bleeding 0.02 (89) 0.02 (0.02) 0.02 (0.02) 0.02
(0.02)
0.04
(0.04)
0.03 (0.02)
Admitted under
cardiologist
0.55 (98) 0.62 (0.59) 0.61 (0.58) 0.64
(0.60)
0.61
(0.60)
0.59 (0.60)
CCU, coronary care unit.
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Adjusted HRs for mortality varied according to which drug was omitted from the discharge prescription,
tending to be higher for omission of either a beta-blocker, an ACEI or a statin compared with omission of
aspirin or clopidogrel (Table 34).
Hazard ratios for drug omissions diminished sharply beyond the first 30 days, although this was less marked for
beta-blockers or statins. When patients were grouped by the number of omitted drugs, Cox analysis showed
a dose–response relationship of increasing hazard for 30-day mortality but, within each group, HRs varied
according to which drugs were omitted (Figure 62a). Compared to patients discharged on all five secondary
prevention drugs, those with single omission of clopidogrel showed a similar mortality hazard (HR 1.00, 95% CI
0.92 to 1.07), whereas those with single omission of aspirin showed a small excess hazard (HR 1.18, 95% CI
1.07 to 1.30). Single omissions of beta-blockers, ACEIs or statins were associated with a greater hazard, all
with point estimates > 1.33. This pattern repeated itself as the number of omitted secondary prevention
drugs increased, with combinations of omission that included aspirin and clopidogrel tending to be associated
with a lower hazard of 30-day mortality than combinations that included beta-blockers, ACEIs or statins.
The pattern was similar for mortality between 30 days and 1 year but, beyond 1 year, associations between
specific combinations of discharge drug omissions and hazard of death were less clear (Figure 62b).
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FIGURE 61 Kaplan–Meier mortality curves stratified by number of omitted secondary prevention drugs prescribed
at discharge at 30 days and 1 year, and prevalence of omission compared with no omitted drugs among patients
with a first STEMI or NSTEMI in MINAP.
TABLE 34 Hazard ratios and 99% CIs for death associated with drug omission among patients with a first STEMI or
NSTEMI in MINAP
Omitted drug 0–30 days, HR (99% CI) 30 days to 1 year, HR (99% CI) ≥ 1 year, HR (99% CI) p-value
Beta-blocker 1.43 (1.33 to 1.54) 1.32 (1.26 to 1.38) 1.36 (1.30 to 1.45) 0.849
ACEI 1.49 (1.37 to 1.62) 1.22 (1.17 to 1.28) 1.09 (1.05 to 1.15) < 0.001
Statin 1.49 (1.35 to 1.64) 1.20 (1.13 to 1.28) 1.27 (1.19 to 1.38) 0.940
Aspirin 1.18 (1.07 to 1.30) 1.07 (1.02 to 1.13) 1.05 (1.00 to 1.12) 0.121
Clopidogrel 1.00 (0.92 to 1.07) 1.01 (0.97 to 1.05) 1.05 (1.00 to 1.09) 0.988
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Discussion
The relationship between the number of secondary prevention drugs omitted from the discharge
prescription of patients with AMI and subsequent mortality depends on which drugs are omitted. Effect
sizes were greatest in the first 30 days and were most evident for omission of beta-blockers, ACEIs or
statins, which increased the hazard of death by > 40%. HRs tended to decrease in the longer term,
particularly for omission of ACEIs, but for omission of beta-blockers and statins the hazard of death
remained > 27% after 1 year of follow-up. Omission of aspirin from the discharge prescription caused only
a small increase in the hazard of death, the point estimate dropping below 10% after the first 30 days,
whereas omission of clopidogrel had little discernible effect on mortality.
The present study confirmed an association between the number of prescribed secondary prevention drugs
and mortality,397–401 which persisted after full adjustment for all covariates. However, the size of this
national cohort allowed us to analyse for the first time the effects of all possible combinations of drug
omissions on mortality. The data showed important class effects, omissions of antiplatelet agents
having less effect on the dose–response relationship than other secondary prevention drugs, particularly
beta-blockers and statins. This was most evident for mortality in the first 30 days, when treatment effects
were least likely to be distorted by non-adherence and the influence of new comorbidities, but the pattern
remained perceptible at 1 year and beyond.
We found that single omission of aspirin from the discharge prescription of patients who received all other
secondary prevention drugs was associated with a 30-day mortality increase of about 13%, falling to
< 5% beyond the first year. Moreover, combinations of omitted drugs that included aspirin tended to
increase the hazard of death less than combinations including beta-blockers and statins. The data reflect
aspirin’s short-term protective effect, demonstrated in the Second International Study of Infarct Survival
(ISIS-2) trial,403 but also highlight the caution that others have counselled404 in generalising randomised trial
data beyond parameters of patient selection and treatment duration. Thus, patients randomised to aspirin
in ISIS-2 received just 6 weeks of treatment and, although sustained benefits for this group have been
reported,405 our own landmark analysis shows significant diminution of benefit in the longer term.
Unlike aspirin, omission of beta-blockers or statins from the discharge prescription was associated with a
marked increase in the hazard of death in the first 30 days, with only minor reductions in the effect size
during the first year and beyond. Our findings provide a strong case for long-term treatment with these
drugs after AMI. Omission of ACEIs also increased the early hazard of death but, unlike beta-blockers and
statins, the effect size diminished sharply beyond 1 year, when combinations of discharge prescriptions
that omitted ACEIs were associated with a < 10% increase in the hazard of death. Our study provides no
mechanistic insights, but it is possible to speculate that the pattern of diminishing hazard we found with
omission of ACEIs from the discharge prescription reflects the protection they provide against left
ventricular remodelling, which has its main impact during the first few months after AMI.406
We were unable to demonstrate any association of clopidogrel omission with increased mortality and, like
aspirin, combinations of omitted drugs that included clopidogrel tended to increase the hazard of death less
than combinations including beta-blockers and statins. This is consistent with clinical trials that have shown
reductions in composite end points for patients randomised to clopidogrel without clear effects on death
from cardiovascular or non-cardiovascular causes.407 However, in the current era of primary PCI, there is
good evidence that clopidogrel can protect against stent thrombosis in the first year after AMI, although
guideline recommendations to discontinue treatment beyond the first year appear borne out by our findings.
Combinations of drugs that are recommended lifelong but have not been evaluated in RCTs should be
investigated in observational studies for associations with fatal and non-fatal outcomes over the remaining
life expectancy.
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Conclusions
Our findings remind clinicians and guideline groups that, although randomised trials are the most robust
means of evaluating the efficacy of specific treatments, information about comparative effectiveness is
available only from trials that randomise patients to two or more different agents. Examples include ISIS-2,
which showed comparable effectiveness for streptokinase and aspirin,403 and Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico (GISSI)-3, which showed effectiveness limited to lisinopril, not
transdermal nitrate.408
Our study highlights the variable consequences of specific drug omissions and reminds clinicians of the
need to set thresholds for omitting beta-blockers or statins from the discharge prescription at a high level
in order to avoid substantial long-term increases in the hazard of death. Our study also shows that the
diminution of effectiveness apparent for all secondary prevention drugs in the longer term appears more
marked for aspirin and ACEIs. Nevertheless, small reductions in the hazard of death beyond 1 year persist
for both these drug classes, and our data do not provide a basis for recommending their discontinuation.
This study confirms that in patients with AMI, a discharge prescription that includes all five classes of
secondary prevention drugs is associated with the most favourable prognosis, but suggests that beta-blockers
and statins contribute the greatest protection against death, particularly in the longer term. The effectiveness
of all drug classes tends to diminish with time but this is particularly marked for aspirin and ACEIs.
Study 27: do beta-blockers reduce mortality after acute myocardial
infarction in adults with chronic obstructive pulmonary disease?
This study is based on the peer-reviewed paper by Quint et al.59 Sections of the text have been
reproduced/adapted from the original article. Copyright © 2013, British Medical Journal Publishing Group.
This is an open-access article distributed under the terms of Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/3.0/). This document may be redistributed and reused, subject
to certain conditions.
Introduction
Patients with COPD have lower survival after AMI than patients without COPD.406,409–412 Historical concerns
that beta-blockers might be harmful in COPD probably contribute to their underuse in AMI, even though
these concerns have been challenged by recent evidence.413 Hence, the underuse of beta-blockers in
COPD patients with AMI may be an important missed opportunity to improve cardiovascular outcomes.
We used the CALIBER linked data sets to quantify the association between COPD and mortality after AMI to
investigate whether or not the use and timing of prescription of beta-blockers in patients with COPD after a
first AMI was associated with improved survival, and to identify factors related to the use of beta-blockers in
patients with COPD.
Methods
We included patients with COPD experiencing their first AMI from 1 January 2003 to 31 December 2008
as recorded in MINAP. Patients were defined as having COPD if the Read-coded diagnosis was recorded in
CPRD before or after AMI. Two or more exacerbations per year were defined as frequent exacerbations.414
Information on COPD and drug prescriptions was obtained from CPRD. The primary outcome was all-cause
mortality after AMI in patients with COPD stratified by beta-blocker prescription during hospital admission.
We used Cox proportional hazards models to produce adjusted HRs to determine whether or not mortality
differed by prescription of a beta-blocker.
Results
We included 1063 COPD patients with a MINAP record of AMI during the study period. Over half (55%)
were never prescribed a beta-blocker and 23% were on a beta-blocker before AMI. The remainder (22%),
who were prescribed a beta-blocker at the time of AMI, were younger and less likely to have a history of
hypertension, cerebrovascular disease, PAD, heart failure, dyslipidaemia or angina before their AMI.
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They were also more likely to have infrequent exacerbations and were less likely to have been prescribed
diuretics before their AMI. Of the beta-blockers prescribed during hospital admission, 93.8%
were cardioselective.
After adjustment for history of smoking and sex, and stratification by age, patients with COPD prescribed a
beta-blocker during hospital admission for AMI and those prescribed a beta-blocker before an AMI had
better survival than those never prescribed a beta-blocker (HR 0.45, 95% CI 0.34 to 0.60; p < 0.001; and
0.72, 95% CI 0.57 to 0.90; p = 0.004, respectively) (Figure 63).
After adjustment for age, sex, history of smoking, and frequency of exacerbations, survival analysis with
cardiac and non-cardiac death as the outcome showed an improved survival in those prescribed a
beta-blocker than those not prescribed a beta-blocker during the hospital admission for AMI (HR for
cardiac deaths 0.57, 95% CI 0.38 to 0.86; p = 0.03; and non-cardiac deaths 0.49, 95% CI 0.32 to 0.75;
p = 0.01). Among patients prescribed a beta-blocker during hospital admission, 203 (87.1%) were still
taking it at 6 months, 185 (79.4%) at 1 year and 142 (60.9%) at 2 years.
Discussion
This is the largest study of the effect of beta-blockers on survival after AMI in patients with COPD.414–416
Use of a beta-blocker after a first AMI was associated with lower subsequent mortality, a benefit that
persisted after adjustment for age and cardiovascular comorbidities. Only 38.6% of people with COPD
received a beta-blocker during the hospital admission for AMI, however, indicating an important missed
opportunity for improving care. Despite earlier studies reporting improved survival after AMI in COPD
patients prescribed beta-blockers,415 the reluctance to prescribe remains a worldwide phenomenon that
cannot be attributed to problems with tolerability, our own data showing that nearly 80% of patients
prescribed a beta-blocker were still taking it at 1 year.
The lower mortality in COPD patients prescribed a beta-blocker was due to a reduction in both cardiac and
non-cardiac deaths, consistent with previous suggestions that their benefits extend beyond cardiac effects.416,417
There is evidence that beta-blockers do not worsen lung function in patients with COPD,416,417 so severity of
disease or lack of spirometry should not deter their prescription in AMI, particularly use of cardioselective
agents. A RCT is justified to examine the effectiveness of beta-blockers after AMI in patients with COPD.
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FIGURE 63 Kaplan–Meier estimated survival and 95% CIs after AMI in patients with COPD prescribed a
beta-blocker before MI, during hospital admission for myocardial infarction or never, excluding deaths on day of
diagnosis, in MINAP. MI, myocardial infarction. Reproduced from Quint et al.59 Copyright © 2013, British Medical
Journal Publishing Group. This is an open-access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the
original work is properly cited.
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The main limitation of our study is that residual confounding, including confounding by contraindications,
cannot be excluded, and there is also the risk of healthy user bias.
Conclusions
Our data suggest that beta-blockers should be used more widely in patients with COPD who have had an
AMI. Low rates of use represent an important missed opportunity for treatment. Safety to date is good in
these patients, but further evaluation of the safety of beta-blockers in this high-risk group might be
required to change current prescribing practice.
Study 28: clopidogrel and its interaction with proton pump inhibitors
This study is based on the peer-reviewed paper by Douglas et al.60 Sections of the text have been
reproduced/adapted from the original article. Copyright © 2012, British Medical Journal Publishing Group.
Copyright © 2012, British Medical Journal Publishing Group. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by-nc/2.0/), which permits use, distribution, and reproduction in any medium, provided the original work
is properly cited, the use is non commercial and is otherwise in compliance with the license.
Introduction
In patients with AMI receiving dual antiplatelet therapy with aspirin and clopidogrel, the risk of gastric
bleeding can be reduced by coprescription of a PPI. However, PPIs inhibit cytochrome P450 2C19, the
enzyme that converts clopidogrel to its active form. This interaction reduces clopidogrel activity as
measured by platelet activation studies, but whether or not this has important clinical effects has been
hard to determine, with conflicting evidence from outcome studies.382–393 We used CALIBER linked data
sets to conduct two observational studies to investigate this possible drug interaction, the first using a
traditional cohort design, and the second using a self-controlled case series design to eliminate the fixed
confounding between people that can affect case–control or cohort designs.418
Methods
Patients were selected if they were recorded in the CPRD from 1 January 2003 onwards and had at least
12 months between first registration and first recorded prescription for clopidogrel. Patients also had to be
concurrently prescribed aspirin as recorded in the database. Follow-up was censored at the earliest of
stopping treatment with clopidogrel, stopping treatment with aspirin, occurrence of an outcome of
interest, death, transfer out of the practice, last data collection date for the practice or 31 July 2009.
Follow-up time was then classified according to whether or not the patient was receiving a PPI as recorded
in the database. Treatment with aspirin was assumed to be continuous but for clopidogrel and PPI
exposure, where possible, we calculated the anticipated length of each prescription based on pack size
and dosing instructions. We undertook an observational cohort study and a self-controlled case series.
The primary outcome was a composite end point of all-cause mortality or incident AMI.
Results
Observational cohort study
We identified 24,471 patients receiving clopidogrel in combination with aspirin, of whom 9111 (37%) also
received a PPI from the date of first clopidogrel prescription. The crude HR for the primary outcome was
1.41 (95% CI 1.31 to 1.52) during PPI exposure relative to non-exposure, reducing to 1.37 (95% CI 1.27
to 1.48) after adjustment for age, sex, BMI, smoking, alcohol, diabetes, PAD, CHD, ischaemic stroke and
cancer. Exposure to ranitidine, a non-PPI antacid, produced similar adjusted hazards for the primary
outcome of 1.20 (95% CI 0.99 to 1.46), as did exposure to strong (paroxetine or fluoxetine) and weak
(citalopram) 2C19-inhibiting antidepressants (1.42, 95% CI 1.17 to 1.72 and 1.52, 95% CI 1.32 to 1.76,
respectively) (Figure 64).
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FIGURE 64 Association between PPIs, ranitidine, paroxetine/fluoxetine, or citalopram and the composite end point of
all-cause mortality or incident AMI among patients receiving dual antiplatelet therapy with aspirin and clopidogrel:
a cohort analysis and self-controlled case series analysis. Relative risk expressed as HR for cohort analysis and IRR for
self-controlled case series. MI, myocardial infarction. Reproduced from Douglas et al.60 Copyright © 2012, British Medical
Journal Publishing Group. This is an open-access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by-nc/2.0/), which permits use, distribution, and reproduction in any
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Self-controlled case series
Exposure to a PPI concurrently with clopidogrel and aspirin gave an IRR of 0.75 (95% CI 0.55 to 1.01), adjusted
for age. For the secondary exposures of interest, the IRR for AMI was 0.57 (95% CI 0.31 to 1.06) for ranitidine,
1.65 (95% CI 0.87 to 3.15) for paroxetine/fluoxetine and 0.84 (95% CI 0.49 to 1.45) for citalopram.
Discussion
The large sample size available within the CALIBER data set has allowed us to resolve the conflicting results
of smaller studies that have investigated the clinical consequences of interactions between clopidogrel and
PPIs. The cohort analysis of > 24,000 patients receiving clopidogrel and aspirin showed that exposure to
PPIs was associated with an increased risk of all outcomes including AMI and all-cause mortality. However,
comparable results were seen with other drug exposures, including drugs that would not be expected to
interact with clopidogrel (such as ranitidine and citalopram), suggesting that the association is unlikely to
be causal but driven by differences between PPI users and non-users. Consistent with this were the results
of the within-person study design, which removed the influence of differences between people and
showed no association between PPI exposure and AMI. Thus, a plausible explanation for these results is
that the increased risk of both vascular and non-vascular harmful outcomes seen in patients receiving PPIs
and other long-term drugs could be caused by confounding between people.
Our overall findings are consistent with several studies that failed to find an association between PPIs and
less favourable outcomes in clopidogrel users.383,387–393 Of note, the case–control study by Valkhoff et al.393
did find a harmful association but when comparisons were restricted to former or current users of PPIs, the
association disappeared, again suggesting a biased result driven by confounding between people. The only
randomised trial designed to specifically answer this question was stopped early and so is underpowered
and unable to rule out a clinically relevant effect.392 The available results, however, did not point towards
any harmful association.
Our findings point to the need for new methods by which a learning health system can interrogate the
safety of drugs and drug–drug interactions in a more timely and more scaled fashion.
Conclusions
The drug interaction between PPIs and clopidogrel does not result in clinical harm. PPIs should continue
to be seen as important prophylactic drugs in patients on dual antiplatelet therapy with aspirin and
clopidogrel who are at high risk of gastrointestinal bleeding.
Study 29: discontinuation of clopidogrel after acute coronary
syndrome – frequency, predictors and clinical consequences
This study is based on the peer-reviewed paper by Boggon et al.61 Sections of the text have been
reproduced/adapted from the original article; published on behalf of the European Society of Cardiology.
All rights reserved. © The Author 2011. The online version of this article has been published under an
open-access model; the Journal, Learned Society and Oxford University Press are attributed as the original
place of publication.
Introduction
Guideline recommendations are for dual antiplatelet therapy with aspirin and clopidogrel to continue for
12 months after AMI (NSTEMI and STEMI) with aspirin monotherapy thereafter. In patients who do not fill
their prescriptions for clopidogrel early after hospital discharge, the risk of recurrent thrombotic events is
significantly increased.419 This takes no account of the potential risk associated with discontinuation of
treatment later after discharge, although there is little information available about patient adherence to
clopidogrel therapy after AMI. The extent to which patients are non-adherent to dual antiplatelet therapy
in the 12 months following AMI represents an important missed opportunity to optimise care and reduce
recurrent events. In the present study we have used CALIBER data to document relationships between
clopidogrel discontinuation and coronary events in the 12 months after NSTEMI and STEMI. Our specific
DOI: 10.3310/pgfar05040 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hemingway et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
objectives were (1) to define the extent to which clopidogrel treatment (initiated in hospital) is continued in
primary care, (2) to identify factors predictive of clopidogrel discontinuation and (3) to analyse the hazard
of death or recurrent AMI associated with clopidogrel discontinuation.
Methods
We studied 7543 patients aged ≥ 40 years, with a MINAP-recorded diagnosis of NSTEMI or STEMI (ACS) who
were discharged from hospital to home from 2003 to 2009. Logistic regression was used to determine the
characteristics associated with GP prescribing of clopidogrel within 3 months of hospital discharge. Characteristics
included the in-hospital presentation (BP and heart rate), treatment strategy (reperfusion strategy and coronary
intervention), diagnosis recorded in MINAP, demographics (age, sex, socioeconomic status, calendar year and
geographical region), medical history (diabetes and angina/AMI), prior GP prescribing (clopidogrel, aspirin and
warfarin), and lifestyle behaviours (alcohol consumption, smoking status and BMI) recorded in the General
Practice Research Database (GPRD), and prior hospitalisations (all-cause and cardiovascular related) recorded in
HES. If there were no records of BMI, smoking status or alcohol consumption, indicators of missingness were
used. ORs and 95% CIs were calculated. As statins are routinely prescribed following ACS, information on statin
discontinuation was used to compare clopidogrel discontinuation with another evidence-based treatment.
Discontinuation of clopidogrel or statin was defined as no prescriptions for the medication within a period
defined as the estimated duration of the prescription plus a grace period of 91 days. Cox regression was used to
assess the same set of characteristics for association with clopidogrel discontinuation within the first year of
discharge, with the additional time-dependent characteristic of any bleeding within the treatment period.
Clopidogrel prescription on hospital discharge was included only in the MINAP data set after 2005 and had no
duration information associated with it, so this parameter was not analysed in this study. Bleeding was defined as
any bleeding event (major or minor) in the patient’s GPRD or HES record. HRs and 95% CIs were calculated.
Patients were followed for up to 1 year for incidences of subsequent AMI (as recorded in MINAP, GPRD or
HES) or death (as recorded in ONS). Descriptive Cox regression was used to identify the characteristics
associated with these outcomes with clopidogrel treatment following discharge entered into the model as
a time-dependent covariate, categorised as follows: no treatment, 0–3 months’ use, 3–11 months’ use,
11+ months’ use and discontinued use. This allowed a patient to move from one categorisation of
clopidogrel exposure to another over time.
Results
Only 68.6% of the 4108 patients with NSTEMI and 62.8% of the 2915 patients with STEMI received a
primary care clopidogrel prescription in the first 3 months. Clopidogrel discontinuation after the first
prescription was substantially more frequent compared with statins, both for NSTEMI and for STEMI
(Figure 65).
Clopidogrel prescribing
The adjusted odds of receiving a primary care clopidogrel prescription (see Figure 65) in the first 3 months
increased from 1.45 (95% CI 1.11 to 1.89) in 2004 to 5.78 (95% CI 4.20 to 7.96) in 2009. The odds were
higher in younger age groups and decreased progressively with advancing age (for age 70–79 years, 0.64,
95% CI 0.47 to 0.85; for age ≥ 80 years, 0.52, 95% CI 0.39 to 0.71) compared with age 40–49 years.
In patients managed with percutaneous intervention during the hospital admission, the odds of receiving a
clopidogrel prescription were substantially higher (6.19, 95% CI 4.80 to 7.99) than for patients in whom
no coronary intervention was performed. Clopidogrel prescribing increased over time from 35% in 2003 to
79% in 2009.
Clopidogrel discontinuation during first year
The adjusted HR for clopidogrel discontinuation was higher in patients aged ≥ 80 years (HR 1.50, 95% CI
1.16 to 1.94), and those who had a bleeding event after leaving hospital (HR 1.34, 95% CI 1.03 to 1.73).
Comparing patients who did and did not undergo in-hospital revascularisation, the adjusted hazard for
clopidogrel discontinuation was higher following CABG (HR 1.82, 95% CI 0.99 to 3.35) than PCI (HR 0.72,
95% CI 0.63 to 0.83).
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Bleeding complications
In patients prescribed clopidogrel in primary care within 3 months of discharge, the rates of bleeding per
100 patient-years were similar following NSTEMI (12.03, 95% CI 10.62 to 13.64) and STEMI (10.55, 95% CI
8.96 to 12.42).
Death and non-fatal acute myocardial infarction
In patients prescribed clopidogrel in primary care, the rate of death and non-fatal AMI in the first year post
discharge (per 100 person-years) was reduced by > 50% in NSTEMI (from HR 48.4, 95% CI 44.4 to 52.8, to
HR 22.4, 95% CI 20.5 to 24.5) and STEMI (from HR 23.6, 95% CI 20.7 to 26.8, to HR 11.7, 95% CI 10.1 to
13.6). The Cox analysis (Figure 66) confirmed that clopidogrel prescribing during the first year following
discharge was associated with a lower hazard of death or non-fatal AMI than for patients who received no
prescriptions. Clopidogrel discontinuation at any time within 12 months was independently associated with
an increased risk of death or AMI both compared with untreated patients (HR 1.45, 95% CI 1.22 to 1.73)
and with those patients persisting with clopidogrel treatment (HR 2.62, 95% CI 2.17 to 3.17).
Discussion
This study shows that failure to complete a 12-month course of clopidogrel after AMI is common and
represents an important missed opportunity to reduce mortality and recurrent thrombotic events after AMI.
Clopidogrel adherence, as reflected by prescription rates, declines more steeply compared with statins in
the first 12 months and is followed by an even steeper decline thereafter (see Figure 66), consistent with
guideline recommendations.330,420
Guideline recommendations are for clopidogrel to continue for 12 months in patients with NSTEMI and
STEMI treated with drug-eluting stents.330,420
However, we found that in around half of all patients with NSTEMI, prescription of clopidogrel was
discontinued within the first 12 months after discharge from hospital. The trajectory of decline for
clopidogrel prescription was steeper than for statins, suggesting that it was driven by factors additional to
general compliance issues, including underprescription in older age groups and bleeding complications,
which were more frequent than observed in the original randomised trial.407
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The main finding in the present study was the association between clopidogrel discontinuation in the first
12 months and the outcome following either NSTEMI or STEMI. Clopidogrel prescription during this period
was associated with a reduction in the hazard of death or non-fatal AMI compared with patients who
received no prescription, consistent with trial evidence of clopidogrel’s prognostic benefit in patients with
ACS.407 Importantly, among those patients prescribed clopidogrel who then had it discontinued, the hazard
of death or non-fatal AMI was significantly greater than for patients who continued to receive a
clopidogrel prescription.
Our findings are consistent with those of Ho et al.,419 who reported that any delay in filling clopidogrel
prescriptions after hospital discharge in patients treated with drug-eluting stents was associated with
nearly twice the rate of coronary events during follow-up for 22 months. Our findings are also consistent
with other observational studies in US and Australian populations where discontinuation of clopidogrel
therapy within 1 year of stenting was associated with worse outcomes.421–423 Further research,
incorporating methods of causal inference, is required to fully investigate the extent to which the
association between clopidogrel discontinuation and adverse events we identified was causal or was
confounded by the influence of unrecorded comorbidities or bleeding events.
Our study has important limitations. Data on hospital clopidogrel prescribing, both during the admission
and on discharge, were not comprehensively recorded and was not included in the study. Although GP
prescription information was robust, we do not know if clopidogrel was collected or taken by individual
patients or was prescribed by a third party. This limited the focus of the study to clopidogrel prescriptions
within primary care. Also, we cannot determine whether or not the association between clopidogrel
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FIGURE 66 Characteristics associated with death or AMI in the first year after discharge among patients with a
first-recorded diagnosis of STEMI or NSTEMI in MINAP. Data are HRs (95% CIs) adjusted for age, sex, discharge
diagnosis, socioeconomic status, medical history of angina/AMI, calendar year and geographical region. a, These
analyses are restricted to those prescribed clopidogrel. Modified from Boggon et al.61 Published on behalf of the
European Society of Cardiology. All rights reserved. © The Author 2011. The online version of this article has
been published under an open-access model. Users are entitled to use, reproduce, disseminate, or display the
open-access version of this article for non-commercial purposes provided that the original authorship is properly
and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of
publication with correct citation details given.
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discontinuation and adverse events was causal or was confounded by the influence of unrecorded
comorbidities or bleeding events.407,422–424 Healthy user bias is difficult to avoid in studies of this type;
however, similar healthy user bias will apply to prescribing of statins, which showed a slower decline in
prescribing than clopidogrel.424 Although our outcome analysis was adjusted for baseline factors that
included prior coronary events and hospitalisations (all-cause and cardiovascular), we do not know if the
patients who discontinued clopidogrel were predisposed to adverse outcomes through other mechanisms.
Conclusions
This is the first study to use linked registries to determine the prognostic associations of clopidogrel
discontinuation in patients discharged from hospital after NSTEMI and STEMI. Our data show that
discontinuation of clopidogrel during the first 12 months is common, particularly in older patients, and is
associated with an increased risk of death or recurrent AMI. If the association between clopidogrel
discontinuation and death or AMI is causal, ensuring that adherence to treatment is maintained in all
patients for a full 12 months after discharge from hospital represents an important opportunity to improve
cardiovascular outcomes in this high-risk group.
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Chapter 12 Acute myocardial infarction: variation
between hospitals in short-term mortality outcomes
Abstract
Background
Variation in patient outcomes between hospitals is ubiquitous across a range of diseases. No studies have
compared outcomes after AMI across hospitals adjusted for case mix.
Objectives
(1) To assess interhospital variation in mortality following AMI, adjusted for case mix, and whether or not
variation can help to identify and rank underperforming hospitals. (2) To examine the impact of hospital
characteristics and quality of primary care on mortality after AMI. (3) To compare interhospital variation
across different health-care systems. (4) To identify processes of care that may contribute to variation in
outcomes between hospitals.
Methods
Analysis of UK and Swedish AMI disease registry data, and an ethnographic study of AMI care in the UK.
Results
(1) Thirty-day mortality varied substantially between UK hospitals. Up to four severely underperforming
hospitals could be identified with high confidence, although there was considerable uncertainty in adjusted
mortality rates. (2) We found no clear relationship between the number of patients admitted to individual
hospitals or the quality of BP management in primary care and 30-day mortality rates for AMI patients.
(3) Interhospital variation in 30-day mortality was greater in the UK than in Sweden, with the lowest
mortality in hospitals adhering to guideline-recommended procedures and treatments. (4) We identified
five processes that appeared to facilitate good care.
Conclusions
Variation in hospital performance was only partly explained by differences in case mix and use of
guideline-recommended treatments. A systematic quality improvement programme, akin to that
implemented in Sweden, may reduce variation in practice and patient outcomes across UK hospitals.
The studies in this chapter relate to patients presenting for the first time with ACS (see Figure 52).
Introduction
Whereas the previous chapters in this report have focused on individual patients, in this chapter we
investigate clustering at the level of the hospital and investigate opportunities for intervention at a different
locus. National quality improvement registries are an important component of EHRs. Variation in patient
outcomes between hospitals has been a consistent finding across a broad range of common diseases425,426
and has attracted interest from policy-makers because of the insight it provides into overall system
performance.81 Understanding hospital variation in mortality for AMI is particularly important because
effective drug and procedural interventions are available to improve the quality of care. Policy-makers might
choose to deliver these interventions at a national level to reduce variation across the hospital service or at
hospital level by applying management strategies used in top-performing hospitals to those with less
favourable outcomes.
Measuring hospital performance is a central component of the UK Government’s transparency agenda,
which increasingly calls for process measures of performance to be complemented by hard outcome
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indicators.84 Indeed, Dr Foster has been publishing mortality data using the Hospital Standardised Mortality
Ratio (HSMR) for every UK hospital since 2001.427 This has revealed widespread variation in death rates
between English hospitals but is based on HES and is limited by lack of information on case-mix factors
and emergency treatment, making performance comparisons between hospitals difficult to interpret.
Compared with HES, MINAP provides a much richer source of data for patients admitted to UK hospitals
with AMI,86 enabling us to provide a more nuanced view of interhospital variation in care. We carried out
two novel studies using MINAP data to analyse variation in outcomes between hospitals and to provide
insight into the performance of the UK’s NHS. The first study provides a detailed view of variation in
short-term mortality between hospitals in England and Wales, adjusted for case mix, and has important
implications for efforts to identify underperformance and rank hospital performance. The second compares
variation across hospitals in England and Wales with that seen in Sweden, to provide an international
benchmark and to explore the role of interhospital variation in national differences in short-term mortality.
To investigate the extent to which differences between hospitals are explained by factors open to change
in NHS, we carried out a preliminary volume–outcome analysis of patients with AMI admitted to all
hospitals in England and Wales to investigate the impact of hospital characteristics and quality of primary
care on 30-day mortality after AMI.
As we found that interhospital variation in mortality is not wholly explained by difference in case mix or
use of guideline-recommended treatments, we have also sought to identify factors affecting the quality of
care delivery that might influence outcomes. We adopted an ethnographic approach, examining NSTEMI
care in 10 hospitals with contrasting levels of 30-day mortality. Through interviews with health-care
workers and patients, and observation of daily practice, we sought to identify processes of care that might
influence adherence to guidelines and contribute to interhospital variation in mortality.
Study 30: interhospital variation in mortality – UK hospitals
This study is based on previously unpublished data by O Nicholas (Department of Epidemiology and Public
Health, University College London) and A Timmis (Farr Institute of Health Informatics Research and Barts
Health NHS Trust), 2015.
Introduction
Existing research into interhospital variation in patient outcomes after AMI has major limitations. We found
no previous studies of interhospital variation in 30-day mortality that included detailed case-mix and
treatment data from all hospitals in one country. Investigation has often been restricted to subsets of
hospitals contributing data to voluntary registries, which may not be representative of other hospitals
within the same health-care system.428–432 In other studies, attention focused on hospitals grouped by
academic status, geographical region or receipt of achievement awards, not on individual hospitals within
these groupings.431,433,434 Selection at patient level often means that whole segments of the population
are excluded, with many studies confining their analyses to patients aged ≥ 65 years428,430,432 or to STEMI
patients.429,431,433 Across all studies, patient-level data are sparse, with some studies providing information
about demographic factors only435 and most providing little information about infarct severity.429–433,435–438
Information about in-hospital treatments is nearly always absent428,430,432,434,435,437 or, when available, has
not been used to inform individual hospital performance.429,431,433
We have sought to address these limitations using data from the UK, one of the few countries in which all
hospitals participate in a national registry of patients admitted with AMI (MINAP), which records data on
case mix, treatment and mortality.86 We have chosen 30-day mortality for patients treated within individual
hospitals as the outcome of interest because it is sufficiently early after the index AMI to capture the
influence that hospital effects might have on outcomes without confounding by later factors such as
non-concordance with treatment and new comorbidities. We aimed to determine (1) the extent of clinically
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important interhospital variation in 30-day mortality after admission for AMI; (2) the extent to which
the variation is explained by case mix, treatments received in hospital and other hospital-level factors;
(3) whether or not underperforming hospitals can be reliably identified; and (4) whether or not hospitals
can be reliably ranked by 30-day mortality.
Methods
Patient population
Using the MINAP registry, we selected patients aged ≥ 30 years, with a first STEMI or NSTEMI in the period
1 January 2004 to 6 August 2009 (n = 316,648). AMI was defined by the discharge diagnosis recorded in
MINAP, based on the consensus definitions of the Joint ESC/American College of Cardiology for AMI
subtypes,439 raised cardiac biomarkers (creatine kinase or troponin) with or without ST-segment elevation
on the resting ECG. All case-mix, treatment and hospital-level factors listed in Table 35 were obtained
from the MINAP registry.
TABLE 35 Case-mix, treatments, complications and hospital-level factors from MINAP
Case-mix, treatment and hospital factors
Patients
(N= 316,648) Hospitals (N= 236)
Observed, means
or proportions
(% recorded)
Observed, median
(first, third quartile)
Imputed, median
(first, third quartile)
Case mix
Demographics
Age (years) 69.9 (100) 69.7 (67.8, 71.6) 69.7 (67.8, 71.5)
Female 0.35 (100) 0.35 (0.31, 0.38) 0.35 (0.31, 0.38)
Ethnicity non-white 0.05 (85) 0.02 (0.01, 0.07) 0.02 (0.01, 0.06)
IMD 22.7 (90) 20.0 (16.0, 28.0) 21.1 (16.6, 27.4)
AMI phenotype and ECG
NSTEMI 0.61 (100) 0.63 (0.51, 0.71) 0.63 (0.51, 0.71)
STEMI 0.39 (100) 0.37 (0.29, 0.49) 0.37 (0.29, 0.49)
ECG abnormal 0.93 (92) 0.94 (0.91, 0.97) 0.93 (0.91, 0.96)
Risk factors
Current smoker 0.30 (91) 0.30 (0.26, 0.34) 0.29 (0.25, 0.34)
Diabetes 0.18 (93) 0.18 (0.16, 0.20) 0.18 (0.16, 0.20)
Hypertension 0.47 (93) 0.47 (0.43, 0.51) 0.47 (0.43, 0.51)
Haemodynamics
SBP (mmHg) 141 (85) 141 (138, 143) 140 (139, 143)
Heart rate (b.p.m.) 8.3 (85) 82 (80, 84) 82 (80, 84)
Left ventricular function < 50% 0.40 (17) 0.42 (0.33, 0.54) 0.42 (0.40, 0.44)
Blood markers
Pooled troponin I or T upper quintile 0.13 (43) 0.07 (0.01, 0.22) 0.14 (0.10, 0.19)
Glucose (mmol/l) 8.3 (58) 8.4 (8.1, 8.6) 8.3 (8.1, 8.4)
Haemoglobin (g/dl) 13.5 (31) 13.6 (13.3, 13.9) 13.6 (13.5, 13.8)
continued
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TABLE 35 Case-mix, treatments, complications and hospital-level factors from MINAP (continued )
Case-mix, treatment and hospital factors
Patients
(N= 316,648) Hospitals (N= 236)
Observed, means
or proportions
(% recorded)
Observed, median
(first, third quartile)
Imputed, median
(first, third quartile)
Creatinine (mmol/l) 107.7 (35) 105.9 (101.4, 112.2) 105.3 (102.0, 108.7)
Cholesterol (mmol/l) 5.1 (70) 5.1 (5.0, 5.3) 5.1 (4.9, 5.1)
History of CVD
AMI 0.19 (94) 0.18 (0.16, 0.21) 0.19 (0.16, 0.21)
Other 0.35 (84) 0.35 (0.30, 0.40) 0.36 (0.31, 0.40)
Prior treatment
Aspirin 0.59 (53) 0.59 (0.51, 0.65) 0.59 (0.51, 0.65)
Beta-blocker 0.27 (59) 0.24 (0.21, 0.28) 0.25 (0.23, 0.28)
ACEI or ARB 0.34 (59) 0.31 (0.27, 0.36) 0.31 (0.28, 0.35)
Statin 0.39 (60) 0.36 (0.32, 0.42) 0.37 (0.34, 0.41)
Previous revascularisation
PCI 0.05 (90) 0.05 (0.03, 0.07) 0.05 (0.04, 0.07)
CABG 0.05 (91) 0.05 (0.04, 0.06) 0.05 (0.04, 0.06)
Delay
Time from symptom onset to arrival (hours) 2.7 (81) 2.7 (2.3, 3.1) 2.7 (2.5, 3.1)
Treatment and complications
Acute management
Reperfusion therapy 0.80 (44) 0.79 (0.68, 0.88) 0.76 (0.70, 0.82)
IIb/IIIa inhibition 0.07 (82) 0.04 (0.01, 0.10) 0.04 (0.02, 0.09)
CABG 0.02 (86) 0.01 (0.00, 0.02) 0.01 (0.01, 0.02)
Heparin 0.95 (74) 0.97 (0.94, 0.98) 0.96 (0.94, 0.98)
Discharge medication
Aspirin 0.90 (90) 0.93 (0.88, 0.95) 0.92 (0.88, 0.96)
Clopidogrel 0.75 (56) 0.78 (0.65, 0.86) 0.76 (0.69, 0.82)
Beta-blocker 0.74 (89) 0.75 (0.69, 0.81) 0.75 (0.70, 0.86)
ACEI or ARB 0.79 (89) 0.81 (0.75, 0.87) 0.81 (0.75, 0.86)
Statin 0.89 (90) 0.92 (0.87, 0.95) 0.92 (0.88, 0.96)
Complications
Bleeding 0.02 (88) 0.01 (0.01, 0.03) 0.01 (0.01, 0.03)
Hospital-level factors
Admitted to CCU 0.55 (99) 0.57 (0.46, 0.74) 0.57 (0.45, 0.74)
Admitted under cardiologist 0.56 (98) 0.66 (0.33, 0.81) 0.65 (0.35, 0.81)
Cases per year 192 171 (90, 255) a
CCU, coronary care unit.
a Data not available.
Observed and imputed data are presented, including mean values for the cohort and quartile values of hospital means.
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Case mix
A simple summary of case mix comprised age, admission heart rate and admission SBP, as previously
validated in MINAP and other studies.440,441 A more comprehensive measure of case mix included
demographic factors [age, sex, self-reported ethnic group and the IMD at lower-layer super output area,88
AMI phenotype (STEMI, NSTEMI)], risk factors (smoking status, diabetes, hypertension), cardiac history
(previous angina, heart failure, ACS, cerebrovascular disease), previous PCI, previous CABG, prior
cardioprotective drugs (aspirin, beta-blocker, ACEI, statin) and admission concentrations of haemoglobin,
creatinine, glucose and cholesterol.
In-hospital treatment
We included data on acute medications common to STEMI and NSTEMI (aspirin before or at the time of
admission, thienopyridine, heparin), reperfusion therapy (for STEMI only, thrombolysis or primary PCI), time
from pain onset to reperfusion therapy, angiography during admission (for NSTEMI only) and discharge
medications (aspirin, thienopyridine, beta-blocker, ACEI, statin).
Hospital-level factors
We included data on the number of prior ACSs, the proportion of patients admitted under a cardiologist
and the availability of an on-site catheter laboratory. All hospital-level factors were calculated per hospital
per year, and each patient record was amended to include the relevant statistic for the year of admission.
Primary outcome
The primary outcome was all-cause mortality at 30 days after hospital admission.
Statistical analysis
We compared 30-day mortality for individual hospitals with mean 30-day mortality across the study
population. We chose a mortality ≥ 40% above average as reflecting clinically important hospital
underperformance, being equivalent in terms of risk to adding ≥ 5 years to the age of every patient according
to our fully adjusted model. We modelled interhospital variation in 30-day mortality taking account of observed
case-mix, treatment and hospital-level factors listed in Table 35. We treated observed factors as fixed effects
(whether at the hospital or patient level) and allowed for random effects at the hospital level. We included all
hospitals, no matter how small the number of patients, as our random-effects modelling using empirical Bayes
ensures shrinkage to the mean of outlying but uncertain estimates. We successively introduced case-mix and
treatment variables into the model to assess their contribution to apparent mortality variation between
hospitals. We compared the likelihood of our posterior estimates of random effects under the assumption of
little variance (SD ≤ 0.07, equivalent under our fully adjusted model to 1 year of age) with the assumption
of greater variance (SD > 0.07) to evaluate the likelihood of true variation. Our modelling used parametric
survival, allowing for different survival trajectories for STEMI and NSTEMI, with calendar-year-specific hazards,
proportional hazards for the effects of covariates, and hospital-level random effects split into a constant
component and a 30-day component in order to adjust for unmodelled factors that might otherwise bias
30-day assessment. We assumed secondary prevention drugs to take effect from discharge and not before. For
adjusted funnel plots, we plotted estimated hazard against the precision of the estimate, where the precision
was taken to be 1.96 over the 95% interval size all squared.442 For year-by-year distributions of estimated
hospital hazards, we combined calendar-year-specific hazards with estimated hospital hazards. For analysis we
imputed missing covariate data (comprising 23% of all covariate data) independently for STEMI and NSTEMI,
making the assumption that covariates appearing in the fully adjusted model together with the logarithm of
time to death or censoring443 had a multivariate normal distribution444 with a linear trend with respect to
calendar time in mean. To this end we employed Gibbs sampling to generate a 600-long chain from which we
selected 10 hypothetical data sets from the last 300.402 We used model covariates for imputation with the
addition of angiography. Models were fitted to each data set using maximum likelihood. All analyses were
carried out in Matlab version 7.14 (Mathworks, Natick, MA, USA) and software written in C++ version 11
(Intel, Santa Clara, CA, USA).
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Results
Study population
We identified 316,648 patients experiencing a first STEMI or NSTEMI between 1 January 2004 and
6 August 2009. During that period, we estimated a 47% (95% CI 39% to 55%) improvement in 30-day
mortality, representing an average annual improvement of 6.7% (95% CI 5.7% to 7.6%).
Case-mix, treatment and hospital-level factors
Interhospital variation in factors used for modelling the primary outcome is shown in Table 35. Differences
between average and interhospital variability of factors based on non-missing observations and
observations that included imputed data were small, and we used the imputed data to maximise patient
inclusion in the modelling process. Interhospital variations in case-mix, treatment and hospital-level factors
were often large, as reflected in the IQRs across all hospitals, NSTEMI for example accounting for ≤ 51%
and ≥ 71% of cases in lower- and upper-quartile hospitals. Rates of reperfusion therapy also varied,
ranging from ≤ 68% to ≥ 88% in lower- and upper-quartile hospitals. Similar variation was seen in
hospital-level factors, with the proportion of patients receiving cardiac care unit treatment ranging from
≤ 46% to ≥ 74% in lower- and upper-quartile hospitals. Imputation of data preserved interhospital
variation in covariates.
Variation in 30-day mortality
Crude 30-day mortality for the whole study population was 9.4% (IQR 6.5–11.2%) but among the 3760
patients with complete data for all 39 case-mix variables used for modelling it was 0.9% (IQR 0.0–7.7%),
reflecting the 23% missing covariate data. This necessitated the use of imputed data sets to generate
adjusted models of hospital variation. The SD of log-hazard across all hospitals was 0.33 (95% CI 0.31 to
0.35), hospitals with a 30-day mortality > 1 SD either side of the average adding or subtracting at least
28% [1-exp (–0.33)] to the average risk, depending on whether performance was bad or good. In 34
hospitals (14.4%, 95% CI 11.9% to 17.4%) mortality was ‘excessive’, as defined by a mortality of ≥ 40%
above average. Adjustment for case mix, whether ‘simple’ (age, heart rate and SBP) or ‘full’, and then for
treatment- and hospital-level factors, reduced hospital variation in 30-day mortality. Thus, the SD of
log-hazard across all hospitals was 0.24 (95% CI 0.23 to 0.25) in the fully adjusted model, significantly
exceeding our assumption of no variation (p < 0.001) – hospitals with a 30-day mortality > 1 SD either side
of the average adding or subtracting at least 21% [1-exp (–0.24)] to the average risk. In the fully adjusted
model, 15 hospitals (6.4%, 95% CI 4.7% to 8.5%) met the ≥ 40% criterion for excessive 30-day mortality
which, given an estimated HR of 1.07 for each year of age, was equivalent to adding at least 5 years of
age to each patient treated in underperforming hospitals (Figure 67).
Hospital ranking
Hospitals were ranked by the fully adjusted point estimates of their 30-day mortality hazards (Figure 68).
The 95% CIs around these estimates were wide, and across most of the hospitals in England and Wales
there was considerable uncertainty about the rankings, making it difficult to draw robust inferences about
relative performance. This is further illustrated in Figure 68b, which shows the probability of any particular
hospital being among the 15 worst-performing hospitals with an excess 30-day mortality of ≥ 40%.
For the 11 lowest-ranked hospitals, the chances were greater than evens of any of them being among the
15 worst performers. Greater certainty about severe underperformance was possible for two hospitals,
in which the probability of being ranked among the worst performers exceeded 90%. The funnel plot
(Figure 69) indicated 12 hospitals lying above the line of ≥ 40% excess risk, with four outside the 99%
confidence limit for underperformance.
Discussion
Our study is nationally comprehensive in terms of hospitals included (100%), and in terms of recording of
acute and discharge treatments, we showed that the 30-day mortality rate for over 300,000 patients with
AMI varied substantially between hospitals. Unlike previous studies, we used a metric comprehensible to
patients and policy-makers, and showed that about one in 20 hospitals had an excess mortality equivalent
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to increasing the age of patients they cared for by at least 5 years. Up to two severely underperforming
hospitals could be identified with high levels of confidence, but for most hospitals ranking estimates based
on adjusted 30-day mortality were imprecise and not a reliable indication of performance.
The rich patient-level data available within MINAP that were used to model the primary outcome showed
considerable variation between hospitals in terms of case mix but also of emergency management.
The importance of case-mix adjustment for understanding hospital variation has been repeatedly
emphasised,81,436,445,446 the data confirming substantial interhospital differences in major determinants of
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FIGURE 69 Funnel plot of estimated hospital performance for AMI 30-day mortality in MINAP. Each circle represents
one hospital with 95% (grey lines) and 99% (black lines) control limits. Hospitals above the horizontal line have
> 1.4 times worse mortality than the average across all hospitals, with a probability ranging from 0.54 to 1.
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FIGURE 68 Hospitals ranked by (a) performance and (b) probability of being in the worst-performing 6% (15 out of
236) of hospitals in MINAP. Data are median hospital log-hazard for 30-day mortality with 95% (lines) and 99%
(dots) fully adjusted CIs.
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outcome such as age, rates of diabetes and proportions of current smokers. Unlike many previous studies
of hospital variation, we were also able to examine emergency treatment delivered in hospital and
secondary prevention drugs prescribed at discharge. Again, substantial differences between hospitals were
found, particularly in rates of reperfusion therapy, but also in the key secondary prevention drugs
recommended in international guidelines. Some have argued that process measures such as these provide
advantages for evaluating hospital performance – being a direct measure of the standard of care and less
likely to generate institutional stigma than mortality estimates.447
Despite wide differences between hospitals in case mix and emergency care, patient-level treatment and
hospital-level factors explained only a proportion of the absolute variation in mortality, reducing by 50% the
estimated number of underperforming hospitals. We found that adjusting for treatment appeared to explain
some variation when the case-mix adjustment was simple (based on a small number of factors) and explained
more when case-mix adjustment was full. When we used all the available data to account for case mix,
further adjustment for treatment had no impact on variation in 30-day mortality, highlighting the limitations
of studies of interhospital variation that have taken only partial account of case-mix factors. Much of the
interhospital variation we identified remains unexplained and must be attributed to unmeasured or poorly
measured factors. Unmeasured patient-level aspects of care include dose, timing and compliance with
prescribed medication, behavioural interventions (e.g. smoking cessation) and genetic differences. Unmeasured
hospital-level factors include process measures and hospital characteristics that other investigators have
associated with interhospital variability but were unavailable for modelling in the present study.351
Notably, although we identified serious interhospital variation in 30-day mortality, we could confidently
identify only up to four hospitals that were underperforming according to our criteria. For all other
hospitals, the uncertainty around individual hospital mortality estimates, as reflected by wide overlapping
CIs, made specific hospital rankings imprecise as a measure of performance, confirming the limitations of
hospital league tables.448 The failure of treatment factors to explain more than a small part of the variability
in hospital 30-day mortality suggests that policy-makers may need to look at organisational and other
hospital-level factors to identify the main determinants of underperformance.
The variation in 30-day mortality between hospitals in England and Wales cannot be ignored and requires
strategies to restore prognostic equity. Our results suggest that a strategy confined to targeting up to
four underperforming hospitals that can be identified with confidence would have a very limited impact
on AMI mortality at a population level, and should be combined with a strategy of system-wide quality
improvement across all hospitals, analogous to the Rose population-wide, as opposed to a risk-based,
prevention strategy.449 We found little evidence that differences in case-mix or emergency management
between hospitals made substantial contribution to differences in performance, and identified a need for
qualitative research to examine organisational culture within hospitals, there being evidence that a culture
supportive of efforts to improve AMI care is associated with better performance within selected US hospitals.351
An important question, not resolved by our study, is whether or not the interhospital variation in mortality
within England and Wales is generalisable to other settings or is a function of the health-care system itself,
driven by postcode lottery or other organisational factors. The finding of similar variation in outcomes from
studies in the USA does not resolve the question because studies included only selected hospitals and not
the entire hospital base. Only Sweden has a unified health-care system in which, as in England and Wales,
all hospitals participate in a national registry of patients admitted with AMI (SWEDEHEART) recording data
on case mix, treatment and mortality.7
We have taken up this important opportunity for an international comparison and report our findings for
study 32.
Our study has important limitations that are inherent in any large registry analysis. In modelling the primary
outcome, we were restricted to data recorded in the MINAP registry. Although this includes a broad range
of demographic, case-mix and treatment factors, we were limited to those factors conventionally recorded
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as part of quality of care. These factors only partially explained the interhospital outcome differences we
observed, suggesting that the data recorded in MINAP and other registries needs to be expanded to
capture more relevant quality measures, including a broader range of hospital-level factors. We were also
limited by missing data in 23% of data entries. Absence of data can itself influence mortality estimates,450
as reflected in the reduced crude mortality rate we observed in the subset of patients with complete
case-mix data used for survival modelling. This emphasises the importance of the imputation process we
adopted in the present study, which maximised patient inclusion in the modelling process while producing
only modest changes in average values for case-mix and treatment factors.
Further research is required to obtain real-time risk-adjusted, treatment-adjusted estimates of between-hospital
variation in mortality and a wider range of non-fatal outcomes.
Conclusions
In using national registry data to assess hospital-level mortality for patients with AMI in England and
Wales, we have shown for the first time serious variation between hospitals, about one in 20 of which
has an excess mortality of ≥ 40%. Underperformance was not explained by differences in case-mix or
treatment factors, and qualitative work is now needed to determine the extent to which the organisational
culture within hospitals, or other patient-level factors, might have contributed. Promotion of prognostic
equity across all hospitals represents an important opportunity to reduce coronary mortality substantially in
England and Wales.
Study 31: extent to which differences between hospitals are
explained by factors open to change in the NHS – impact of hospital
characteristics and quality of primary care on 30-day mortality after
acute myocardial infarction
This study is based on previously unpublished data by S-C Chung (Farr Institute of Health Informatics
Research) and A Timmis (Farr Institute of Health Informatics Research and Barts Health NHS Trust), 2015.
Introduction
Case-mix and treatment factors influencing prognosis early after AMI are well recognised55 but there is
less information about the way in which hospital characteristics might be influential. There is a suggestion
that outcomes might be better in large-volume primary PCI units but, as NICE commented in the 2013
myocardial infarction guideline,451 the quality of data is poor and still leaves the question open. Indeed, in
that guideline, NICE identified volume–outcome relationships as one of its main research recommendations.
Similarly, few data are available on how the quality of primary care influences early hospital outcomes after
AMI. In study 10 we have already reported a sharp increase in primary care consultations in the weeks
preceding hospital admission with ACS and how this provides a potential opportunity to implement
treatment to protect against progression to coronary occlusion. However, we have no information available
about those patients in whom AMI is prevented or the treatment they received.
Hypertension is a well-established risk factor for CVD and is the most prevalent treatable cause of vascular
events.452 The management and control of high BP is therefore one of the most important components
of primary and secondary strategies for prevention of cardiovascular mortality and morbidity at patient
level.453 However, uncertainty remains in the association between hospital AMI mortality and individual
BP control.
The target measurement for BP control recommended in JNC 8 guidelines for the management of high
BP in adults is < 150/90 mmHg for patients aged ≥ 60 years and < 140/90 mmHg for those aged
≤ 60 years, and for patients diagnosed with diabetes or with chronic kidney disease (regardless of age).168
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The development of JNC 8 was based on results from clinical trials. In actual clinical practise, it is unclear
whether or not hospital outcome of AMI survival is associated with BP control target defined by JNC 8.
In the absence of hospital characteristics and primary prevention on 30-day mortality after AMI, our
objectives in this study were, first, to investigate the hospital volume–outcome association in AMI care and
second, to investigate the association between hospital AMI outcome and BP control in primary care. For
each patient, BP control was indicated by the mean of all the BP measurements during the study period,
and mean deviation of these measures from the control target defined by JNC 8.
Methods
National registry for hospital care for acute coronary syndrome
To investigate the hospital volume–outcome association in AMI care, we used MINAP registry data. MINAP
included information on case-mix, treatment and in-hospital outcome of patients admitted to all acute
hospital units providing AMI care in England and Wales (n = 242). Eligible patients were identified by age
at admission of at least 30 years and admitted to AMI hospital between 1 January 2004 and 31 December
2010. The diagnosis of AMI was based on guidelines from the ESC, American College of Cardiology and
American Heart Association.454 For multiple admissions of the same patient, we used the earliest record.
We identified 17 case-mix measures in MINAP, which included demographic factors (age, sex, year of
hospitalisation), risk factors (smoking, history of diabetes and hypertension), AMI severity (troponin I or T
concentration, SBP and heart rate at admission to hospital and cardiac arrest), history of prior heart failure,
cerebrovascular disease and AMI, procedure and medication use prior to hospitalisation (antiplatelet
treatment with aspirin, clopidogrel or both, previous PCI and CABG).
Linked primary care, secondary care and patient outcome data
To investigate the association between primary care and hospital AMI outcome, we used CALIBER data
and administrative health data from primary care, secondary care and disease registries. We used linked
CALIBER data to investigate whether or not BP control may be associated with hospital AMI outcome.
Inclusion criteria were incident hypertensive patients defined according to the JNC 8 guidelines168 who
developed an AMI during study follow-up, patients aged ≥ 18 years registered with CPRD practices
consenting to data linkage with at least 1 year of ‘up to standard’ general practice follow-up, and followed
on or after 1 January 1997 with at least 1 year of study follow-up between study inclusion and 25 March
2010. AMI diagnoses were identified in CPRD, HES, ONS and MINAP records. Patients were excluded if
they had prior history of atherosclerotic disease, or history of hypertension before study inclusion or if
there was < 6 months since diagnosis with hypertension. Patients with pregnancy-induced hypertension
were eligible for inclusion 9 months after the date of diagnosis. Patients with drug-induced hypertension
were eligible for inclusion 6 months after the date of diagnosis.
Follow-up
The study period was between 1 January 1997 and 25 March 2010, which was the administrative
censoring date of the database. Patient follow-up commenced on the date when the patient first met all
the inclusion criteria and ended on the exit date from the cohort (last practice visit, deregistration, death).
Blood pressure measurement and study outcome
Baseline BP was defined as BP at study entry. For each eligible patient, we calculated mean BP over
repeated measures the patient acquired during study follow-up. We calculated deviation of each follow-up
BP measurement in relation to BP control targets recommended in the JNC 8 guidelines168 (< 140/90 mmHg
or < 150/90 for patients aged ≥ 60 years without diabetes and chronic kidney disease).
Target BP control was defined in relation to BP values recommended in the JNC 8 guidelines168 for
management of adults with high BP (< 140/90 mmHg or < 150/90 for patients aged ≥ 60 years without
diabetes and chronic kidney disease). For each eligible patient, we calculated the deviation of each BP
measurement in relation to recommended values, and mean BP value over repeated measures.
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Mortality outcomes
The primary clinical outcome was all-cause mortality within 30 days of hospitalisation.
Statistical analysis
For hospital volume–outcome association in AMI care, we compared the crude hospital proportions of case
mix, treatments and 30-day mortality by year of hospitalisation. Because the hospital proportions were not
normally distributed, the IQR was used to describe the observed variation.
The association between unadjusted hospital 30-day mortality and hospital admission volume was
initially investigated graphically, then by correlation analysis. To account for patient case mix, we
constructed generalised mixed models for each of the guideline-recommended treatment and 30-day
mortality using the 17 variables described above. Using these models, the predicted probability of receiving
guideline-recommended treatments and death at 30 days after hospital admission was estimated for each
patient and summarised at the hospital level to obtain the expected hospital proportions. For each hospital,
the observed mortality was divided by expected hospital 30-day mortality to obtain the HSMR. Hospital
case-mix-standardised 30-day mortality rates were determined by multiplying each HSMR by the crude AMI
30-day mortality rate of the study population. The association between case-mix-standardised hospital
treatment proportions and standardised hospital mortality was estimated by correlation analysis.
The analysis was stratified by year of hospitalisation.
For the preliminary analysis to investigate the association between patient BP control and hospital AMI
outcome, we categorised study hospitals according to AMI hospital mortality quartiles. The distribution
of patient baseline BP, mean BP over repeated measures during study period, mean difference from BP
control target over repeated measures taken during study period were summarised according to quartiles
of hospitals.
Analyses were performed using SAS version 9.0 (SAS Institute, Cary, NC, USA).
Results
Hospital volume–outcome association in acute myocardial infarction care
Hospital-level case mix
A lower median proportion of STEMI patients were observed in 2010 (27.5%) than in 2007 (40.2%) and
2004 (38%). Compared with 2004, in 2010 there was a higher hospital proportion of patients with a
history of diabetes, but a lower hospital proportion of smokers. In 2010, there was a greater hospital
proportion of patients admitted with prior treatment of PCI or CABG (Table 36).
We found a weak positive correlation between hospital volume and unadjusted 30-day mortality (Figure 70),
hospitals with higher volumes tending to have a higher mortality (Pearson correlation coefficient = 0.14,
p = 0.03). The association attenuated after standardised for case-mix factors. However, the annualised
analysis indicated that the positive association was largely confined to the early study period before 2008
(2006 and 2007) and disappeared thereafter, such that no association between hospital volume and
outcome was apparent in more recent years (Table 37).
Primary care and hospital acute myocardial infarction outcome
A total of 196,212 incident hypertensive patients were identified. The average follow-up time was 5 years
and 3 months, and 2825 hypertensive patients (1.4%) who developed AMI during follow-up (mean
follow-up 5.83 years) were included in the analysis. We did not identify any differences in baseline BP at
diagnosis, mean BP or variation from target BP by hospital AMI mortality quartile during the study period
(Table 38).
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Discussion
In this preliminary volume–outcome analysis of patients with AMI admitted to all hospitals in England and
Wales, we found no clear relationship between the number of patients admitted to individual hospitals
and 30-day mortality rates. Indeed, the tendency was for outcomes to be somewhat worse in high-volume
centres. The positive association between hospital volume and case-mix-adjusted 30-day mortality,
however, was weak and largely confined to the early study period before 2008 when rates of primary PCI
were relatively low. Later in the study period, huge changes in management strategies for AMI were
established in the UK, with increasing rates of primary PCI for patients with STEMI who were largely
managed in heart attack centres, and a slower trend towards more aggressive interventional management
of patients with NSTEMI. In this environment, a large proportion of patients with ACS are either admitted
directly or transferred to heart attack centres.
TABLE 36 Distribution of hospital-specific case-mix variables by admission year in MINAP
Case-mix variables
Year
2004 2007 2010
Hospital number 233 228 225
% STEMI, median (IQR) 38 (23.8) 40.2 (25.9) 27.5 (30.5)
Age (years), mean (SD) 69.4 (3.7) 69.2 (4.4) 69.9 (4.4)
% Female (IQR) 34.3 (7.9) 33.7 (7.3) 34.7 (8.6)
MI severity, median (IQR)
SBP (mmHg) 140 (7.5) 139 (7) 139 (7)
Heart rate (b.p.m.) 78.3 (4) 79.5 (3.5) 79 (4)
Troponin I (ng/ml) 7 (16) 4.3 (7.8) 2.3 (3.4)
Troponin T (ng/ml) 0.9 (2) 0.7 (1.4) 0.8 (3.5)
Risk factor, median (IQR)
% Current smoking 30.8 (9) 29.5 (10.9) 26.6 (10.4)
% History of diabetes 16.1 (5.9) 16.7 (6.2) 19.4 (5.8)
% History of hypertension 43.5 (9.4) 47.8 (11.8) 49.7 (10.7)
History of CVD, median (IQR)
% Heart failure 5.2 (5.1) 4 (4.6) 4.7 (4.8)
% Previous AMI 20 (6.5) 17.1 (6.3) 17.3 (6.7)
% Cardiac arrest 1.8 (2.1) 1.8 (1.7) 1.9 (2.6)
% Stroke 7.6 (5.4) 7.5 (5.1) 8.9 (5.1)
Treatment prior to admission, median (IQR)
% Single antiplatelet 20.1 (19.6) 26.9 (15) 22.1 (19.5)
% Combined antiplatelet 0 (0) 2.7 (3.8) 2.1 (3.4)
% PCI 3.4 (4.4) 5.6 (4.7) 6.1 (4.7)
% CABG 3.9 (2.5) 4.4 (3.1) 5.4 (3.1)
MI, myocardial infarction.
Distribution of hospital-specific % for STEMI, female, all risk factors, history of CVD, treatment prior to admission;
distribution of hospital-specific mean for age; distribution of hospital-specific median for SBP, heart rate, and troponin
values. Median and IQR of hospital proportions.
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TABLE 37 Correlation by year of admission between hospital volume and hospital 30-day mortality in MINAP
Year
Hospital volume and unadjusted
hospital 30-day mortality
Hospital volume and standardised
hospital 30-day mortality
Correlation coefficient p-value Correlation coefficient p-value
2004 0.28455 < 0.0001 –0.03348 0.6111
2005 0.01813 0.7841 –0.10995 0.0955
2006 0.3206 < 0.0001 0.15108 0.0211
2007 0.2468 0.0002 0.16118 0.0148
2008 0.04499 0.4963 0.05311 0.4218
2009 0.06114 0.356 0.12801 0.0525
2010 –0.03241 0.6287 0.08630 0.1972
2004–10 0.13996 0.0295 0.09013 0.1622
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FIGURE 70 Relationship between hospital volume (number of patients admitted with AMI between 2004 and 2010)
and hospital 30-day mortality in MINAP.
TABLE 38 Distribution of patient baseline BP, BP over repeated measures and mean difference from BP control
target, by hospital groups defined by AMI mortality in MINAP
Hospital grouped
by volume-
weighted 30-day
AMI mortality (n)
Patients
(N)
BP at study entry
(mmHg), mean (SD)
BP during study
period (mmHg),
mean (SD)
Difference of BP measure
and control target
(mmHg), mean (SD)
SBP DBP SBP DBP SBP DBP
< 17.4% (67) 704 160.6 (18.5) 90.2 (10.8) 144.4 (13.6) 81.4 (7.6) –1.4 (13.3) –8.6 (7.6)
≥ 17.4% to < 23.9%
(36)
676 161.2 (17.8) 90.4 (10.6) 144.7 (14.2) 81.3 (7.7) –1.5 (13.9) –8.7 (7.7)
≥ 23.9% to < 33.3%
(46)
702 162.4 (19.0) 89.9 (10.8) 147.1 (13.7) 81.9 (7.5) 0.6 (13.7) –8.1 (7.5)
≥ 33.3% (66) 743 162.2 (18.7) 90.2 (11.0) 147.6 (14.2) 82.4 (7.7) 1.3 (14.1) –7.6 (7.7)
Overall (215) 2825 161.6 (18.5) 90.2 (10.8) 146 (14) 81.8 (7.6) –0.2 (13.8) –8.2 (7.6)
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In this preliminary analysis, we found no relationship between the quality of BP management in primary
care and 30-day mortality for patients with AMI. Research on hospital AMI care has frequently been
blinded to primary care for AMI and truncated at hospital discharge, owing to the unavailability of primary
health-care data. As AMI is a chronic long-term condition, initiating from atherosclerosis during the
teenage years and continuing to long-term rehabilitation after hospitalisation, by enabling the availability
of data, information and knowledge of patient care, the study shows the capacity for using linked EHRs for
an integrated understanding of AMI care.
Next, steps should be to describe the time in BP control as defined in JNC 8 guidelines,168 assess the
association between yearly time in BP control and the onset of other fatal and non-fatal CVD outcomes,
assess the association between deviation of SBP and DBP in relation to recommended target values and
the onset of CVD outcomes. Factors associated with yearly duration of time in therapeutic range are to be
identified and adjusted in the observed association.
Conclusions
Our finding of a neutral volume–outcome relationship after 2008 is unsurprising if it reflects an even
spread of expertise across those centres. Further work is necessary to assess the distribution of AMI
patients across hospitals and other hospital characteristics that contribute to patient outcomes.
Study 32: interhospital variation in mortality – international
comparisons
This study is based on the peer-reviewed paper by Chung et al.62
Introduction
To date, interhospital variation in the treatment and outcomes of AMI have been analysed only within
individual countries. Although this has provided information about national scope for health system
improvement, it has been uninformative about system performance relative to other countries. This
represents an important missed opportunity for learning from other health-care systems and for international
benchmarking of performance. In this study we compare for the first time interhospital variation in treatment
and outcomes of patients with AMI in Sweden and the UK, the only two countries in the world with
continuous national AMI registries in which participation is mandated in all hospitals.7,86 The comparison was
facilitated and made more relevant by the similarity of the health systems in the two countries, both of
which provide universal care that is free at the point of contact. Our earlier study identified a significant
difference in 30-day mortality after AMI between Sweden and the UK,55 and we now seek to determine if
this is reflected in differences in interhospital variation in AMI care and outcomes between the two countries.
Our specific objectives were to compare Sweden and the UK regarding interhospital variation in (1) the use
of AMI guideline-recommended treatment and (2) crude and case-mix-adjusted 30-day mortality.
Methods
Eligible hospitals and patients
All hospital units providing AMI care in Sweden (n = 87) and in England and Wales (n = 242) were included
in the study. Eligible patients were aged ≥ 30 years and admitted between 1 January 2004 and 31 December
2010. AMI diagnosis was based on guidelines from the ESC/American College of Cardiology/American
Heart Association.454 For multiple admissions of the same patient, we used the earliest record. The data
validation7,86 quality and comparability of variable definitions regarding AMI diagnosis, patient case mix,
evidence-based hospital treatment strategies and discharge medication variables in SWEDEHEART/RIKS-HIA
and MINAP are described in our earlier study (study 16).55
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Case-mix variables
The 17 case-mix measures included demographic factors (age, sex, admission year), risk factors (smoking,
history of diabetes and hypertension), AMI severity (troponin, admission SBP, admission heart rate),
history of prior heart failure (cardiac arrest admission, cerebrovascular disease, or AMI), procedure and
medication use prior to hospital admission (antiplatelet treatment with aspirin, clopidogrel or both,
PCI, CABG).
Guideline-recommended treatment
Guideline-recommended treatment for STEMI patients358,455–458 included reperfusion therapy (primary PCI,
any fibrinolysis therapy) and medication for AMI patients surviving at hospital discharge, including the
use of antiplatelet therapy (any or combined antiplatelet medication), beta-blockers, ACEIs or ARBs,
and statins.
Mortality outcomes
The primary clinical outcome was all-cause mortality within 30 days after hospital admission. Each country
has a national unique identifier, which was used to link patients with the National Population Registry
(in Sweden) and the ONS death registry (in the UK) to ascertain vital status and date of death (available
for 99.3% and 98.7% of patients, respectively).
Statistical analysis
We compared the crude hospital proportions of case mix, treatment and 30-day mortality during the period
2004–10 and by admission year in Sweden and the UK. Hospital rates for treatment and 30-day mortality were
derived from patient data and weighted by hospital volume. Given that hospital rates were not normally
distributed, IQR was used for describing the observed variation. To standardise patient case mix, we constructed
a generalised mixed model with the 17 case-mix variables described above. The model incorporated hospital
random effect to account for clustering of patient data at hospital level. Predicted mortality of each patient was
summarised by admitted hospitals to obtain the estimated hospital 30-day mortality based on case-mix model.
The estimated mortality was divided by the observed hospital 30-day mortality to obtain the standardised
mortality ratio of each hospital, and hospital case-mix-standardised mortality was determined by multiplying the
standardised mortality ratio by the crude AMI 30-day mortality of the country. To assess the association of
hospital treatment variation with AMI 30-day mortality risk, we summarised volume-weighted hospital 30-day
mortality by hospital guideline-recommended treatment use quartiles, where hospitals were classified by the
percentage of treatment use in admitted patients into the lowest (first quartile), medium–low (second quartile),
medium–high (third quartile) and highest (fourth quartile).
We developed a generalised mixed model, adding the variables of hospital treatment quartiles to
the 17 case-mix variables, to compare the case-mix-adjusted risk ratios between hospital treatment use
quartiles and mortality risk in Sweden and the UK. The model incorporated hospital random effect to
control for clustering of patient data at the hospital level. The numbers of patients with missing data were
evaluated and managed by multiple imputation. Analyses were performed by SAS version 9.0 in London
using secure remote access with a common protocol.
Results
Hospital-level case mix
Hospital-level measures of infarct severity, including heart rate, SBP and troponin were comparable for
Sweden and the UK (Table 39). A higher proportion of Swedish patients were female, with a history of
diabetes or heart disease. Although the proportion of patients with STEMI at hospital level was greater
in the UK than in Sweden during 2004–7, it was more comparable in 2010 (31.7% ± 14.6% vs.
33.3% ± 24.4%, respectively).
ACUTE MYOCARDIAL INFARCTION: VARIATION BETWEEN HOSPITALS IN SHORT-TERM MORTALITY OUTCOMES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
200
Hospital-level treatment
Hospital use of primary PCI was higher (61.9% vs. 34.9%) and variation was lower (IQR 16.1% vs. 50.7%)
in Sweden than in the UK. In both countries, the increasing use of primary PCI reduced interhospital
variation between 2004 and 2010 (Figure 71), as reflected in reductions of IQRs from 41.6% to 12.8% in
Sweden and from 29.2% to 17.3% in the UK. The use of any reperfusion therapy for STEMI patients was
higher in UK hospitals owing to greater use of thrombolytic therapy and, although interhospital variation in
the use of reperfusion therapy decreased in Sweden between 2004 and 2010, it increased in the UK.
Hospital variation in the pre-discharge prescription of secondary prevention drugs was lowest for
antiplatelet drugs in both Sweden (IQR 4.7% in 2004 and 2.9% in 2010) and the UK (IQR 4.8% in 2004
and 4.2% in 2010). Beta-blocker prescription was higher in Sweden than in the UK, with less variation in
Sweden (IQR 4.9%) than in the UK (IQR 10.1%). Conversely, use of ACEIs/ARBs and statins was greater in
TABLE 39 Case-mix variables by admission year in the UK (MINAP) and Sweden (SWEDEHEART/RIKS-HIA registry)
Variable
Sweden UK
2004 2007 2010 2004 2007 2010
Hospital number 75 76 81 233 228 225
% STEMI, median (IQR) 31.2 (8) 27.8 (12.3) 31.3 (11.2) 38 (23.8) 40.2 (25.9) 27.5 (30.5)
Age (years), mean (SD) 72.2 (3.1) 71.2 (3.2) 70.7 (2.2) 69.4 (3.7) 69.2 (4.4) 69.9 (4.4)
% Female (IQR) 37.6 (6.7) 36.9 (6) 35.1 (7.1) 34.3 (7.9) 33.7 (7.3) 34.7 (8.6)
AMI severity, median (IQR)
% SBP (mmHg) 144.3 (10) 145 (10) 145 (8.5) 140 (7.5) 139 (7) 139 (7)
% Heart rate (b.p.m.) 77 (5) 77 (5) 78 (4) 78.3 (4) 79.5 (3.5) 79 (4)
% Troponin I (ng/ml) 4.4 (6.4) 3.7 (5) 3.1 (3.4) 7 (16) 4.3 (7.8) 2.3 (3.4)
% Troponin T (ng/ml) 1 (2.7) 0.7 (0.6) 0.8 (1.6) 0.9 (2) 0.7 (1.4) 0.8 (3.5)
Risk factor, median (IQR)
% Current smoking 22.2 (6.3) 22.4 (6.1) 23.1 (6.6) 30.8 (9) 29.5 (10.9) 26.6 (10.4)
% History of diabetes 23.7 (4.4) 22.2 (5.9) 22.3 (5.7) 16.1 (5.9) 16.7 (6.2) 19.4 (5.8)
% History of hypertension 42.4 (8.9) 46.5 (9.1) 49.1 (7.6) 43.5 (9.4) 47.8 (11.8) 49.7 (10.7)
History of CVD, median (IQR)
% Heart failure 12.5 (6.2) 9.3 (6.7) 6.7 (4.1) 5.2 (5.1) 4 (4.6) 4.7 (4.8)
% Previous AMI 29.4 (6) 21.5 (5.1) 18.7 (4.1) 20 (6.5) 17.1 (6.3) 17.3 (6.7)
% Cardiac arrest 0.9 (1.6) 1.2 (1.2) 1.4 (1.9) 1.8 (2.1) 1.8 (1.7) 1.9 (2.6)
% Stroke 7 (14.3) 10 (4.3) 8.6 (3.7) 7.6 (5.4) 7.5 (5.1) 8.9 (5.1)
Treatment prior to admission, median (IQR)
% Single antiplatelet 41.1 (7.4) 37 (6.8) 33.5 (7.1) 20.1 (19.6) 26.9 (15) 22.1 (19.5)
% Combined antiplatelet 3 (3) 3.8 (2.5) 3.3 (2.7) 0 (0) 2.7 (3.8) 2.1 (3.4)
% PCI 6.8 (3) 7.6 (4.4) 8.4 (3.6) 3.4 (4.4) 5.6 (4.7) 6.1 (4.7)
% CABG 7.2 (3.3) 7.8 (3.3) 7.4 (3.2) 3.9 (2.5) 4.4 (3.1) 5.4 (3.1)
Reproduced from Chung et al.62 © 2015 British Medical Journal Publishing Group. This is an open-access article distributed
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UK than in Swedish hospitals with somewhat greater variation in Sweden (11.6% and 11.9%, respectively)
than in the UK (10.1% and 4.8%, respectively).
Interhospital variation in 30-day mortality
During the study period, crude hospital 30-day mortality in Sweden (7%) was lower than in the UK
(10.1%) and showed less variation (IQR 2.1–5.7%). Both mortality and interhospital variation fell between
2004 and 2010, from 9.3% (IQR 3%) to 6.5% (IQR 2.8%) in Sweden and from 12.8% to 7.6% (IQR
5.5–7.5%) in the UK (Figure 72). In Sweden, hospital variation in 30-day mortality was greater for STEMI
(IQR 2.5%) than for NSTEMI (IQR 1.8%), in contrast to the UK, where interhospital variation was greater
for NSTEMI (IQR 5.4–7.1%). However, hospital case-mix proportions showed that patients with NSTEMI
were older, more commonly female and had a greater prevalence of chronic disease. After adjustment, the
hospital distribution of standardised 30-day mortality in Sweden (8.4%) was lower than in the UK (9.7%)
and showed less variation (IQR 2.6–3.5%) (Figure 73).
Thirty-day mortality by hospital treatment quartiles
In both Sweden and the UK, lower volume-weighted 30-day mortality was reported in hospitals using
guideline-recommended treatments more often. The difference was most notable for treatment of STEMI
with primary PCI, where comparison of lowest- (Q1) and highest-quartile (Q4) hospitals showed volume-
weighted 30-day mortality rates of 10.7% (95% CI 10.1% to 11.3%) versus 6.6% (95% CI 6% to 7.1%)
in Sweden and 12.7% (95% CI 12.4% to 13%) versus 5.8% (95% CI 5.1% to 6.4%) in the UK. In both
Sweden and the UK, there was a similar trend for diminishing odds of 30-day mortality for patients with
STEMI as hospital primary PCI use increased, with a comparison of Q4 and Q1 hospitals showing an
odds of 0.69 (95% CI 0.6 to 0.78) in Sweden and 0.63 (95% CI 0.56 to 0.7) in the UK. Absolute risk
differences between Q1 and Q4 hospitals for any reperfusion and discharge medication were lower for
Sweden than the UK. For example, differences in volume-weighted STEMI mortality between Q1 and Q4
hospitals for any reperfusion use were 3.4% in Sweden and 6.4% in the UK. For discharge medications,
the Q1–4 differences for Sweden and the UK were, respectively, 3.3% and 5.3% for any antiplatelet drug,
3.7% and 5.2% for dual antiplatelet therapy, 0.7% and 5.1% for beta-blockers, 2.6% and 3.2% for
ACEIs/ARBs, and 3.7% and 5.3% for statins. If Q1 hospitals had the same volume-weighted mortality rate
as Q4 hospitals, more than 2000 lives in Sweden and 11,000 lives in the UK would have be saved or
prolonged. After standardisation by patient case mix, differences in excess deaths between treatment use
quartiles were smaller, but similar trends remained (Figure 74).
Discussion
This is the first hospital-level international comparison of the characteristics, treatment and outcomes of
patients with AMI admitted to all hospitals across Sweden and the UK. In both countries, hospital practice
variation and hospital 30-day mortality were inversely related to the use of guideline-recommended
treatments, with hospitals in the upper use quartiles showing less practice variation and lower 30-day
mortality. A comparative analysis showed that interhospital variation in the use of primary PCI was greater
in the UK than in Sweden and was associated with greater variation in 30-day mortality. The data suggest
that more consistent health care across all hospitals not only would reduce practice variation but also
would deliver improved outcomes.
Treatment variation
UK hospitals showed a distinct temporal trend in the use of reperfusion therapy, with the clinical
consensus appearing to favour thrombolytic therapy from 2004 to 2007, with an increasing use of primary
PCI thereafter, but not matching Sweden’s use until 2010. The switch towards increasing UK hospital
use of primary PCI in 2008 was associated with a significant reduction in interhospital practice variation
and corresponded with the launch of a national policy initiative the same year favouring primary PCI.
In Sweden, reductions in hospital variation in the use of primary PCI diminished in 2006, reflecting a
national consensus that had moved away from thrombolytic therapy at least 2 years earlier than in
the UK. This 2-year delay in the implementation of primary PCI in the UK appears to have had salutary
consequences, judging by the favourable 30-day mortality odds for STEMI patients receiving treatment in
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high- versus low-use hospitals. Thus, our data suggest that reducing hospital variation in primary PCI use
has the potential to lower STEMI mortality in the UK and Sweden by 37% and 31%, respectively.
Interhospital variation in the use of guideline-recommended secondary prevention therapy was less
marked than variation in reperfusion therapy in both Sweden and the UK. It was particularly low for any
antiplatelet drugs, with interhospital variation in both countries of < 4% associated with the smallest
mortality variation between the lowest- (Q1) and highest-quartile (Q4) hospitals for use of these drugs.
The association of low levels of interhospital variation in any antiplatelet drug treatment with low mortality
variation between hospitals may provide a useful benchmark for other secondary prevention drugs. If
variations between Swedish and UK hospitals in the prescription of all secondary prevention drugs were
reduced to the levels recorded for any platelet drugs, important reductions in mortality variation could
be achieved.
Mortality variation
It was a major finding of this study that hospital-level 30-day mortality for patients with AMI was not only
higher in the UK but also showed greater variation than in Sweden. Thus, the distribution of case-mix-
standardised 30-day mortality for UK hospitals was broader based and shifted to the right compared with
Swedish hospitals. Our data suggest that variations in hospital treatment explained about half of the
variation in hospital mortality in Sweden, where antiplatelet drugs and statins probably had an important
role, and 27% of the variation in hospital mortality in the UK, where primary PCI use, dual antiplatelet
therapy and beta-blockers appeared more important. Although risk differences between hospital quartiles
for secondary prevention drugs were smaller than for reperfusion therapy, reducing variation in the use of
secondary prevention drugs has greater potential to reduce mortality, as they benefit all patients with AMI,
whereas reducing variation in reperfusion therapy would benefit only STEMI patients.
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Policy implications
Our study provides no information about what, beyond variations in hospital treatment, might drive the
residual mortality variation between hospitals. Other investigators have reported that multiple factors might
be involved, including hospital structure (staff expertise, hospital volume, resources),438,459–463 processes
of care (treatment protocol, problem-solving)351,459,461,463 and organisational culture.351,438,463 We found
that more patients in both Sweden and the UK were admitted to hospitals in the lowest treatment use
quartiles but, although volume-weighted 30-day mortality was higher in these hospitals, differences in the
case-mix-adjusted odds of 30-day mortality between quartiles was less striking, suggesting that factors other
than underuse of guideline-recommended treatments are contributing to the mortality excess in low-quartile
hospitals. Indeed, it is possible that the low use of guideline-recommended treatment in such hospitals is ‘the
canary in the coal mine’, which signals difficulties in implementing high-quality care. These implementation
difficulties might include patient vulnerability and other hospital-level and regional factors, emphasising the
importance of looking beyond the prescription of guideline-recommended drugs in developing quality
improvement programmes. In this scenario, quality improvement might best be achieved not only by
targeting underperforming hospitals, but also by the development of system-wide initiatives that aim to
deliver equitable management across all national hospitals from time of admission through to discharge and
beyond. This no doubt accounted for the success of the UK’s National Service Framework for Coronary Heart
Disease in 2000,81 but Sweden has a more comprehensive nationwide programme of quality improvement
that includes public reporting of hospital mortality, rapid diffusion of new technologies,464 more complete
use of evidence-based practice,465 and a more established system for evaluating and reporting the quality
and outcomes of care.466 This system-wide approach is likely to account, at least in part, for the reduced
variation in hospital care of patients with AMI in Sweden. Our results suggest that a national UK strategy
aimed at increasing use of guideline-recommended treatments in Q1 hospitals, combined with system-wide
quality improvement, could reduce hospital variation in care to Swedish levels, with a leftward shift of the
distribution of case-mix-standardised 30-day hospital mortality.
Our study has limitations. First, the contribution that unmeasured case-mix factors make to variability
in hospital outcomes cannot be determined. However, it is unlikely to be large because case-mix
standardisation gave comparable results to crude hospital proportions. Second, we could not evaluate
international differences in management AMI care prior to hospital admission, which may potentially
influence in-hospital treatment and outcomes. However, this is unlikely to explain higher variation in the
UK, because we found that time from symptom onset to admission, an indicator of pre-hospital
management, was similar to that in Sweden.55 Third, national registries do not capture all patients
admitted with AMI, and this may be more common in the UK than in Sweden. Patients who are not
captured tend to be older and not admitted under the care of a cardiologist, and this could lead to an
underestimation of the true hospital care and outcome differences. Finally, missing values may introduce
bias in our case-mix model. However, we have previously reported that estimates for the association
between case-mix variables and 30-day mortality, based on multiple imputed data, were verified by
estimates based on complete-case analysis.55
International comparisons are an integral component of contemporary prognosis research.29 They are
informative about the relative performance of health-care systems and further comparisons with other
national registries are now needed, including those from the USA,358 China467 and New Zealand.468 In these
countries, participation in registries is often voluntary, and research will be required to understand the
impact of hospital selection. Opportunities for more ambitious comparisons along the care pathway are
provided by linkage to national EHRs, permitting the analysis of non-fatal events before and after
hospital admission and longer-term outcomes. Our findings also have policy implications for reducing
interhospital variability in health care, with further work necessary to determine the competing benefits of
targeting underperforming hospitals or developing a national programme of quality improvement for
implementation across all hospitals.
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Conclusions
This study has shown that interhospital variation in guideline-recommended treatment is greater in the UK
than in Sweden. This is associated with, and may partly account for, the higher hospital 30-day mortality in
the UK. A system-wide national programme modelled on Sweden’s quality improvement programme has
the potential to reduce practice variation if implemented across all UK hospitals, with reductions in hospital
30-day mortality towards Swedish levels.
Study 33: variation in coronary care study – a qualitative study
on hospital processes and patient experience
Three manuscripts are in preparation.63–65
Introduction
Investigations of hospitals with poor outcomes, exemplified by the Francis Report,83 have sparked growing
concern about the quality of nursing and medical care in the NHS. Furthermore, our investigations indicate
that interhospital variation in mortality is only partly explained by patient characteristics and differences in
treatment or other hospital-level factors, suggesting that other aspects of care are having a significant
impact on patient outcomes.
A better understanding of the processes of cardiac care associated with improved patient outcomes could
provide important information to guide hospital and commissioning policy. One of the few studies
examining care processes for patients with AMIs351 identified a range of characteristics that distinguished
high- from low-performing hospitals in the USA, including the presence of clinical champions, empowered
nursing staff and engaged pharmacists, strong communication and co-ordination across disciplines and
departments, and greater involvement of senior managers. This study, however, was based on interview
data without observations of care and excluded hospitals that did not carry out primary PCI.
Although NICE420 recommends coronary angiography within 96 hours depending on the GRACE risk
assessment,469,470 previous studies have shown that delivery on these recommendations is inconsistent
between hospitals. In part, this may reflect the need for complex collaboration between emergency staff
and follow-on cardiac services and co-ordinated nursing support.471,472 Using an ethnographic approach,
we have examined the management of NSTEMI in 10 hospitals with contrasting levels of 30-day mortality,
to identify processes of care that might influence guideline adherence and contribute to variation in
outcomes between hospitals. We focused on NSTEMI care because this condition is more common and
has a worse prognosis than STEMI, with more initial diagnostic uncertainty and a less well-defined
management pathway. Moreover, STEMI patients have benefited from national initiatives in the UK to
reduce the time to primary PCI.
Methods
Study design
We undertook an ethnographic study, comprising observations of NSTEMI care, interviews with clinical
staff and patients and scrutiny of medical records.
Hospital sample
We used MINAP to identify a sample of 30 hospitals in the top or bottom third for 30-day case-mix-
adjusted mortality. We selected a purposive sample of eight hospitals, four from the top tertile and four
from the bottom, and with variation in coronary interventional facilities, teaching status, volume of cardiac
admissions and geography. Two pilot hospitals from the middle tertile were added to the sample to refine
the fieldwork. The research team was blinded to hospital performance status until after the analysis of
ethnographic data. Only one of the hospitals that were approached declined to take part and another was
chosen to replace it. We obtained initial permission from the clinical lead for cardiology in each hospital
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and then sought verbal assent followed by written consent before observations and interviews of staff and
patients. Study procedures were approved by local Research Ethics Committees (reference 10/H0107/75).
Data collection
At each hospital, we collected data from (1) observation of the care of a sample of NSTEMI patients from
admission through to discharge; (2) interviews with clinicians and managers at each site; (3) interviews
with patients and family members, and telephone interviews 30 days after discharge; and (4) patients’
medical records. Observations and interviews were carried out during a 2-week period of intensive
fieldwork at each hospital (June 2011 to August 2012), in relevant emergency departments, medical
assessment units, coronary care units, catheter laboratories and cardiac and general medical wards,
focusing on the processes of admission, diagnosis, treatment and discharge. Patient participants were
purposefully selected to represent a diversity of age, sex and clinical situation. Staff participants were
selected to represent maximum variation of roles but similar types of staff were involved across all sites.
Interviews were audio-recorded where permission was given and observational data were collected in
detailed paper FNs.
Data analysis
In our analysis we aimed to articulate care processes – from initial hospital presentation of patients with a
possible NSTEMI through to their discharge – that appeared to facilitate good-quality care, as represented
in NICE guidelines and the perceptions of clinicians and patients who we interviewed. Interview topic
guides and observations were informed by experiences at the two pilot sites. Analysis using constant
comparison,210 looking for similarities and differences in the data, was used to identify and explore aspects
of hospital organisation and processes. Strong themes emerged in core areas. Discussion of themes with
the wider team brought multiple disciplinary perspectives to the analysis. Once the core processes had
been agreed, the researcher collecting the primary data ranked each hospital with regard to each process.
These rankings were based on perceived adherence to NICE guidance in the care of individual patients,
with cross-checking between interview and observational data. The rankings for each process were based
on data sets for the hospitals taken as a whole; we used all the data sources and incorporated factors such
as overall team working and formal organisational mechanisms on, for example, how actively NSTEMI
patients were searched for, as well as the contributions of exceptional individuals. We were not able to
adequately represent different care for unusual groups of patients in the rankings but have referred to this
in the main text. Using a similar method, a second researcher independently ranked each hospital as a
whole (i.e. not broken down by care process) and there was broad agreement in overall rankings. Patients
and staff participants are represented by codes P1, P2, etc. and S1, S2, etc., respectively. The different
sources of data are designated interview (INT), observation (OB), audio-recording (AR) and FNs.
Results
Study hospitals and sample characteristics
The 10 participating hospitals varied in their organisation of care for NSTEMI patients (Table 40). Table 41
describes the study recruitment and type of data collected from 199 hospital staff, 68 patients and
732 hours of observation.
Key non-ST-segment elevation myocardial infarction care processes
We identified five processes that appeared to facilitate good care. These were (1) early specialist
assessment; (2) active patient monitoring and appropriate action; (3) cross-disciplinary communication;
(4) co-ordinated discharge and initiation of secondary prevention prior to discharge; and (5) visible
cardiology leadership. Underpinning these five processes was a perception by clinicians of responsibility for
and ‘ownership’ of the process of care for NSTEMI patients. We have ordered the five processes by their
temporal trajectory in NSTEMI care from initial hospital entry through to discharge. None of the hospitals in
the sample had all the care processes in place for all patients, although one hospital stood out as having
most of them (hospital 5).
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Early specialist assessment
Although NICE guidelines for NSTEMI patients begin at diagnosis, the diagnostic process is a crucial stage,
which directs care and determines further treatment. Only a minority of hospitals in our sample had a
system of early specialist filtering by the cardiology team. For example, in hospital 3, staff talked about the
lack of early cardiology involvement in triaging possible NSTEMI patients:
We are developing a number of different strategies which allow us to . . . improve the cardiology
interface with general medicine . . . Not all of it is as actively managed as we’d like it to be . . . most of
the ACS cases go to the general medical wards and then we have to extract them.
S57, director of cardiology, hospital 3, INT: AR
Most, but not all, hospitals used lists of troponin measurements as a method of identifying patients with a
NSTEMI that had been missed or that was not diagnosable on admission. According to the ACS nurses in
hospital 8, although a laborious task, checking troponin lists was an essential failsafe.
It is frustrating I can visit 10 different wards in a day and none of them turn out for me . . . but I may
find that one of those patients has come in with a cardiac presentation or had a cardiac event whilst
they’ve been in and I may find that nobody else has noticed that they had a raised troponin and ECG
changes . . . but there’s only one way to do it.
S147, cardiac nurse, hospital 8, INT: AR
Active patient monitoring and appropriate action
The status or stability of NSTEMI patients can quickly change, so it is vital that they are monitored closely,
with investigation and treatment changed when appropriate. Active patient monitoring and response
could be achieved in various ways. For example, specialist cardiac nurses help to support a patient’s care
not only by identifying possible NSTEMI patients but also by prescribing, chasing up test results, acting as a
liaison or advocate and by nursing on specialist cardiac wards. One example of an integrated cardiac nurse
role was found in hospital 5, which had twice-daily consultant-led ward rounds accompanied by a registrar
and an experienced cardiac nurse acting as a ‘progress chaser’ (19 January 2012, OB: FN). Hospital 5 also
had overnight specialist registrar cover.
At night the cardiac patients are seen, reviewed and medications appropriate started and plans made
on the night shift so that group of patients aren’t waiting until 8 o’clock for a consultant to see them
before a plan starts . . . and the night registrar does the [8 a.m.] triage round because he’s the one
that knows the patients, and if they don’t know the patients there’s trouble . . . also if we had any
patients on [cardiac ward] that then become unwell you’ve got a cardiac registrar that’s reviewing
them, you haven’t [got] a junior doctor who’s not sure.
S97, cardiac matron, hospital 5, INT: AR
TABLE 41 Summary of data collected for the variation in coronary care study
Type of data collection
Hospitals
Total (N)1 2 3 4 5 6 7 8 9 10
Patients recruited 13 1 8 7 8 7 6 6 7 5 68
Interviews with patients 7 1 6 7 8 7 5 4 4 4 53
Staff recruited 36 14 15 14 21 20 26 13 20 20 199
Staff interviews 13 5 12 13 17 12 12 16 21 21 142
Total hours on site 75 23 81 84 88 80 88 80 73 60 732
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Monitoring in other hospitals was sometimes less effective. Hospital 4 had remote telemetry, that is,
cardiac monitoring of patients on diverse wards with data screens at a central nursing station. The
monitoring task was allotted to a small proportion of skilled and experienced nurses in the coronary care
unit, whose direct care responsibility for patients on the unit sometimes limited their capacity to act on
remote telemetry data.
If you cannot spare anybody to go running off without endangering the unit, then you have to keep
going through the channels of phone calls . . . and looking at a monitor of a patient in real time that
you can see is getting progressively worse, in front of your eyes . . . you know there’s nothing you can
do . . . That patient would be dying . . . you start phoning the wards. If you can get through straight
away, brilliant. But there have been a couple of occasions where you are phoning against an engaged
signal on all the numbers you know.
S73, senior staff nurse, coronary care unit, hospital 4, INT: AR
In some hospitals patient monitoring and appropriate action was restricted to a subset of patients.
For example, in hospital 5 there was a formal policy that patients aged > 85 years should go to medicine
of the elderly wards and not be under the care of cardiologists unless they were particularly ‘bright’
(25 January 2012, OB: FN) or already known to the cardiology service. One 87-year-old patient was
admitted with chest pain and shortness of breath. She was given a diagnosis of NSTEMI and cared for on a
medicine for the elderly ward. She continued to have chest pain but, to her frustration and the frustration
of nurses involved in her care, she was not reviewed by a cardiologist nor did she have the investigations
specified in her management plan. After waiting 7 days, she asked to be discharged and died at home
5 days later (P34, hospital 5, OB: FN and patient notes).
Cross-disciplinary communication
Non-ST-segment elevation myocardial infarction care involves multiple disciplines, including catheter
and pathology laboratory services, radiographers, specialist nursing, pharmacy and other clinical specialities
for co-occurring conditions. Co-ordination of cross-disciplinary care is essential to facilitate diagnosis, risk
assessment and further investigations. Good cross-disciplinary communication was evident in hospital 5.
What used to happen was we’d find that the junior doctors would forget to put patients on the list
[for coronary angiography] which is obviously dangerous. Because if they’re not on the list we don’t
know about them. And also what happened was the admissions unit would send a cardiology patient
to where the bed was, so it might not be in cardiology it might be at the other end of the hospital . . .
and we put nurses in charge . . . we put in these nurses, speciality nurses with cardiology experience
. . . nurse prescribers, and they then take responsibility for the flow of the patients, so we decide
where the patients go not medical staff, so we have ownership, so we deal with who comes in the
front door.
S97, cardiac matron, hospital 5, INT: AR
In hospital 5 there were also examples of these skilled cardiac nurses, who were able to challenge
doctors’ decisions.
Nurse calls for a registrar from cardiac ward. She queries a drug for a patient. Daltoparin prescribed,
but, the patient is anaemic. The registrar says this is a really good call by the nurse, she is completely
right. He makes a note to ask the consultant who wrote it up, and tells nurse not to give it yet.
Another drug written up, potassium, but patient’s level is raised so nurse didn’t give it. Another good
call says the doctor.
30 January 2012, hospital 5, OB: FN
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An example of poor cross-disciplinary communication comes from hospital 6, where the cardiology staff
had limited control over and poor access to the catheter laboratory, which they perceived as inhibiting
appropriate angiography and angioplasty.
Although the cardiac lab[oratory] has got cardiology tech[nician]s and cardiology consultants, it has
radiology nurses and radiology radiographers and they’re situated in the radiology department. So
radiology gets to call the shots on what’s happening on the ground, which is potentially difficult for
cardiology because there are many processes down there that could be better . . .
S120, consultant cardiologist, hospital 6, INT: AR
Co-ordinated discharge and secondary prevention
Secondary prevention medication and cardiac rehabilitation are the most effective means of reducing
future cardiac events and reducing post-AMI morbidity and mortality in NSTEMI patients.349 In our study,
only a minority of hospitals began discharge planning and secondary prevention early in a patient’s stay,
despite the priority given to this in NICE guidance. For example, in hospital 9, staff talked frankly about
NSTEMI patients not being prioritised for rehabilitation services.
This position in rehab[ilitation] is absolutely appalling . . . they will build up a rehab team and then for
whatever reason go through cost-cutting exercise and then the rehab team is cut to virtually nothing
and the losers on that, they are not the STEMIs, they are the NSTEMIs, every single time.
S161, staff nurse, hospital 9, INT: AR
Most hospitals experienced delays with discharge paperwork and discharge medication. For example, one
patient in hospital 4, aged 82 years (P27), was discharged with two medications missing and without her
planned angiogram. Only hospital 5 had developed a comprehensive discharge system, enabled by nurse
prescribers, but it excluded patients who were not under the care of cardiologists, including most patients
aged > 85 years. In hospital 5 a dedicated cardiac pharmacist and technician worked with clinicians
checking medications every day in anticipation of discharge. Each patient had a 30-day supply of discharge
drugs in a locked bedside box to minimise delay. Discharged patients left the cardiac ward with a date
1 week later for multidisciplinary cardiac rehabilitation, which included a cardiac pharmacist.
In many hospitals without a comprehensive discharge system, the relatively brief in-patient episode
(5–6 days on average) for NSTEMI patients,25 as well as pressures of staffing, resources and prioritising of
STEMI patients, meant that follow-up largely became the responsibility of general practice. For example, in
hospital 6, although there was a cardiac pharmacist, she was not fully integrated into a cardiac team or
linked to the rehabilitation services:
In a lot of cases, it may be more prudent to say, ‘GP to review in a week’s time’ and amend a dose.
We’ve done that on a few occasions where, we’ve needed a bed . . . an important part of medicines is
the discharge counselling of patients, because we get a lot of rebound patients that come in, and you
go through a drug history with them . . . the supplies we’ve supplied them with have run out, they’ve
reverted back to what they had at home, which has been a wrong combination of medicines or
the wrong dose . . . And making sure they have a good understanding of what’s changed . . . it’s
something that’s not readily passed over to patients . . . you see more than 50 patients a day. I can’t
get round and counsel them all.
S109, cardiac pharmacist, hospital 6, INT: AR
Visible cardiology leadership
Generally, those hospitals that appeared to provide good NSTEMI care had visible cardiology leadership
that drove the management of cardiac patients and championed cardiology within the whole hospital.
This leadership responded to problems and difficulties as they arose, as well as engaged with changes in
technology, interventions and new evidence about effective care. In one hospital, the leadership was a
recognisable set of individuals. Staff could approach these individuals with concerns or ideas, and the
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leadership team had sufficient resources and authority to act. For example, hospital 5 had a leadership
team of three people who had led the cardiac department through big changes.
Cardiac matron explains that when the current nurse training was first introduced it was all wrong and
they had to start again slowly from scratch with the staff more on board. Taken 12 years to get to this
level of flexibility and been very hard in the last 24–18 months, but now working very well.
31 January 2012, hospital 5, OB: FN
Hospitals that did not have a visible cardiology leadership struggled with threats of catheter laboratory
closure (hospital 4), catheter laboratory access restrictions (hospitals 2, 4 and 6), restrictions on expansion
(hospitals 6, 8 and 10) or poor co-ordination of cardiac care with other key departments, such as accident
and emergency (hospitals 3, 9 and 10). Staff in one cardiac department were particularly frustrated about
their current role in cardiac care and lack of consultation.
[Ambulance] crews are confused about where to take people and at what time of day. Hardly any ACS
patients in CCU [coronary care unit] now. There are more chronic conditions and a lot of care of the
elderly, which they say is time-consuming and deskilling. Staff describe ward as dumping ground. Staff
feel sad and demoralised. Staff nurse says no one has informed the staff officially that this is what is
happening. There has been no meeting, no official letters, no word at all.
11 August 2011, hospital 2, OB: FN
Table 42 summarises our ranking of the hospitals for each of the care processes. Although some hospitals
had consistently good or poor processes, most demonstrated a mixed pattern.
Discussion
We have identified five major care processes that appeared to facilitate good NSTEMI care that was
consistent with NICE guidance420 (Table 43), as well as the perceptions of clinicians and patients,
summarising evidence for each of the key processes and the related NICE guidance.
Early specialist assessment and appropriate action
Early specialist assessment was essential for achieving an early diagnosis, not missing NSTEMI patients,
directing care and determining further treatment. It was especially important for patients with multiple
morbidities or unusual presentations. Early specialist cardiological assessment ensures that patients at
medium or highest risk are monitored more closely,473 placed in a cardiac ward and prioritised for timely
intervention, such as PCI within 24–96 hours, consistent with NICE guidelines.
Active patient monitoring
There were good examples of cardiac nurses with broad roles, twice-daily specialist ward rounds and
specialist night cover. NICE guidelines emphasise that treatments should be introduced at the first sign of
instability and interventions brought forward when unstable symptoms do not respond to treatment.
Active monitoring is required to identify the patients at highest risk.474,475
Cross-disciplinary communication
Early intervention in NSTEMI patients saves lives,476,477 requiring timely cardiac catheterisation, as
recommended in NICE354 and other478 guidelines. Catheter laboratories often have to fit NSTEMI
patients around the needs of elective stable chest pain diagnostic procedures, which requires effective
cross-disciplinary communication.
Co-ordinated discharge and secondary prevention
Patients with NSTEMI can usually be discharged 24 hours after coronary intervention (3–4 days after
admission),479 which leaves little time for organising guideline-recommended interventions, such as lifestyle
advice and enrolment in cardiac rehabilitation. Early planning is, therefore, crucial but is often not enacted.
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TABLE 43 Evidence for five key processes that appear to facilitate good NSTEMI care and relation to NICE guidance
Key process
Examples from interviews and observational data illustrating
how key processes facilitated or inhibited good-quality care
Link to good-quality care
as specified in NICE CG94420
1. Early specialist
assessment
Cardiology are in and out of A&E all the time, they lead A&E
on policy and clinical work. Low risk patients all have 1 hour &
8 hour Troponin T tests. They may go to the A&E observation
unit to wait for the results, or they may be sent into MAU
[medical assessment unit] if the A&E team think they should
see a cardiologist sooner rather than later
14 September 2011, hospital 1 OB: FN
NSTEMI patients may not be identified in several different ways
without specialist early intervention:
Interviewer: When does cardiology get involved?
Respondent: It depends . . . It’s just a bit hit and miss, if the
patient’s there and the consultant’s on the floor . . . If it’s a
not particularly straightforward they can ask one of the,
between 9 to 5, one of the cardiology team to pop down and
see the patient just to get a bit more information on it. It
depends which teams, it might be the gastroenterologist team
that day or the cardiology team, or the rheumatologist team,
it depends
Interviewer: When does the cardiologist get called in if
someone is thought to be ACS . . . where do they start to
come into the pathway?
Respondent: . . . it may be the A&E department, the majority
of time it may be when they’ve gone through either to
[secondary assessment units] to await the second Trop[onin] T
. . . If it’s a definitely NSTEMI they will be referred to the
cardiology, who will pick them up for further investigations
such as angiography
S77, hospital 4, INT: AR
Focus is on early identification
of patients with NSTEMI and
assessment of risk
2. Active patient
monitoring and
appropriate action
Only five hospitals out of the 10 used GRACE or TIMI risk scoring
to inform management of NSTEMI patients (see Table 40)
I try and catch people down in A&E and EAU [emergency
assessment unit] before they go to the wards . . . I go through
the diagnosis and look to see if there’s anybody with chest
pain . . . [A&E staff] they’ll catch me and say . . . I’ve got this
patient on 5b I’d like you to have a look for me . . . mopping
up any loose ends as well because often they’re seen by junior
doctors and then seen by more senior doctors . . . you’ll come
in and take the patient if you feel that there’s a need. So
you’re not just, the patients aren’t just relying on being
recognised by the medical doctor . . . And if tests are needed
then I will expedite those tests . . . It’s all about being
proactive . . . I can get things moving
S11, cardiac specialist nurse, Hospital 3, INT: AR
No link system of prioritising multimorbid patients into
cardiology beds, and cardiac patients may not see a
cardiologist for several days due to the infrequency of ward
rounds. This happened to two patients in the study who went
home without their promised angiograms after being kept
waiting on non-specialist wards. No evidence of any scoring
being used
30 November 2012, hospital 4, OB: FN
Use risk assessment to guide
clinical management and
balance the benefit of a
treatment against any risk of
related adverse events in the
light of this assessment
Perform angiography as soon
as possible for patients who
are clinically unstable or at
high ischaemic risk
continued
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TABLE 43 Evidence for five key processes that appear to facilitate good NSTEMI care and relation to NICE
guidance (continued )
Key process
Examples from interviews and observational data illustrating
how key processes facilitated or inhibited good-quality care
Link to good-quality care
as specified in NICE CG94420
3. Cross-disciplinary
collaborative
communication
Timely response to requests from nursing staff to assess NSTEMI
patients and make decisions about angiography was challenging in
some hospitals with a high turnover of junior doctors:
Interviewed senior cardiologist. He says junior doctors are
made aware when they come into cardiology that the nurses
are highly skilled and know the patients better than they do, if
they call it’s because it’s needed. Usually a flurry of emails
when the new juniors come in, & sometimes they have to be
taken aside and advised this is how the department works best
25 January 2012, hospital 5, OB: FN
. . . the doctors change every few months so sometimes you
feel you go back to square one with them again when you
have to, you phone and say ‘oh I’m really worried about this
patient, their blood pressure’s this, their ECG is this, can you
come and see them?’. And they’ll fire another load of
questions back at you, but once they know the team up here
and they know our skills and knowledge, then they respond
so it’s just every time you get a new tranche of doctors you
have to sort of go through that, just for the first few days
S26, nurse, hospital 2, INT: AR
Offer coronary angiography
(with follow-on PCI if
indicated) within 96 hours of
first admission to hospital
to patients who have an
intermediate or higher risk
of adverse cardiovascular
events if they have no
contraindications to
angiography (such as active
bleeding or comorbidity)
4. Co-ordinated
discharge and
secondary
prevention
Respondent A: Here we’re part of their team so when they’re
deciding who they’re discharging they tell me or they tell
[name]. So . . .
Respondent B: So instead of them getting it all ready and
think ‘oh god we need to tell pharmacy’. . .
Respondent A: They’re telling us when they’re deciding which
ones are going home so they’re highlighting it on the board
so that we can see straight away . . . it’s finding out who the
co-ordinator is . . . then I will visit their lockers, and make
they’re got everything, make sure that everything that’s
written on the drug chart is right before they even start the
[to take out medications]
S81 and S82, cardiology team, hospital 5, INT: AR
Respondent: I think an important part of medicines is the
discharge counselling of patients, because we get a lot of
rebound patients that come in, um, and you go through a drug
history with them, and you find that, because the supplies we’ve
supplied them with have run out, they’ve reverted back to what
they had at home, which has been a wrong combination of
medicines or the wrong dose and there’s overlapping . . .
making sure [patients] have a good understanding of what’s
changed while they’re in hospital, because they lose all control
of their tablets and doses while they’re in hospital – somebody
else does it – so it’s that education [that’s needed] that’s not
readily passed over to patients . . . I will try and counsel as many
patients as I can on, on what medicines they’re on, and what
changes we’ve made . . . [But] you see more than 50 patients a
day. Um, so I can’t get round and counsel them all . . .
Interviewer: So, so where does rehab care come into that?
Do you, do you link up with rehab care, at all?
Respondent: I haven’t had the opportunity
S109, cardiology team, hospital 6, INT: AR
Before discharge offer
patients advice and
information about:
l their diagnosis and
arrangements for
follow-up
l cardiac rehabilitation
l management of
cardiovascular risk factors
and drug therapy for
secondary prevention
l lifestyle changes
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Visible cardiology leadership
Patients who are cared for in specialist cardiology wards or under cardiological supervision typically have
better outcomes.480 In order to achieve this level of supervision, there must be visible and accessible
cardiology leadership.
Organisational culture
Each of these five dimensions may be influenced by the organisational culture at the NHS hospital trust
level, at the clinical directorate level or at the ward level. We acknowledge that our approach did not
explicitly focus on these contextual influences, partly because these have been more commonly
studied elsewhere.
Strengths and limitations
A major strength of this study was our ability to observe, as well as to interview, staff and patients about the
delivery of care.481,482 Another strength was that we were blinded to the estimates of 30-day post-admission
mortality for AMI patients. A major limitation was that we were unable to link our findings with variation in
the fully adjusted 30-day mortality outcomes for our hospital sample because the parallel statistical analysis
resulted in a model with such wide CIs around mortality estimates for most hospitals that we could not
draw robust inferences about individual hospital performance. Another limitation was that the ranking of
hospitals by implementation of the care processes was conducted in detail only by one fieldworker,
although the overall ranking of hospitals was consistent with a second researcher’s assessment.
TABLE 43 Evidence for five key processes that appear to facilitate good NSTEMI care and relation to NICE
guidance (continued )
Key process
Examples from interviews and observational data illustrating
how key processes facilitated or inhibited good-quality care
Link to good-quality care
as specified in NICE CG94420
5. Visible cardiology
leadership
[A senior nurse] has always been at the forefront of
development, she always put cardiology forward for anything
she’s very motivating and she’s an absolutely brilliant leader
. . . we did [a] pilot on this ward and we rolled it out across
the ward, and the data from that proved that it was going to
be a cost-saving exercise . . . and that system proved beyond
all doubt that it is a very much faster system to discharge
patients . . . you’re part of the team anyway and the
leadership here makes it go out of the way to make sure you
feel part of the team . . . and just not one person . . . Dr
[name] everybody . . . I think we are quite an exception we
always were, whatever important people are visiting the trust,
they are brought to cardiology
S81 and S82, cardiology team, hospital 5, INT: AR
. . . we do feel collectively as a cardiology department that we
are being restrained . . . we feel that we’re being held back
not only with our elective numbers but with our treat and
return for whatever reason, be it political whatever I don’t
know . . . They’d rather have work done at the tertiary centres
. . . for PCIs it’s [number] so that’s our planned amount, for
diagnostic angiograms its [number] . . . we could do more . . .
[But] say we go over the magic [number] then will we be
penalised because we’ve used X number of stents at £600,
£700, £400 a stent and all the consumables that go with that
. . . So it’s kind of juggling it around and making sure that we
number one get that target and do it in a safe manner for
the patients . . . why are they kind of insinuating that we’re
overachieving and that we’re doing more work that we should
be doing . . . we as an organisation seem unsure what they
want from us
S79, senior nurse, hospital 4, INT: AR
When the role of
revascularisation or the
revascularisation strategy is
unclear, resolve this by
discussion involving an
interventional cardiologist,
cardiac surgeon and other
health-care professionals
relevant to the needs of the
patient
A&E, accident and emergency; rehab, rehabilitation.
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Relationship to other studies
Our findings are consistent with, and extend other research on, NSTEMI care. For example, Curry et al.351
identified ‘empowered nurses’ as a key characteristic of top-performing hospitals, a finding confirmed
by other studies.472,483,484 In our study, specialist cardiac nurses featured in all of the five key processes
we identified as underpinning high-quality NSTEMI care. Curry et al.351 did not highlight early initial
assessment, but the importance we ascribe to this process is consistent with studies by investigators in
Canada485 and England.486,487 Better information about AMI for patients is a key finding of several
studies483,488–490 and a core feature of good-quality discharge. The importance of strong interdisciplinary
communication and co-ordination has also been emphasised.491,492
Implications for health service practice
Our findings reinforce key messages of the independent inquiry into care at the Mid-Staffordshire NHS
Foundation Trust hospitals83 with regard to misdiagnosis, in particular, failure to follow up investigations,
poor discharge management and lack of communication between staff about what needs to be done.
Ethnography is the appropriate method for studying hospital culture, a major concern of the Francis
Report83 and of the Keogh Review of hospital mortality,493 which highlighted poor-quality of care in 14 UK
hospitals. Findings from the application of ethnographic methods can inform quality improvement, with
the caveat that the depth and detail of our data were based on contracts of confidentiality and the trust of
participating staff, which would be more difficult to achieve in the context of external quality monitoring.
One use of qualitative data from ethnographic evaluations could be quantitative categorisation and
ranking (see Table 1) that would complement measures of hospital outcomes such as mortality
or readmission.
Public and user involvement in the design and conduct of the study
This study retained the expertise of two public and user group representatives (DT and JW) throughout,
who attended and contributed to all the steering meetings. Their input remained useful and grounded in
patient concerns. They helped to keep the focus on identifying actionable hospital-level factors rather than
on factors that could not be changed, thereby increasing the possible relevance of the study for patient
benefit. The representatives also helped to remind us of the importance of discharge and cardiac
rehabilitation, and this has led to us considering future research topics on cardiac rehabilitation. To this
end, our public and user group representatives have also reviewed some early thoughts and plans for
future plans and projects. With more expertise in statistical methods, DT and JW were both helpful in
pointing out where our qualitative methodology was not being explained clearly or where we were not
justifying our approach sufficiently.
Conclusions
Our ethnographic method applied across hospital sites allowed us to characterise features of hospital
culture that supported or undermined the quality of care for NSTEMI patients. We identified five processes
that underpin good-quality hospital care for patients with NSTEMI. Better management of these processes
is likely to improve the quality of care and outcomes for patients with NSTEMI.
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Chapter 13 Conclusions and implications for
clinical practice and further research
This NIHR programme illustrates the current potential of emerging ‘big data’ arising from linking EHRs atdifferent stages of a patient’s journey (see Figure 75) to offer important, actionable insights into the
diagnosis, risk stratification and cost-effective treatment of people at risk of, or with, angina, SCAD or AMI.
Our research programme set out to address new opportunities for improving quality of care and outcomes
for patients with SCAD and ACS, by assembling and exploiting anonymised data resources integrated
across the patient journey, and at different levels of care spanning primary and secondary acute and
ambulatory care. We provide exemplars of an approach that has potential application across different
disease areas, including those with the largest health-care burden (e.g. cancer, dementia, respiratory
conditions, musculoskeletal conditions and mental health) as well as rare diseases. EHRs are, in many
respects, agnostic to disease or clinical specialty and these features can be further exploited. Our findings
should be interpreted within the context of temporal changes in the risk and management of CVDs over
the past decade; for example, the availability of new medications, and different treatment targets and
competing risks of CVD mortality and events among different populations. Our research findings
(summarised in Table 3) and our approach using linked EHRs have informed national and international
public health policy (Table 44), clinical guidelines and the development of underpinning methods,
which have subsequently been implemented, and which have had an important impact on health care and
TABLE 44 Relevance and impact of this NIHR research programme to national policy
Policy report Report contents/recommendation(s)
Farr Institute of Health Informatics
Research action/response
Bloor C, Sriskandarajah R, Croxford V,
White H. Strategy for UK Life
Sciences. London: Department for
Business, Innovation and Skills; 201216
Launch of cross-funder call for centres in
e-health
Investigators on this programme were
successful in the competition and
established the Farr Institute London
Department for Business, Innovation &
Skills. Strategy for UK Life Sciences
One Year On. London: Department for
Business, Innovation & Skills; 2012494
and Strengthening the UK’s Capability
in Health Informatics Research
Conference Report; 2013495
Funding of £19M from a consortium of
10 UK government and charity research
funders led by the MRC was awarded to
establish four e-health research centres
based in London, Manchester, Dundee
and Swansea (Farr Institute of Health
Informatics Research)
Speech by the Chancellor of the
Exchequer to the Royal Society1
leading to MRC capital award via the
Department for Business, Innovation &
Skills
The speech made several references
to ‘big data’. In his speech, George Osborne
said that the UK has ‘some of the world’s
best and most complete data-sets in
healthcare’, and ‘the UK is well placed for
the big data revolution’ (© Crown copyright;
contains public sector information licensed
under the Open Government Licence v3.0).1
Big health data was one of the eight great
technologies quoted in the speech
Established the physical headquarters
of Farr London and e-infrastructure
including ISO27001-accredited
data safe haven for handling
patient-identifiable data
Academy of Medical Sciences.
Realising the Potential of Stratified
Medicine. London: Academy of
Medical Sciences; 2013496
The Farr Institute was named in
Recommendation 3 of the report for
consistent policy on governance for all
research safe havens that support data
sharing and harmonisation across
biomedical and health informatics centres
N/A
continued
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TABLE 44 Relevance and impact of this NIHR research programme to national policy (continued )
Policy report Report contents/recommendation(s)
Farr Institute of Health Informatics
Research action/response
Academy of Medical Sciences. Data in
Safe Havens. London: Academy of
Medical Sciences; 2014497
The report named the Farr Institute,
highlighting cross-centre collaboration
underpinned by consistent governance,
with independent review and audit,
across sites
We participated in the workshop
convened by the Academy in
partnership with the MRC and the
Wellcome Trust, on 24 March 2014
Association of the British
Pharmaceutical Industry. Big Data
Road Map. London: Association of the
British Pharmaceutical Industry;
2013498
The Farr Institute is named in multiple
places in the report and made
recommendations to the Farr in research
around the life cycle of a drug, and
training and capacity development
We held the Farr ABPI forum in
December 2014 with a constant
memorandum of understanding for
future collaboration
Farr addresses the gap in well-trained
data scientists
HSCIC. Information and Technology
for Better Care 2015–20 Draft Report
for Consultation. Leeds: HSCIC;
2015499
One of the five major objectives outlined
in the draft report is to ‘Make better use
of health and care information’ by
maximising the value and benefits that
data can provide, and minimising the
administrative burden of data collection
on care providers with the overall vision
for the UK to ‘be seen as one of the best
places globally to conduct research and
the collection and use of the nation’s care
data will have made a substantial
contribution to the development of health
and social care services’ (Copyright ©
2016, Re-used with the permission of the
Health and Social Care Information
Centre, also known as NHS Digital.
All rights reserved)
We are currently co-ordinating a Farr
response to the HSCIC strategy in the
light of the Partridge review500 and
response to care data
CPRD collaboration with the Farr
Institute
N/A CPRD, along with the Farr Institute,
are to develop a memorandum of
understanding between Farr and
CPRD for research for patient benefit
Caulfield M, Davies DK, Fowler T,
Mahon-Pearson J, Turnbull C,
Woods K. Genomics England Clinical
Interpretation Partnership (GeCIP):
Guidance for Expressions of Interest to
Form Domains Within GeCIP. London:
Genomics England; 2014501
GeCIP supports the 100,000 Genomes
project,19 a NHS transformation programme
to sequence 100,000 genomes from
patients with rare inherited disorders,
cancer and infectious diseases
It is anticipated that the scientific
activities undertaken within GeCIP
will include . . . capitalising upon
electronic health records research
infrastructure, such as, the Farr
Institute . . . to build upon and add
value to the clinical, laboratory, and
health records data. The evaluation
of whole genome sequence data in
the context of rich and extended
phenotypes and exposures derived
from electronic health records. To do
this it is expected that GeCIP
members will . . . engage with
existing infrastructure, such as . . .
the Farr Institute
Reproduced with permission501
Farr London (directed by Harry
Hemingway) has led a national effort
to harness the interpretation of the
EHRs. This includes work on people
with rare cardiac diseases such as
inherited cardiomyopathy
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our capacity to carry out research for patient benefit. We have published 25 papers (see Table 3) in
high-impact journals based on analyses from our CALIBER data platform and we have used qualitative
methods, systematic reviews and data from our novel, bespoke cohort to address our aims. We leveraged
£39M from 10 funders, including NIHR, for EHR research and the establishment of the Farr Institute of
Health Informatics Research in 2013 comprising four dedicated centres across the UK, including Farr
London (directed by Harry Hemingway).
In this chapter, we summarise the impact and implications of our NIHR-funded research in the following areas:
l the capacity to use EHRs to understand and improve quality and outcomes of care
l the evidence from EHRs used in clinical practice guidelines from NICE and professional societies
l research governance, methods and training
l media, journals and national recognition
l recommendations for future EHR research.
Capacity to use electronic health records to understand and
improve quality and outcomes of care
The huge translational potential of the UK’s EHRs for enhancing our understanding and management of
CVDs, developing risk models and personalised treatment strategies, and running low-cost, high-volume
clinical trials has been recognised by central government in its policy announcements and funding
commitments.72 However, prior to our NIHR research programme (awarded in 2008), the culture was very
different, with concerns voiced by practising clinicians and researchers that the data quality of NHS record
sources did not make them fit for research purposes. What research existed was mainly confined to single
disease or procedure registries, or to HES data. There had been no research linking several sources of data
in order to paint a detailed picture of the patient journey.
TABLE 44 Relevance and impact of this NIHR research programme to national policy (continued )
Policy report Report contents/recommendation(s)
Farr Institute of Health Informatics
Research action/response
National Information Board.
Personalised Health and Care 2020.
Using Data and Technology to
Transform Outcomes for Patients and
Citizens. A Framework for Action.
National Information Board; 201417
Our objective is to establish England as
one of the world’s leading centres for
innovation in digital health and
care services
© Crown copyright; contains public
sector information licensed under the
Open Government Licence v3.0
The Farr Institute’s efforts are central
to the delivery of Genomics England
and personalised care medicine
Department of Health. Cardiovascular
Disease Outcomes Strategy: Improving
Outcomes for People with or at Risk
of Cardiovascular Disease. London:
Department of Health; 201372
The NHS Commissioning Board and
Public Health England will look to
establish a cardiovascular intelligence
network (CVIN) bringing together
epidemiologists, analysts, clinicians
and patient representatives. The CVIN,
working with the HSCIC, will bring
together existing CVD data and
identify how to use it best
© Crown copyright 2013; contains
public sector information licensed under
the Open Government Licence v3.0
We are working with the National
Clinical Director for Heart Disease for
NHS England and the Chairperson
of the NCVIN, Professor Huon Grey,
and the Director for Knowledge &
Intelligence (Northern and Yorkshire) at
Public Health England, Professor Brian
Ferguson, to contribute insights from
the CALIBER programme into the NCVIN
ABPI, Association of the British Pharmaceutical Industry; GeCIP, Genomics England Clinical Interpretation Partnership; HSCIC,
Health and Social Care Information Centre; N/A, not applicable; NCVIN, National Cardiovascular Health Intelligence Network.
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Our CALIBER research programme has contributed, along with other initiatives, to realising this potential.
There has been a marked change in research culture, whereby interrogation of EHRs is now seen as
integral to our understanding of the quality and outcomes of care of CVD, and for identifying and
quantifying the importance of potential missed opportunities of care.
Evidence of our contribution to this ‘new culture’ comes from a variety of sources, detailed in the
following section.
Our cognate set of research findings
Our detailed results are summarised in Table 3.
Fitness for purpose: data quality in the Electronic Health Record
An overarching finding across studies in this programme is that the data have sufficient clinical validity to
provide a useful signal in clinical epidemiological research. This is an essential pre-requisite if these data
are to form a ‘scaffold’ on which to build further research programmes. One illustration of this is the
relationship between SBP and the risk of heart attack (Figure 75). The linear relationships that have been
shown by combining multiple individually small, high-cost consented cohorts, is replicated in a single larger
cohort, where recruitment, BP measurement and follow-up of (a wide range of) outcomes is zero cost for
the research funder. At the same time, efforts by the Royal College of Physicians, among other institutions,
to improve the quality of discharge summaries, for example, are important. The linear increase in risk is
seen across a broad range of BP measurements.
Situating our findings in a translational framework
Our health systems need to innovate new interventions, to evaluate them in clinical trials and to ensure that the
implementation of effective treatments in clinical practice is rapid and complete. Our exemplars illustrate key
stages along this pathway in the ‘prequel’ to trials, trial conduct and the subsequent implementation of findings
(‘sequel’) (Figure 76). From the perspective of the pharmaceutical industry, the Association of the British
Pharmaceutical Industry (ABPI) Big Data Road Map498 highlighted the importance of EHRs in the life cycle of a
drug. Thus, we present findings on the unmet need, namely clinical areas in which new drugs or new
applications of existing drugs can be targeted. The use of CALIBER phenotyping approaches is informing
approaches in discovery efforts such as the UK Biobank.107 We illustrate how the EHRs can examine associations
across a wide range of disease end points and have the statistical scale and clinical resolution to identify those
end points that are likely to be the most important for inclusion in the primary end points of trials. We provide
evidence on the validity of drug targets, for example heart rate-lowering drugs. We demonstrate how risk
1 2 3 4 5 1 2 3 4 5
90 – 114
115 – 129
130 – 139
140 – 159
160 – 179
> 180
BP (mmHg)
Hazard of first AMI
(a) (b)
FIGURE 75 Systolic blood pressure recorded in primary care and hazard of a first AMI among a cohort of
1.25 million people in CALIBER initially free from CVD. (a) Age 30–59 years; and (b) age 60–79 years. Reproduced
in part from Rapsomaniki et al.38 Copyright © 2014 Rapsomaniki et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited.
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prediction models may be developed and validated, and used to stratify patient selection and inform funders
about real-world cost-effectiveness at different levels of treatment benefit. Thus, at early and late phases of
translation EHRs may provide opportunities to address the first and second translational blocks.
Situating our findings in the context of a learning health-care system502
In the 2015 State of the Union address, Barack Obama announced a new personalised medicine initiative:
Tonight I launch a New Precision Medicine Initiative . . . to give all of us access to the personalized
information we need to keep ourselves and our families healthier. [The Initiative will] catalyze a new
era of data-based and more precise medical treatment.
White House Fact Sheet2
The situation of the health-care system today is that data are largely inaccessible, which results in missed
opportunities and waste (Figure 77).
The vision (Figure 78) is the development of a continuously learning science health-care system that joins
together science, evidence and care to provide seamless care that is ‘efficient, delivers increased value, and
is continuously innovating and improving in its ability to deliver high value to patients’.502
The Farr Institute–Association of British Pharmaceutical Industries forum
In order to enhance the scale and impact of these, and other, exemplars we launched the Farr–ABPI forum
with 25 companies and 14 universities represented among the 120 delegates at the first meeting in
December 2014. Addressed by the new Life Sciences Minister, George Freeman MP, we announced at this
meeting the signing of a memorandum of understanding between ABPI and the Farr Institute to accelerate
collaboration both at the pre-competitive and competitive phase.
ClinicAl disease research using LInked Bespoke studies and Electronic
health Records
Raw EHR data require significant amounts of pre-processing in order to be transformed into research-ready
variables for statistical analysis. We have established a methodological framework and novel approaches
using CALIBER data (Figure 79) to address the challenges associated with EHR data. By means of an iterative
and collaborative cross-disciplinary framework we created, validated and curated EHR disease and risk factor
phenotypes. Farr London is working to achieve data linkages, tools for visualisation and interrogation, and
standard statistical approaches, whereby the interrogation of clinical outcomes in relation to drug safety,
with diverse EHR linkages including primary and secondary
care, and disease and death registries
Computable
trial protocols
Eligibility Consent Randomisation Data capture Long-term 
follow-up
Accessing, integrating and phenotyping diverse EHR sources
to create deeper phenotypes 
from hospitals, m-health, 
genomics and imaging
Large biobanked cohorts National EHR sources Emerging EHR sources
Trial design Trial conduct Implementation
(e.g. standardised)
(e.g. by genotype
or phenotype)
(e.g. generic 
consent and
consenting tools)
(e.g. rapid, dependent on
genotype/phenotype)
(e.g. automated
outcomes, SUSARs)
(e.g. effective 
automated
collection)
Unmet
need?
Trials
pipeline
1. Clinical
epidemiology
2. Informatics
tools
3. Underpinning
data platform
Diverse EHR
data sources
Specify
end-points?
Risk prediction
algorithms?
Target
validation?
Develop
interventions?
Size and significance of the
second translational gap?
(e.g. HCM) (e.g. HDL-C) (e.g. harm vs. 
benefit)
(e.g. resting HR) (e.g. pre-emptive 
genomics)
(e.g. BP real-world evidence)
Prequel Sequel
FIGURE 76 Exploiting diverse EHRs for clinical research exemplars driving design, conduct and implementation of
clinical trials. HCM, hypertrophic cardiomyopathy; HDL-C, high-density lipoprotein cholesterol; HR, heart rate;
SUSAR, suspected unexpected serious adverse reaction.
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quality of care and pathways of care over the patient journey becomes an established, high-quality
component of clinical research. We have developed and evaluated e-health data based around multiple
imputation methodology, which addresses issues in record linkage, missing data and measurement error, as
well as methods for causal inference. Research into the design of solid information systems that will harness
clinical knowledge and improve the delivery of health services requires close engagement with everyday
health care to develop systems that are to be used and are useful. We anticipate that the showcasing of this
report will result in the use of the CALIBER platform expanding substantially.
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FIGURE 78 Vision for providing best care at lower cost through a continuously learning science health-care system.
Figure reprinted, with permission, from Best Care at Lower Cost: The Path to Continuously Learning Health Care in
America, 2013 by the National Academy of Sciences, Courtesy of The National Academies Press, Washington, DC.502
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FIGURE 77 Missed opportunities and waste in the current health-care system. Figure reprinted, with permission,
from Best Care at Lower Cost: The Path to Continuously Learning Health Care in America, 2013 by the National
Academy of Sciences, Courtesy of The National Academies Press, Washington, DC.502
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The Myocardial Ischaemia National Audit Project and the National Institute
for Cardiovascular Outcomes Research: from audit to research platform
A further indication of the new research culture to which our NIHR programme has contributed is the
evolution of the national cardiovascular registries from stand-alone audit tools to linked engines of
research. The first step in this evolution was the establishment in 2005 of the MINAP Academic Group
(chaired by Adam D Timmis, and including Harry Hemingway and Spiros Denaxas as members), which was
charged with developing the research potential of the MINAP heart attack registry by means of the safe
distribution of data sets to research groups across the UK. The MINAP Academic Group’s success is
reflected in > 60 MINAP papers that have been published in the last 9 years, some of which have been
presented in this report. Our group contributed significantly to this large research output and, significantly,
established international collaborations with investigators across multiple centres in analysis of pre-hospital
thrombolysis503 and with the ACTION (USA)57 and SWEDEHEART (Sweden)55 investigators in ongoing
comparative analyses. The outputs from these analyses have provided the first whole-country international
comparisons of the management and outcomes of AMI, providing a new benchmark against which to
assess service delivery in the UK.
Meanwhile, the new research culture has extended its footprint at NICOR which, following a successful
Healthcare Quality Improvement Partnership bid from a group that included Harry Hemingway and Adam
D Timmis, now houses all the major national cardiovascular registries [National Adult Cardiac Surgery Audit
(NACSA), National Audit of Percutaneous Coronary Intervention, National Audit of Cardiac Rhythm
Management (CRM), National Audit of Congenital Heart Disease (CHD), National Heart Failure Audit and
MINAP], and is making data available to research groups across the cardiovascular spectrum. These
developments contributed to establishment of the Farr Institute of Health Informatics Research.
The Farr Institute of Health Informatics Research
The translational potential of the UK’s EHRs for enhancing our understanding and management of CVDs
and other diseases, for developing risk models and personalised treatment strategies, and for running
low-cost, high-volume clinical trials has been recognised by central government72 and considerable funds
have been made available for EHR research. In 2012, a consortium of 10 UK funders, including NIHR and led
by the MRC, awarded £19M for the establishment of four research centres in London, Manchester, Scotland
and Wales (the Farr Institute of Health Informatics Research), which were charged with harnessing the
research potential of EHRs for research to improve health and health care. In 2013, a further £20M of MRC
capital was awarded after the speech by the Chancellor of the Exchequer, George Osborne, to the Royal
Society1 to establish physical institutes and e-infrastructure, including ISO27001 data safe havens.504
The Farr Institute London (under the directorship of Harry Hemingway), in addition to its work in CVDs,
has rapidly developing research programmes across diabetes, infection and child and maternal health,
spanning the translational cycle and exploiting our nationally leading informatics strengths in areas of
major clinical and public health importance to develop more effective treatments, improve drug safety,
identify risks to public health and gain insight into the cause and development of diseases by linking
anonymised patient records and health research data. The Farr Institute is developing innovative
methodological approaches to the health informatics data cycle, which is central to high-quality patient
care and translational research, particularly where we can scale innovation across the UK and drive
capacity development through the strategic development across partner organisations of training and
career opportunities for clinicians, those in technical and enabling roles, and the wide range of academic
disciplines relevant to health informatics research, and where we can promote a new culture of
engagement between the public, patients, clinicians and researchers based on the joint development of
consent models and EHR research to improve patient care and public health.
UK Life Sciences Strategy
A major focus of our NIHR programme and the UK Life Sciences Strategy16 is based on record linkage of
national electronic registries recording primary care (CPRD), heart attack (MINAP), hospital admission (HES)
and cause-specific mortality (ONS) data. Our record linkage platform was a precursor to two significant
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developments in the field of linked EHRs. First, the establishment of an informatics platform for research in
the form of the CPRD was recommended in the Strategy for UK Life Sciences report.16 CPRD, a £60M
investment by the NIHR and MHRA, was launched in March 2012 and provides access to data that support
clinical trials and population observational studies on an unprecedented scale.494
National Institute for Health Research and the Health
Informatics Collaborative
Our programme of research, and the work of the Farr Institute more generally, has directly catalysed other
NIHR investments. These include the HIC, an initiative to identify and share data across the five large
biomedical research centres in England.
Department of Health Cardiovascular Disease Outcomes Strategy
As recommended in the Department of Health Cardiovascular Disease Outcomes Strategy,72 CVD
represents a single family of diseases and conditions linked by common risk factors and the direct effect
they have on CVD mortality and morbidity, and they should be managed as such. We used data to
deconstruct CVD into 12 different phenotypes and demonstrated heterogeneous associations with BP and
other major coronary risk factors.37,38,232
In recognition of the growing importance of ‘real-world evidence’ from EHR studies, NICE has established
a new committee on observational data, of which Harry Hemingway is a member.
Clinical practice guidelines from the National Institute for
Health and Care Excellence and professional societies
Research based on EHR has begun to inform clinical guidelines. The research that underpinned our NIHR
programme application has informed national guidance in the last 5 years (Table 45). Co-investigator
Adam D Timmis chaired – and Chief Investigator Harry Hemingway was a member of – the National
Guideline Development Groups on the investigation of chest pain (NICE CG95).202 Adam D Timmis also
chaired the group that produced the management of stable angina guideline (NICE CG126),508 which was
published 1 year later, and coauthored the ESC guideline on the management of SCAD.233
Over the past 50 years, the exercise ECG had been the most widely used non-invasive test for investigating
suspected angina in patients. However, our multicentre study of UK chest pain clinics, showing that the
exercise ECG added little to risk assessment,505 led to a paradigm change in diagnostic testing, with NICE
recommending that the exercise ECG should no longer be used in the investigation of patients with
suspected angina.202 This recommendation has since gone on to change clinical practice. Thus, in 2010,
it was reported that:
The proportion of the study population before and after the guidelines undergoing exercise testing
was 50.1% vs 0.0%; for calcium score/CT coronary angiography 0.0% vs 14.7%; for functional
imaging 25.6% vs 13.4%; and for invasive coronary angiography 15.3% vs 25.8%.
Haq et al.506
The proportion of patients who did not require further testing was 30.0% before compared with 31.0%
after guidelines, a figure that remained unchanged. In 2013, it was reported that ‘implementation of the
2010 NICE guidance . . . resulted in a greater proportion of initial discharge to primary care with less
frequent outpatient review and similar rates of referral for coronary angiography’.507
This shift in clinical practice has led to an increase in the use of CT coronary angiography, as its high
diagnostic sensitivity makes it more useful than the exercise ECG as a rule-out test in patients with a low
probability of disease.515 Its use in patients with an intermediate pre-test probability of disease is also
increasing based on evidence of superior prognostic performance compared with the exercise ECG.516
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TABLE 45 Influence of our work on clinical guidelines
Clinical area
Policy
document Influence on policy
Guideline
recommendation Impact
Investigation
of chest pain
NICE CG95202 AD Timmis chaired
and H Hemingway
was a member of
guideline development
group. Citations to our
research: Sekhri et al.;505
Zaman et al.147
Do not use exercise ECG
to diagnose or exclude
stable angina for people
without known CAD
1.3.6.5
For people with
confirmed CAD (for
example, previous MI,
revascularisation,
previous angiography),
offer non-invasive
functional testing when
there is uncertainty about
whether chest pain is
caused by myocardial
ischaemia. . . . An
exercise ECG may be
used instead of
functional imaging
1.3.4.8
Do not define typical and
atypical features of
anginal chest pain and
nonanginal chest pain
differently in men
and women
1.3.3.2
Do not define typical and
atypical features of
anginal chest pain and
non-anginal chest pain
differently in ethnic
groups
1.3.3.3
‘The proportion of the study
population before and after
the guidelines undergoing
exercise testing was 50.1%
vs 0.0%; for calcium score/
CT coronary angiography
0.0% vs 14.7%; for
functional imaging 25.6% vs
13.4%; and for invasive
coronary angiography
15.3% vs 25.8%’.506 The
proportion of patients who
did not require further
testing was 30.0% before
compared with 31.0% after
guidelines, a figure that
remained unchanged
In 2013, it was reported that
‘implementation of the 2010
NICE guidance. . .resulted in
a greater proportion of initial
discharge to primary care
with less frequent outpatient
review and similar rates of
referral for coronary
angiography’507
These two recommendations
(arising from Zaman et al.147)
for the first time make an
unequivocal statement to
clinicians that typical anginal
pain does not differ by sex
and ethnicity. This is
important because it has
previously been used as a
post hoc justification of why
rates of procedure use might
differ between these groups
Management
of stable
angina
NICE CG126508 Citations to our
research: Griffin
et al.509
When either procedure
would be appropriate,
explain to the person the
risks and benefits of PCI
and CABG for people
with anatomically less
complex disease whose
symptoms are not
satisfactorily controlled
with optimal medical
treatment. If the person
does not express a
preference, take account
of the evidence that
suggests that PCI may be
the more cost-effective
procedure in selecting
the course of treatment
1.5.5
Our studies on
appropriateness (Griffin
et al.509) have been part
of a growing evidence base
which has led to a slowing
in the rate of increase of PCI
for SCAD
Previous prognostic models
have not been validated. We
have addressed this gap
using an external data set to
validate our prognostic
models, and demonstrate
how real-world clinical data
(as distinct from research
data) contribute important
prognostic information in
unselected patients
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TABLE 45 Influence of our work on clinical guidelines (continued )
Clinical area
Policy
document Influence on policy
Guideline
recommendation Impact
When either procedure
would be appropriate,
take into account the
potential survival
advantage of CABG over
PCI for people with
multivessel disease
whose symptoms are not
satisfactorily controlled
with optimal medical
treatment and who:
have diabetes or are
over 65 years or have
anatomically complex
three-vessel disease, with
or without involvement
of the left main stem
1.5.6
Discuss the following with
people whose symptoms
are satisfactorily controlled
with optimal medical
treatment: their prognosis
without further
investigation (noting that
existing prognostic risk
scores have not been
validated)
1.5.11
Offer people optimal
drug treatment for the
initial management of
stable angina. Optimal
drug treatment consists
of one or two
anti-anginal drugs as
necessary plus drugs for
secondary prevention of
cardiovascular disease
1.4.1
(Rapsomaniki et al.52).
Evidence from our study
suggests implementation of
the CALIBER prognostic
models in EHRs in clinical
practice would support
risk stratification, as
recommended in clinical
guidelines
Our work on secondary
prevention showed that
omission of secondary
prevention drugs from the
discharge prescription of
patients with AMI has a
variable effect depending on
the specific drug omissions.
The data suggest that
beta-blockers and statins are
associated with the greatest
protection against death
that is sustained in the
longer term. However, the
benefits of continuing
treatment with antiplatelet
drugs and ACEIs appear to
decline beyond the first
12 months
NICE.
Management of
Stable Angina.
Evidence
Update 23510
Citations to our
research: Sutaria
et al.511
Prognostic value of
natriuretic peptides:
The evidence found by
the review comprised
early-phase studies of
limited quality. There is
therefore currently a
lack of robust, clinically
meaningful evidence for
the use of natriuretic
peptides in prognosis of
stable coronary disease.
This is consistent with
the absence of
recommendations from
NICE CG126 for the
use of biomarkers in
prognosis of stable
angina
1.3
Based on our published
findings (Sutaria et al.511),
the evidence update
recommended extending
existing systematic reviews
continued
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Our research further influenced these NICE guidelines by showing that relationships between typicality
of symptoms and prognosis in patients with suspected angina are unaffected by sex and ethnicity.
Based on these findings, NICE CG95202 stated: ‘Do not define typical and atypical features of anginal and
non-anginal chest pain differently in men and women (or) in ethnic groups.’ Indeed, our research, which
was cited in the 2013 ESC guideline on the management of SCAD, has shown that angina is almost as
common in women as in men with similar prognostic associations.517
TABLE 45 Influence of our work on clinical guidelines (continued )
Clinical area
Policy
document Influence on policy
Guideline
recommendation Impact
During the development
of the Evidence Update,
the following evidence
uncertainties were
identified for the NHS
Evidence UK Database of
Uncertainties about the
Effects of Treatments
(UK DUETs)
General principles for
treating people with
stable angina
l Biomarkers in SCAD
for prognosis
What is needed?
l Extending existing
systematic reviews
Management
of SCAD
Montalescot
et al.233
Coinvestigator Adam D
Timmis was a member
of the guideline
development group
and coauthored the
guideline
Citations to our
research: Hemingway
et al.49
Sutaria et al.511
Biochemical tests:
Although there may
be some additional
prognostic value in other
biomarkers, there is
insufficient evidence to
recommend the routine
use of natriuretic
peptides, haemostasis
markers or genetic
testing in the
management of patients
with SCAD233
6.2.1.1
One important area that
we highlight is the need
to identify clear clinical
terms that can help in
decision-making. For
example, the term SCAD is
used to cover people with
a history of myocardial
infarction and those
without. Furthermore, there
is no current consensus on
the definition of the time
after an AMI at which
patients become stable nor
what risk should be defined
as ‘high’
Management
of ACS
NICE technology
appraisal
guidance on
ticagrelor
(TA236)512
Making
recommendations
about the prolonged
use of dual antiplatelet
therapy after AMI513
Ticagrelor combined with
low-dose aspirin is
recommended for up to 1
year as a possible treatment
for some people with ACS
Evidence to the committee
included unmet need in four
countries (USA, UK, France
and Sweden), and the extent
to which participants
selected into the Pegasus
trial had different rates of
the primary benefit end
point (atherothrombolic
events) and the primary
safety end point (major
bleeding)513,514
MI, myocardial infarction.
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All the contemporary guidelines for patients with SCAD emphasise the importance of prognosis in guiding
management decisions, starting with an evaluation based on simple clinical parameters. However, existing
prognostic models have been based on data collected for research purposes rather than the information
that clinicians record in real-world practice, and none has been recommended for clinical use. An
important potential impact of our work, therefore, has been the presentation of a clinically applicable
prognostic model for patients with SCAD that incorporates the broad range of clinical characteristics
highlighted by these guidelines, many of which (atrial fibrillation, cancer, liver disease, depression, anxiety
and haemoglobin) have not previously been incorporated in prognostic models for SCAD.
Research governance, methods and training
Impact of methodological contributions
Prognosis research findings should be integral to clinical decision-making, health-care policy and discovering
and evaluating new approaches to patient management. We have discussed a worrying gap between the
potential and actual impact of prognosis research on health, with studies often falling a long way short of
the high standards required in other fields, such as therapeutic trials and genetic epidemiology. Our
PROGRESS initiative published a series of 24 recommendations as a framework for researching clinical
outcomes, to promote high-quality prognosis research leading to patient benefit, which centred on how the
field can be developed and its impact broadened,29–32 and we have promoted transparency of research,
emphasising measures such as registration of studies, sharing of data and protocols.33
Following our and others’115 recommendations, the open-access journal PLOS Medicine took the significant
step of publishing new guidelines for observational studies to facilitate assessment of the reliability of
published observational research.518 These included: (1) submission of Strengthening the Reporting of
OBservational studies in Epidemiology (STROBE; www.strobe-statement.org/index.php?id=available-
checklists) or Standards for Reporting Diagnostic Accuracy (STARD; www.equator-network.org/reporting-
guidelines/stard/) checklists at the time of submission of manuscripts to the journal; (2) incorporation of
data-sharing requirements in PLOS data policy; (3) clear specification of hypotheses, what was done and
any deviation from the protocol by researchers; and (4) submission of analytic protocols on submission of
the manuscript to the journal, whereby the ‘. . . goal (is) not only to establish these practices for PLOS
Medicine but to advocate for such transparency as a standard within the research community’.518
Training and capacity development
It is widely acknowledged that there is a substantial international shortfall in people trained to make sense
of, and analyse, EHR data. The Farr Institute of Health Informatics Research is addressing this concern and
will train a new cadre of health informaticians and related methodologists, providing the academic and
professional underpinning of world-leading e-health innovation from the UK. We are also committed to
offering opportunities in the form of a doctoral training programme, a series of taught courses and career
development and leadership development.
Our NIHR programme has supported a number of postgraduate degrees and career development positions
with a total of 13 Master of Science dissertations and 12 doctoral awards arising from the programme.
Individual awards are listed in Appendix 8.
We have presented our findings at key conferences (see Appendix 9). We held three prognosis research
workshop meetings in London in 2011, which were attended by opinion leaders in the field and journal
editors and which led to the development of five thematic papers published in the BMJ and PLOS
Medicine. The themes were as follows: (1) What is the prognosis of this disease?; (2) Is this a causal factor
for disease?; (3) What impact does this risk prediction model have?; (4) Is there treatment-factor
interaction?; and (5) What is the case for study registration and analytic protocol publication?
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We held short courses on the concepts, methods and clinical application of prognosis research in 2013 and
2014 at our annual international PROGRESS summer school at Keele University. We have also been involved
in running courses at the Netherlands Institute for Health Sciences Erasmus Short course programme and, in
March 2015, Farr London ran a unique, intensive programme of 13 inter-related short courses spanning a
wide range of basic and applied health research applications in the field of EHRs. This training heralded a
unique opportunity for high-quality training harnessing EHRs for research for people from a wide range of
backgrounds, including health care, epidemiology, biostatistics, health informatics, NHS information
technology, bioinformatics, genomics and computer science, and at different career stages.
Media, journals and national awards
Media
Our research has generated media interest across national radio, television and clinical journals. Our work
on 1-year survivors of heart attack was featured on ITV’s ‘This Morning’ (September 2014) and in a series
of radio broadcasts over 1 day (BBC Newcastle, September 2014).
New scientific journals
Circulation: Quality and Outcomes was the first cardiac journal devoted to the new prognosis research
culture. It was launched in 2008, with Harry Hemingway an Editorial Board member, and has played an
important part in defining the scope of EHR research and disseminating its outputs. Soon to be launched
is the European Heart Journal: Quality of Care and Outcomes, the second journal in this field with Adam D
Timmis appointed the founding editor. The involvement of our group in the editorial boards of these new
journals is based largely on international recognition of the quality of our EHR research programme.
National awards
Adam D Timmis’ work in utilising electronic registry data for evaluating chest pain clinics resulted in his
work being shortlisted for the BMJ Group Award for Outstanding Achievement in Evidence Based
Healthcare. Quint et al.59 were voted runners up in the BMJ UK research paper of the year award (2014)
for their work on the effect of beta-blockers on mortality after AMI in adults with COPD (see Chapter 11).
The award recognises original UK research that has the potential to contribute significantly to improving
health and health care.
Recommendations for future research
We propose three priority directions for further research. First, there is an urgent need to ‘unlock’ more
detailed data within hospitals, to expand the coverage of the UK’s 65 million population with primary care
data available for research, and to expand and make sustainable the range of record linkages (e.g. to a
wider range of disease registries). Second, there should be major expansion in the underlying methods
and applications of scaled approaches to using EHR to design and carry out trials and interpret the
implementation of trial results. This is important for delivering learning health systems and patient benefit.
Third, large-scale, disease agnostic DNA and biological collections linked to such EHRs are required in order
to deliver precision medicine and innovate discovery of new drug targets or repurpose existing drugs.
Our work has highlighted a number of priority research questions with the potential to have an impact on
patient benefit in two areas:
1. Next steps in realising the potential of EHR research, which is agnostic to disease, relevant across
different stages of translation and applicable to both prevention and treatment.
2. CVD-specific clinical questions for patients at risk of, and with, CVD. A summary of these clinically
specific recommendations is presented in Table 3.
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Research approaches with electronic health records
The CALIBER resource consists of a combination of highly trained staff, data resources and tools,
specialised infrastructure, and training and support. CALIBER operates a collaboration-driven data-sharing
model and promotes the transparent and scalable use of EHR data for research by utilising a structured
approach for developing and validating phenotyping algorithms and providing a central, online repository
for the storage and distribution of algorithms, documentation (flow charts, free-text description,
pseudocode) and metadata. To date, the resource has supported 51 individual projects with more than
50 published manuscripts and more than 1000 citations across a range of diseases including, but not
limited to, multimorbidity, dementia, lower back pain, cancer, type 2 diabetes, infection and epilepsy.
Details on CALIBER are available at www.caliberresearch.org/ and information on how to access the
CALIBER resource is available at www.ucl.ac.uk/health-informatics.
More research is needed that combines EHRs with other forms of research and data to unlock better
health care, both for individuals and the wider population. The development of new programmes of
prognosis research exploiting EHRs to define, phenotype and follow up patients, and a comprehensive set
of cohorts with established disease should be a made a priority, as the capability to link and analyse ‘big
data’ burgeons. Key areas for investment are outlined below.
Hospital informatics
Most data in the NHS reside in hospitals, where they have been inaccessible for research. A wealth of
phenotypic data exist locked within individual hospital electronic systems and, as such, remain largely
untapped for research use. The quality of blood, imaging and other diagnostic data are all improving,
and developments are already under way to enable collaborative sharing of NHS data to facilitate clinical
research (e.g. the NIHR HIC). The Genomics England 100,000 Genomes Project – an ambitious discovery
project involving the sequencing of 100,000 genomes and linkage of genomic information to EHR data) –
makes this a priority area.19
Structured interoperable electronic health records
Electronic health records system design has been predominantly vendor-led, leading to differences in the
way clinical information is structured and difficulties in integrating care records from multiple health-care
sites. Although this is primarily a task for the NHS rather than researchers, demonstrations of interoperable
EHR will be a major lever for future health research.519 The openEHR archetypes (openEHR Release 1.0.2
Architecture overview, 2008; see www.openehr.org/releases/1.0.2/architecture/overview.pdf) are a set of
clinician-led clinical information models, with an international governance and review framework. Vendors
of EHR systems can adopt openEHR archetypes to ensure that patients’ medical records are accessible to
their caregivers and are organised in a way that facilitates audit and research.
Wider coverage of greater parts of the population
The majority of the UK’s 65 million population is registered with a GP, and records are nearly all
computerised. Efforts are required to ensure that coverage of the population is accessible to researchers up
from the current level (e.g. < 10% in CPRD).
Strategic approach to record linkages
Many national sources of health record data remain in silos, unlinked and of limited value for research for
patient benefit. Efforts to date for record linkage have been largely ad hoc. This impedes international
competitiveness by comparison with, for example, Sweden or Denmark. Specifically in CVD, CPRD, NICOR
and HES would be an early priority, with an extension to social care and laboratory databases.
Efforts to understand and improve the quality of electronic health record data
This will involve policy action as well as research cross-referencing multiple structured and unstructured
sources of data. Investigation of electronic free text recorded by GPs, and further research to understand
how EHR data are coded and how coding may be improved, is required.
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Use of electronic health record data in clinical trials to further enhance the
translational potential of electronic health record data
There is a major need for new trial models in clinical research. There is widespread concern that existing
models of the clinical trial pipeline are ‘broken’ because they are too costly and slow, and because
important clinical areas remain undertrialled. EHRs, because of their scale and phenotypic depth, may
contribute to solving some of these problems, and may provide wholly new opportunities to understand
and improve cardiovascular health. There is a need for new studies to develop and evaluate novel tools for
rapidly and efficiently addressing issues related to the design and conduct of trials, including EHR
phenotyping (using clinical, imaging, genomic and sensor data), and increase discoverability and
accessibility of these data for research purposes (‘prequel to sequel’ approaches to the trials pipeline).
Our research has highlighted the usefulness of EHR data to understanding outcomes in CVD. Use of ‘big
data’ should now be extended to investigate how EHRs can understand and improve quality and outcomes
of care in other devastating disease areas, such as cancer and dementia.
Cardiovascular disease-specific research recommendations
Our findings also point to a number of specific recommendations for further research, across the patient
journey and for different CVD phenotypes.
How does cardiovascular disease first present?
Research efforts should take account of the way in which CVD first presents in the 21st century,
with the importance of PAD and heart failure and other chronic conditions (and the decline of AMI and
acute stroke).
Incidence of coronary heart disease and influence of health inequalities on
outcomes (see Chapter 3)
l Estimates of national and global burden of CVDs need to take account of the modern epidemic in
which heart failure, PAD and other chronic diseases are becoming more common than AMI and stroke.
Male sex, older age, South Asian ethnicity and low social deprivation, despite being associated with
many CVDs, are not associated with all, and this heterogeneity has implications for research into risk
prediction, aetiology and prognosis.
l Large cohort studies identified through the linkage of primary care, ACS registry, hospitalisation and
cause-specific death data are warranted to better understand how South Asian ethnicity influences the
onset and progression of coronary disease and other CVDs. Such studies will allow longitudinal patterns
of risk, and missed opportunities to lower risk before admission and after discharge, to be evaluated.
Understanding the impact of risk factor modification in cardiovascular
diseases deconstructed into 12 different phenotypes (see Chapter 4)
l Our novel, contemporary, high-resolution studies showed heterogeneous associations for BP across a
wide range of CVDs. New and existing clinical trials investigating the effectiveness of BP-lowering
strategies should include other common initial CVD presentations as the primary outcome.
l New approaches are required to close the second translational gap in BP lowering. This may include
research on clinical decision support for multiple drug classes to achieve target BP levels and other
interventions, as well as understanding how best to lower absolute cardiovascular risk.
Initial presentation of coronary disease and opportunities for earlier diagnosis
(see Chapter 5)
l Contemporary prognostic models should be developed based on the characteristics of patients
presenting with unspecified chest pain so that those at risk of cardiovascular events can be more
accurately identified.
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l Further research is warranted to better characterise the phenotypes, causes and prognosis of
unheralded STEMI and NSTEMIs to improve the usability of EHRs for research. Analyses comparing AMI
patients with a control group of patients without AMI, including a comparison of missed opportunities
for care in measuring and controlling elevated risk, is warranted.
l Further development of natural language processing algorithms such as FMA and S3CM may improve
the usability of EHR for research on CVDs and symptoms.
Further evaluation of the potential for use of clinical decision support in
assessment of angina in chest pain clinics (see Chapter 6)
l The assessment of chest pain is difficult, and, although the diagnosis of angina may be enhanced by a
suitable CDSS, our study showed that incorporating such potentially useful tools into clinical practice is
challenging. More research is needed to explore the potential for developing new tools to aid clinical
decision-making with a greater likelihood of being adopted in practice.
Intensifying collaborative efforts in prognosis research (see Chapter 7)
l Collaborative research based on individual patient data should be encouraged, in order to strengthen
prognostic model development and external validation. This is timely, with new standards to improve
the quality of prognosis research29,518 and new opportunities to link clinical health-care data with other
sources of electronic information and bespoke data at scale.
l Proposals to link clinical data systems locally and embed patient consent for research into clinical care
would mitigate the complexities of obtaining complete data and recruiting patients in busy clinical
settings, and thereby increase the utility of such cohorts.
Further evaluation of prognostic risk factors (see Chapter 8)
l With biomarker and -omics research generating a wealth of possible new factors to incorporate into
models, the extent to which new markers add value to existing models needs to be evaluated.
Improved methodology and further research, including the design of new clinical trials and clinical
cohorts, is warranted to assess the incremental prognostic value of biomarkers in risk stratification
of patients.
l We recommend new clinical trials to assess whether or not haemoglobin levels are causal and whether
or not clinicians should intervene to increase haemoglobin levels.
l In designing randomised trials, the target population, the choice of composition of the primary end
point and the likely rate at which the end point accrues can all be informed by the examination of
linked EHRs.
l New clinical cohorts are needed with published pre-specified statistical analytic protocols and
prospective registration of studies, which can be pooled to evaluate the true usefulness of the role of
CRP in prognosis in SCAD.
l More work should be carried out to determine the effect of mechanistic differences for the differential
genetic effect, to enhance understanding of the underlying reasons. Our findings argue for a
consortium of studies set in individuals with established CHD to better understand the genomic
susceptibility to subsequent CHD events and also to perform detailed analysis, including assessment for
selection biases, which is not possible with literature-based meta-analyses.
l Methods for dynamic risk prediction in which the patterns of change of clinically measured biomarkers
can be incorporated into clinical decision support models in clinical practice are required.
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Evaluation of prognostic risk models and cost-effective targeting of interventions
(see Chapter 9)
l Further independent evaluation of prognostic models is required in different settings, including
different EHR systems, health-care organisations and geographic locations to guide their use in
clinical practice.
l Economic evaluation is needed to establish the appropriateness of using our and other prognostic
models in practice. Models should be extended to explicitly capture the trajectory of prognostic risk
factors over time, to address broader questions around the cost-effectiveness of interventions that
target underlying risk factors.
Opportunities to improve cardiovascular outcomes for acute coronary
syndrome patients during and after hospitalisation (see Chapter 10)
l International harmonisation of detailed measures of quality of care in clinical registries, such as
pathways of care, is needed to identify and evaluate additional patient-level health-care factors that are
not measured here, which might explain differences between countries.
l Outcomes should be compared with those in other countries, such as France, Hungary, Poland and the
USA, through the assessment of national registries.
l Linkage to national EHRs will extend comparisons to include ambulatory care before and after
admission for heart attack, non-fatal events and longer-term outcomes.
l Outcomes research specifically designed to follow care into the primary care setting is warranted to
quantify the full implication of CMOCs.
l Further studies are needed to better explain patterns of clinical practice within and outside the UK,
such as rates of coronary angiography and PCI.
l Future research, both in larger prospective epidemiological studies and RCTs, of the promotion of GP
smoking cessation interventions, the association between interventions and cessation, and the effects
on long-term clinical outcomes is warranted.
Improving outcomes for acute coronary syndrome patients beyond clinical trials
(see Chapter 11)
l We have shown that ‘real-world’ data can provide important information beyond that generated by
clinical trials to guide prescribing decisions.
l Combinations of drugs that are recommended to be taken for the rest of a patient’s life but that have
not been evaluated in RCTs should be investigated in observational studies for associations with fatal
and non-fatal outcomes over the remaining life expectancy.
l A RCT is justified to examine the effectiveness of beta-blockers after AMI in patients with COPD.
l Methods are required by which a learning health system can interrogate the safety of drugs and
drug–drug interactions in a timelier and more scaled fashion.
l Further research, incorporating methods of causal inference, is required to fully investigate the extent
to which the association between clopidogrel discontinuation and adverse events we identified was
causal or was confounded by the influence of unrecorded comorbidities or bleeding events.
International comparisons (see Chapter 12)
International comparisons of care and outcome registries are needed to identify key areas that could be
targeted to improve outcomes and inform new research and policy initiatives to improve the quality of
health systems. International comparisons are an integral component of contemporary prognosis research
and further comparisons with other national registries, for example in the USA, China and New Zealand,
are needed to inform the relative performance of health-care systems. Further work is required to
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determine the competing benefits of targeting underperforming hospitals or developing a national
programme of quality improvement for implementation across all hospitals. In particular:
l further research is required to obtain real-time, risk-adjusted, treatment-adjusted estimates of
between-hospital variation in mortality and a wider range of non-fatal outcomes
l further work is necessary to assess the distribution of AMI patients across hospitals and other hospital
characteristics that contribute to patient outcomes
l opportunities for more ambitious comparisons along the care pathway should be exploited by linkage
to national EHRs, which would permit an analysis of non-fatal events before and after hospital
admission and longer-term outcomes
l mixed-methods research is required to inform actions to reduce hospital variations in care
and outcomes.
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Appendix 1 Summary of published papers
relating to individual studies in the programme
Study
number Authors Title Journal
Year of
publication
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2012
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Prognosis Research Strategy
(PROGRESS) 1: a framework for
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Timmis A, et al.57
International comparisons of the
management of patients with
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2014
25 Boggon R, Timmis A,
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following acute coronary syndrome:
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2014
27 Quint JK, Herrett E,
Bhaskaran K, Timmis A,
Hemingway H, Wedzicha JA,
Smeeth L59
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BMJ 2013
28 Douglas IJ, Evans SJ,
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Clopidogrel and interaction with
proton pump inhibitors: comparison
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BMJ 2012
29 Boggon R, van Staa TP,
Timmis A, Hemingway H,
Ray KK, Begg A, et al.61
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acute coronary syndromes:
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myocardial infarction – a hospital
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(MINAP-GPRD)
European Heart
Journal
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32 Chung SC, Sundström J,
Gale CP, James S, Deanfield J,
Wallentin L, et al.62
Comparison of hospital variation in
acute myocardial infarction care and
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cohort study using nationwide
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BMJ 2015
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Appendix 2 Transcript from clinician interview
on what role can computerised decision support play
in clinical decision-making in the Optimising the
Management of Angina study?
INT-NAB: Yeah but sometimes you need, you need to make thing, make sense of yourself, you don’t
totally rely on technology to, to make your own decision or change your own decision. But that
depends on experience and, and err other factors. [. . .] You need to guide the technology not the
technology guide you.
FS2-FG: There will always be outside cases [. . .] and I think it would be wrong to try and make a tool
that [. . .] does everything because then it would be, because it would lose meaning, you know.
FS3-FG: I think the whole nature of it, it would have to err on the side of caution wouldn’t it . . .
because that’s the way these tool kits work because you haven’t got the whole experience aspect
behind it to be able to make a judgement, that’s what the tool can’t do, is to do that judgement side
of it.
INT-VAL: If you’ve got a full validated tool [. . .] and you’ve got good studies that support it and all the
rest of it then you probably would trust it, but I think initially, well like I do with this, I would use it to
compare my decision with what . . . I mean it’s difficult because subsequently the tool represents a
guideline doesn’t it! That’s how it is in my mind, and you’re still thinking ‘OK this is what I think I
need to do’ and I know what the guidelines written on a piece of paper say, and maybe I should be
doing that, but my gut feeling tells me ‘before you do that maybe you ought to do something else’.
INT-SUJ: It works like I said, it does work 85% of the time, I mean there are patients who will never fit
into the protocol, that always happens but that needs to be discussed anyway I think, so OMA actually
sort of, in a way screens patients who fit into the straight part of it and the good thing is for the
people fitting into the straight part of it, it gives you a decision so that it could be used by the juniors.
Now if they don’t fit into the straight part where it is good, the juniors need to discuss with
the seniors.
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Appendix 3 Transcript from clinician interview
on clinicians’ perceptions of possible uses of the
Optimising the Management of Angina clinical
decision support system in clinical practice
Reassurance
I think part of it does because you kind of sometimes you’ve got that niggle at the back of your mind
. . . are you making the right decision or not . . . and most of the time it is clear cut one way or
another but you will always have that kind of borderline patients and there is something in the back
of your mind that thinks wow, I’m not 100% and as a reassuring tool maybe or not or partially yes
steer your decision, I think yes, it will be useful.
INT-VAL
Training for junior doctors
I think it would be useful for less experienced professionals, you know that’s the most important thing
. . . because it gives you a suggestion. N and myself we are both are doctors and we can decided on
our own. J is very experienced but in many other areas you find many juniors doing it or even not
doctors doing the chest pain clinic.
INT-SUJ
Helping to implement National Institute for Health and Care
Excellence guidance
That was what stuck in my mind, because that was the first question. What does the tool say? So I
think where, certainly a couple of the cardiologists that are fully on board with this, I think where they
see it fitting in is helping to imbed what NICE requires us to do.
INT-JT
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Appendix 4 Participant consent form used in the
Clinical Cohorts in Coronary disease Collaboration
study
My Healthy Heart 
Participant consent form
Chief investigator:  Professor Harry Hemingway  
 
Thank you for reading the information sheet about the ‘My Healthy Heart’ study 
examination.  Please read this consent form carefully and put your initials in the boxes by 
the items to which you agree or give your consent. Please put a line through the box if you 
do not wish to give your consent to a particular item.  
 
1. I have read and understand the information sheet dated 10th July 2012 (version 1.2A), and  
and have had the opportunity to ask questions.       
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time  
without giving any reason.  
 
3. I understand that I may be contacted again by the study team (e.g. to answer some more 
questions and/or attend another assessment visit), but this is optional. 
 
4. I give permission for long-term storage and use of my blood samples for health-related research 
purposes (even after my incapacity or death), and relinquish all rights to these samples which I 
am donating to the My Healthy Heart study. 
 
5. I give permission for full access to my past, present and future medical and other health-related 
records, and for long-term storage and use of this and other information about me, for health-
related research purposes (even after my incapacity or death).  I understand that information held 
and managed by The Health and Social Care Information Centre and other central UK NHS 
bodies may be used in order to help contact me or provide information about my health status. 
DOI: 10.3310/pgfar05040 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hemingway et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
291
6. I understand that all research data will be anonymised in a form that will preclude me from being 
identified personally, and all data will be stored securely at the study co-ordinating centre.  
7. I understand that none of my results will be given to me including my blood results.
 
 
 
8. I agree to take part in this study. 
 
 
 
 
___________________________    __________________       __________________________ 
Name of participant (CAPITALS)        SIGNATURE                         Date (dd/mm/yyyy)      
 
__________________________       __________________     ______________________ 
Name of person taking consent     SIGNATURE                          Date (dd/mm/yyyy)       
(CAPITALS)
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Appendix 5 Clinical Cohorts in Coronary disease
Collaboration blood resource: sample collection
and processing
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Appendix 6 Clinical Cohorts in Coronary disease
Collaboration participant baseline health
questionnaire
My Healthy Heart 
Baseline Questionnaire  
Thank you for agreeing to take part in the “My Healthy Heart” study which is seeking to 
improve early detection of possible heart disease and care of people with chest pain or 
chest discomfort.   
 
It is important that you answer all the questions in this questionnaire, which should take 
approximately 5 minutes to complete. Please take your time and answer questions as 
honestly as possible. All information you provide will be kept strictly confidential.  If you 
have any difficulty with any of the questions, the research nurse will be able to help you at 
the clinic.   
 
Please hand your completed questionnaire to the research nurse at the clinic. 
For more information about the study, please contact 
SECTION 1:Background information about you 
   
1a. What is your sex?      Male1                Female2 
 
1b. At what age did you complete your 
continuous full time education? 
 
_________ years 
 
 
      Do not know0 
 
 
SECTION 2: Your general health 
 
The next questions are about your general health. Please indicate which of the statements 
best describe your own health today. Please answer all questions. Please tick only one 
option from each question 
 
2. Mobility   
I have no problems in  
walking about1 
I have some problems  
in walking about2 
I am confined to bed3 
 
 
  
3. Self-care   
I have no problems  
with self care1 
I have some problems 
washing or dressing  
myself2 
I am unable to wash  
or dress myself3 
 
 
  
4. Usual activities (e.g. work, study, housework, family or leisure activities) 
I have no problems 
performing my usual  
activities1 
I have some problem 
performing my usual  
activities2 
I am unable to  
perform my usual  
activities3 
   
5. Pain/discomfort   
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I have no pain  
or discomfort1 
I have moderate pain/ 
discomfort2 
I have extreme pain/ 
discomfort3 
   
   
6. Anxiety/depression   
I am not anxious or  
Depressed1 
I am moderately  
anxious or depressed2 
I am extremely  anxious  
or depressed3 
SECTION 3: Your chest pain general health 
The following questions relate to chest pain, chest tightness or angina you may have 
experienced. Please answer all the questions in this section 
7. Have you ever had any pain or discomfort in 
your chest? 
      Yes1                            No2  
     If no, go to Section 4 
   
8. Do you get this pain or discomfort if you walk 
uphill or hurry? 
      Yes1                            No2 
   
9. Do you get this pain when you walk at an 
ordinary pace on the level? 
      Yes1                            No2 
   
10. When you get this pain or discomfort, what do you do? 
  Stop1    Slow down2              Continue at the                     Not applicable4 
             same pace3 
   
11. Does the pain go away when you 
stand still? 
                    Yes1                        No2 
   
12. How soon does the pain go away? Within 10 minutes  
or less1 
           More than  
         10 minutes2 
 
13. Please mark with an ‘X’ on the diagram below each area you experience pain or discomfort 
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For male participants:                                        For female participants: 
 
Right side                             Left side               Right side                          Left side 
14. Please tick one box that 
best describes your chest 
pain or tightness 
 
I get chest pain or tightness on strenuous exercise1 
 
 
I get chest pain or chest tightness on walking more than 
200 yards on the flat, or climbing stairs rapidly or in the 
cold or under emotional stress2 
 
 
I get chest pain or chest tightness on walking 100-200 
yards on the flat3 
 
 
I get chest pain or chest tightness on any physical 
activity, including at rest4 
 
 
SECTION 4: More about you 
 
Over the last 2 weeks, how often have you been bothered by any of the following 
problems? Please select one answer from each of the following questions: 
15. Little interest or pleasure in doing things 
 
Not at all1 
 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
 
16. Feeling down, depressed or hopeless 
 
Not at all1 
 
 
Several days2 
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More than half the days3 Nearly every day4 
 
17. Trouble falling or staying asleep, or sleeping too much 
 
Not at all1 
 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
18. Feeling tired or having little energy 
 
Not at all1 
 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
19. Poor appetite or overeating 
 
Not at all1 
 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
20. Feeling bad about yourself - or that you are a failure or have let yourself or your family 
down 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
21. Trouble concentrating on things, such as reading the newspaper or watching television 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
22. Moving or speaking so slowly that other people could have noticed. Or the opposite - being 
so fidgety or restless that you have been moving around a lot more than usual 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
23. Thoughts that you would be better off dead, or of hurting yourself in some way 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
24. Feeling nervous, anxious or on edge? 
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Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
25. Not being able to stop or control worrying? 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
26. Worrying too much about different things? 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
27. Having trouble relaxing? 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
 
28. Being so restless that it is hard to sit still? 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
29. Becoming easily annoyed or irritable? 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
 
 
30. Feeling afraid, as if something awful might happen? 
Not at all1 
 
Several days2 
 
More than half the days3 Nearly every day4 
 
SECTION 5:  Ethnicity 
 
31. Please state in which country you were born:________________________ 
 
32. What is your ethnic group? 
White: White British1                              White Irish2  
 Any other white 
background3 
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Mixed race: White and black 
Caribbean4 
          White and black African5  
  
White and Asian6 
  
 Any other mixed background7 
 
 
     
Asian or Asian British: Indian8                                 Pakistani9  
 
Bangladeshi10 
  
 Any other Asian background11 
 
 
     
Black or black British: Caribbean12                                   African13  
 
Any other black 
background14 
   
     
Chinese15     
     
Other ethnic group: 
 
Please state which16 
 
 ______________________  
     
Do not know    
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Appendix 7 Clinical Cohorts in Coronary disease
Collaboration case record form for extraction of
clinical data from the electronic health record
Clinical Cohorts in Coronary disease 
Collaboration  (4C)  
Clinical Case Record Form  
VERSION 1.1 (14.08.13) 
 
 
 
 
 
Case notes reviewed by (recruiter ID):  __ __ __                                                     Date of case note review: __ __ /__ __ / 
__ __          
       
 (full name, for external reviewers):  
 
Site: 001  002  003   004   
Method of admission/setting 
  Elective planned1  Inpatient transfer2  Emergency3  
Final diagnosis 
 
 Stable angina1  Unstable angina2  STEMI3  
NSTEMI4  Non-CAD chest pain5   Other6   
 Specify other: 
 
 
Outcome 
 
 No treatment1  Medical management2  PCI3  
 Surgery4  Further investigation5  Other6  
 Specify further investigation: Specify other:  
 
 
 
 
 
 
       
        
       
Affix unique patient identifier label here 
Patient deceased?      Yes1                                                    Enter date of death          
          D D M M Y Y Y Y 
 
Date of recruitment                                                               
          D D M M Y Y Y Y 
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SECTION A: HISTORY/PHYSICAL EXAMINATION 
A1.  HISTORY OF CHEST PAIN 
1.1 Chest pain/discomfort as a presenting symptom 
Yes1    No2 (go to qn A2)    
1.2  Other symptoms or reasons referred for investigation (tick all that apply) 
Shortness of breath1   Non-specific symptoms8   Palpitations3            Other pain9         
Dizziness10  Syncope11  Pre-operative12      Not recorded7          
Other5  Specify: 
1.3 Chest pain characterization in the history 
Typical1  Atypical2  Non-cardiac4  
1.4 Physician diagnosis 
Stable exertional 
   angina (go to qn A1.5)1 
 ACS: Unstable angina8 
(go to qn A1.7) 
 ACS: STEMI9           
(go to qn A1.7)        
Non-cardiac chest pain4       
(go to qn A2) 
    ACS: NSTEMI10  
(go to qn 1.7)  
 
1.5 If stable angina, based on the history provided about the patient’s activity level select CCS class (select only one option) 
Angina only during strenuous or prolonged exertion at work or recreation1          
Slight limitation, with angina only during vigorous physical activity2  
Symptoms with everyday living activities, i.e. moderate limitation3  
Inability to perform any activity without angina or angina at rest, i.e. severe limitation4  
1.6 If stable angina, pre-test probability of coronary artery disease 
 
Low1  Medium2  High3  
Duke % probability of CAD  
1.7    If ACS 
Peak troponin level                          Units                                Troponin T or Troponin I value recorded? 
 
 
T1                                    I2 
 
ECG changes:  ST elevation7     ST depression1     Yes, not further specified8      Other3 (e.g. T wave inversion)       None0
 
       
A2.  RISK FACTORS (at time of index investigation) 
2.1 Smoking  Current smoker1                              Ex-smoker2                      Never smoked4 
2.2 Hypertension  Yes1                           Year of diagnosis   
 
2.3 Hyperlipidaemia  Yes1                           Year of diagnosis:   
 
2.4 Diabetes mellitus  Yes1                           Year of diagnosis:   
 
 1Type 1 
 2Type 2 
2.5 Body weight  Normal weight1          Overweight2          Obese3          Morbidly obese4              
Elevated5 
 
2.6 Family history (1st 
degree relative) of 
coronary heart disease 
 
   Relation                      Age at diagnosis Diagnosis 
 
   Mother1  
 
MI1                   CAD2     
% 
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A3.    PHYSICIAN DIAGNOSED PREVIOUS CARDIAC HISTORY Include all events leading to but not including the current 
admission  
 Yes1 
 No2 (go to qn A4)                 
Ischaemic heart 
disease (IHD) or 
coronary heart 
disease (CHD) 
 
Yes1 
 Date of first 
diagnosis
 
        
D D M M Y Y Y Y 
 
Treatment (first admission for IHD/CHD):           PCI1      Medical2        Surgery3  
Myocardial 
infarction (MI) 
 
Yes1 
Number of total 
MIs  
         
Date of first 
MI 
 
        
D D M M Y Y Y Y 
 
Type (first MI if known):                                  STEMI1       NSTEMI2            
Unstable angina  
Yes1 
Number of total 
admissions 
  
Date of first 
admission 
for unstable 
angina 
 
        
D D M M Y Y Y Y 
 
Angiogram  
Yes1 
Number of total 
angiograms 
         
Date of first 
Angiogram 
 
        
D D M M Y Y Y Y 
 
Positive1  
 
   Father2   MI1                   CAD2  
2.7 Body measurements – record measurements closest to index   
        
D D M M Y Y Y Y 
Date of measurements
 
 
 
Body weight   ______stones _____ pounds                   OR 
 
 _______ kg            AND 
 
 ______ BMI 
 
 Height 
 
 _______feet _______ inches                   OR  _______ cm 
 
 
2.8   Blood pressure reading  
  1) Enter value at index or before, but closest to 
index investigation 
       
D D M M Y Y Y Y 
 
2) Enter value after, but closest to index 
investigation  
3)  
        
D D M M Y Y Y Y 
 
Systolic BP   
Diastolic BP
 
Method of BP 
measurement 
Invasive1  (ascending aorta)        
Non-invasive2                              
Invasive1  (ascending aorta)        
Non-invasive2                              
2.9  Heart rate 
 
  
mmHg mmHg 
mmHg mmHg 
                                   bpm                                    bpm 
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Percutaneous 
coronary 
intervention (PCI) 
 
Yes1 
Number of total 
PCIs 
         
Date of first 
PCI 
        
D D M M Y Y Y Y 
 
Number of total 
vessels 
revascularised 
ever (prior to 
index) 
 
 
Number of total stents ever (prior to index) 
 
 
 
Coronary artery 
bypass graft 
(CABG) 
 
Yes1 
Number of total 
surgeries 
         
Date of first 
CABG 
 
        
D D M M Y Y Y Y 
 
Number of total vessels bypassed ever (prior to index) 
 
 
Heart failure 
 
 
Yes1 
Type:  Ischaemic1    Non-ischaemic cardiomyopathy2      Hypertensive3     Other4
 
 
NYHA class at enrolment:           I1                     II2                      III3            IV4     
Latest LVEF value 
Good1                
Mild2                               
Moderate3           
Severe4          
 
Enter month and year of 
LVEF result 
                            Y        Y        
M      M       Y        Y         
      
Arrhythmia  
Yes1 
Date of first diagnosis 
 
        
D D M M Y Y Y Y 
Type of arrhhythmia (at first diagnosis): 
Atrial fibrillation1       Ventricular tachycardia2        Supraventricular tachycardia3        
Bradyarrhythmia4                        Atrial flutter5                      Other6 (state below)   
 
1st device:  Pacemaker1  Implantable cardioverter defibrillator2  Biventricular pacemaker3  
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                                                                                              (ICD) 
Date first device inserted 
 
        
D D M M Y Y Y Y 
A4. NON-CARDIAC HISTORY 
 Yes1 
 No2 (go to Section B)                 
Peripheral arterial 
disease 
 
Yes1
Location:  
Abdominal aortic 
aneurism1     
Lower limb 
ischaemia2           
Date of 
first 
diagnosis 
 
        
D D M M Y Y Y Y 
 
Stroke 
 
 
Yes1
Type of stroke:          
Ischaemic1                
         
Haemorrhagic2          
    
Date of 
first 
diagnosis 
 
        
D D M M Y Y Y Y 
 
TIA  
Yes1 
 Date of 
first 
diagnosis 
 
        
D D M M Y Y Y Y 
 
Chronic 
obstructive 
pulmonary 
disease/asthma 
Yes1 
On treatment?           
Yes1                      
No0      
Date of 
first 
diagnosis 
 
        
D D M M Y Y Y Y
 
Chronic renal 
disease 
 
Yes1 
Aetiology:                  
Hypertension1           
                 
Diabetes mellitus2     
          Other3        
            
Date of 
first 
diagnosis 
 
        
D D M M Y Y Y Y 
 
Treatment: 
None0                        
   
Haemodialysis1         
            
Chronic peritoneal 
dialysis2    
 
(e)GFR at 
enrolment  
Value                              GFR1  eGFR2  
 
Units                          
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Obstructive sleep 
apnoea 
 
Yes1 
Treated?                    
Yes1                     
No0      
Date of 
first 
diagnosis 
 
        
D D M M Y Y Y Y 
 
Depression  
Yes1 
Treated?                   
Yes1                      
No0      
Date of 
first 
diagnosis 
        
D D M M Y Y Y Y 
 
Cancer  
Yes1 
Type of cancer   Date of 
first 
diagnosis 
 
        
D D M M Y Y Y Y 
 
Other diagnoses                                                  
Year of diagnosis 
 
Diagnosis 1                                                             
 
Diagnosis 2                                                            
 
Diagnosis 3 
                 
 
    
    
    
                                                             Year of diagnosis 
 
Diagnosis 4                                                                  
 
Diagnosis 5                                                             
 
Diagnosis 6                 
 
    
    
    
SECTION B: CORONARY CATHETERISATION  
B. Results of index (preferred) or non-index angiogram soonest after date of index investigation  
 
1.1 Invasive coronary angiogram +/- PCI = NATIVE VESSELS 
 
Enter date of procedure 
                                          
        
  D D M M Y Y Y Y 
Normal study 
 Yes1                
 Had 
previous 
stent? 
(tick if 
yes1) 
Occlusion 
now (state 
% or 
mod/sev/ 
blocked)) 
Treated 
now? 
(enter 
BMS or 
DCS for 
type) 
 Had 
previous 
stent? 
(tick if 
yes1) 
Occlusion 
now (state 
% or 
mod/sev/ 
blocked)) 
Treated 
now? 
(enter 
BMS or 
DCS for 
type) 
 Had 
previous 
stent? 
(tick if 
yes1) 
Occlusio
n now 
(state % 
or 
mod/sev/ 
blocked)) 
Treat
ed 
now
? 
(ente
r 
BMS 
or 
DCS 
for 
type) 
LM    P LAD 
before 1st 
branch 
   P LAD 
after 1st 
branch  
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D1    Septal     D2    
Mid LAD 
 
Distal LAD Ramus 
P LCX 
 
   OM1    OM2    
OM3 
 
   M LCX    D LCX    
P RCA    MRCA 
 
   D RCA     
PDA 
 
   PLV 
branch 
    
Dominance 
 
Right1                     
Left2                                
Co-dominance3            
LVEF 
      
               
Good1                   Mild2                              
Moderate3              Severe4             
 
Outcome 
(state) 
 
1.2 Coronary CT angiogram 
 
Enter date of procedure 
                                               
        
  D D M M Y Y Y Y 
Normal study 
 Yes1                
 Had 
previous 
stent? 
(tick if yes1) 
Occlusion now 
(state % or 
mod/severe/
blocked) 
 Had 
previous 
stent? 
(tick if yes1) 
Occlusion now 
(state % or 
mod/severe/
blocked) 
 Had 
previous 
stent? (tick 
if yes1) 
Occlusio
n now 
(state % 
or 
mod/sev
ere/ 
blocked) 
LM   P LAD before 
1st branch 
 
  P LAD after 
1st branch  
  
D1 
 
  Septal    D2   
Mid LAD 
 
  Distal LAD   Ramus   
P LCX 
 
  OM1   OM2   
OM3 
 
  M LCX   D LCX   
P RCA   MRCA 
 
  D RCA    
PDA   PLV branch 
 
   
Dominance 
 
Right1                     
Left2                                 
Co-dominance3            
LVEF 
             
                     
Good1                   Mild2               
Moderate3           Severe4         
 
Outcome 
(state) 
 
 
 
  % 
  % 
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1.3 Invasive coronary angiogram +/- PCI = GRAFTS 
 
Enter date of procedure 
                                          
        
  D D M M Y Y Y Y 
Normal study 
 Yes1                
 Type of 
graft 
(state 
IMA1 or 
vein graft 
(VG)2) 
Occlusion 
now (state 
% or 
mod/sev/ 
blocked)) 
Treated 
now? 
(enter 
BMS or 
DCS for 
type) 
 Type of 
graft 
(state 
IMA1 or 
vein graft 
(VG)2) 
Occlusion 
now (state 
% or 
mod/sev/ 
blocked)) 
Treated 
now? 
(enter 
BMS or 
DCS for 
type) 
 Type of 
graft 
(state 
IMA1 or 
vein 
graft 
(VG)2) 
Occlusio
n now 
(state % 
or 
mod/sev/ 
blocked)) 
Treate
d now? 
(enter 
BMS 
or DCS 
for 
type) 
LM    P LAD 
before 1st 
branch 
   P LAD 
after 1st 
branch  
   
D1 
 
   Septal 
  
   D2    
Mid LAD 
 
   Distal LAD    Ramus    
P LCX  
 
   OM1    OM2    
OM3 
 
   M LCX    D LCX    
P RCA    MRCA 
 
   D RCA    
PDA 
 
PLV 
branch 
Dominance 
 
Right1                     
Left2                                 
Co-dominance3            
LVEF 
      
               
Good1                   Mild2                              
Moderate3              Severe4             
 
Outcome 
(state) 
 
 
1.4 Overall assessment  (from 1.1, 1.2 or 1.3) 
Normal angiogram1               
 
1 diseased vessel2                     
 
2 diseased vessel3                              
 
3 diseased vessel4                     
 
 
  
  % 
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SECTION C: OTHER INVESTIGATIONS
TESTS CARRIED OUT AT INDEX (PREFERRED) OR SOONEST BEFORE/AFTER INDEX, 
IF RELATED TO INDEX INVESTIGATION Collected from test reports or discharge summary 
C1. Resting ECG findings  
Test 
performed:          
 Yes1  
 No2  
(If no, go to 
QC2)            
Date of resting ECG closest to 
index investigation 
 
        
D D M M Y Y Y Y 
 
Normal study (if the conclusion 
states normal) 
 Yes1  
LBBB 
 Yes1 
RBBB 
 Yes1 
Paced 
 Yes1 
 
Type 
 Single-chamber1 
 Dual-chamber2 
Rate-responsive3
 Other (state below)4 
Abnormal findings (from text) 
       
        
___________________________________________________________________
       
        
___________________________________________________________________ 
 
        
___________________________________________________________________ 
 
        
____________________________________________________________________ 
 
C2. Exercise electrocardiogram finding  
Test performed:       Yes1  
 No2  
(If no, go to QC3)    
Date of exercise ECG closest to index 
investigation 
 
        
D D M M Y Y Y Y 
 
Normal study (if the conclusion states 
normal) 
Yes1
Minutes exercised 
 
BP response  
Normal1                Abnormal2    
Excessive high/fall? 
Excessive High1              Excessive 
Fall2  
mins 
DOI: 10.3310/pgfar05040 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hemingway et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
309
Pre-test HR:  Age predicted max HR reached 
Yes1          
Maximal HR reached:  
  >1 mm ST segment flattening/down 
sloping 
Yes1          
Leads      I1           aVF4        V17         V410   
 
       II2          aVL5        V28          V511   
 
                III3        aVR6        V39          V612   
 
ST elevation 
Yes1          
Leads      I1           aVF4        V17         V410   
 
       II2          aVL5        V28          V511   
 
                III3        aVR6        V39          V612   
 
Territory of ECG changes:                   Anterior1         Lateral2        Inferior3  
Ventricular ectopy during test 
Yes1         
Chest pain during test 
Yes1  
 
C3. Resting trans-thoracic echocardiogram findings 
Test performed:    
                         
 
 
 
 
 
 Yes1  
 No2  
(If no, go to QC4)    
Date of resting trans-thoracic echo 
closest to index investigation 
 
        
D D M M Y Y Y Y 
 
Normal study (if the conclusion states 
normal) 
Yes1   
LVEF 
LVEF (from text) 
Good1                          Mild2                
    Moderate3                   Severe4     
 
Regional wall motion abnormality 
Yes1  (Go to C8 to enter results) 
Left atrial size 
 
LVED dimension 
 
% 
cm  __________AP  
di t ( )
  ___________ 
Area (cm2)
bpm bpm 
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Any significant valve disease?           Yes1  
  
Tick the appropriate combination: 
 
 Aortic1 Mitral2 Tricuspid3 Pulmonary4 
Stenosis1 Moderate1     
Severe2     
Regurgitation2 Moderate1     
Severe2     
 
C4. Stress echocardiogram test findings 
Test performed:        Yes1  
No2  
(If no, go to QC5)    
Date of stress echo test 
closest to index 
investigation 
 
        
D D M M Y Y Y Y 
 
Normal study (if the 
conclusion states normal) 
Yes1          
Regional wall motion abnormality 
Yes1  (Go to C8 to enter results) 
LVEF
 
 
Good1                  Mild2              
Moderate3            Severe4       
Was ischaemia induced?
Yes1                                 Stressor:    Adenosine1                
                                                                        Dobutamine2                  
                                                                        Dipyridamole3                   
C5. Nuclear myocardial perfusion test findings 
Test performed:          
 
 Yes1  
 No2  
 (If no, go to QC6)      
Date of nuclear myocardial perfusion test 
closest to index investigation  
 
        
D D M M Y Y Y Y 
 
Normal study (if the conclusion states 
normal) 
Yes1           
Was ischaemia induced? 
 
Yes1   
 
Stressor :   Adenosine1                                
                    Dobutamine2                     
                    Dipyridamole3                            
LVEF 
 
Good1                          Mild2                     
Moderate3                   Severe4           
% 
% 
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Tick the appropriate combination  
 
 
 
Type of 
perfusion 
defect 
 
 
 
Severity 
Ba
sa
l a
nte
rio
r1  
Ba
sa
l a
nte
ro
se
pta
l2
Ba
sa
l in
fer
os
ep
tal
 3  
Ba
sa
l in
fer
ior
4  
Ba
sa
l in
fer
ola
ter
al 
5  
Ba
sa
l a
nte
ro
lat
er
al 
6  
Mi
d-
an
ter
ior
 7  
Mi
d-
an
ter
os
ep
tal
 8  
Mi
d-
inf
er
os
ep
tal
9  
Mi
d-
inf
er
ior
 10
 
Mi
d-
inf
er
ola
ter
al1
1  
Mi
d-
an
ter
ola
ter
al1
2  
Ap
ica
l a
nte
rio
r13
 
Ap
ica
l s
ep
tal
14
 
Ap
ica
l in
fer
ior
15
 
La
ter
al1
6  
Ap
ex
17
 
 
Reversible1 
Mild1                  
Moderate2                  
Severe3                  
Fixed2                  
If fixed, give details 
 
C6. CMR test findings 
Test performed:     
 
 Yes1  
 No2  
 (If no, go to QC7)     
Date of CMR test closest to index 
investigation  
 
        
D D M M Y Y Y Y 
 
Normal study (if the conclusion states 
normal) 
Yes1           
Was ischaemia induced? 
 
Yes1   
Stressor :   Adenosine1                                 
Dobutamine2                 
                    Dipyridamole3                              
LVEF 
 
Good1                          Mild2                     
Moderate3                   Severe4            
Tick the appropriate combination  
 
 
 
Type of 
perfusion 
defect 
 
 
 
Severity 
Ba
sa
l a
nte
rio
r1  
Ba
sa
l a
nte
ro
se
pta
l2  
Ba
sa
l in
fer
os
ep
tal
 3  
Ba
sa
l in
fer
ior
4  
Ba
sa
l in
fer
ola
ter
al 
5  
Ba
sa
l a
nte
ro
lat
er
al 
6  
Mi
d-
an
ter
ior
 7  
Mi
d-
an
ter
os
ep
tal
 8  
Mi
d-
inf
er
os
ep
tal
9  
Mi
d-
inf
er
ior
 10
 
Mi
d-
inf
er
ola
ter
al1
1  
Mi
d-
an
ter
ola
ter
al1
2  
Ap
ica
l a
nte
rio
r13
 
Ap
ica
l s
ep
tal
14
 
Ap
ica
l in
fer
ior
15
 
La
ter
al1
6  
Ap
ex
17
 
 
Reversible1 
Mild1                  
Moderate2                  
Severe3                  
Fixed2                  
If fixed, give details 
 
 
% 
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Present:  Yes1  
 No2  
 (If no, go to Section D)            
Source of 
information: 
Resting                       
          
echocardiogram1 
Stress                         
          
echocardiogram2 
Nuclear myocardial     
          perfusion 
scan3 
MRI stress                  
          perfusion 
scan4 
Tick the appropriate combination  
 
 
 
 
Ba
sa
l a
nte
rio
r1  
Ba
sa
l a
nte
ro
se
pta
l2  
Ba
sa
l in
fer
os
ep
tal
 3  
Ba
sa
l in
fer
ior
4  
Ba
sa
l in
fer
ola
ter
al 
5  
Ba
sa
l a
nte
ro
lat
er
al
6  
Mi
d-
an
ter
ior
 7  
Mi
d-
an
ter
os
ep
tal
 8  
Mi
d-
inf
er
os
ep
tal
9  
Mi
d-
inf
er
ior
 10
 
Mi
d-
inf
er
ola
ter
al1
1  
Mi
d-
an
ter
ola
ter
al1
2  
Ap
ica
l a
nte
rio
r13
 
Ap
ica
l s
ep
tal
14
 
Ap
ica
l in
fer
ior
15
 
La
ter
al1
6  
Ap
ex
17
 
Hypokinetic1                  
Dyskinetic2                  
Akinetic3                  
  C7. CT calcium scoring test findings 
Test performed:        Yes1  
 No2  
 (If no, go to QC8)         
Date of CT calcium scoring test  
closest to index investigation 
        
D D M M Y Y Y Y 
 
Territory of calcium 
LAD1          RCA2          LCX3 
 
Agatston score: 
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SE
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IO
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Me
to
pr
olo
l4 
 
 
 
 
 
 
 
 
 
 
 
Me
to
pr
olo
4 
 
 
 
 
 
 
 
 
 
 
 
Ot
he
r s
ta
te
 n
am
e1
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ot
he
r s
ta
te
 
na
me
10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An
tip
lat
ele
t 
 
Ye
s1
 
 
As
pir
in1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Ye
s1
 
 
As
pir
in1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cl
op
ido
gr
el2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cl
op
ido
gr
el2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ot
he
r s
ta
te
 n
am
e1
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ot
he
r s
ta
te
 
na
me
10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An
tic
oa
gu
lan
t 
 
Ye
s1
 
 
He
pa
rin
1   
 
 
 
 
 
 
 
 
 
 
 
 
 
Ye
s1
 
 
He
pa
rin
1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
W
ar
fa
rin
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
W
ar
fa
rin
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ot
he
r s
ta
te
 n
am
e1
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ot
he
r s
ta
te
 
na
me
10
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
314
 
At
 ti
m
e o
f i
nd
ex
 in
ve
st
ig
at
ion
 
Do
se
 
Un
it 
OD
1 /B
D2
/T
DS
3 /Q
DS
4 
 
On
 d
isc
ha
rg
e 
Do
se
 
Un
it 
OD
1 /B
D2
/T
DS
3 /Q
DS
4  
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Appendix 8 Postgraduate qualifications and
career development
Master of Science dissertations/Bachelor of Medicine, Bachelor
of Surgery
Abell B. The Feasibility, Validity and Reproducibility of Novel Clinical Measurement Devices in the
Assessment of Coronary Heart Disease: A Pilot Study in 22 Participants. MSc in Clinical and Experimental
Medicine. London: University College London; 2010.
Crowther M. Improving the Quality of Care of Patients with Angina and Heart Attack. MSc in Medical
Statistics. NIHR Research Methods Fellowship Programme. Leicester: University of Leicester; 2010.
Mole G. Gender Differences in Coronary Disease Investigation and Outcomes. MBBS. Brighton: Brighton
and Sussex Medical School; 2011.
Kim H. The Impact of Drug Choice and Combinations on the Mortality and Morbidity among Stable
Angina Patients in England: Prospective Approach using CALIBER Database. MSc in Health and Society:
Social Epidemiology. London: University College London; 2011.
Zhang J. Smoking Effects on Different Manifestations of Coronary Heart Disease. MSc in Health and
Society: Social Epidemiology. London: University College London; 2011.
Furr J. Internal Validation of the Accuracy of Diagnostic Categorizations in Coronary Heart Disease:
Descriptive, Outcome and Temporal Analysis in a Linked Database. MSc in Health and Society: Social
Epidemiology. London: University College London; 2011.
Choi M. Aetiological Effects of Depression on Different Phenotypes of Coronary Heart Disease: The Roles
of Age, Sex and Region. MSc in Health and Society: Social Epidemiology. London: University College
London; 2011.
Zhao M. The Association of Exercise ECG Variable beyond ST-segment with Prognosis in Patients with
Suspected or Confirmed Coronary Disease: A Systematic Review and Meta-Analysis. MSc in Preventative
Cardiology. London: Imperial College London; 2011.
Shah A. Comparison of Methods for Handling Missing Data in the CALIBER Dataset. MSc in Medical
Statistics. London: London School of Hygiene and Tropical Medicine; 2012.
Fidler M. Hypertension Management, Social Deprivation, and Coronary-Specific Endpoints in 1,349,867 Patients:
A CALIBER Study. MSc Health and Society: Social Epidemiology. London: University College London; 2012.
Root A. The Effect of Visit-to-Visit Blood Pressure Variability on Cardiovascular Events in a Hypertensive
Primary Care Cohort. MSc Epidemiology. London: London School of Hygiene and Tropical Medicine; 2013.
Chen Y. Primary Care Utilisation and Acute Myocardial Infarction Hazards: An Open Cohort CALIBER Study.
MSc in Health and Society: Social Epidemiology. London: University College London; 2013.
Ukandu M. Study of the Association between Cerebrovascular Disease and Socio-economic Deprivation in
Hypertensive Patients: A CALIBER Study. MSc in Health and Society: Social Epidemiology. London:
University College London; 2013.
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Fellowships/Doctor of Philosophy studentships
Warren-Gash C. Medical Research Council. The Role of Influenza and Acute Respiratory Infections as
Triggers for Acute Cardiovascular Events. PhD Thesis. London: London School of Hygiene and Tropical
Medicine; 2012.
Herrett E. Medical Research Council. Myocardial Infarction as the First Manifestation of Atherosclerotic
Disease. PhD Thesis. London: London School of Hygiene and Tropical Medicine; 2012.
Johnson R. Shared Decision Making for Cardiovascular Conditions. NIHR In-Practice Fellowship. Bristol:
University of Bristol; 2012.
George J. Gender Differences in Outcomes for 30,000 Myocardial Infarction Patients: Longitudinal Study
Before and After Hospitalisation. NIHR Doctoral Fellowship. London: University College London; 2013.
Crowther M. Dynamic Clinical Risk Predictions in Personalised Medicine: Development and Application of
Joint Models for Repeatedly Measured Biomarkers and Time-to-Event Data in Biomedical Research. NIHR
Doctoral Research Fellowship. Leicester: University of Leicester; 2015.
Shah A. Differential Leucocyte Counts and the Prognosis of Specific Coronary Phenotypes. Wellcome
Research Training Fellowship. London: University College London; 2015.
Archangelidi O. Heart Rate and Prognosis of Stable Coronary Disease. Servier-funded studentship. London:
University College London; 2015.
Patel R. NIHR Clinical Lectureship in Cardiology. NIHR Clinical Lectureship. London: University College
London; 2015.
Pasea L. Antithrombotic Therapies in Cardiovascular Diseases. Industry partnership PhD studentship with
AstraZenica. London: University College London; 2016.
Wallace J. Examining the Determinants in the Time Course of Atrial Fibrillation: Factors Affecting Risk and
Prognosis. Part of work for PhD thesis. London: Medical Research Council and University College London;
not completed.
Hafidha Hikmayani N. Quality of Care in Incident Type 2 Diabetes: Attainment over Time, Treatment and
Cardiovascular Prognosis. PhD thesis (Islamic Development Bank–University College London Joint
Scholarship). London: University College London; in progress (date of completion: 2018).
Johnson R. Shared Decision Making for Cardiovascular Conditions. NIHR Doctoral Fellowship. Bristol:
University of Bristol; ongoing (date of fellowship end: 2019).
Medical trainees
Juttner K, NIHR Academic Clinical Fellow, was involved in investigating relationships between depression
and anxiety and CHD outcomes.
Zhang X, academic Foundation Year 2 junior doctor, developed the 4C questionnaire and manual.
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Appendix 9 Invited talks and conferences
2009
Hemingway H. Epidemiology of Specific Coronary Phenotypes. Paper presented at the Royal Society of
Medicine, London, January 2009.
Hemingway H. Higher Resolution Enquiry: How Electronic Health Records might Contribute to
Understanding Coronary Disease Inequalities. Paper presented at the Wellcome Trust Symposium on
Electronic Health Records. London, April 2009.
Hemingway H. Higher Resolution Enquiry: How Electronic Health Records might Contribute to
Understanding Coronary Disease Inequalities. Paper presented at the Royal Statistical Society, London,
April 2009.
Hemingway H. Opportunities in Large Scale Electronic Health Record Linkages: CALIBER. Paper presented
at the Yale–UCL Collaboration, Yale, CT, May 2009.
Hemingway H. Higher Treating Chronic Stable Angina: Who’s Winning, Who’s Losing and Why? Paper
presented at the British Cardiovascular Society, London, June 2009.
Hemingway H. Evolution of Prognosis Research: 10 Steps Forward. Paper presented at the Deutsche
Gesellschaft fuer Epidemiologie, Münster, September 2009.
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